|
|
|
Scientific Literature, PPAR
-
Aasum E, Khalid AM, Gudbrandsen OA, How OJ, Berge RK, Larsen TS. Fenofibrate modulates cardiac and hepatic metabolism and increases ischemic tolerance in diet-induced obese mice.
J. Mol. Cell. Cardiol. 44: 201-209 (2008).
-
Abbott BD. Review of the expression of peroxisome proliferators activated receptors alpha (PPARalpha), beta (PPARbeta), and gamma (PPARgamma) in rodent and human development.
Reprod. Toxicol. 27: 246-257 (2009).
-
Abbott BD, Wolf CJ, Schmid JE, Das KP, Zehr RD, Helfant L, Nakayama S, Lindstrom AB, Strynar MJ, Lau CS. Perfluorooctanoic acid (PFOA)-induced developmental toxicity in the mouse is dependent on expression of peroxisome proliferator activated receptor-alpha (PPARalpha).
Toxicol. Sci. 98: 571-581 (2007).
*
-
Abedin M, Lim J, Tang TB, Park D, Demer LL, Tintut Y. n-3 Fatty acids inhibit vascular calcification via the p38-MAPK and peroxisome proliferator-activated receptor-gamma pathways.
Circ. Res. 98: 727-729 (2006).
*
-
Abedin SA, Thorne JL, Battaglia S, Maguire O, Hornung L, Doherty AP, Mills IG, Campbell MJ. Elevated NCOR1 disrupts a network of dietary-sensing nuclear receptors in bladder cancer cells.
Carcinogenesis 30: 449-456 (2009).
*
-
Aberle J, Hopfer I, Beil FU, Seedorf U. Association of peroxisome proliferator-activated receptor delta +294T/C with body mass index and interaction with peroxisome proliferator-activated receptor alpha L162V.
Int. J. Obes. (Lond.) 30: 1709-1713 (2006).
-
Aceves C, Garcia-Solis P, Arroyo-Helguera O, Vega-Riveroll L, Delgado G, Anguiano B. Antineoplastic effect of iodine in mammary cancer: participation of 6-iodolactone (6-IL) and peroxisome proliferator-activated receptors (PPAR).
Mol. Cancer 8: 33 (2009).
-
Ackert-Bicknell C, Rosen C. The genetics of PPARG and the skeleton.
PPAR Res. 2006: 93258 (2006).
*
-
Adachi M, Kurotani R, Morimura K, Shah Y, Sanford M, Madison BB, Gumucio DL, Marin HE, Peters JM, Young HA, Gonzalez FJ. PPARgamma in colonic epithelial cells protects against experimental inflammatory bowel disease.
Gut 55: 1104-1113 (2006).
*
-
Adamiec R, Gacka M, Dobosz T, Szymaniec S, Bednarska-Chabowska D, Sadakierska-Chudy A. Stimulation of the peroxisome proliferator-activated receptor gamma (PPARgamma) and the expression of selected blood monocyte cytokine genes in diabetic macroangiopathy.
Atherosclerosis 194: e108-e115 (2007).
-
Adamkiewicz J, Kaddatz K, Rieck M, Wilke B, Muller-Brusselbach S, Muller R. Proteomic profile of mouse fibroblasts with a targeted disruption of the peroxisome proliferator activated receptor-beta/delta gene.
Proteomics 7: 1208-1216 (2007).
*
-
Adamo KB, Dent R, Langefeld CD, Cox M, Williams K, Carrick KM, Stuart JS, Sundseth SS, Harper ME, McPherson R, Tesson F. Peroxisome proliferator-activated receptor gamma 2 and acyl-CoA synthetase 5 polymorphisms influence diet response.
Obesity (Silver Spring) 15: 1068-1075 (2007).
*
-
Adida A, Spener F. Adipocyte-type fatty acid-binding protein as inter-compartmental shuttle for peroxisome proliferator activated receptor gamma agonists in cultured cell.
Biochim. Biophys. Acta 1761: 172-181 (2006).
*
-
Afif H, Benderdour M, Mfuna-Endam L, Martel-Pelletier J, Pelletier JP, Duval N, Fahmi H. Peroxisome proliferator-activated receptor gamma1 expression is diminished in human osteoarthritic cartilage and is down-regulated by interleukin-1beta in articular chondrocytes.
Arthritis Res. Ther. 9: R31 (2007).
*
-
Agassandian M, Miakotina OL, Andrews M, Mathur SN, Mallampalli RK. P. aeruginosa and sPLA2 IB stimulate ABCA1-mediated phospholipid efflux via ERK-activation of PPARalpha/RXR.
Biochem. J. 403: 409-420 (2007).
*
-
Aggelidou E, Iordanidou P, Demetriades C, Piltsi O, Hadzopoulou-Cladaras M. Functional characterization of hepatocyte nuclear factor-4alpha dimerization interface mutants.
FEBS J. 273: 1948-1958 (2006).
*
-
Ahlawat P, Srinivas NR. Allometric prediction of the human pharmacokinetic parameters for naveglitazar.
Eur. J. Drug Metab. Pharmacokinet. 33: 187-190 (2008).
-
Ahmed I, Furlong K, Flood J, Treat VP, Goldstein BJ. Dual PPAR alpha/gamma agonists: promises and pitfalls in type 2 diabetes.
Am. J. Ther. 14: 49-62 (2007).
-
Ahmed RA, Murao K, Imachi H, Yu X, Li J, Wong NC, Ishida T. Human scavenger receptor class B type 1 is regulated by activators of peroxisome proliferators-activated receptor-gamma in hepatocytes.
Endocrine 35: 233-242 (2009).
-
Ahmed W, Orasanu G, Nehra V, Asatryan L, Rader DJ, Ziouzenkova O, Plutzky J. High-density lipoprotein hydrolysis by endothelial lipase activates PPARalpha. A candidate mechanism for high-density lipoprotein-mediated repression of leukocyte adhesion.
Circ. Res. 98: 490-498 (2006).
*
-
Ahmed W, Ziouzenkova O, Brown J, Devchand P, Francis S, Kadakia M, Kanda T, Orasanu G, Sharlach M, Zandbergen F, Plutzky J. PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?
J. Intern. Med. 262: 184-198 (2007).
*
-
Ahmetov II, Mozhayskaya IA, Flavell DM, Astratenkova IV, Komkova AI, Lyubaeva EV, Tarakin PP, Shenkman BS, Vdovina AB, Netreba AI, Popov DV, Vinogradova OL, Montgomery HE, Rogozkin VA. PPARalpha gene variation and physical performance in Russian athletes.
Eur. J. Appl. Physiol. 97: 103-108 (2006).
-
Ahmetov II, Mozhayskaya IA, Lyubaeva EV, Vinogradova OL, Rogozkin VA. PPARG gene polymorphism and locomotor activity in humans.
Bull. Exp. Biol. Med. 146: 630-632 (2008).
-
Ahn J, Albanes D, Berndt SI, Peters U, Chatterjee N, Freedman ND, Abnet CC, Huang WY, Kibel AS, Crawford ED, Weinstein SJ, Chanock SJ, Schatzkin A, Hayes RB; for the Prostate, Lung, Colorectal, and Ovarian (PLCO) Trial Project Team. Vitamin D-related genes, serum vitamin D concentrations, and prostate cancer risk.
Carcinogenesis 30: 769-776 (2009).
*
-
Ahn JH, Shin MS, Jung SH, Kang SK, Kim KR, Rhee SD, Jung WH, Yang SD, Kim SJ, Woo JR, Lee JH, Cheon HG, Kim SS. Indenone derivatives: a novel template for peroxisome proliferator-activated receptor gamma (PPARgamma) agonists.
J. Med. Chem. 49: 4781-4784 (2006).
*
-
Ahn KO, Lim SW, Yang HJ, Li C, Sugawara A, Ito S, Choi BS, Kim YS, Kim J, Yang CW. Induction of PPAR gamma mRNA and protein expression by rosiglitazone in chronic cyclosporine nephropathy in the rat.
Yonsei. Med. J. 48: 308-316 (2007).
*
-
Ahsan MK, Okuyama H, Hoshino Y, Oka SI, Masutani H, Yodoi J, Nakamura H. Thioredoxin-binding protein-2 deficiency enhances methionine-choline deficient diet-induced hepatic steatosis but inhibits steatohepatitis in mice.
Antioxid. Redox Signal. May 18 [Epub ahead of print] (2009).
-
Aiello A, Pandini G, Frasca F, Conte E, Murabito A, Sacco A, Genua M, Vigneri R, Belfiore A. Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells.
Endocrinology 147: 4463-4475 (2006).
*
-
Ajmo JM, Liang X, Rogers CQ, Pennock B, You M. Resveratrol alleviates alcoholic fatty liver in mice.
Am. J. Physiol. Gastrointest. Liver Physiol. 295: G833-G842 (2008).
*
-
Akahori T, Sho M, Hamada K, Suzaki Y, Kuzumoto Y, Nomi T, Nakamura S, Enomoto K, Kanehiro H, Nakajima Y. Importance of peroxisome proliferator-activated receptor-gamma in hepatic ischemia/reperfusion injury in mice.
J. Hepatol. 47: 784-792 (2007).
*
-
Akbiyik F, Cinar K, Demirpence E, Ozsullu T, Tunca R, Haziroglu R, Yurdaydin C, Uzunalimoglu O, Bozkaya H. Ligand-induced expression of peroxisome proliferator-activated receptor alpha and activation of fatty acid oxidation enzymes in fatty liver.
Eur. J. Clin. Invest. 34: 429-435 (2004).
-
Akiyama TE, Baumann CT, Sakai S, Hager GL, Gonzalez FJ. Selective intranuclear redistribution of PPAR isoforms by RXR alpha.
Mol. Endocrinol. 16: 707-721 (2002).
*
-
Akiyama TE, Meinke PT, Berger JP. PPAR ligands: potential therapies for metabolic syndrome.
Curr. Diab. Rep. 5: 45-52 (2005).
-
Akiyama TE, Sakai S, Lambert G, Nicol CJ, Matsusue K, Pimprale S, Lee YH, Ricote M, Glass CK, Brewer HB Jr, Gonzalez FJ. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux.
Mol. Cell. Biol. 22: 2607-2619 (2002).
*
-
Akkiz H. Hepatocellular carcinoma pathogenesis: does PPAR alpha polymorphism have a role in hepatocarcinogenesis associated with HBV and HCV infections?
Turk. J. Gastroenterol. 19: 231-233 (2008).
*
-
Al-Hasani H, Joost HG. Nutrition-/diet-induced changes in gene expression in white adipose tissue.
Best Pract. Res. Clin. Endocrinol. Metab. 19: 589-603 (2005).
-
Al-Khalili L, Bouzakri K, Glund S, Lonnqvist F, Koistinen HA, Krook A. Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle.
Mol. Endocrinol. 20: 3364-3375 (2006).
*
-
Alarcon de la Lastra C, Sanchez-Fidalgo S, Villegas I, Motilva V. New pharmacological perspectives and therapeutic potential of PPAR-gamma agonists.
Curr. Pharm. Des. 10: 3505-3524 (2004).
-
Alarcon-Aguilar FJ, Almanza-Perez J, Blancas G, Angeles S, Garcia-Macedo R, Roman R, Cruz M. Glycine regulates the production of pro-inflammatory cytokines in lean and monosodium glutamate-obese mice.
Eur. J. Pharmacol. 599: 152-158 (2008).
*
-
Alaynick WA. Nuclear receptors, mitochondria and lipid metabolism.
Mitochondrion 8: 329-337 (2008).
-
Aleksunes LM, Yeager RL, Klaassen CD. Application of multivariate statistical procedures to identify transcription factors that correlate with MRP2, 3, and 4 mRNA in adult human livers.
Xenobiotica 39: 514-522 (2009).
*
-
Aleman G, Torres N, Tovar AR. Peroxisome proliferator-activated receptors (PPARs) in obesity and insulin resistance development.
Rev. Invest. Clin. 56: 351-367 (2004).
-
Aleshin S, Grabeklis S, Hanck T, Sergeeva M, Reiser G. PPARgamma positively and PPARalpha negatively control COX-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels.
Mol. Pharmacol. May 29 [Epub ahead of print] (2009).
*
-
Alevizaki M, Mantzou E, Cimponeriu A, Saltiki K, Philippou G, Wiersinga W. The Pro(12)Ala PPARgamma gene polymorphism: possible modifier of the activity and severity of thyroid associated orbitopathy (TAO).
Clin. Endocrinol. (Oxf.) 70: 464-468 (2009).
-
Alexis JD, Wang N, Che W, Lerner-Marmarosh N, Sahni A, Korshunov VA, Zou Y, Ding B, Yan C, Berk BC, Abe JI. Bcr kinase activation by angiotensin II inhibits peroxisome proliferator-activated receptor gamma transcriptional activity in vascular smooth muscle cells.
Circ. Res. 104: 69-78 (2009).
-
Ali FY, Davidson SJ, Moraes LA, Traves SL, Paul-Clark M, Bishop-Bailey D, Warner TD, Mitchell JA. Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARbeta.
FASEB J. 20: 326-328 (2006).
*
-
Alibin CP, Kopilas MA, Anderson HD. Suppression of cardiac myocyte hypertrophy by conjugated linoleic acid: role of peroxisome proliferator-activated receptors alpha and gamma.
J. Biol. Chem. 283: 10707-10715 (2008).
*
-
Aligeti VR, Gandhi M, Braden R, Rezk A, Elam MB. Effect of combination lipid-modifying therapy on the triglyceride lowering effect of fish oil.
Am. J. Med. Sci. 333: 168-172 (2007).
-
Allahtavakoli M, Shabanzadeh A, Roohbakhsh A, Pourshanazari A. Combination therapy of rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, and NMDA receptor antagonist (MK-801) on experimental embolic stroke in rats.
Basic Clin. Pharmacol. Toxicol. 101: 309-314 (2007).
*
-
Allen T, Zhang F, Moodie SA, Clemens LE, Smith A, Gregoire F, Bell A, Muscat GE, Gustafson TA. Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity.
Diabetes 55: 2523-2533 (2006).
*
-
Alleva DG, Johnson EB, Lio FM, Boehme SA, Conlon PJ, Crowe PD. Regulation of murine macrophage proinflammatory and anti-inflammatory cytokines by ligands for peroxisome proliferator-activated receptor-gamma: counter-regulatory activity by IFN-gamma.
J. Leukoc. Biol. 71: 677-685 (2002).
*
-
Allgayer H. Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease.
Aliment. Pharmacol. Ther. 18 Suppl. 2: 10-14 (2003).
*
-
Allgayer H, Kruis W. PPAR-ligands: a clinically important regulatory system with multiple options in the treatment of diabetes mellitus, inflammatory bowel disease and in the chemoprevention of colon cancer?
Z. Gastroenterol. 41: 1035-1038 (2003).
-
Allred CD, Talbert DR, Southard RC, Wang X, Kilgore MW. PPARgamma1 as a molecular target of eicosapentaenoic acid in human colon cancer (HT-29) cells.
J. Nutr. 138: 250-256 (2008).
*
-
Almendro V, Fuster G, Busquets S, Ametller E, Figueras M, Argiles JM, Lopez-Soriano FJ. Effects of IL-15 on rat brown adipose tissue: uncoupling proteins and PPARs.
Obesity (Silver Spring) 16: 285-289 (2008).
*
-
Alnouti Y, Klaassen CD. Regulation of sulfotransferase enzymes by prototypical microsomal enzyme inducers in mice.
J. Pharmacol. Exp. Ther. 324: 612-621 (2008).
*
-
Alnouti Y, Klaassen CD. Tissue distribution, ontogeny, and regulation of aldehyde dehydrogenase (Aldh) enzymes mRNA by prototypical microsomal enzyme inducers in mice.
Toxicol. Sci. 101: 51-64 (2008).
*
-
Alsarra IA, Brockmann WG, Cunningham ML, Badr MZ. Hepatocellular proliferation in response to agonists of peroxisome proliferator-activated receptor alpha: a role for Kupffer cells?
J. Carcinog. 5: 26 (2006).
*
-
Altmann R, Hausmann M, Spottl T, Gruber M, Bull AW, Menzel K, Vogl D, Herfarth H, Schölmerich J, Falk W, Rogler G. 13-Oxo-ODE is an endogenous ligand for PPARgamma in human colonic epithelial cells.
Biochem. Pharmacol. 74: 612-622 (2007).
*
-
Alvaro A, Rosales R, Masana L, Vallve JC. Polyunsaturated fatty acids down-regulate in vitro expression of the key intestinal cholesterol absorption protein NPC1L1: no effect of monounsaturated nor saturated fatty acids.
J. Nutr. Biochem. May 13 [Epub ahead of print] (2009).
*
-
Alwayn IP, Andersson C, Lee S, Arsenault DA, Bistrian B, Gura KM, Nose V, Zauscher B, Moses MA, Puder M. Inhibition of matrix metalloproteinases increases PPAR-alpha and IL-6 and prevents dietary-induced hepatic steatosis and injury in a murine model.
Am. J. Physiol. Gastrointest. Liver Physiol. 291: G1011-G1019 (2006).
*
-
Aly HH, Shimotohno K, Hijikata M. 3D cultured immortalized human hepatocytes useful to develop drugs for blood-borne HCV.
Biochem. Biophys. Res. Commun. 379: 330-334 (2009).
*
-
Ambrosio AL, Dias SM, Polikarpov I, Zurier RB, Burstein SH, Garratt RC. Ajulemic acid, a synthetic nonpsychoactive cannabinoid acid, bound to the ligand binding domain of the human peroxisome proliferator-activated receptor gamma.
J. Biol. Chem. 282: 18625-18633 (2007).
*
-
Ameen C, Edvardsson U, Ljungberg A, Asp L, Akerblad P, Tuneld A, Olofsson SO, Linden D, Oscarsson J. Activation of peroxisome proliferator-activated receptor alpha increases the expression and activity of microsomal triglyceride transfer protein in the liver.
J. Biol. Chem. 280: 1224-1229 (2005).
*
-
Amengual J, Ribot J, Bonet ML, Palou A. Retinoic acid treatment increases lipid oxidation capacity in skeletal muscle of mice.
Obesity (Silver Spring) 16: 585-591 (2008).
*
-
Amoruso A, Bardelli C, Gunella G, Fresu LG, Ferrero V, Brunelleschi S. Quantification of PPAR-gamma protein in monocyte/macrophages from healthy smokers and non-smokers: a possible direct effect of nicotine.
Life Sci. 81: 906-915 (2007).
*
-
Amoruso A, Bardelli C, Gunella G, Ribichini F, Brunelleschi S. A novel activity for substance P: stimulation of peroxisome proliferator-activated receptor-gamma protein expression in human monocytes and macrophages.
Br. J. Pharmacol. 154: 144-152 (2008).
*
-
Amsaguine-Safir S, Bianchi A, Collet P, Huin-Schohn C, Jeanvoine A, Becuwe P, Kremarik-Bouillaud P, Domenjoud L, Keller JM, Schohn H, Dauca M. Induction of the expression of the peroxisome proliferator-activated receptor alpha (PPARalpha) by clofibrate in jerboa tissues.
Microsc. Res. Tech. 61: 185-190 (2003).
*
-
Anderson SP, Dunn C, Laughter A, Yoon L, Swanson C, Stulnig TM, Steffensen KR, Chandraratna RA, Gustafsson JA, Corton JC. Overlapping transcriptional programs regulated by the nuclear receptors peroxisome proliferator-activated receptor alpha, retinoid X receptor and liver X receptor in mouse liver.
Mol. Pharmacol. 66: 1440-1452 (2004).
*
-
Anderson SP, Dunn CS, Cattley RC, Corton JC. Hepatocellular proliferation in response to a peroxisome proliferator does not require TNFalpha signaling.
Carcinogenesis 22: 1843-1851 (2001).
*
-
Anderson SP, Howroyd P, Liu J, Qian X, Bahnemann R, Swanson C, Kwak MK, Kensler TW, Corton JC. The transcriptional response to a peroxisome proliferator-activated receptor alpha agonist includes increased expression of proteome maintenance genes.
J. Biol. Chem. 279: 52390-52398 (2004).
*
-
Anderson SP, Yoon L, Richard EB, Dunn CS, Cattley RC, Corton JC. Delayed liver regeneration in peroxisome proliferator-activated receptor-alpha-null mice.
Hepatology 36: 544-554 (2002).
*
-
Andersson C, Zaman MM, Jones AB, Freedman SD. Alterations in immune response and PPAR/LXR regulation in cystic fibrosis macrophages.
J. Cyst. Fibros. 7: 68-78 (2008).
-
Andreeva-Gateva P. Peroxisome proliferator activated receptors PPARs: their role in carbohydrate and lipid metabolism.
Ann. Biol. Clin. (Paris) 61: 295-303 (2003).
-
Andrulionyte L, Kuulasmaa T, Chiasson JL, Laakso M. Single nucleotide polymorphisms of the peroxisome proliferator-activated receptor-alpha gene (PPARA) influence the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial.
Diabetes 56: 1181-1186 (2007).
*
-
Andrulionyte L, Peltola P, Chiasson JL, Laakso M. Single nucleotide polymorphisms of PPARD in combination with the Gly482Ser substitution of PGC-1A and the Pro12Ala substitution of PPARG2 predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial.
Diabetes 55: 2148-2152 (2006).
*
-
Andrulionyte L, Zacharova J, Chiasson JL, Laakso M; for the STOP-NIDDM Study Group. Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial.
Diabetologia 47: 2176-2184 (2004).
*
-
Anghel SI, Wahli W. Fat poetry: a kingdom for PPARgamma.
Cell Res. 17: 486-511 (2007).
*
-
Annicotte JS, Culine S, Fajas L. Role of PPARgamma in the control of prostate cancer growth: a new approach for therapy.
Bull. Cancer 94: 135-137 (2007).
-
Antoun J, Goulitquer S, Amet Y, Dreano Y, Salaun JP, Corcos L, Plee-Gautier E. CYP4F3B is induced by PGA1 in human liver cells: a regulation of the 20-HETE synthesis.
J. Lipid Res. 49: 2135-2141 (2008).
*
-
Aoki T, Asaki T, Hamamoto T, Sugiyama Y, Ohmachi S, Kuwabara K, Murakami K, Todo M. Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.
Bioorg. Med. Chem. Lett. 18: 2128-2132 (2008).
*
-
Aoki Y, Maeno T, Aoyagi K, Ueno M, Aoki F, Aoki N, Nakagawa J, Sando Y, Shimizu Y, Suga T, Arai M, Kurabayashi M. Pioglitazone, a peroxisome proliferator-activated receptor gamma ligand, suppresses bleomycin-induced acute lung injury and fibrosis.
Respiration 77: 311-319 (2009).
-
Aouabdi S, Gibson GG, Plant N. Transcriptional regulation of the PXR gene: identification and characterization of a functional PPARalpha-binding site within the proximal promoter of the PXR gene.
Drug Metab. Dispos. 34: 138-144 (2006).
*
-
Aoyama T, Peters JM, Iritani N, Nakajima T, Furihata K, Hashimoto T, Gonzalez FJ. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha).
J. Biol. Chem. 273: 5678-5684 (1998).
*
-
Aprahamian T, Bonegio RG, Richez C, Yasuda K, Chiang LK, Sato K, Walsh K, Rifkin IR. The peroxisome proliferator-activated receptor gamma agonist rosiglitazone ameliorates murine lupus by induction of adiponectin.
J. Immunol. 182: 340-346 (2009).
-
Araki E, Igata M, Motoshima H, Tsuruzoe K. Polymorphisms of PPARs and metabolic disorders.
Nippon Rinsho 63: 617-622 (2005).
-
Araki H, Tamada Y, Imoto S, Dunmore B, Sanders D, Humphrey S, Nagasaki M, Doi A, Nakanishi Y, Yasuda K, Tomiyasu Y, Tashiro K, Print C, Charnock-Jones DS, Kuhara S, Miyano S. Analysis of PPARalpha-dependent and PPARalpha-independent transcript regulation following fenofibrate treatment of human endothelial cells.
Angiogenesis Apr 9 [Epub ahead of print] (2009).
-
Araki M, Nozaki Y, Motojima K. Transcriptional regulation of metabolic switching PDK4 gene under various physiological conditions.
Yakugaku Zasshi 127: 153-162 (2007).
-
Araki O, Ying H, Furuya F, Zhu X, Cheng SY. Thyroid hormone receptor beta mutants: dominant negative regulators of peroxisome proliferator-activated receptor gamma action.
Proc. Natl. Acad. Sci. U.S.A. 102: 16251-16256 (2005).
*
-
Araya Y, Kasuga JI, Toyota K, Hirakawa Y, Oyama T, Makishima M, Morikawa K, Hashimoto Y, Miyachi H. Structure-based design and synthesis of fluorescent PPARalpha/delta co-agonist and its application as a probe for fluorescent polarization assay of PPARdelta ligands.
Chem. Pharm. Bull. (Tokyo) 56: 1357-1359 (2008).
-
Are A, Aronsson L, Wang S, Greicius G, Lee YK, Gustafsson JA, Pettersson S, Arulampalam V. Enterococcus faecalis from newborn babies regulate endogenous PPARgamma activity and IL-10 levels in colonic epithelial cells.
Proc. Natl. Acad. Sci. U.S.A. 105: 1943-1948 (2008).
*
-
Aronoff DM, Serezani CH, Carstens JK, Marshall T, Gangireddy SR, Peters-Golden M, Reddy RC. Stimulatory effects of peroxisome proliferator-activated receptor-gamma on Fcgamma receptor-mediated phagocytosis by alveolar macrophages.
PPAR Res. 2007: 52546 (2007).
*
-
Artis DR, Lin JJ, Zhang C, Wang W, Mehra U, Perreault M, Erbe D, Krupka HI, England BP, Arnold J, Plotnikov AN, Marimuthu A, Nguyen H, Will S, Signaevsky M, Kral J, Cantwell J, Settachatgull C, Yan DS, Fong D, Oh A, Shi S, Womack P, Powell B, et al. Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent.
Proc. Natl. Acad. Sci. U.S.A. 106: 262-267 (2009).
*
-
Artmann A, Petersen G, Hellgren LI, Boberg J, Skonberg C, Nellemann C, Hansen SH, Hansen HS. Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine.
Biochim. Biophys. Acta 1781: 200-212 (2008).
*
-
Arulmozhi DK, Dwyer DS, Bodhankar SL. Antipsychotic induced metabolic abnormalities: an interaction study with various PPAR modulators in mice.
Life Sci. 79: 1865-1872 (2006).
*
-
Arundel C, Lewis JH. Drug-induced liver disease in 2006.
Curr. Opin. Gastroenterol. 23: 244-254 (2007).
-
Arzuaga X, Reiterer G, Majkova Z, Kilgore MW, Toborek M, Hennig B. PPARalpha ligands reduce PCB-induced endothelial activation: possible interactions in inflammation and atherosclerosis.
Cardiovasc. Toxicol. 7: 264-272 (2007).
*
-
Arzuaga X, Ren N, Stromberg A, Black EP, Arsenescu V, Cassis LA, Majkova Z, Toborek M, Hennig B. Induction of gene pattern changes associated with dysfunctional lipid metabolism induced by dietary fat and exposure to a persistent organic pollutant.
Toxicol. Lett. May 22 [Epub ahead of print] (2009).
*
-
Asai T, Okumura K, Takahashi R, Matsui H, Numaguchi Y, Murakami H, Murakami R, Murohara T. Combined therapy with PPARalpha agonist and L-carnitine rescues lipotoxic cardiomyopathy due to systemic carnitine deficiency.
Cardiovasc. Res. 70: 566-577 (2006).
*
-
Asakawa A, Toyoshima M, Harada KH, Fujimiya M, Inoue K, Koizumi A. The ubiquitous environmental pollutant perfluorooctanoicacid inhibits feeding behavior via peroxisome proliferator-activated receptor-alpha.
Int. J. Mol. Med. 21: 439-445 (2008).
*
-
Asaki T, Aoki T, Hamamoto T, Sugiyama Y, Ohmachi S, Kuwabara K, Murakami K, Todo M. Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.
Bioorg. Med. Chem. 16: 981-994 (2008).
*
-
Asayama K, Sandhir R, Sheikh FG, Hayashibe H, Nakane T, Singh I. Increased peroxisomal fatty acid beta-oxidation and enhanced expression of peroxisome proliferator-activated receptor-alpha in diabetic rat liver.
Mol. Cell. Biochem. 194: 227-234 (1999).
-
Asnani S, Theuma P, Fonseca VA. PPARgamma agonists and vascular risk factors: potential effects on cardiovascular disease.
Metab. Syndr. Relat. Disord. 1: 23-32 (2003).
-
Atherton HJ, Bailey NJ, Zhang W, Taylor J, Major H, Shockcor J, Clarke K, Griffin JL. A combined 1H NMR spectroscopy and mass spectrometry-based metabolomic study of the PPAR-alpha null mutant mouse defines profound systemic changes in metabolism linked to the metabolic syndrome.
Physiol. Genomics 27: 178-186 (2006).
*
-
Atherton HJ, Gulston MK, Bailey NJ, Cheng KK, Zhang W, Clarke K, Griffin JL. Metabolomics of the interaction between PPAR-alpha and age in the PPAR-alpha-null mouse.
Mol. Syst. Biol. 5: 259 (2009).
*
-
Atherton HJ, Jones OA, Malik S, Miska EA, Griffin JL. A comparative metabolomic study of NHR-49 in Caenorhabditis elegans and PPAR-alpha in the mouse.
FEBS Lett. 582: 1661-1666 (2008).
*
-
Atkins KB, Irey B, Xiang N, Brosius 3rd FC. A rapid, PPARgamma-dependent, effect of pioglitazone on phosphorylation of myosin phosphatase targeting subunit - MYPT.
Am. J. Physiol. Cell. Physiol. 296: C1151-C1161 (2009).
*
-
Atug O, Tahan V, Eren F, Tiftikci A, Imeryuz N, Hamzaoglu HO, Tozun N. Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma (PPARgamma) gene in inflammatory bowel disease.
J. Gastrointestin. Liver Dis. 17: 433-437 (2008).
*
-
August A, Mueller C, Weaver V, Polanco TA, Walsh ER, Cantorna MT. Nutrients, nuclear receptors, inflammation, immunity lipids, PPAR, and allergic asthma.
J. Nutr. 136: 695-699 (2006).
*
-
Aung CS, Faddy HM, Lister EJ, Monteith GR, Roberts-Thomson SJ. Isoform specific changes in PPARalpha and beta in colon and breast cancer with differentiation.
Biochem. Biophys. Res. Commun. 340: 656-660 (2006).
*
-
Auwerx J. Nuclear receptors. I. PPAR gamma in the gastrointestinal tract: gain or pain?
Am. J. Physiol. Gastrointest. Liver Physiol. 282: G581-G585 (2002).
*
-
Auwerx J, Cock TA, Knouff C. PPAR-gamma: a thrifty transcription factor.
Nucl. Recept. Signal. 1: e006 (2003).
*
-
Auwerx J, Schoonjans K, Fruchart JC, Staels B. Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects.
J. Atheroscler. Thromb. 3: 81-89 (1996).
-
Avallone R, Demers A, Rodrigue-Way A, Bujold K, Harb D, Anghel S, Wahli W, Marleau S, Ong H, Tremblay A. A growth hormone-releasing peptide that binds scavenger receptor CD36 and ghrelin receptor upregulates ABC sterol transporters and cholesterol efflux in macrophages through a PPARgamma-dependent pathway.
Mol. Endocrinol. 20: 3165-3178 (2006).
*
-
Awais M, Sato M, Umezawa Y. A fluorescent indicator to visualize ligand-induced receptor/coactivator interactions for screening of peroxisome proliferator-activated receptor gamma ligands in living cells.
Biosens. Bioelectron. 22: 2564-2569 (2007).
*
-
Awara WM, El-Sisi AE, El-Refaei M, El-Naa MM, El-Desoky K. Insulinotropic and anti-inflammatory effects of rosiglitazone in experimental autoimmune diabetes.
Rev. Diabet. Stud. 2: 146-156 (2005).
*
-
Ayoub SS, Botting RM, Joshi AN, Seed MP, Colville-Nash PR. Activation of macrophage peroxisome proliferator-activated receptor-gamma by diclofenac results in the induction of cyclooxygenase-2 protein and the synthesis of anti-inflammatory cytokines.
Mol. Cell. Biochem. 327: 101-110 (2009).
*
-
Azukizawa S, Kasai M, Takahashi K, Miike T, Kunishiro K, Kanda M, Mukai C, Shirahase H. Synthesis and biological evaluation of (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids: a novel series of PPARgamma agonists.
Chem. Pharm. Bull. (Tokyo) 56: 335-345 (2008).
-
Azzi A, Gysin R, Kempna P, Munteanu A, Negis Y, Villacorta L, Visarius T, Zingg JM. Vitamin E mediates cell signaling and regulation of gene expression.
Ann. N. Y. Acad. Sci. 1031: 86-95 (2004).
*
-
Azzi A, Gysin R, Kempna P, Munteanu A, Villacorta L, Visarius T, Zingg JM. Regulation of gene expression by alpha-tocopherol.
Biol. Chem. 385: 585-591 (2004).
-
Baba MI, Kaul D, Grover A. Importance of blood cellular genomic profile in coronary heart disease.
J. Biomed. Sci. 13: 17-26 (2006).
*
-
Badawi AF, Badr MZ. Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma.
Int. J. Oncol. 20: 1109-1122 (2002).
-
Badii R, Bener A, Zirie M, Al-Rikabi A, Simsek M, Al-Hamaq AO, Ghoussaini M, Froguel P, Wareham NJ. Lack of association between the Pro(12)Ala polymorphism of the PPAR-gamma2 gene and type 2 diabetes mellitus in the Qatari consanguineous population.
Acta Diabetol. 45: 15-21 (2008).
*
-
Badr MZ, Shnyra A, Zoubine M, Norkin M, Herndon B, Quinn T, Miranda RN, Cunningham ML, Molteni A. Phthalate-induced liver protection against deleterious effects of the Th1 response: a potentially serious health hazard.
PPAR Res. 2007: 49671 (2007).
*
-
Baffy G. Kupffer cells in non-alcoholic fatty liver disease: the emerging view?
J. Hepatol. 51: 212-223 (2009).
-
Bahadir O, Uzunlulu M, Oguz A, Bahadir MA. Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome.
Hypertens. Res. 30: 49-53 (2007).
-
Bai P, Houten SM, Huber A, Schreiber V, Watanabe M, Kiss B, de Murcia G, Auwerx J, Menissier-de Murcia J. PARP-2 controls adipocyte differentiation and adipose tissue function through the regulation of the activity of the RXR/PPARgamma heterodimer.
J. Biol. Chem. 282: 37738-37746 (2007).
*
-
Bailey CJ. Drugs on the horizon for diabesity.
Curr. Diab. Rep. 5: 353-359 (2005).
-
Bajaj M, Suraamornkul S, Hardies LJ, Glass L, Musi N, Defronzo RA. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
Diabetologia 50: 1723-1731 (2007).
*
-
Bajwa PJ, Lee JW, Straus DS, Lytle C. Activation of PPARgamma by rosiglitazone attenuates intestinal Cl- secretion.
Am. J. Physiol. Gastrointest. Liver Physiol. May 14 [Epub ahead of print] (2009).
*
-
Baker PR, Lin Y, Schopfer FJ, Woodcock SR, Groeger AL, Batthyany C, Sweeney S, Long MH, Iles KE, Baker LM, Branchaud BP, Chen YE, Freeman BA. Fatty acid transduction of nitric oxide signaling: identification of unsaturated fatty acid nitro derivatives and PPAR receptor-dependent signaling activity.
J. Biol. Chem. 280: 42464-42475 (2005).
*
-
Balakumar P, Rose M, Ganti SS, Krishan P, Singh M. PPAR dual agonists: are they opening Pandora's box?
Pharmacol. Res. 56: 91-98 (2007).
*
-
Balakumar P, Rose M, Singh M. PPAR ligands: are they potential agents for cardiovascular disorders?
Pharmacology 80: 1-10 (2007).
-
Balasubramaniyan N, Shahid M, Suchy FJ, Ananthanarayanan M. Multiple mechanisms of ontogenic regulation of nuclear receptors during rat liver development.
Am. J. Physiol. Gastrointest. Liver Physiol. 288: G251-G260 (2005).
*
-
Balcerzyk A, Zak I, Krauze J. Synergistic effect between polymorphisms of PPARA and ABCA1 genes on the premature coronary artery disease.
Acta Cardiol. 62: 233-238 (2007).
-
Baldan A, Relat J, Marrero PF, Haro D. Functional interaction between peroxisome proliferator-activated receptors-alpha and Mef-2C on human carnitine palmitoyltransferase 1beta (CPT1beta) gene activation.
Nucleic Acids Res. 32: 4742-4749 (2004).
*
-
Balint BL, Nagy L. Selective modulators of PPAR activity as new therapeutic tools in metabolic diseases.
Endocr. Metab. Immune Disord. Drug Targets 6: 33-43 (2006).
-
Ban K, Kozar RA. Enteral glutamine: a novel mediator of PPARgamma in the postischemic gut.
J. Leukoc. Biol. 84: 595-599 (2008).
*
-
Banga A, Unal R, Tripathi P, Pokrovskaya I, Owens RJ, Kern PA, Ranganathan G. Adiponectin translation is increased by the PPARgamma agonists pioglitazone and omega-3 fatty acids.
Am. J. Physiol. Endocrinol. Metab. 296: E480-E489 (2009).
*
-
Bao Y, Li R, Jiang J, Cai B, Gao J, Le K, Zhang F, Chen S, Liu P. Activation of peroxisome proliferator-activated receptor gamma inhibits endothelin-1-induced cardiac hypertrophy via the calcineurin/NFAT signaling pathway.
Mol. Cell. Biochem. 317: 189-196 (2008).
*
-
Barak Y, Sadovsky Y, Shalom-Barak T. PPAR signaling in placental development and function.
PPAR Res. 2008: 142082 (2008).
*
-
Baranova A. PPAR ligands as potential modifiers of breast carcinoma outcomes.
PPAR Res. 2008: 230893 (2008).
*
-
Baranowski M, Blachnio-Zabielska A, Zabielski P, Gorski J. Pioglitazone induces lipid accumulation in the rat heart despite concomitant reduction in plasma free fatty acid availability.
Arch. Biochem. Biophys. 477: 86-91 (2008).
*
-
Barbera MJ, Schluter A, Pedraza N, Iglesias R, Villarroya F, Giralt M. Peroxisome proliferator-activated receptor alpha activates transcription of the brown fat uncoupling protein-1 gene. A link between regulation of the thermogenic and lipid oxidation pathways in the brown fat cell.
J. Biol. Chem. 276: 1486-1493 (2001).
*
-
Barbier O, Duran-Sandoval D, Pineda-Torra I, Kosykh V, Fruchart JC, Staels B. Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme.
J. Biol. Chem. 278: 32852-32860 (2003).
*
-
Barbier O, Fontaine C, Fruchart JC, Staels B. Genomic and non-genomic interactions of PPARalpha with xenobiotic-metabolizing enzymes.
Trends Endocrinol. Metab. 15: 324-330 (2004).
*
-
Barbier O, Torra IP, Duguay Y, Blanquart C, Fruchart JC, Glineur C, Staels B. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis.
Arterioscler. Thromb. Vasc. Biol. 22: 717-726 (2002).
*
-
Barbier O, Trottier J, Kaeding J, Caron P, Verreault M. Lipid-activated transcription factors control bile acid glucuronidation.
Mol. Cell. Biochem. 326: 3-8 (2009).
*
-
Barbier O, Villeneuve L, Bocher V, Fontaine C, Torra IP, Duhem C, Kosykh V, Fruchart JC, Guillemette C, Staels B. The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene.
J. Biol. Chem. 278: 13975-13983 (2003).
*
-
Baregamian N, Mourot JM, Ballard AR, Evers BM, Chung DH. PPAR-gamma agonist protects against intestinal injury during necrotizing enterocolitis.
Biochem. Biophys. Res. Commun. 379: 423-427 (2009).
*
-
Barish GD, Atkins AR, Downes M, Olson P, Chong LW, Nelson M, Zou Y, Hwang H, Kang H, Curtiss L, Evans RM, Lee CH. PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis.
Proc. Natl. Acad. Sci. U.S.A. 105: 4271-4276 (2008).
*
-
Barish GD, Narkar VA, Evans RM. PPARdelta: a dagger in the heart of the metabolic syndrome.
J. Clin. Invest. 116: 590-597 (2006).
*
-
Barlic J, Zhang Y, Foley JF, Murphy PM. Oxidized lipid-driven chemokine receptor switch, CCR2 to CX3CR1, mediates adhesion of human macrophages to coronary artery smooth muscle cells through a peroxisome proliferator-activated receptor gamma-dependent pathway.
Circulation 114: 807-819 (2006).
-
Barrera G, Toaldo C, Pizzimenti S, Cerbone A, Pettazzoni P, Dianzani MU, Ferretti C. The role of PPAR ligands in controlling growth-related gene expression and their interaction with lipoperoxidation products.
PPAR Res. 2008: 524671 (2008).
*
-
Barroso I, Luan J, Sandhu MS, Franks PW, Crowley V, Schafer AJ, O'rahilly S, Wareham NJ. Meta-analysis of the Gly482Ser variant in PPARGC1A in type 2 diabetes and related phenotypes.
Diabetologia 49: 501-505 (2006).
*
-
Barter P. Managing diabetic dyslipidaemia-beyond LDL-C:HDL-C and triglycerides.
Atheroscler. Suppl. 7: 17-21 (2006).
-
Bartke A, Bonkowski M, Masternak M. THow diet interacts with longevity genes.
Hormones (Athens) 7: 17-23 (2008).
-
Bassaganya-Riera J, Hontecillas R. CLA and n-3 PUFA differentially modulate clinical activity and colonic PPAR-responsive gene expression in a pig model of experimental IBD.
Clin. Nutr. 25: 454-465 (2006).
-
Bassaganya-Riera J, Hontecillas R, Beitz DC. Colonic anti-inflammatory mechanisms of conjugated linoleic acid.
Clin. Nutr. 21: 451-459 (2002).
-
Bassaganya-Riera J, Misyak S, Guri AJ, Hontecillas R. PPAR gamma is highly expressed in F4/80(hi) adipose tissue macrophages and dampens adipose-tissue inflammation.
Cell. Immunol. May 5 [Epub ahead of print] (2009).
*
-
Bassaganya-Riera J, Reynolds K, Martino-Catt S, Cui Y, Hennighausen L, Gonzalez F, Rohrer J, Benninghoff AU, Hontecillas R. Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease.
Gastroenterology 127: 777-791 (2004).
*
-
Bassols J, Ortega FJ, Moreno-Navarrete JM, Peral B, Ricart W, Fernandez-Real JM. Study of the proinflammatory role of human differentiated omental adipocytes.
J. Cell. Biochem. Jun 2 [Epub ahead of print] (2009).
-
Bastin J, Aubey F, Rotig A, Munnich A, Djouadi F. Activation of peroxisome proliferator activated receptor pathway stimulates the mitochondrial respiratory chain and can correct deficiencies in patients' cells lacking its components.
J. Clin. Endocrinol. Metab. 93: 1433-1441 (2008).
*
-
Basu-Modak S, Braissant O, Escher P, Desvergne B, Honegger P, Wahli W. Peroxisome proliferator-activated receptor beta regulates acyl-CoA synthetase 2 in reaggregated rat brain cell cultures.
J. Biol. Chem. 274: 35881-35888 (1999).
*
-
Batheja P, Song Y, Wertz P, Michniak-Kohn B. Effects of growth conditions on the barrier properties of a human skin equivalent.
Pharm. Res. 26: 1689-1700 (2009).
*
-
Batista-Pinto C, Rocha E, Castro LF, Rodrigues P, Lobo-da-Cunha A. Seasonal and gender variation of peroxisome proliferator activated receptors expression in brown trout liver.
Gen. Comp. Endocrinol. 161: 146-152 (2009).
*
-
Baumgardner JN, Shankar K, Korourian S, Badger TM, Ronis MJ. Undernutrition enhances alcohol-induced hepatocyte proliferation in the liver of rats fed via total enteral nutrition.
Am. J. Physiol. Gastrointest. Liver Physiol. 293: G355-G364 (2007).
*
-
Beaven SW, Tontonoz P. Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia.
Annu. Rev. Med. 57: 313-329 (2006).
*
-
Beck F, Plummer S, Senior PV, Byrne S, Green S, Brammar WJ. The ontogeny of peroxisome-proliferator-activated receptor gene expression in the mouse and rat.
Proc. Biol. Sci. 247: 83-87 (1992).
-
Becker J, Delayre-Orthez C, Frossard N, Pons F. Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases?
Fundam. Clin. Pharmacol. 20: 429-447 (2006).
*
-
Becker J, Delayre-Orthez C, Frossard N, Pons F. Regulation of peroxisome proliferator-activated receptor-alpha expression during lung inflammation.
Pulm. Pharmacol. Ther. 21: 324-330 (2008).
-
Bedu E, Desplanches D, Pequignot J, Bordier B, Desvergne B. Double gene deletion reveals the lack of cooperation between PPARalpha and PPARbeta in skeletal muscle.
Biochem. Biophys. Res. Commun. 357: 877-881 (2007).
*
-
Bedu E, Wahli W, Desvergne B. Peroxisome proliferator-activated receptor beta/delta as a therapeutic target for metabolic diseases.
Expert Opin. Ther. Targets 9: 861-873 (2005).
-
Beekum OV, Fleskens V, Kalkhoven E. Posttranslational modifications of PPAR-gamma: fine-tuning the metabolic master regulator.
Obesity (Silver Spring) 17: 213-219 (2009).
*
-
Behshad R, Cooper KD, Korman NJ. A retrospective case series review of the peroxisome proliferator-activated receptor ligand rosiglitazone in the treatment of atopic dermatitis.
Arch. Dermatol. 144: 84-88 (2008).
*
-
Beier K, Volkl A, Fahimi HD. TNF-alpha downregulates the peroxisome proliferator activated receptor-alpha and the mRNAs encoding peroxisomal proteins in rat liver.
FEBS Lett. 412: 385-387 (1997).
*
-
Beigneux AP, Davies BS, Bensadoun A, Fong LG, Young SG. GPIHBP1 - a GPI-anchored protein required for the lipolytic processing of triglyceride-rich lipoproteins.
J. Lipid Res. 50: S57-S62 (2009).
*
-
Beigneux AP, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. The acute phase response is associated with retinoid X receptor repression in rodent liver.
J. Biol. Chem. 275: 16390-16399 (2000).
*
-
Belanger AJ, Luo Z, Vincent KA, Akita GY, Cheng SH, Gregory RJ, Jiang C. Hypoxia-inducible factor 1 mediates hypoxia-induced cardiomyocyte lipid accumulation by reducing the DNA binding activity of peroxisome proliferator-activated receptor alpha/retinoid X receptor.
Biochem. Biophys. Res. Commun. 364: 567-572 (2007).
*
-
Bellosta S, Bernini F. Modulation of macrophage function and metabolism.
Handb. Exp. Pharmacol. 170: 665-695 (2005).
-
Beltowski J, Wojcicka G, Jamroz A. Peroxisome proliferator-activated receptors (PPAR) in pathophysiology of the circulatory system and prospective use of agonists of these receptors in therapy.
Postepy. Hig. Med. Dosw. 57: 199-217 (2003).
-
Belvisi MG, Hele DJ. Peroxisome proliferator-activated receptors as novel targets in lung disease.
Chest 134: 152-157 (2008).
*
-
Belvisi MG, Hele DJ, Birrell MA. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation.
Eur. J. Pharmacol. 533: 101-109 (2006).
*
-
Bendinelli P, Piccoletti R, Maroni P. Leptin rapidly activates PPARs in C2C12 muscle cells.
Biochem. Biophys. Res. Commun. 332: 719-725 (2005).
*
-
Bendlova B, Vejralkova D, Vcelak J, Lukalova P, Burkonova D, Kunelova M, Vrbikova J, Dvorakova K, Vondra K, Vankova M. PPARgamma2 Pro12Ala polymorphism in relation to free fatty acids concentration and composition in lean healthy Czech individuals with and without family history of diabetes type 2.
Physiol. Res. 57 Suppl. 1: S77-S90 (2008).
*
-
Benigni A, Zoja C, Tomasoni S, Campana M, Corna D, Zanchi C, Gagliardini E, Garofano E, Rottoli D, Ito T, Remuzzi G. Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone.
J. Am. Soc. Nephrol. 17: 1624-1632 (2006).
*
-
Bennett AJ, Sovio U, Ruokonen A, Martikainen H, Pouta A, Hartikainen AL, Franks S, Elliott P, Jarvelin MR, McCarthy MI. No evidence that established type 2 diabetes susceptibility variants in the PPARG and KCNJ11 genes have pleiotropic effects on early growth.
Diabetologia 51: 82-85 (2008).
*
-
Bentinger M, Turunen M, Zhang XX, Wan YJ, Dallner G. Involvement of retinoid X receptor alpha in coenzyme Q metabolism.
J. Mol. Biol. 326: 795-803 (2003).
*
-
Bento-Abreu A, Tabernero A, Medina JM. Peroxisome proliferator-activated receptor-alpha is required for the neurotrophic effect of oleic acid in neurons.
J. Neurochem. 103: 871-881 (2007).
-
Beraza N, Malato Y, Vander Borght S, Liedtke C, Wasmuth HE, Dreano M, de Vos R, Roskams T, Trautwein C. Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis.
Gut 57: 655-663 (2008).
-
Bergamo P, Luongo D, Maurano F, Mazzarella G, Stefanile R, Rossi M. Conjugated linoleic acid enhances glutathione synthesis and attenuates pathological signs in MRL/lpr mice.
J. Lipid Res. 47: 2382-2391 (2006).
*
-
Bergasa NV, Mason A, Floreani A, Heathcote J, Swain MG, Jones DE, Lindor KM, Bassendine MF, Worman HJ. Primary biliary cirrhosis: report of a focus study group.
Hepatology 40: 1013-1020 (2004).
*
-
Berge RK, Tronstad KJ, Berge K, Rost TH, Wergedahl H, Gudbrandsen OA, Skorve J. The metabolic syndrome and the hepatic fatty acid drainage hypothesis.
Biochimie 87: 15-20 (2005).
-
Berger A, Mutch DM, German JB, Roberts MA. Dietary effects of arachidonate-rich fungal oil and fish oil on murine hepatic and hippocampal gene expression.
Lipids Health Dis. 1: 2 (2002).
*
-
Berger A, Roberts MA, Hoff B. How dietary arachidonic- and docosahexaenoic- acid rich oils differentially affect the murine hepatic transcriptome.
Lipids Health Dis. 5: 10 (2006).
*
-
Berger J, Moller DE. The mechanisms of action of PPARs.
Annu. Rev. Med. 53: 409-435 (2002).
*
-
Berger J, Wagner JA. Physiological and therapeutic roles of peroxisome proliferator-activated receptors.
Diabetes Technol. Ther. 4: 163-174 (2002).
-
Berger JP, Akiyama TE, Meinke PT. PPARs: therapeutic targets for metabolic disease.
Trends Pharmacol. Sci. 26: 244-251 (2005).
*
-
Bergeron R, Yao J, Woods JW, Zycband EI, Liu C, Li Z, Adams A, Berger JP, Zhang BB, Moller DE, Doebber TW. Peroxisome proliferator-activated receptor (PPAR)-alpha agonism prevents the onset of type 2 diabetes in ZDF rats: a comparison to PPARgamma agonism.
Endocrinology 147: 4252-4262 (2006).
*
-
Bernardo A, Bianchi D, Magnaghi V, Minghetti L. Peroxisome proliferator-activated receptor-gamma agonists promote differentiation and antioxidant defenses of oligodendrocyte progenitor cells.
J. Neuropathol. Exp. Neurol. Jun 16 [Epub ahead of print] (2009).
-
Bernardo A, Minghetti L. Regulation of glial cell functions by PPAR-gamma natural and synthetic agonists.
PPAR Res. 2008: 864140 (2008).
*
-
Berruyer C, Pouyet L, Millet V, Martin FM, Legoffic A, Canonici A, Garcia S, Bagnis C, Naquet P, Galland F. Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor gamma activity.
J. Exp. Med. 203: 2817-2827 (2006).
*
-
Berry A, Balard P, Coste A, Olagnier D, Lagane C, Authier H, Benoit-Vical F, Lepert JC, Seguela JP, Magnaval JF, Chambon P, Metzger D, Desvergne B, Wahli W, Auwerx J, Pipy B. IL-13 induces expression of CD36 in human monocytes through PPARgamma activation.
Eur. J. Immunol. 37: 1642-1652 (2007).
*
-
Berry DC, Noy N. Is PPARbeta/delta a retinoid receptor?
PPAR Res. 2007: 73256 (2007).
*
-
Berry DC, Noy N. All-trans-retinoic acid represses obesity and insulin resistance by activating both peroxisome proliferation-activated receptor beta/delta and retinoic acid receptor.
Mol. Cell. Biol. 29: 3286-3296 (2009).
*
-
Berthiaume M, Laplante M, Festuccia WT, Berger JP, Thieringer R, Deshaies Y. Additive action of 11beta-HSD1 inhibition and PPAR-gamma agonism on hepatic steatosis and triglyceridemia in diet-induced obese rats.
Int. J. Obes. (Lond.) 33: 601-604 (2009).
*
-
Bertolotti M, Gabbi C, Anzivino C, Mitro N, Godio C, De Fabiani E, Crestani M, Del Puppo M, Ricchi M, Carulli L, Rossi A, Loria P, Carulli N. Decreased hepatic expression of PPAR-gamma coactivator-1 in cholesterol cholelithiasis.
Eur. J. Clin. Invest. 36: 170-175 (2006).
-
Bertram JS, Vine AL. Cancer prevention by retinoids and carotenoids: independent action on a common target.
Biochim. Biophys. Acta 1740: 170-178 (2005).
*
-
Bertz J, Zang C, Liu H, Wachter M, Possinger K, Phillip Koeffler H, Elstner E. Compound 48, a novel dual PPAR alpha/gamma ligand, inhibits the growth of human CML cell lines and enhances the anticancer-effects of imatinib.
Leuk. Res. 33: 686-692 (2009).
-
Besler C, Doerries C, Giannotti G, Luscher TF, Landmesse U. Pharmacological approaches to improve endothelial repair mechanisms.
Expert Rev. Cardiovasc. Ther. 6: 1071-1082 (2008).
-
Beuers U, Kullak-Ublick GA, Pusl T, Rauws ER, Rust C. Medical treatment of primary sclerosing cholangitis: a role for novel bile acids and other (post-)transcriptional modulators?
Clin. Rev. Allergy Immunol. 36: 52-61 (2009).
*
-
Beyer AM, Baumbach GL, Halabi CM, Modrick ML, Lynch CM, Gerhold TD, Ghoneim SM, de Lange WJ, Keen HL, Tsai YS, Maeda N, Sigmund CD, Faraci FM. Interference with PPARgamma signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling.
Hypertension 51: 867-871 (2008).
-
Beyer TP, Chen Y, Porter RK, Lu D, Schmidt RJ, Mantlo NB, Konrad RJ, Cao G. Peroxisome proliferator-activated receptor alpha agonists regulate cholesterol ester transfer protein.
Lipids 43: 611-618 (2008).
-
Beyer TP, Schmidt RJ, Foxworthy P, Zhang Y, Dai J, Bensch WR, Kauffman RF, Gao H, Ryan TP, Jiang XC, Karathanasis SK, Eacho PI, Cao G. Coadministration of a liver X receptor agonist and a peroxisome proliferator activator receptor-alpha agonist in mice: effects of nuclear receptor interplay on high-density lipoprotein and triglyceride metabolism in vivo.
J. Pharmacol. Exp. Ther. 309: 861-868 (2004).
*
-
Beysen C, Murphy EJ, Nagaraja H, Decaris M, Riiff T, Fong A, Hellerstein MK, Boyle PJ. A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes.
J. Lipid Res. 49: 2657-2663 (2008).
*
-
Bhatia V, Viswanathan P. Insulin resistance and PPAR insulin sensitizers.
Curr. Opin. Investig. Drugs 7: 891-897 (2006).
-
Bhatt DL, Chew DP, Grines C, Mukherjee D, Leesar M, Gilchrist IC, Corbelli JC, Blankenship JC, Eres A, Steinhubl S, Tan WA, Resar JR, Almahameed A, Abdel-Latif A, Tang HW, Brennan D, McErlean E, Hazen SL, Topol EJ. Peroxisome proliferator-activated receptor gamma agonists for the prevention of adverse events following percutaneous coronary revascularization - results of the PPAR study.
Am. Heart J. 154: 137-143 (2007).
*
-
Bhavsar SK, Singh S, Giri S, Jain MR, Santani DD. Effect of saponins from Helicteres isora on lipid and glucose metabolism regulating genes expression.
J. Ethnopharmacol. Jun 5 [Epub ahead of print] (2009).
-
Bianchi A, Moulin D, Sebillaud S, Koufany M, Galteau MM, Netter P, Terlain B, Jouzeau JY. Contrasting effects of peroxisome-proliferator-activated receptor (PPAR)gamma agonists on membrane-associated prostaglandin E2 synthase-1 in IL-1beta-stimulated rat chondrocytes.
Arthritis Res. Ther. 7: R1325-R1337 (2005).
*
-
Bickston SJ, Comerford LW, Cominelli F. Future therapies for inflammatory bowel disease.
Curr. Gastroenterol. Rep. 5: 518-523 (2003).
-
Bilban M, Haslinger P, Prast J, Klinglmuller F, Woelfel T, Haider S, Sachs A, Otterbein LE, Desoye G, Hiden U, Wagner O, Knofler M. Identification of novel trophoblast invasion-related genes: heme oxygenase-1 controls motility via PPARgamma.
Endocrinology 150: 1000-1013 (2009).
*
-
Bility MT, Devlin-Durante MK, Blazanin N, Glick AB, Ward JM, Kang BH, Kennett MJ, Gonzalez FJ, Peters JM. Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) inhibits chemically-induced skin tumorigenesis.
Carcinogenesis 29: 2406-2414 (2008).
*
-
Billiet L, Furman C, Larigauderie G, Copin C, Page S, Fruchart JC, Brand K, Rouis M. Enhanced VDUP-1 gene expression by PPARgamma agonist induces apoptosis in human macrophage.
J. Cell. Physiol. 214: 183-191 (2008).
*
-
Billin AN. PPAR-beta/delta agonists for type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home.
Expert Opin. Investig. Drugs 17: 1465-1471 (2008).
-
Billoni N, Buan B, Gautier B, Collin C, Gaillard O, Mahe YF, Bernard BA. Expression of peroxisome proliferator activated receptors (PPARs) in human hair follicles and PPAR alpha involvement in hair growth.
Acta Derm. Venereol. 80: 329-334 (2000).
-
Bionaz M, Baumrucker CR, Shirk E, Vanden Heuvel JP, Block E, Varga GA. Characterization of Madin-Darby bovine kidney cell line for peroxisome proliferator-activated receptors: temporal response and sensitivity to fatty acids.
J. Dairy Sci. 91: 2808-2813 (2008).
-
Biscetti F, Gaetani E, Flex A, Tamar A, Hopkins T, Straface G, Pecorini G, Stigliano E, Smith RC, Angelini F, Castellot JJ Jr, Pola R. Selective activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPAR gamma induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism.
Diabetes 57: 1394-1404 (2008).
*
-
Biserni A, Giannessi F, Sciarroni AF, Milazzo FM, Maggi A, Ciana P. In vivo imaging reveals selective peroxisome proliferator activated receptor modulator activity of the synthetic ligand 3-(1-(4-chlorobenzyl)-3-t-butylthio-5-isopropylindol-2-yl)-2,2-dimethylpropanoic acid (MK-886).
Mol. Pharmacol. 73: 1434-1443 (2008).
*
-
Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system.
Br. J. Pharmacol. 129: 823-834 (2000).
*
-
Bishop-Bailey D, Wray J. Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation.
Prostaglandins Other Lipid Mediat. 71: 1-22 (2003).
-
Blanquart C, Barbier O, Fruchart JC, Staels B, Glineur C. Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation.
J. Steroid Biochem. Mol. Biol. 85: 267-273 (2003).
-
Blanquart C, Barbier O, Fruchart JC, Staels B, Glineur C. Peroxisome proliferator-activated receptor alpha (PPARalpha ) turnover by the ubiquitin-proteasome system controls the ligand-induced expression level of its target genes.
J. Biol. Chem. 277: 37254-37259 (2002).
*
-
Blanquart C, Mansouri R, Paumelle R, Fruchart JC, Staels B, Glineur C. The protein kinase C signalling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor alpha (PPARalpha).
Mol. Endocrinol. 18: 1906-1918 (2004).
*
-
Blanquicett C, Roman J, Hart CM. Thiazolidinediones as anti-cancer agents.
Cancer Ther. 6(A): 25-34 (2008).
-
Blaschke F, Bruemmer D, Law RE. Will the potential of peroxisome proliferator-activated receptor agonists be realized in the clinical setting?
Clin. Cardiol. 27: IV3-IV10 (2004).
-
Blaschke F, Spanheimer R, Khan M, Law RE. Vascular effects of TZDs: new implications.
Vascul. Pharmacol. 45: 3-18 (2006).
-
Blaschke F, Takata Y, Caglayan E, Law RE, Hsueh WA. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes.
Arterioscler. Thromb. Vasc. Biol. 26: 28-40 (2006).
*
-
Blazovics A, Hagymasi K, Pronai L. Cytokines, prostaglandins, nutritive and non-nuitritive factors in inflammatory bowel diseases.
Orv. Hetil. 145: 2523-2529 (2004).
-
Boberg J, Metzdorff S, Wortziger R, Axelstad M, Brokken L, Vinggaard AM, Dalgaard M, Nellemann C. Impact of diisobutyl phthalate and other PPAR agonists on steroidogenesis and plasma insulin and leptin levels in fetal rats.
Toxicology 250: 75-81 (2008).
*
-
Bocca C, Bozzo F, Francica S, Colombatto S, Miglietta A. Involvement of PPARgamma and E-cadherin/beta-catenin pathway in the antiproliferative effect of conjugated linoleic acid in MCF-7 cells.
Int. J. Cancer 121: 248-256 (2007).
*
-
Bocca C, Bozzo F, Martinasso G, Canuto RA, Miglietta A. Involvement of PPARalpha in the growth inhibitory effect of arachidonic acid on breast cancer cells.
Br. J. Nutr. 100: 739-750 (2008).
*
-
Bocher V, Chinetti G, Fruchart JC, Staels B. Role of the peroxisome proliferator-activated receptors (PPARS) in the regulation of lipids and inflammation control.
J. Soc. Biol. 196: 47-52 (2002).
-
Bocher V, Pineda-Torra I, Fruchart JC, Staels B. PPARs: transcription factors controlling lipid and lipoprotein metabolism.
Ann. N. Y. Acad. Sci. 967: 7-18 (2002).
*
-
Boden G, Zhang M. Recent findings concerning thiazolidinediones in the treatment of diabetes.
Expert Opin. Investig. Drugs 15: 243-250 (2006).
-
Bodmer M, Meier C, Kraenzlin ME, Meier CR. Risk of fractures with glitazones: a critical review of the evidence to date.
Drug Saf. 32: 539-547 (2009).
-
Bogazzi F, Russo D, Locci MT, Chifenti B, Ultimieri F, Raggi F, Viacava P, Cecchetti D, Cosci C, Sardella C, Acerbi G, Gasperi M, Martino E. Peroxisome proliferator-activated receptor (PPAR)gamma is highly expressed in normal human pituitary gland.
J. Endocrinol. Invest. 28: 899-904 (2005).
-
Bogdanova K, Uherkova L, Poczatkova H, Rypka M, Vesely J. mRNA levels of peroxisome proliferator-activated receptors and their coactivators are affected by glucose deprivation and oleate in human hepatoma hepG2 cells.
Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 151: 237-245 (2007).
*
-
Bohme M, Nitz I, Doring F, Klapper M. Analysis of the transcriptional regulation of the FABP2 promoter haplotypes by PPARgamma/RXRalpha and Oct-1.
Biochim. Biophys. Acta 1779: 616-621 (2008).
*
-
Boitier E, Gautier JC, Roberts R. Advances in understanding the regulation of apoptosis and mitosis by peroxisome-proliferator activated receptors in pre-clinical models: relevance for human health and disease.
Comp. Hepatol. 2: 3 (2003).
*
-
Bonfield TL, Thomassen MJ, Farver CF, Abraham S, Koloze MT, Zhang X, Mosser DM, Culver DA. Peroxisome proliferator-activated receptor-gamma regulates the expression of alveolar macrophage macrophage colony-stimulating factor.
J. Immunol. 181: 235-242 (2008).
-
Bongartz T, Coras B, Vogt T, Scholmerich J, Muller-Ladner U. Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study.
Rheumatology (Oxford) 44: 126-129 (2005).
*
-
Bonilla S, Redonnet A, Noel-Suberville C, Groubet R, Pallet V, Higueret P. Effect of a pharmacological activation of PPAR on the expression of RAR and TR in rat liver.
J. Physiol. Biochem. 57: 1-8 (2001).
-
Bonilla S, Redonnet A, Noel-Suberville C, Pallet V, Garcin H, Higueret P. High-fat diets affect the expression of nuclear retinoic acid receptor in rat liver.
Br. J. Nutr. 83: 665-671 (2000).
*
-
Bonofiglio D, Gabriele S, Aquila S, Catalano S, Gentile M, Middea E, Giordano F, Ando S. Estrogen receptor alpha binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor gamma signaling in breast cancer cells.
Clin. Cancer Res. 11: 6139-6147 (2005).
*
-
Bonora E. Protection of pancreatic beta-cells: is it feasible?
Nutr. Metab. Cardiovasc. Dis. 18: 74-83 (2007).
-
Bordet R, Ouk T, Petrault O, Gele P, Gautier S, Laprais M, Deplanque D, Duriez P, Staels B, Fruchart JC, Bastide M. PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases.
Biochem. Soc. Trans. 34: 1341-1346 (2006).
*
-
Bordoni A, Di Nunzio M, Danesi F, Biagi PL. Polyunsaturated fatty acids: from diet to binding to PPARs and other nuclear receptors.
Genes & Nutrition 1: 95-106 (2006). *
-
Bordoni A, Di Nunzio M, Danesi F, Biagi PL. Polyunsaturated fatty acids: from diet to binding to PPARs and other nuclear receptors.
Genes Nutr. 1: 95-106 (2006).
-
Borel V, Gallot D, Marceau G, Sapin V, Blanchon L. Placental implications of peroxisome proliferator-activated receptors in gestation and parturition.
PPAR Res. 2008: 758562 (2008).
*
-
Boris M, Kaiser C, Golblatt A, Elice MW, Edelson SM, Adams JB, Feinstein DL. Effect of pioglitazone treatment on behavioral symptoms in autistic children.
J. Neuroinflammation 4: 3 (2007).
*
-
Borland MG, Foreman JE, Girroir EE, Zolfaghari R, Sharma AK, Amin SM, Gonzalez FJ, Ross AC, Peters JM. Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) inhibits cell proliferation in human HaCaT keratinocytes.
Mol. Pharmacol. 74: 1429-1442 (2008).
*
-
Bosse Y, Weisnagel SJ, Bouchard C, Despres JP, Perusse L, Vohl MC. Combined effects of PPARgamma2 P12A and PPARalpha L162V polymorphisms on glucose and insulin homeostasis: the Quebec Family Study.
J. Hum. Genet. 48: 614-621 (2003).
*
-
Bougarne N, Paumelle R, Caron S, Hennuyer N, Mansouri R, Gervois P, Staels B, Haegeman G, De Bosscher K. PPARalpha blocks glucocorticoid receptor alpha-mediated transactivation but cooperates with the activated glucocorticoid receptor alpha for transrepression on NF-kappaB.
Proc. Natl. Acad. Sci. U.S.A. 106: 7397-7402 (2009).
*
-
Bouhlel MA, Brozek J, Derudas B, Zawadzki C, Jude B, Staels B, Chinetti-Gbaguidi G. Unlike PPARgamma, PPARalpha or PPARbeta/delta activation does not promote human monocyte differentiation toward alternative macrophages.
Biochem. Biophys. Res. Commun. Jun 12 [Epub ahead of print] (2009).
-
Boulanger A, McLemore P, Copeland NG, Gilbert DJ, Jenkins NA, Yu SS, Gentleman S, Redmond TM. Identification of beta-carotene 15, 15'-monooxygenase as a peroxisome proliferator-activated receptor target gene.
FASEB J. 17: 1304-1306 (2003).
*
-
Boulias K, Katrakili N, Bamberg K, Underhill P, Greenfield A, Talianidis I. Regulation of hepatic metabolic pathways by the orphan nuclear receptor SHP.
EMBO J. 24: 2624-2633 (2005).
*
-
Bouton D, Escriva H, de Mendonca RL, Glineur C, Bertin B, Noel C, Robinson-Rechavi M, de Groot A, Cornette J, Laudet V, Pierce RJ. A conserved retinoid X receptor (RXR) from the mollusk Biomphalaria glabrata transactivates transcription in the presence of retinoids.
J. Mol. Endocrinol. 34: 567-582 (2005).
*
-
Bouwens M, Afman LA, Müller M. Activation of peroxisome proliferator-activated receptor alpha in human peripheral blood mononuclear cells reveals an individual gene expression profile response.
BMC Genomics 9: 262 (2008).
*
-
Boyer JF, Balard P, Authier H, Faucon B, Bernad J, Mazieres B, Davignon JL, Cantagrel A, Pipy B, Constantin A. TNF alpha and adalimumab differentially regulate CD36 expression in human monocytes.
Arthritis Res. Ther. 9: R22 (2007).
*
-
Boyle PJ. Diabetes mellitus and macrovascular disease: mechanisms and mediators.
Am. J. Med. 120: S12-S17 (2007).
*
-
Bozkurt D, Taskin H, Sezak M, Bicak S, Sen S, Ok E, Duman S. Rosiglitazone, a peroxisome proliferator-activated receptor agonist, improves peritoneal alterations resulting from an encapsulated peritoneal sclerosis model.
Adv. Perit. Dial. 24: 32-38 (2008).
-
Bozzo F, Bocca C, Colombatto S, Miglietta A. Antiproliferative effect of conjugated linoleic acid in caco-2 cells: involvement of PPARgamma and APC/beta-catenin pathways.
Chem. Biol. Interact. 169: 110-121 (2007).
*
-
Bragt MC, Popeijus HE. Peroxisome proliferator-activated receptors and the metabolic syndrome.
Physiol. Behav. 94: 187-197 (2008).
*
-
Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat.
Endocrinology 137: 354-366 (1996).
*
-
Bright JJ, Kanakasabai S, Chearwae W, Chakraborty S. PPAR regulation of inflammatory signaling in CNS diseases.
PPAR Res. 2008: 658520 (2008).
*
-
Bright JJ, Walline CC, Kanakasabai S, Chakraborty S. Targeting PPAR as a therapy to treat multiple sclerosis.
Expert Opin. Ther. Targets 12: 1565-1575 (2008).
-
Brinckerhoff CE, Sporn MB. Retinoids and rexinoids for the 21st century: a brave new world for arthritis.
J. Rheumatol. 30: 211-213 (2003).
-
Brody F, Hill S, Celenski S, Kar R, Kluk B, Pinzone J, Fu S. Expression of ectonucleotide pyrophosphate phosphodiesterase and peroxisome proliferator activated receptor gamma in morbidly obese patients.
Surg. Endosc. 21: 941-944 (2007).
*
-
Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.
Circulation 115: 518-533 (2007).
*
-
Brown KK, Henke BR, Blanchard SG, Cobb JE, Mook R, Kaldor I, Kliewer SA, Lehmann JM, Lenhard JM, Harrington WW, Novak PJ, Faison W, Binz JG, Hashim MA, Oliver WO, Brown HR, Parks DJ, Plunket KD, Tong WQ, Menius JA, Adkison K, Noble SA, Willson TM. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat.
Diabetes 48: 1415-1424 (1999).
*
-
Brown PJ, Smith-Oliver TA, Charifson PS, Tomkinson NC, Fivush AM, Sternbach DD, Wade LE, Orband-Miller L, Parks DJ, Blanchard SG, Kliewer SA, Lehmann JM, Willson TM. Identification of peroxisome proliferator-activated receptor ligands from a biased chemical library.
Chem. Biol. 4: 909-918 (1997).
-
Brown PJ, Winegar DA, Plunket KD, Moore LB, Lewis MC, Wilson JG, Sundseth SS, Koble CS, Wu Z, Chapman JM, Lehmann JM, Kliewer SA, Willson TM. A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity.
J. Med. Chem. 42: 3785-3788 (1999).
-
Browning SR, Briley JD, Briley LP, Chandra G, Charnecki JH, Ehm MG, Johansson KA, Jones BJ, Karter AJ, Yarnall DP, Wagner MJ. Case-control single-marker and haplotypic association analysis of pedigree data.
Genet. Epidemiol. 28: 110-122 (2005).
*
-
Bruck R, Weiss S, Aeed H, Pines M, Halpern Z, Zvibel I. Additive inhibitory effect of experimentally induced hepatic cirrhosis by agonists of peroxisome proliferator activator receptor gamma and retinoic acid receptor.
Dig. Dis. Sci. 54: 292-299 (2009).
*
-
Brune S, Kolsch H, Ptok U, Majores M, Schulz A, Schlosser R, Rao ML, Maier W, Heun R. Polymorphism in the peroxisome proliferator-activated receptor alpha gene influences the risk for Alzheimer's disease.
J. Neural. Transm. 110: 1041-1050 (2003).
*
-
Brunelleschi S, Bardelli C, Amoruso A, Gunella G, Ieri F, Romani A, Malorni W, Franconi F. Minor polar compounds extra-virgin olive oil extract (MPC-OOE) inhibits NF-kappaB translocation in human monocyte/macrophages.
Pharmacol. Res. 56: 542-549 (2007).
*
-
Brunelli L, Cieslik KA, Alcorn JL, Vatta M, Baldini A. Peroxisome proliferator-activated receptor-delta upregulates 14-3-3varepsilon in human endothelial cells via CCAAT/enhancer binding protein-beta.
Circ. Res. 100: e59-e71 (2007).
*
-
Brunmair B, Staniek K, Dorig J, Szocs Z, Stadlbauer K, Marian V, Gras F, Anderwald C, Nohl H, Waldhausl W, Furnsinn C. Activation of PPAR-delta in isolated rat skeletal muscle switches fuel preference from glucose to fatty acids.
Diabetologia 49: 2713-2722 (2006).
*
-
Bu PL, Zhao XQ, Wang LL, Zhao YX, Li CB, Zhang Y. Tong-xin-luo capsule inhibits left ventricular remodeling in spontaneously hypertensive rats by enhancing PPAR-gamma expression and suppressing NF-kappaB activity.
Chin. Med. J. (Engl.) 121: 147-154 (2008).
-
Buckley DB, Klaassen CD. Induction of mouse UDP-glucuronosyltransferase mRNA expression in liver and intestine by activators of AhR, CAR, PXR, PPARalpha, and Nrf2.
Drug Metab. Dispos. 37: 847-856 (2009).
*
-
Buettner R, Parhofer KG, Woenckhaus M, Wrede CE, Kunz-Schughart LA, Scholmerich J, Bollheimer LC. Defining high-fat-diet rat models: metabolic and molecular effects of different fat types.
J. Mol. Endocrinol. 36: 485-501 (2006).
*
-
Bugge A, Grontved L, Aagaard MM, Borup R, Mandrup S. The PPARgamma2 A/B-domain plays a gene specific role in transactivation and co-factor recruitment.
Mol. Endocrinol. 23: 794-808 (2009).
*
-
Bujold K, Rhainds D, Jossart C, Febbraio M, Marleau S, Ong H. CD36-mediated cholesterol efflux is associated with PPARgamma activation via a MAPK-dependent COX-2 pathway in macrophages.
Cardiovasc. Res. Apr 17 [Epub ahead of print] (2009).
*
-
Bulhak AA, Jung C, Ostenson CG, Lundberg JO, Sjoquist PO, Pernow J. PPAR-alpha activation protects the type 2 diabetic myocardium against ischemia-reperfusion injury: involvement of the PI3-kinase/Akt and NO pathway.
Am. J. Physiol. Heart Circ. Physiol. 296: H719-H727 (2009).
*
-
Bulhak AA, Sjoquist PO, Xu CB, Edvinsson L, Pernow J. Protection against myocardial ischaemia/reperfusion injury by PPAR-alpha activation is related to production of nitric oxide and endothelin-1.
Basic Res. Cardiol. 101: 244-252 (2006).
-
Bull AW. The role of peroxisome proliferator-activated receptor gamma in colon cancer and inflammatory bowel disease.
Arch. Pathol. Lab. Med. 127: 1121-1123 (2003).
*
-
Bunger M, Hooiveld GJ, Kersten S, Muller M. Exploration of PPAR functions by microarray technology - a paradigm for nutrigenomics.
Biochim. Biophys. Acta 1771: 1046-1064 (2007).
*
-
Bunger M, van den Bosch HM, van der Meijde J, Kersten S, Hooiveld GJ, Muller M. Genome-wide analysis of PPARalpha activation in murine small intestine.
Physiol. Genomics 30: 192-204 (2007).
*
-
Burch LR, Zhou K, Donnelly LA, Doney AS, Brady J, Goddard C, Morris AD, Hansen MK, Palmer CN. A single nucleotide polymorphism on exon-4 of the gene encoding PPARdelta is associated with reduced height in adults and children.
J. Clin. Endocrinol. Metab. Apr 21 [Epub ahead of print] (2009).
*
-
Burgermeister E, Chuderland D, Hanoch T, Meyer M, Liscovitch M, Seger R. Interaction with MEK causes nuclear export and downregulation of PPARgamma.
Mol. Cell. Biol. 27: 803-817 (2007).
*
-
Burgermeister E, Schnoebelen A, Flament A, Benz J, Stihle M, Gsell B, Rufer A, Ruf A, Kuhn B, Marki HP, Mizrahi J, Sebokova E, Niesor E, Meyer M. A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1 alpha (PGC1alpha), prevents triglyceride accumulation and potentiates insulin signaling in vitro.
Mol. Endocrinol. 20: 809-830 (2006).
*
-
Burns KA, Vanden Heuvel JP. Modulation of PPAR activity via phosphorylation.
Biochim. Biophys. Acta 1771: 952-960 (2007).
*
-
Buroker NE, Barboza J, Huang JY. The IkappaBalpha gene is a peroxisome proliferator-activated receptor cardiac target gene.
FEBS J. 276: 3247-3255 (2009).
*
-
Buroker NE, Young ME, Wei C, Serikawa K, Ge M, Ning XH, Portman MA. The dominant negative thyroid hormone receptor beta mutant Delta337T alters peroxisome proliferator-activated receptor alpha signaling in heart.
Am. J. Physiol. Endocrinol. Metab. 292: E453-E460 (2007).
*
-
Burrage PS, Schmucker AC, Ren Y, Sporn MB, Brinckerhoff CE. Retinoid X receptor and peroxisome proliferator-activated receptor-gamma agonists cooperate to inhibit matrix metalloproteinase gene expression.
Arthritis Res. Ther. 10: R139 (2008).
*
-
Burstein S. PPAR-gamma: a nuclear receptor with affinity for cannabinoids.
Life Sci. 77: 1674-1684 (2005).
*
-
Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, Shockey G, Davidson JA. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.
Clin. Ther. 27: 1181-1195 (2005).
*
-
Bush CR, Havens JM, Necela BM, Su W, Chen L, Yanagisawa M, Anastasiadis PZ, Guerra R, Luxon BA, Thompson EA. Functional genomic analysis reveals crosstalk between peroxisome proliferator-activated receptor gamma (PPAR-gamma) and calcium signaling in human colorectal cancer cells.
J. Biol. Chem. 282: 23387-23401 (2007).
*
-
Butt C, Gladman D, Rahman P. PPAR-gamma gene polymorphisms and psoriatic arthritis.
J. Rheumatol. 33: 1631-1633 (2006).
*
-
Buzzetti R, Petrone A, Ribaudo MC, Alemanno I, Zavarella S, Mein CA, Maiani F, Tiberti C, Baroni MG, Vecci E, Arca M, Leonetti F, Mario UD. The common PPAR-gamma2 Pro12Ala variant is associated with greater insulin sensitivity.
Eur. J. Hum. Genet. 12: 1050-1054 (2004).
*
-
Cabrero A, Alegret M, Sanchez RM, Adzet T, Laguna JC, Vazquez M. Bezafibrate reduces mRNA levels of adipocyte markers and increases fatty acid oxidation in primary culture of adipocytes.
Diabetes 50: 1883-1890 (2001).
*
-
Cabrero A, Cubero M, Llaverias G, Alegret M, Sanchez R, Laguna JC, Vazquez-Carrera M. Leptin down-regulates peroxisome proliferator-activated receptor gamma (PPAR-gamma) mRNA levels in primary human monocyte-derived macrophages.
Mol. Cell. Biochem. 275: 173-179 (2005).
*
-
Cabrero A, Cubero M, Llaverias G, Jove M, Planavila A, Alegret M, Sanchez R, Laguna JC, Carrera MV. Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages.
Metabolism 52: 652-657 (2003).
*
-
Cabrero A, Laguna JC, Vazquez M. Peroxisome proliferator-activated receptors and the control of inflammation.
Curr. Drug Targets Inflamm. Allergy 1: 243-248 (2002).
-
Caglayan E, Stauber B, Collins AR, Lyon CJ, Yin F, Liu J, Rosenkranz S, Erdmann E, Peterson LE, Ross RS, Tangirala RK, Hsueh WA. Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis.
Diabetes 57: 2470-2479 (2008).
*
-
Calabro P, Samudio I, Safe SH, Willerson JT, Yeh ET. Inhibition of tumor-necrosis-factor-alpha-induced endothelial cell activation by a new class of PPAR-gamma agonists.
J. Vasc. Res. 42: 509-516 (2005).
*
-
Caldwell SH, Argo CK, Al-Osaimi AM. Therapy of NAFLD: insulin sensitizing agents.
J. Clin. Gastroenterol. 40 Suppl. 1: S61-S66 (2006).
-
Calkin AC, Allen TJ, Lassila M, Tikellis C, Jandeleit-Dahm KA, Thomas MC. Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse.
Atherosclerosis 195: 17-22 (2007).
-
Calkin AC, Giunti S, Jandeleit-Dahm KA, Allen TJ, Cooper ME, Thomas MC. PPAR-alpha and gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse.
Nephrol. Dial. Transplant. 21: 2399-2405 (2006).
-
Calkin AC, Jandeleit-Dahm KA, Sebekova E, Allen TJ, Mizrahi J, Cooper ME, Tikellis C. PPARs and diabetes-associated atherosclerosis.
Curr. Pharm. Des. 13: 2736-2741 (2007).
-
Calkin AC, Thomas MC. PPAR agonists and cardiovascular disease in diabetes.
PPAR Res. 2008: 245410 (2008).
*
-
Calleja C, Messaddeq N, Chapellier B, Yang H, Krezel W, Li M, Metzger D, Mascrez B, Ohta K, Kagechika H, Endo Y, Mark M, Ghyselinck NB, Chambon P. Genetic and pharmacological evidence that a retinoic acid cannot be the RXR-activating ligand in mouse epidermis keratinocytes.
Genes Dev. 20: 1525-1538 (2006).
*
-
Calviello G, Resci F, Serini S, Piccioni E, Toesca A, Boninsegna A, Monego G, Ranelletti FO, Palozza P. Docosahexaenoic acid induces proteasome-dependent degradation of beta-catenin, down-regulation of survivin and apoptosis in human colorectal cancer cells not expressing COX-2.
Carcinogenesis 28: 1202-1209 (2007).
*
-
Campbell IW. The clinical significance of PPAR gamma agonism.
Curr. Mol. Med. 5: 349-363 (2005).
-
Campolongo P, Roozendaal B, Trezza V, Cuomo V, Astarita G, Fu J, McGaugh JL, Piomelli D. Fat-induced satiety factor oleoylethanolamide enhances memory consolidation.
Proc. Natl. Acad. Sci. U.S.A. 106: 8027-8031 (2009).
*
-
Canaple L, Rambaud J, Dkhissi-Benyahya O, Rayet B, Tan NS, Michalik L, Delaunay F, Wahli W, Laudet V. Reciprocal regulation of BMAL1 and PPARalpha defines a novel positive feedback loop in the rodent liver circadian clock.
Mol. Endocrinol. 20: 1715-1727 (2006).
*
-
Canton RF, Peijnenburg AA, Hoogenboom RL, Piersma AH, van der Ven LT, van den Berg M, Heneweer M. Subacute effects of hexabromocyclododecane (HBCD) on hepatic gene expression profiles in rats.
Toxicol. Appl. Pharmacol. 231: 267-272 (2008).
*
-
Cao LQ, Chen XL, Wang Q, Huang XH, Zhen MC, Zhang LJ, Li W, Bi J. Upregulation of PTEN involved in rosiglitazone-induced apoptosis in human hepatocellular carcinoma cells.
Acta Pharmacol. Sin. 28: 879-887 (2007).
*
-
Capeau J. The story of adiponectin and its receptors AdipoR1 and R2: to follow.
J. Hepatol. 47: 736-738 (2007).
-
Capeau J, Magre J, Lascols O, Caron M, Bereziat V, Vigouroux C, Bastard JP. Diseases of adipose tissue: genetic and acquired lipodystrophies.
Biochem. Soc. Trans. 33: 1073-1077 (2005).
*
-
Capobianco E, Martínez N, Higa R, White V, Jawerbaum A. The effects of maternal dietary treatments with natural PPAR ligands on lipid metabolism in fetuses from control and diabetic rats.
Prostaglandins Leukot. Essent. Fatty Acids 79: 191-199 (2008).
*
-
Capobianco E, White V, Higa R, Martínez N, Jawerbaum A. Effects of natural ligands of PPARgamma on lipid metabolism in placental tissues from healthy and diabetic rats.
Mol. Hum. Reprod. 14: 491-499 (2008).
-
Cardell LO, Hagge M, Uddman R, Adner M. Downregulation of peroxisome proliferator-activated receptors (PPARs) in nasal polyposis.
Respir. Res. 6: 132 (2005).
*
-
Carey AL, Petersen EW, Bruce CR, Southgate RJ, Pilegaard H, Hawley JA, Pedersen BK, Febbraio MA. Discordant gene expression in skeletal muscle and adipose tissue of patients with type 2 diabetes: effect of interleukin-6 infusion.
Diabetologia 49: 1000-1007 (2006).
*
-
Carfi' M, Croera C, Ferrario D, Campi V, Bowe G, Pieters R, Gribaldo L. TBTC induces adipocyte differentiation in human bone marrow long term culture.
Toxicology 249: 11-18 (2008).
*
-
Cariello NF, Romach EH, Colton HM, Ni H, Yoon L, Falls JG, Casey W, Creech D, Anderson SP, Benavides GR, Hoivik DJ, Brown R, Miller RT. Gene expression profiling of the PPAR-alpha agonist ciprofibrate in the cynomolgus monkey liver.
Toxicol. Sci. 88: 250-264 (2005).
*
-
Carlberg C, Dunlop TW. An integrated biological approach to nuclear receptor signaling in physiological control and disease.
Crit. Rev. Eukaryot. Gene Expr. 16: 1-22 (2006).
-
Carmel JF, Tarnus E, Cohn JS, Bourdon E, Davignon J, Bernier L. High expression of apolipoprotein E impairs lipid storage and promotes cell proliferation in human adipocytes.
J. Cell. Biochem. 106: 608-617 (2009).
*
-
Carmena R. Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance.
Am. Heart J. 150: 859-870 (2005).
*
-
Carmena R, Betteridge DJ. Statins and diabetes.
Semin. Vasc. Med. 4: 321-332 (2004).
-
Carmona MC, Louche K, Lefebvre B, Pilon A, Hennuyer N, Audinot-Bouchez V, Fievet C, Torpier G, Formstecher P, Renard P, Lefebvre P, Dacquet C, Staels B, Casteilla L, Penicaud L. S 26948, a new specific PPARgamma modulator (SPPARM) with potent antidiabetic and antiatherogenic effects.
Diabetes 56: 2797-2808 (2007).
*
-
Carter AB, Misyak SA, Hontecillas R, Bassaganya-Riera J. Dietary modulation of inflammation-induced colorectal cancer through PPARgamma.
PPAR Res. 2009: 498352 (2009).
*
-
Carvajal K, Hernandez-Esquivel Mde L, Moreno-Sanchez R. PPARs, metabolic syndrome and cardiac diseases.
Arch. Cardiol. Mex. 77 Suppl. 4: S4-S66-S76 (2007).
-
Casals-Casas C, Feige JN, Desvergne B. Interference of pollutants with PPARs: endocrine disruption meets metabolism.
Int. J. Obes. (Lond.) 32 Suppl. 6: S53-S61 (2008).
*
-
Casey WM, Brodie T, Yoon L, Ni H, Jordan HL, Cariello NF. Correlation analysis of gene expression and clinical chemistry to identify biomarkers of skeletal myopathy in mice treated with PPAR agonist GW610742X.
Biomarkers 13: 364-376 (2008).
-
Cassuto H, Kochan K, Chakravarty K, Cohen H, Blum B, Olswang Y, Hakimi P, Xu C, Massillon D, Hanson RW, Reshef L. Glucocorticoids regulate transcription of the gene for phosphoenolpyruvate carboxykinase (GTP) in the liver via an extended glucocorticoid regulatory unit.
J. Biol. Chem. 280: 33873-33884 (2005).
*
-
Casteilla L, Cousin B, Carmona M. PPARs and adipose cell plasticity.
PPAR Res. 2007: 68202 (2007).
*
-
Castelein H, Declercq PE, Baes M. DNA binding preferences of PPAR alpha/RXR alpha heterodimers.
Biochem. Biophys. Res. Commun. 233: 91-95 (1997).
*
-
Castrillo A, Tontonoz P. PPARs in atherosclerosis: the clot thickens.
J. Clin. Invest. 114: 1538-1540 (2004).
*
-
Castriota G, Thompson GM, Lin Y, Scherer PE, Moller DE, Berger JP. Peroxisome proliferator-activated receptor gamma agonists inhibit adipocyte expression of alpha1-acid glycoprotein.
Cell Biol. Int. 31: 586-591 (2007).
*
-
Catalano M, Cortelazzo A, Santi R, Contino L, Demicheli M, Yilmaz Y, Zorzetto M, Campo I, Lanati N, Emanuele E. The Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma2 gene is associated with plasma levels of soluble RAGE (Receptor for Advanced Glycation Endproducts) and the presence of peripheral arterial disease.
Clin. Biochem. 41: 981-985 (2008).
*
-
Cazzola M, Matera MG, Rogliani P, Page C. Treating systemic effects of COPD.
Trends Pharmacol. 28: 544-550 (2007).
*
-
Cecil JE, Watt P, Palmer CN, Hetherington M. Energy balance and food intake: the role of PPARgamma gene polymorphisms.
Physiol. Behav. 88: 227-233 (2006).
*
-
Celinski K, Madro A, Prozorow-Krol B, Korolczuk A, Cichoz-Lach H, Slomka M, Korobowicz E. Rosiglitazone, a peroxisome proliferator-activated receptor gamma (PPAR-gamma)-specific agonist, as a modulator in experimental acute pancreatitis.
Med. Sci. Monit. 15: BR21-BR29 (2009).
-
Ceni E, Crabb DW, Foschi M, Mello T, Tarocchi M, Patussi V, Moraldi L, Moretti R, Milani S, Surrenti C, Galli A. Acetaldehyde inhibits PPARgamma via H(2)O(2)-mediated c-Abl activation in human hepatic stellate cells.
Gastroenterology 131: 1235-1252 (2006).
*
-
Ceperuelo-Mallafre V, Miranda M, Chacon MR, Vilarrasa N, Megia A, Gutierrez C, Fernandez-Real JM, Gomez JM, Caubet E, Fruhbeck G, Vendrell J. Adipose tissue expression of the glycerol channel aquaporin-7 gene is altered in severe obesity but not in type 2 diabetes.
J. Clin. Endocrinol. Metab. 92: 3640-3645 (2007).
*
-
Cesario RM, Stone J, Yen WC, Bissonnette RP, Lamph WW. Differentiation and growth inhibition mediated via the RXR:PPARgamma heterodimer in colon cancer.
Cancer Lett. 240: 225-233 (2006).
*
-
Cha DR, Zhang X, Zhang Y, Wu J, Su DM, Han JY, Fang X, Yu B, Breyer MD, Guan Y. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice.
Diabetes 56: 2036-2045 (2007).
*
-
Chakravarthy MV, Pan Z, Zhu Y, Tordjman K, Schneider JG, Coleman T, Turk J, Semenkovich CF. "New" hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis.
Cell. Metab. 1: 309-322 (2005).
*
-
Chalasani N, Teal E, Hall SD. Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes.
Am. J. Gastroenterol. 100: 1317-1321 (2005).
*
-
Chambers KT, Weber SM, Corbett JA. PGJ2 stimulated beta-cell apoptosis is associated with prolonged UPR activation.
Am. J. Physiol. Endocrinol. Metab. 292: E1052-E1061 (2007).
*
-
Chambrier C, Bastard JP, Rieusset J, Chevillotte E, Bonnefont-Rousselot D, Therond P, Hainque B, Riou JP, Laville M, Vidal H. Eicosapentaenoic acid induces mRNA expression of peroxisome proliferator-activated receptor gamma.
Obes. Res. 10: 518-525 (2002).
*
-
Chan BY, Gartland A, Wilson PJ, Buckley KA, Dillon JP, Fraser WD, Gallagher JA. PPAR agonists modulate human osteoclast formation and activity in vitro.
Bone 40: 149-159 (2007).
*
-
Chan E, Tan CS, Deurenberg-Yap M, Chia KS, Chew SK, Tai ES. The V227A polymorphism at the PPARA locus is associated with serum lipid concentrations and modulates the association between dietary polyunsaturated fatty acid intake and serum high density lipoprotein concentrations in Chinese women.
Atherosclerosis 187: 309-315 (2006).
-
Chan LS, Wells RA. Manipulation of reciprocal salt bridges at the heterodimerization interface alters the dimerization properties of mouse RXRalpha and PPARgamma1.
Biochem. Biophys. Res. Commun. 358: 1080-1085 (2007).
*
-
Chan SS, Schedlich LJ, Twigg SM, Baxter RC. Inhibition of adipocyte differentiation by insulin-like growth factor binding protein-3.
Am. J. Physiol. Endocrinol. Metab. 296: E654-E663 (2009).
*
-
Chanda D, Lee CH, Kim YH, Noh JR, Kim DK, Park JH, Hwang JH, Lee MR, Jeong KH, Lee IK, Kweon GR, Shong M, Oh GT, Chiang JY, Choi HS. Fenofibrate differentially regulates PAI-1 gene expression via AMPK-dependent induction of orphan nuclear receptor SHP.
Hepatology [In Press] (2009).
-
Chandalia A, Clarke HJ, Clemens LE, Pandey B, Vicena V, Lee P, Lavan BE, Gregoire FM. MBX-102/JNJ39659100, a novel non-TZD selective partial PPAR-gamma agonist lowers triglyceride independently of PPAR-alpha activation.
PPAR Res. 2009: 706852 (2009).
*
-
Chandra V, Huang P, Hamuro Y, Raghuram S, Wang Y, Burris TP, Rastinejad F. Structure of the intact PPAR-gamma-RXR-alpha nuclear receptor complex on DNA.
Nature 456: 350-356 (2008).
*
-
Chang AJ, Song DH, Wolfe MM. Attenuation of peroxisome proliferator activated receptor gamma (PPARgamma) mediates gastrin-stimulated colorectal cancer cell proliferation.
J. Biol. Chem. 281: 14700-14710 (2006).
*
-
Chang F, Jaber LA, Berlie HD, O'Connell MB. Evolution of peroxisome proliferator-activated receptor agonists.
Ann. Pharmacother. 41: 973-983 (2007).
-
Chang HJ, Lee JH, Hwang KJ, Kim MR, Chang KH, Park DW, Min CK. Transforming growth factor (TGF)-beta1-induced human endometrial stromal cell decidualization through extracellular signal-regulated kinase and Smad activation in vitro: peroxisome proliferator-activated receptor gamma acts as a negative regulator
Fertil. Steril. 90: S1357-S1365 (2008).
-
Chang SC, Rashid A, Gao YT, Andreotti G, Shen MC, Wang BS, Han TQ, Zhang BH, Sakoda LC, Leitzmann MF, Chen BE, Rosenberg P, Chen J, Chanock S, Hsing AW. Polymorphism of genes related to insulin sensitivity and the risk of biliary tract cancer and biliary stone: a population-based case-control study in Shanghai, China.
Carcinogenesis 29: 944-948 (2008).
*
-
Chang XH, Zhang L, Yang R, Feng J, Cheng YX, Cheng HY, Ye X, Fu TY, Cui H. Screening for genes associated with ovarian cancer prognosis.
Chin. Med. J. (Engl.) 122: 1167-1172 (2009).
-
Chao C, Youssef J, Rezaiekhaleigh M, Birnbaum LS, Badr M. Senescence-associated decline in hepatic peroxisomal enzyme activities corresponds with diminished levels of retinoid X receptor alpha, but not peroxisome proliferator-activated receptor alpha.
Mech. Ageing Dev. 123: 1469-1476 (2002).
-
Chao PM, Yang MF, Tseng YN, Chang KM, Lu KS, Huang CJ. Peroxisome proliferation in liver of rats fed oxidized frying oil.
J. Nutr. Sci. Vitaminol. (Tokyo) 51: 361-368 (2005).
-
Charbonnel B. PPAR-alpha and PPAR-gamma agonists for type 2 diabetes.
Lancet Jun 8 [Epub ahead of print] (2009).
-
Chaturvedi D, Ray S, Srivastava AK, Chander R. Omega-(2-naphthyloxy) amino alkanes as a novel class of anti-hyperglycemic and lipid lowering agents.
Bioorg. Med. Chem. 16: 2489-2498 (2008).
*
-
Chaturvedi RK, Adhihetty P, Shukla S, Hennessy T, Calingasan N, Yang L, Starkov A, Kiaei M, Cannella M, Sassone J, Ciammola A, Squitieri F, Beal MF. Impaired PGC-1alpha function in muscle in Huntington's disease.
Hum. Mol. Genet. May 21 [Epub ahead of print] (2009).
-
Chaturvedi RK, Flint Beal M. PPAR: a therapeutic target in Parkinson's disease.
J. Neurochem. 106: 506-518 (2008).
*
-
Chaudhary N, Pfluger PT. Metabolic benefits from Sirt1 and Sirt1 activators.
Curr. Opin. Clin. Nutr. Metab. Care May 26 [Epub ahead of print] (2009).
-
Chavarro JE, Rich-Edwards JW, Rosner BA, Willett WC. Dietary fatty acid intakes and the risk of ovulatory infertility.
Am. J. Clin. Nutr. 85: 231-237 (2007).
*
-
Chearwae W, Bright JJ. PPARgamma agonists inhibit growth and expansion of CD133+ brain tumour stem cells.
Br. J. Cancer 99: 2044-2053 (2008).
*
-
Chegary M, Te Brinke H, Doolaard M, Ijlst L, Wijburg FA, Wanders RJ, Houten SM. Characterization of L-aminocarnitine, an inhibitor of fatty acid oxidation.
Mol. Genet. Metab. 93: 403-410 (2008).
*
-
Chello M, Spadaccio C, Lusini M, Covino E, Blarzino C, De Marco F, Di Domenico F, Coccia R. Advanced glycation end products in diabetic patients with optimized glycaemic control and their effects on endothelial reactivity: possible implications in venous graft failure.
Diabetes Metab. Res. Rev. Apr 29 [Epub ahead of print] (2009).
-
Chemin J, Patel A, Duprat F, Zanzouri M, Lazdunski M, Honore E. Lysophosphatidic acid-operated K+ channels.
J. Biol. Chem. 280: 4415-4421 (2005).
*
-
Chen AB, Hamamura K, Wang G, Xing W, Mohan S, Yokota H, Liu Y. Model-based comparative prediction of transcription-factor binding motifs in anabolic responses in bone.
Genomics Proteomics Bioinformatics 5: 158-165 (2007).
-
Chen C, Xu S, Wang WX, Ding YM, Yu KH, Wang B, Chen XY. Rosiglitazone attenuates the severity of sodium taurocholate-induced acute pancreatitis and pancreatitis-associated lung injury.
Arch. Med. Res. 40: 79-88 (2009).
-
Chen CH, Wang PH, Liu BH, Hsu HH, Mersmann HJ, Ding ST. Serum amyloid A protein regulates the expression of porcine genes related to lipid metabolism.
J. Nutr. 138: 674-679 (2008).
*
-
Chen D, Jin G, Wang Y, Wang H, Liu H, Liu Y, Fan W, Ma H, Miao R, Hu Z, Sun W, Qian J, Jin L, Wei Q, Shen H, Huang W, Lu D. Genetic variants in peroxisome proliferator-activated receptor-gamma gene are associated with risk of lung cancer in a Chinese population.
Carcinogenesis 29: 342-350 (2008).
*
-
Chen GG, Xu H, Lee JF, Subramaniam M, Leung KL, Wang SH, Chan UP, Spelsberg TC. 15-Hydroxy-eicosatetraenoic acid arrests growth of colorectal cancer cells via a peroxisome proliferator-activated receptor gamma-dependent pathway.
Int. J. Cancer 107: 837-843 (2003).
*
-
Chen H, He YW, Liu WQ, Zhang JH. Rosiglitazone prevents murine hepatic fibrosis induced by Schistosoma japonicum.
World J. Gastroenterol. 14: 2905-2911 (2008).
*
-
Chen HH, Lee WJ, Fann CS, Bouchard C, Pan WH. Severe obesity is associated with novel single nucleotide polymorphisms of the ESR1 and PPARgamma locus in Han Chinese.
Am. J. Clin. Nutr. Jun 2 [Epub ahead of print] (2009).
-
Chen HJ, Chen JZ, Wang XX, Yu M. PPAR alpha activator fenofibrate regressed left ventricular hypertrophy and increased myocardium PPAR alpha expression in spontaneously hypertensive rats.
Zhejiang Da Xue Xue Bao Yi Xue Ban 36: 470-476 (2007).
-
Chen J, Mehta JL. Angiotensin II-mediated oxidative stress and pro-collagen-1 expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone.
Am. J. Physiol. Heart Circ. Physiol. 291: H1738-H1745 (2006).
*
-
Chen J, Raymond K. Treatment effect of rifampicin on cholestasis.
The Internet Journal of Pharmacology Vol. 4 (http://www.ispub.com/ostia/index.php?xmlFilePath=journals/ijpharm/vol4n2/colestasis.xml) (2006). *
-
Chen L, Necela BM, Su W, Yanagisawa M, Anastasiadis PZ, Fields AP, Thompson EA. Peroxisome proliferator-activated receptor-gamma promotes epithelial to mesenchymal transformation by Rho GTPase activation of ERK1/2.
J. Biol. Chem. 281: 24575-24587 (2006).
*
-
Chen P, Li C, Pang W, Zhao Y, Dong W, Wang S, Zhang J. The protective role of Per2 against carbon tetrachloride-induced hepatotoxicity.
Am. J. Pathol. 174: 63-70 (2009).
*
-
Chen R, Liang F, Moriya J, Yamakawa JI, Takahashi T, Shen L, Kanda T. Peroxisome proliferator-activated receptors (PPARs) and their agonists for hypertension and heart failure: are the reagents beneficial or harmful?
Int. J. Cardiol. 130: 131-139 (2008).
-
Chen S, Li Y, Li S, Yu C. A Val227Ala substitution in the peroxisome proliferator activated receptor alpha (PPAR alpha) gene associated with non-alcoholic fatty liver disease and decreased waist circumference and waist-to-hip ratio.
J. Gastroenterol. Hepatol. 23: 1415-1418 (2008).
*
-
Chen TJ, Ji CY, Zheng XY, Hu YH. Association of beta3 adrenergic receptor and peroxisome proliferator-activated receptor gamma 2 polymorphisms with insulin sensitivity: a twin study.
Biomed. Environ. Sci. 20: 99-105 (2007).
-
Chen X, Matthews J, Zhou L, Pelton P, Liang Y, Xu J, Yang M, Cryan E, Rybczynski P, Demarest K. Improvement of dyslipidemia, insulin sensitivity, and energy balance by a peroxisome proliferator-activated receptor alpha agonist.
Metabolism 57: 1516-1525 (2008).
*
-
Chen XR, Besson VC, Beziaud T, Plotkine M, Marchand-Leroux C. Combination therapy with fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, and simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, on experimental traumatic brain injury.
J. Pharmacol. Exp. Ther. 326: 966-974 (2008).
-
Chene G, Dubourdeau M, Balard P, Escoubet-Lozach L, Orfila C, Berry A, Bernad J, Aries MF, Charveron M, Pipy B. n-3 and n-6 Polyunsaturated fatty acids induce the expression of COX-2 via PPARgamma activation in human keratinocyte HaCaT cells.
Biochim. Biophys. Acta 1771: 576-589 (2007).
*
-
Cheng AY, Leiter LA. PPAR-alpha: therapeutic role in diabetes-related cardiovascular disease.
Diabetes Obes. Metab. 10: 691-698 (2008).
-
Cheng G, Zhang X, Gao D, Jiang X, Dong W. Resveratrol inhibits MMP-9 expression by up-regulating PPAR alpha expression in an oxygen glucose deprivation-exposed neuron model.
Neurosci. Lett. 451: 105-108 (2009).
-
Cheng PT, Mukherjee R. PPARs as targets for metabolic and cardiovascular diseases.
Mini. Rev. Med. Chem. 5: 741-753 (2005).
-
Cheng S, Afif H, Martel-Pelletier J, Benderdour M, Pelletier JP, Hilal G, Haraoui P, Raynauld JP, Choquette D, Fahmi H. Association of polymorphisms in the peroxisome proliferator-activated receptor gamma gene and osteoarthritis of the knee.
Ann. Rheum. Dis. 65: 1394-1397 (2006).
*
-
Cheng W, Cheng NS, Xiong XZ, Xia QJ, Chen OY, Yan NH, Jing J. Expression of PPAR-gamma in human hilar bile duct carcinoma cell line QBC939 and the effects of PPAR-Y activated by its ligand on the growth of QBC939.
Sichuan Da Xue Xue Bao Yi Xue Ban 37: 745-749 (2006).
-
Cheng X, Klaassen CD. Perfluorocarboxylic acids induce cytochrome p450 enzymes in mouse liver through activation of PPARalpha and CAR transcription factors.
Toxicol. Sci. 106: 29-36 (2008).
*
-
Cheng X, Klaassen CD. Critical role of PPARalpha in perfluorooctanoic acid- and perfluorodecanoic acid-induced down-regulation of Oatp uptake transporters in mouse livers.
Toxicol. Sci. 106: 37-45 (2008).
*
-
Cheng X, Maher JM, Dieter MZ, Klaassen CD. Regulation of mouse organic anion transporting polypeptides (Oatps) in liver by prototypical microsome enzyme inducers that activate distinct transcription factor pathways.
Drug Metab. Dispos. 33: 1276-1282 (2005).
*
-
Cheng Y, Ping J, Xu LM. Effects of curcumin on peroxisome proliferator-activated receptor gamma expression and nuclear translocation/redistribution in culture-activated rat hepatic stellate cells.
Chin. Med. J. (Engl.) 120: 794-801 (2007).
-
Cheon CW, Kim DH, Kim DH, Cho YH, Kim JH. Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells.
World J. Gastroenterol. 15: 310-320 (2009).
*
-
Cheon Y, Nara TY, Band MR, Beever JE, Wallig MA, Nakamura MT. Induction of overlapping genes by fasting and a peroxisome proliferator in pigs: evidence of functional PPAR alpha in non-proliferating species.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 288: R1525-R1535 (2005).
*
-
Cherkaoui-Malki M, Meyer K, Cao WQ, Latruffe N, Yeldandi AV, Rao MS, Bradfield CA, Reddy JK. Identification of novel peroxisome proliferator-activated receptor alpha (PPARalpha) target genes in mouse liver using cDNA microarray analysis.
Gene Expr. 9: 291-304 (2001).
-
Cherry J, Jones HM, Karschner VA, Pekala PH. Post transcriptional control of C/EBPbeta expression: formation of a nuclear HuR-C/EBPbeta mRNA complex determines the amount of message reaching the cytosol.
J. Biol. Chem. 283: 30812-30820 (2008).
*
-
Chess DJ, Lei B, Hoit BD, Azimzadeh AM, Stanley WC. Effects of a high saturated fat diet on cardiac hypertrophy and dysfunction in response to pressure overload.
J. Card. Fail. 14: 82-88 (2008).
-
Chetty VT, Sharma AM. Can PPARgamma agonists have a role in the management of obesity-related hypertension?
Vascul. Pharmacol. 45: 46-53 (2006).
*
-
Cheung C, Akiyama TE, Ward JM, Nicol CJ, Feigenbaum L, Vinson C, Gonzalez FJ. Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor alpha.
Cancer Res. 64: 3849-3854 (2004).
*
-
Chiang JY. Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms.
J. Hepatol. 40: 539-551 (2004).
*
-
Chiang JYL, Li T, Jahan A. Mechanisms of bile acid inhibition of genes in bile acid synthesis.
Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 23. June 18-19 (2004). *
-
Chiba T, Ueki S, Ito W, Kato H, Takeda M, Kayaba H, Furue M, Chihara J. 15-Deoxy-Delta(12,14)-prostaglandin J2 induces IL-8 and GM-CSF in a human airway epithelial cell line (NCI-H292).
Int. Arch. Allergy Immunol. 149 Suppl. 1: 77-82 (2009).
-
Chiche F, Le Guillou M, Chetrite G, Lasnier F, Dugail I, Carpene C, Moldes M, Feve B. The antidepressant phenelzine alters differentiation of cultured human and mouse preadipocytes.
Mol. Pharmacol. 75: 1052-1061 (2009).
*
-
Chikahisa S, Tominaga K, Kawai T, Kitaoka K, Oishi K, Ishida N, Rokutan K, Sei H. Bezafibrate, a PPARs agonist, decreases body temperature and enhances electroencephalogram delta-oscillation during sleep in mice.
Endocrinology 149: 5262-5271 (2008).
*
-
Childs S, Carter F, Lynch CO, Sreenan JM, Lonergan P, Hennessy AA, Kenny DA. Embryo yield and quality following dietary supplementation of beef heifers with n-3 polyunsaturated fatty acids (PUFA).
Theriogenology 70: 992-1003 (2008).
-
Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall.
Z. Kardiol. 90 Suppl. 3: 125-132 (2001).
-
Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation.
Inflamm. Res. 49: 497-505 (2000).
*
-
Chinetti G, Fruchart JC, Staels B. Transcriptional regulation of macrophage cholesterol trafficking by PPARalpha and LXR.
Biochem. Soc. Trans. 34: 1128-1131 (2006).
*
-
Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and inflammation: from basic science to clinical applications.
Int. J. Obes. Relat. Metab. Disord. 27 Suppl. 3: S41-S45 (2003).
-
Chinetti G, Zawadski C, Fruchart JC, Staels B. Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR.
Biochem. Biophys. Res. Commun. 314: 151-158 (2004).
*
-
Chinetti-Gbaguidi G, Fruchart JC, Staels B. Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy.
Curr. Opin. Pharmacol. 5: 177-183 (2005).
-
Chinetti-Gbaguidi G, Fruchart JC, Staels B. Therapeutical effects of PPAR agonists assessed by biomarker modulation.
Biomarkers 10 Suppl. 1: 30-36 (2005).
-
Chinetti-Gbaguidi G, Rigamonti E, Helin L, Mutka AL, Lepore M, Fruchart JC, Clavey V, Ikonen E, Lestavel S, Staels B. Peroxisome proliferator-activated receptor-alpha controls cellular cholesterol trafficking in macrophages.
J. Lipid Res. 46: 2717-2725 (2005).
*
-
Chinetti-Gbaguidi G, Staels B. Measuring biomarkers to assess the therapeutic effects of PPAR agonists?
Pharmacogenomics 8: 1567-1580 (2007).
-
Chintalgattu V, Harris GS, Akula SM, Katwa LC. PPAR-gamma agonists induce the expression of VEGF and its receptors in cultured cardiac myofibroblasts.
Cardiovasc. Res. 74: 140-150 (2007).
*
-
Chintharlapalli S, Papineni S, Jutooru I, McAlees A, Safe S. Structure-dependent activity of glycyrrhetinic acid derivatives as peroxisome proliferator-activated receptor gamma agonists in colon cancer cells.
Mol. Cancer Ther. 6: 1588-1598 (2007).
-
Chintharlapalli S, Papineni S, Safe S. 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes inhibit colon cancer cell and tumor growth through PPARgamma-dependent and PPARgamma-independent pathways.
Mol. Cancer Ther. 5: 1362-1370 (2006).
-
Chira EC, McMillen TS, Wang S, Haw A 3rd, O'Brien KD, Wight TN, Chait A. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice.
Atherosclerosis 195: 100-109 (2007).
-
Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis.
Semin. Liver Dis. 21: 27-41 (2001).
-
Cho MC, Lee HS, Kim JH, Choe YK, Hong JT, Paik SG, Yoon do Y. A simple ELISA for screening ligands of peroxisome proliferator-activated receptor-gamma.
J. Biochem. Mol. Biol. 36: 207-213 (2003).
*
-
Cho MC, Lee K, Paik SG, Yoon DY. Peroxisome proliferators-activated receptor (PPAR) modulators and metabolic disorders.
PPAR Res. 2008: 679137 (2008).
*
-
Cho MC, Lee S, Choi HS, Yang Y, Tae Hong J, Kim SJ, Yoon DY. Optimization of an enzyme-linked immunosorbent assay to screen ligand of peroxisome proliferator-activated receptor alpha.
Immunopharmacol. Immunotoxicol. Mar 4 [Epub ahead of print] (2009).
-
Cho MC, Yoon HE, Kang JW, Park SW, Yang Y, Hong JT, Song EY, Paik SG, Kim SH, Yoon DY. A simple method to screen ligands of peroxisome proliferator-activated receptor delta.
Eur. J. Pharm. Sci. 29: 355-360 (2006).
*
-
Cho N, Momose Y. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress.
Curr. Top. Med. Chem. 8: 1483-1507 (2008).
-
Choi IK, Kim YH, Kim JS, Seo JH. PPAR-gamma ligand promotes the growth of APC-mutated HT-29 human colon cancer cells in vitro and in vivo.
Invest. New Drugs 26: 283-288 (2008).
-
Choi KC, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH, Choi KM. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.
Biochem. Biophys. Res. Commun. 336: 747-753 (2005).
*
-
Choi SJ, Chung SS, Rho EJ, Lee HW, Lee MH, Choi HS, Seol JH, Baek SH, Bang OS, Chung CH. Negative modulation of RXRalpha transcriptional activity by small ubiquitin-related modifier (SUMO) modification and its reversal by SUMO-specific protease SUSP1.
J. Biol. Chem. 281: 30669-30677 (2006).
*
-
Choi SY, Chung JH, Kim DH, Chung SW, Kim JY, Yu BP, Chung HY. Peroxisome proliferator-activated receptor gamma agonist action of 3-methyl-1,2-cyclopentanedione.
Biochim. Biophys. Acta 1770: 1612-1619 (2007).
*
-
Chopra B, Hinley J, Oleksiewicz MB, Southgate J. Trans-species comparison of PPAR and RXR expression by rat and human urothelial tissues.
Toxicol. Pathol. 36: 485-495 (2008).
-
Chou WL, Chuang LM, Khoo KH, Wang AH, Lawson JA, Fitzgerald GA, Chang ZF. Identification of a novel prostaglandin reductase reveals the involvement of prostaglandin E2 catabolism in regulation of PPARgamma activation.
J. Biol. Chem. 282: 18162-18172 (2007).
*
-
Chou YC, Prakash E, Huang CF, Lien TW, Chen X, Su IJ, Chao YS, Hsieh HP, Hsu JT. Bioassay-guided purification and identification of PPARalpha/gamma agonists from Chlorella sorokiniana.
Phytother. Res. 22: 605-613 (2008).
-
Christensen KB, Minet A, Svenstrup H, Grevsen K, Zhang H, Schrader E, Rimbach G, Wein S, Wolffram S, Kristiansen K, Christensen LP. Identification of plant extracts with potential antidiabetic properties: effect on human peroxisome proliferator-activated receptor (PPAR), adipocyte differentiation and insulin-stimulated glucose uptake.
Phytother. Res. Jan 27 [Epub ahead of print] (2009).
-
Christianson JL, Nicoloro S, Straubhaar J, Czech MP. Stearoyl CoA desaturase 2 is required for PPARgamma expression and adipogenesis in cultured 3T3-L1 cells.
J. Biol. Chem. 283: 2906-2916 (2008).
*
-
Christodoulides C, Dyson P, Sprecher D, Tsintzas K, Karpe F. Circulating FGF21 is induced by PPAR agonists but not ketosis in man.
J. Clin. Endocrinol. Metab. Jun 16 [Epub ahead of print] (2009).
-
Chu R, Lim H, Brumfield L, Liu H, Herring C, Ulintz P, Reddy JK, Davison M. Protein profiling of mouse livers with peroxisome proliferator-activated receptor alpha activation.
Mol. Cell. Biol. 24: 6288-6297 (2004).
*
-
Chuang CC, Yang RS, Tsai KS, Ho FM, Liu SH. Hyperglycemia enhances adipogenic induction of lipid accumulation: involvement of extracellular signal-regulated protein kinase 1/2, phosphoinositide 3-kinase/Akt and peroxisome proliferator-activated receptor-gamma (PPARgamma) signaling.
Endocrinology 148: 4267-4275 (2007).
*
-
Chuang JH, Wang PW, Tai MH. An adipocentric view of liver fibrosis and cirrhosis.
Chang Gung Med. J. 27: 855-868 (2004).
-
Chung C, Doll JA, Stellmach VM, Gonzales J, Surapureddi S, Cornwell M, Reddy JK, Crawford SE. Pigment epithelium-derived factor is an angiogenesis and lipid regulator that activates peroxisome proliferator-activated receptor alpha.
Adv. Exp. Med. Biol. 617: 591-597 (2008).
-
Chung JH, Seo AY, Chung SW, Kim MK, Leeuwenburgh C, Yu BP, Chung HY. Molecular mechanism of PPAR in the regulation of age-related inflammation.
Ageing Res. Rev. 7: 126-136 (2008).
-
Chung S, Lapoint K, Martinez K, Kennedy A, Boysen Sandberg M, McIntosh MK. Preadipocytes mediate lipopolysaccharide-induced inflammation and insulin resistance in primary cultures of newly differentiated human adipocytes.
Endocrinology 147: 5340-5351 (2006).
*
-
Chung SS, Choi HH, Cho YM, Lee HK, Park KS. Sp1 mediates repression of the resistin gene by PPARgamma agonists in 3T3-L1 adipocytes.
Biochem. Biophys. Res. Commun. 348: 253-258 (2006).
*
-
Chung SS, Kim M, Youn BS, Lee NS, Park JW, Lee IK, Lee YS, Kim JB, Cho YM, Lee HK, Park KS. Glutathione peroxidase 3 mediates the antioxidant effect of peroxisome proliferator-activated receptor gamma in human skeletal muscle cells.
Mol. Cell. Biol. 29: 20-30 (2009).
*
-
Chung SW, Kang BY, Kim SH, Pak YK, Cho D, Trinchieri G, Kim TS. Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-gamma and nuclear factor-kappa B.
J. Biol. Chem. 275: 32681-32687 (2000).
*
-
Chung SW, Kang BY, Kim TS. Inhibition of interleukin-4 production in CD4+ T cells by peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands: involvement of physical association between PPAR-gamma and the nuclear factor of activated T cells transcription factor.
Mol. Pharmacol. 64: 1169-1179 (2003).
*
-
Churi SB, Abdel-Aleem OS, Tumber KK, Scuderi-Porter H, Taylor BK. Intrathecal rosiglitazone acts at peroxisome proliferator-activated receptor-gamma to rapidly inhibit neuropathic pain in rats.
J. Pain 9: 639-649 (2008).
-
Ciana P, Biserni A, Tatangelo L, Tiveron C, Sciarroni AF, Ottobrini L, Maggi A. A novel PPRE-luciferase reporter mouse reveals gender specificity of peroxisome proliferators activated receptor activity in liver.
Mol. Endocrinol. 21: 388-400 (2007).
*
-
Cianferotti L, Demay MB. VDR-mediated inhibition of DKK1 and SFRP2 suppresses adipogenic differentiation of murine bone marrow stromal cells.
J. Cell. Biochem. 101: 80-88 (2007).
*
-
Cimini A, Ceru MP. Emerging roles of peroxisome proliferator-activated receptors (PPARs) in the regulation of neural stem cells proliferation and differentiation.
Stem Cell Rev. 4: 293-303 (2008).
-
Cimini A, Cristiano L, Benedetti E, D'Angelo B, Ceru MP. PPARs expression in adult mouse neural stem cells: modulation of PPARs during astroglial differentiaton of NSC.
PPAR Res. 2007: 48242 (2007).
*
-
Cindoruk M, Kerem M, Karakan T, Salman B, Akin O, Alper M, Erdem O, Unal S. Peroxisome proliferators-activated alpha agonist treatment ameliorates hepatic damage in rats with obstructive jaundice: an experimental study.
BMC Gastroenterol. 7: 44 (2007).
*
-
Clark RB. The role of PPARs in inflammation and immunity.
J. Leukoc. Biol. 71: 388-400 (2002).
*
-
Clark RB, Bishop-Bailey D, Estrada-Hernandez T, Hla T, Puddington L, Padula SJ. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses.
J. Immunol. 164: 1364-1371 (2000).
*
-
Clarke HJ, Gregoire F, Ma F, Martin R, Zhao S, Lavan BE. Cross-species differential plasma protein binding of MBX-102/JNJ39659100: a novel PPAR-gamma agonist.
PPAR Res. 2008: 465715 (2008).
*
-
Clarke SD, Jump D. Polyunsaturated fatty acids regulate lipogenic and peroxisomal gene expression by independent mechanisms.
Prostaglandins Leukot. Essent. Fatty Acids 57: 65-69 (1997).
-
Clarke SD, Jump DB. Polyunsaturated fatty acid regulation of hepatic gene transcription.
Lipids 31: S7-S11 (1996).
-
Clarke SD, Thuillier P, Baillie RA, Sha X. Peroxisome proliferator-activated receptors: a family of lipid-activated transcription factors.
Am. J. Clin. Nutr. 70: 566-571 (1999).
*
-
Claudel T, Leibowitz MD, Fievet C, Tailleux A, Wagner B, Repa JJ, Torpier G, Lobaccaro JM, Paterniti JR, Mangelsdorf DJ, Heyman RA, Auwerx J. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor.
Proc. Natl. Acad. Sci. U.S.A. 98: 2610-2615 (2001).
*
-
Clemenz M, Frost N, Schupp M, Caron S, Foryst-Ludwig A, Bohm C, Hartge M, Gust R, Staels B, Unger T, Kintscher U. Liver-specific peroxisome proliferator-activated receptor alpha target gene regulation by the angiotensin type 1 receptor blocker telmisartan.
Diabetes 57: 1405-1413 (2008).
*
-
Cluny NL, Keenan CM, Lutz B, Piomelli D, Sharkey KA. The identification of peroxisome proliferator-activated receptor alpha-independent effects of oleoylethanolamide on intestinal transit in mice.
Neurogastroenterol. Motil. 21: 420-429 (2009).
-
Cock TA, Houten SM, Auwerx J. Peroxisome proliferator-activated receptor-gamma: too much of a good thing causes harm.
EMBO Rep. 5: 142-147 (2004).
*
-
Coleman JD, Prabhu KS, Thompson JT, Reddy PS, Peters JM, Peterson BR, Reddy CC, Vanden Heuvel JP. The oxidative stress mediator 4-hydroxynonenal is an intracellular agonist of the nuclear receptor peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta).
Free Radic. Biol. Med. 42: 1155-1164 (2007).
-
Coletta DK, Balas B, Chavez AO, Baig M, Abdul-Ghani M, Kashyap S, Folli F, Tripathy D, Mandarino LJ, Cornell JE, Defronzo RA, Jenkinson CP. Effect of acute physiologic hyperinsulinemia on gene expression in human skeletal muscle in vivo.
Am. J. Physiol. Endocrinol. Metab. 294: E910-E917 (2008).
*
-
Colin S, Bourguignon E, Boullay AB, Tousaint JJ, Huet S, Caira F, Staels B, Lestavel S, Lobaccaro JM, Delerive P. Intestine-specific regulation of PPARalpha gene transcription by liver X receptors.
Endocrinology 149: 5128-5135 (2008).
*
-
Collin M, Murch O, Thiemermann C. Peroxisome proliferator-activated receptor-gamma antagonists GW9662 and T0070907 reduce the protective effects of lipopolysaccharide preconditioning against organ failure caused by endotoxemia.
Crit. Care Med. 34: 1131-1138 (2006).
-
Collino M, Aragno M, Mastrocola R, Benetti E, Gallicchio M, Dianzani C, Danni O, Thiemermann C, Fantozzi R. Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: effects of the PPAR-alpha agonist WY14643.
Free Radic. Biol. Med. 41: 579-589 (2006).
-
Collino M, Patel NS, Thiemermann C. PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury.
Ther. Adv. Cardiovasc. Dis. 2: 179-197 (2008).
-
Commerford SR, Vargas L, Dorfman SE, Mitro N, Rocheford EC, Mak PA, Li X, Kennedy P, Mullarkey TL, Saez E. Dissection of the insulin-sensitizing effect of liver X receptor ligands.
Mol. Endocrinol. 21: 3002-3112 (2007).
*
-
Compe E, Drane P, Laurent C, Diderich K, Braun C, Hoeijmakers JH, Egly JM. Dysregulation of the peroxisome proliferator-activated receptor target genes by XPD mutations.
Mol. Cell. Biol. 25: 6065-6076 (2005).
*
-
Constantin-Teodosiu D, Baker DJ, Constantin D, Greenhaff PL. PPARdelta agonism inhibits skeletal muscle PDC activity, mitochondrial ATP production and force generation during prolonged contraction.
J. Physiol. 587: 231-239 (2009).
*
-
Contestabile A. Benefits of caloric restriction on brain aging and related pathological states: understanding mechanisms to devise novel therapies.
Curr. Med. Chem. 16: 350-361 (2009).
-
Cook WS, Yeldandi AV, Rao MS, Hashimoto T, Reddy JK. Less extrahepatic induction of fatty acid beta-oxidation enzymes by PPAR alpha.
Biochem. Biophys. Res. Commun. 278: 250-257 (2000).
*
-
Coppola G, Marmolino D, Lu D, Wang Q, Cnop M, Rai M, Acquaviva F, Cocozza S, Pandolfo M, Geschwind DH. Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPARgamma pathway as a therapeutic target in Friedreich's ataxia.
Hum. Mol. Genet. 18: 2452-2461 (2009).
*
-
Coras R, Holsken A, Seufert S, Hauke J, Eyupoglu IY, Reichel M, Trankle C, Siebzehnrübl FA, Buslei R, Blumcke I, Hahnen E. The peroxisome proliferator-activated receptor-gamma agonist troglitazone inhibits transforming growth factor-beta-mediated glioma cell migration and brain invasion.
Mol. Cancer Ther. 6: 1745-1754 (2007).
*
-
Cornick CL, Strongitharm BH, Sassano G, Rawlins C, Mayes AE, Joseph AN, O'Dowd J, Stocker C, Wargent E, Cawthorne MA, Brown AL, Arch JR. Identification of a novel agonist of peroxisome proliferator-activated receptors alpha and gamma that may contribute to the anti-diabetic activity of guggulipid in Lep(ob)/Lep(ob) mice.
J. Nutr. Biochem. Oct 14 [Epub ahead of print] (2008).
*
-
Cornwell PD, De Souza AT, Ulrich RG. Profiling of hepatic gene expression in rats treated with fibric acid analogs.
Mutat. Res. 549: 131-145 (2004).
-
Cornwell PD, Ulrich RG. Investigating the mechanistic basis for hepatic toxicity induced by an experimental chemokine receptor 5 (CCR5) antagonist using a compendium of gene expression profiles.
Toxicol. Pathol. 35: 576-588 (2007).
*
-
Corton JC, Anderson SP, Stauber A. Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators.
Annu. Rev. Pharmacol. Toxicol. 40: 491-518 (2000).
*
-
Corton JC, Brown-Borg HM. Peroxisome proliferator-activated receptor gamma coactivator 1 in caloric restriction and other models of longevity.
J. Gerontol. A. Biol. Sci. Med. Sci. 60: 1494-1509 (2005).
-
Corton JC, Lapinskas PJ, Gonzalez FJ. Central role of PPARalpha in the mechanism of action of hepatocarcinogenic peroxisome proliferators.
Mutat. Res. 448: 139-151 (2000).
-
Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors.
Pain Jul 2 [Epub ahead of print] (2008).
-
Costa V, Casamassimi A, Esposito K, Villani A, Capone M, Iannella R, Schisano B, Ciotola M, Di Palo C, Corrado FC, Santangelo F, Giugliano D, Ciccodicola A. Characterization of a novel polymorphism in PPARG regulatory region associated with type 2 diabetes and diabetic retinopathy in Italy.
J. Biomed. Biotechnol. 2009: 126917 (2009).
*
-
Costa V, Foti D, Paonessa F, Chiefari E, Palaia L, Brunetti G, Gulletta E, Fusco A, Brunetti A. The insulin receptor: a new anticancer target for peroxisome proliferator-activated receptor-gamma (PPARgamma) and thiazolidinedione-PPARgamma agonists.
Endocr. Relat. Cancer 15: 325-335 (2008).
-
Cox SL. Tesaglitazar: a promising approach in type 2 diabetes.
Drugs Today (Barc.) 42: 139-146 (2006).
-
Coyle AT, O'keeffe MB, Kinsella BT. 15-Deoxy delta-prostaglandin J suppresses transcription by promoter 3 of the human thromboxane A receptor gene through peroxisome proliferator-activated receptor gamma in human erythroleukemia cells.
FEBS J. 272: 4754-4773 (2005).
*
-
Coyne GS, Kenny DA, Childs S, Sreenan JM, Waters SM. Dietary n-3 polyunsaturated fatty acids alter the expression of genes involved in prostaglandin biosynthesis in the bovine uterus.
Theriogenology 70: 772-782 (2008).
-
Crabb DW. Alcohol deranges hepatic lipid metabolism via altered transcriptional regulation.
Trans. Am. Clin. Climatol. Assoc. 115: 273-287 (2004).
*
-
Crabb DW, Galli A, Fischer M, You M. Molecular mechanisms of alcoholic fatty liver: role of peroxisome proliferator-activated receptor alpha.
Alcohol 34: 35-38 (2004).
*
-
Crabb DW, Liangpunsakul S. Alcohol and lipid metabolism.
J. Gastroenterol. Hepatol. 21 Suppl. 3: S56-S60 (2006).
*
-
Crabb DW, Pinaire J, Chou WY, Sissom S, Peters JM, Harris RA, Stewart M. Peroxisome proliferator-activated receptors (PPAR) and the mitochondrial aldehyde dehydrogenase (ALDH2) promoter in vitro and in vivo.
Alcohol Clin. Exp. Res. 25: 945-952 (2001).
-
Cree MG, Newcomer BR, Read LK, Sheffield-Moore M, Paddon-Jones D, Chinkes D, Aarsland A, Wolfe RR. Plasma triglycerides are not related to tissue lipids and insulin sensitivity in elderly following PPAR-alpha agonist treatment.
Mech. Ageing Dev. 128: 558-565 (2007).
-
Cresci S. The PPAR genes, cardiovascular disease and the emergence of PPAR pharmacogenetics.
Expert Opin. Pharmacother. 6: 2577-2591 (2005).
-
Cresci S. PPAR genomics and pharmacogenomics: implications for cardiovascular disease.
PPAR Res. 2008: 374549 (2008).
*
-
Cresci S. Pharmacogenetics of the PPAR genes and cardiovascular disease.
Pharmacogenomics 8: 1581-1595 (2007).
-
Crisafulli C, Cuzzocrea S. The role of endogenous and exogenous ligands for the peroxisome proliferator-activated receptor alpha (PPAR-alpha) in the regulation of inflammation in macrophages.
Shock Oct 23 [Epub ahead of print] (2008).
-
Crisafulli C, Cuzzocrea S. The role of endogenous and exogenous ligands for the peroxisome proliferator-activated receptor alpha (PPAR-alpha) in the regulation of inflammation in macrophages.
Shock 32: 62-73 (2009).
-
Cristiano L, Cimini A, Moreno S, Ragnelli AM, Paola Ceru M. Peroxisome proliferator-activated receptors (PPARs) and related transcription factors in differentiating astrocyte cultures.
Neuroscience 131: 577-587 (2005).
*
-
Crosby MB, Svenson J, Gilkeson GS, Nowling TK. A novel PPAR response element in the murine iNOS promoter.
Mol. Immunol. 42: 1303-1310 (2005).
*
-
Crowe DL, Chandraratna RA. A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands.
Breast Cancer Res. 6: R546-R555 (2004).
*
-
Csaki C, Matis U, Mobasheri A, Ye H, Shakibaei M. Chondrogenesis, osteogenesis and adipogenesis of canine mesenchymal stem cells: a biochemical, morphological and ultrastructural study.
Histochem. Cell Biol. 128: 507-520 (2007).
-
Cui Y, Lu Z, Bai L, Shi Z, Zhao WE, Zhao B. beta-Carotene induces apoptosis and up-regulates peroxisome proliferator-activated receptor gamma expression and reactive oxygen species production in MCF-7 cancer cells.
Eur. J. Cancer 43: 2590-2601 (2007).
*
-
Cullingford TE, Bhakoo K, Peuchen S, Dolphin CT, Patel R, Clark JB. Distribution of mRNAs encoding the peroxisome proliferator-activated receptor alpha, beta, and gamma and the retinoid X receptor alpha, beta, and gamma in rat central nervous system.
J. Neurochem. 70: 1366-1375 (1998).
-
Cummings JL, Doody R, Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention.
Neurology 69: 1622-1634 (2007).
-
Cunard R. The potential use of PPARalpha agonists as immunosuppressive agents.
Curr. Opin. Investig. Drugs 6: 467-472 (2005).
-
Cunard R, DiCampli D, Archer DC, Stevenson JL, Ricote M, Glass CK, Kelly CJ. WY14,643, a PPAR alpha ligand, has profound effects on immune responses in vivo.
J. Immunol. 169: 6806-6812 (2002).
*
-
Cunard R, Ricote M, DiCampli D, Archer DC, Kahn DA, Glass CK, Kelly CJ. Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors.
J. Immunol. 168: 2795-2802 (2002).
*
-
Cuzzocrea S. Peroxisome proliferator-activated receptors and acute lung injury.
Curr. Opin. Pharmacol. 6: 263-270 (2006).
-
Cuzzocrea S, Bruscoli S, Mazzon E, Crisafulli C, Donato V, Di Paola R, Velardi E, Esposito E, Nocentini G, Riccardi C. Peroxisome proliferator-activated receptor-alpha contributes to the anti-inflammatory activity of glucocorticoids.
Mol. Pharmacol. 73: 323-337 (2008).
*
-
Cuzzocrea S, Di Paola R, Mazzon E, Genovese T, Muia C, Caputi AP. WY 14643, a potent exogenous PPAR-alpha ligand, reduces intestinal injury associated with splanchnic artery occlusion shock.
Shock 22: 340-346 (2004).
*
-
Cuzzocrea S, Di Paola R, Mazzon E, Genovese T, Muia C, Centorrino T, Caputi AP. Role of endogenous and exogenous ligands for the peroxisome proliferators activated receptors alpha (PPAR-alpha) in the development of inflammatory bowel disease in mice.
Lab. Invest. 84: 1643-1654 (2004).
*
-
Cuzzocrea S, Mazzon E, Di Paola R, Peli A, Bonato A, Britti D, Genovese T, Mui C, Crisafulli C, Caputi AP. The role of the peroxisome proliferator-activated receptor-alpha (PPAR-alpha) in the regulation of acute inflammation.
J. Leukoc. Biol. 79: 999-1010 (2006).
*
-
Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Patel NS, Di Paola R, Genovese T, Chatterjee PK, Di Rosa M, Caputi AP, Thiemermann C. Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut.
Br. J. Pharmacol. 140: 366-376 (2003).
*
-
Cwinn MA, Jones SP, Kennedy SW. Exposure to perfluorooctane sulfonate or fenofibrate causes PPAR-alpha dependent transcriptional responses in chicken embryo hepatocytes.
Comp. Biochem. Physiol. C. Toxicol. Pharmacol. 148: 165-171 (2008).
*
-
d'Abramo C, Zingg JM, Pizzuti A, Argellati F, Pronzato MA, Ricciarelli R. In vitro effect of PPAR-gamma2 Pro12Ala polymorphism on the deposition of Alzheimer's amyloid-beta peptides.
Brain Res. 1173: 1-5 (2007).
-
D'Agostino G, La Rana G, Russo R, Sasso O, Iacono A, Esposito E, Mattace Raso G, Cuzzocrea S, Lo Verme J, Piomelli D, Meli R, Calignano A. Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous PPAR-alpha agonist, modulates carrageenan-induced paw edema in mice.
J. Pharmacol. Exp. Ther. 322: 1137-1143 (2007).
*
-
D'Agostino G, La Rana G, Russo R, Sasso O, Iacono A, Esposito E, Mattace Raso G, Cuzzocrea S, Loverme J, Piomelli D, Meli R, Calignano A. Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kappaB nuclear signalling in dorsal root ganglia.
Eur. J. Pharmacol. 613: 54-59 (2009).
-
D'Eon TM, Souza SC, Aronovitz M, Obin MS, Fried SK, Greenberg AS. Estrogen regulation of adiposity and fuel partitioning: evidence of genomic and non-genomic regulation of lipogenic and oxidative pathways.
J. Biol. Chem. 280: 36334-36341 (2005).
*
-
Da Silva Morais A, Abarca-Quinones J, Horsmans Y, Starkel P, Leclercq IA. Peroxisome proliferated-activated receptor gamma ligand, pioglitazone, does not prevent hepatic fibrosis in mice.
Int. J. Mol. Med. 19: 105-112 (2007).
*
-
Da Silva Morais A, Lebrun V, Abarca-Quinones J, Brichard S, Hue L, Guigas B, Viollet B, Leclercq IA. Prevention of steatohepatitis by pioglitazone: implication of adiponectin-dependent inhibition of SREBP-1c and inflammation.
J. Hepatol. 50: 489-500 (2009).
-
Dahten A, Koch C, Ernst D, Schnoller C, Hartmann S, Worm M. Systemic PPARgamma ligation inhibits allergic immune response in the skin.
J. Invest. Dermatol. 128: 2211-2218 (2008).
*
-
Dai X, Sayama K, Shirakata Y, Hanakawa Y, Yamasaki K, Tokumaru S, Yang L, Wang X, Hirakawa S, Tohyama M, Yamauchi T, Takashi K, Kagechika H, Hashimoto K. STAT5a/PPARgamma pathway regulates involucrin expression in keratinocyte differentiation.
J. Invest. Dermatol. 127: 1728-1735 (2007).
*
-
Dai X, Sayama K, Shirakata Y, Tokumaru S, Yang L, Tohyama M, Hirakawa S, Hanakawa Y, Hashimoto K. PPARgamma is an important transcription factor in 1alpha,25-dihydroxyvitamin D3-induced involucrin expression.
J. Dermatol. Sci. 50: 53-60 (2008).
-
Dai X, Souza AT, Dai H, Lewis DL, Lee CK, Spencer AG, Herweijer H, Hagstrom JE, Linsley PS, Bassett DE, Ulrich RG, He YD. PPARalpha siRNA-treated expression profiles uncover the causal sufficiency network for compound-induced liver hypertrophy.
PLoS Comput. Biol. 3: e30 (2007).
*
-
Dallaire P, Bellmann K, Laplante M, Gelinas S, Centeno-Baez C, Penfornis P, Peyot ML, Latour MG, Lamontagne J, Trujillo ME, Scherer PE, Prentki M, Deshaies Y, Marette A. Obese mice lacking iNOS are sensitized to the metabolic actions of PPARgamma agonism.
Diabetes 57: 1999-2011 (2008).
*
-
Danesi F, Di Nunzio M, Boschetti E, Bordoni A. Green tea extract selectively activates peroxisome proliferator-activated receptor beta/delta in cultured cardiomyocytes.
Br. J. Nutr. Dec 5 [Epub ahead of print] (2008).
*
-
Dang CN, Trainer P. Pharmacological management of Cushing's syndrome: an update.
Arq. Bras. Endocrinol. Metabol. 51: 1339-1348 (2007).
*
-
Daoud G, Simoneau L, Masse A, Rassart E, Lafond J. Expression of cFABP and PPAR in trophoblast cells: effect of PPAR ligands on linoleic acid uptake and differentiation.
Biochim. Biophys. Acta 1687: 181-194 (2005).
*
-
Darimont C, Avanti O, Zbinden I, Leone-Vautravers P, Mansourian R, Giusti V, Mace K. Liver X receptor preferentially activates de novo lipogenesis in human preadipocytes.
Biochimie 88: 309-318 (2006).
-
Das KK, Bajpai M, Kong Y, Liu J, Geng X, Das KM. Mesalamine suppresses the expression of a novel tropomyosin isoform, TC22, associated with colonic neoplasia.
Mol. Pharmacol. Apr 15 [Epub ahead of print] (2009).
*
-
Das SK, Chakrabarti R. Role of PPAR in cardiovascular diseases.
Recent Patents Cardiovasc. Drug Discov. 1: 193-209 (2006).
-
Das UN. A defect in the activity of Delta(6) and Delta(5) desaturases may be a factor predisposing to the development of insulin resistance syndrome.
Prostaglandins Leukot. Essent. Fatty Acids 72: 343-350 (2005).
*
-
Das UN. Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules.
Lipids Health Dis. 7: 37 (2008).
*
-
Das UN, Rao AA. Gene expression profile in obesity and type 2 diabetes mellitus.
Lipids Health Dis. 6: 35 (2007).
*
-
Dasgupta S, Roy A, Jana M, Hartley DM, Pahan K. Gemfibrozil ameliorates relapsing-remitting experimental autoimmune encephalomyelitis independent of peroxisome proliferator-activated receptor-alpha.
Mol. Pharmacol. 72: 934-946 (2007).
*
-
Dat NT, Lee K, Hong YS, Ho Kim Y, Van Minh C, Joon Lee J. A peroxisome proliferator-activated receptor-gamma agonist and other constituents from Chromolaena odorata.
Planta Med. Feb 25 [Epub ahead of print] (2009).
-
Davidson MH. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids.
Am. J. Cardiol. 98: S27-S33 (2006).
-
Davies BS, Waki H, Beigneux AP, Farber E, Weinstein MM, Wilpitz DC, Tai LJ, Evans RM, Fong LG, Tontonoz P, Young SG. The expression of GPIHBP1, an endothelial cell binding site for lipoprotein lipase and chylomicrons, is induced by PPARgamma.
Mol. Endocrinol. 22: 2496-2504 (2008).
*
-
Dawson MI, Ye M, Cao X, Farhana L, Hu QY, Zhao Y, Xu LP, Kiselyuk A, Correa RG, Yang L, Hou T, Reed JC, Itkin-Ansari P, Levine F, Sanner MF, Fontana JA, Zhang XK. Derivation of a retinoid X receptor scaffold from peroxisome proliferator-activated receptor gamma ligand 1-di(1H-indol-3-yl)methyl-4-trifluoromethylbenzene.
ChemMedChem. Apr 17 [Epub ahead of print] (2009).
*
-
Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity.
Nat. Rev. Immunol. 2: 748-759 (2002).
*
-
De Cavanagh EM, Piortkowski B, Fraga CG. The interaction between the renin-angiotensin system and peroxisome proliferator activated receptors: a hypothesis including the participation of mitochondria in aging.
Front. Biosci. 12: 1049-1062 (2007).
-
De Gottardi A, Hadengue A, Dumonceau JM. Retinoids, bile acids and PPARs in Barrett's oesophagus.
Gut 57: 137 (2008).
*
-
De Gottardi A, Pazienza V, Pugnale P, Bruttin F, Rubbia-Brandt L, Juge-Aubry CE, Meier CA, Hadengue A, Negro F. Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection.
Aliment. Pharmacol.Ther. 23: 107-114 (2006).
*
-
de Lange P, Lombardi A, Silvestri E, Goglia F, Lanni A, Moreno M. Peroxisome proliferator-activated receptor delta: a conserved director of lipid homeostasis through regulation of the oxidative capacity of muscle.
PPAR Res. 2008: 172676 (2008).
*
-
De Pascale MC, Bassi AM, Patrone V, Villacorta L, Azzi A, Zingg JM. Increased expression of transglutaminase-1 and PPARgamma after vitamin E treatment in human keratinocytes.
Arch. Biochem. Biophys. 447: 97-106 (2006).
*
-
de Rooij SR, Painter RC, Phillips DI, Osmond C, Tanck MW, Defesche JC, Bossuyt PM, Michels RP, Bleker OP, Roseboom TJ. The effects of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 gene on glucose/insulin metabolism interact with prenatal exposure to famine.
Diabetes Care 29: 1052-1057 (2006).
*
-
De Souza AT, Cornwell PD, Dai X, Caguyong MJ, Ulrich RG. Agonists of the peroxisome proliferator activated receptor alpha induce a fiber-type selective transcriptional response in rat skeletal muscle.
Toxicol. Sci. 92: 578-586 (2006).
*
-
De Souza AT, Dai X, Spencer AG, Reppen T, Menzie A, Roesch PL, He Y, Caguyong MJ, Bloomer S, Herweijer H, Wolff JA, Hagstrom JE, Lewis DL, Linsley PS, Ulrich RG. Transcriptional and phenotypic comparisons of Ppara knockout and siRNA knockdown mice.
Nucleic Acids Res. 34: 4486-4494 (2006).
*
-
de Ubago MM, Garcia-Oya I, Perez-Perez A, Canfran-Duque A, Quintana-Portillo R, de Fonseca FR, Gonzalez-Yanes C, Sanchez-Margalet V. Oleoylethanolamide, a natural ligand for PPAR-alpha, inhibits insulin receptor signalling in HTC rat hepatoma cells.
Biochim. Biophys. Acta Apr 2 [Epub ahead of print] (2009).
*
-
de Vogel-van den Bosch HM, Bunger M, de Groot PJ, Bosch-Vermeulen H, Hooiveld GJ, Muller M. PPARalpha-mediated effects of dietary lipids on intestinal barrier gene expression.
BMC Genomics 9: 231 (2008).
*
-
de Wit NJ, Bosch-Vermeulen H, de Groot PJ, Hooiveld GJ, Grootte Bromhaar MM, Jansen J, Muller M, van der Meer R. The role of the small intestine in the development of dietary fat-induced obesity and insulin resistance in C57BL/6J mice.
BMC Med. Genomics 1: 14 (2008).
*
-
Debard C, Cozzone D, Ricard N, Vouillarmet J, Disse E, Husson B, Laville M, Vidal H. Short-term activation of peroxisome proliferator-activated receptor beta/delta increases fatty acid oxidation but does not restore insulin action in muscle cells from type 2 diabetic patients.
J. Mol. Med. 84: 747-752 (2006).
*
-
Debril MB, Renaud JP, Fajas L, Auwerx J. The pleiotropic functions of peroxisome proliferator-activated receptor gamma.
J. Mol. Med. 79: 30-47 (2001).
*
-
Decochez K, Rippley RK, Miller JL, De Smet M, Yan KX, Matthijs Z, Riffel KA, Song H, Zhu H, Maynor HO, Tanaka W, Johnson-Levonas AO, Davies MJ, Gottesdiener KM, Keymeulen B, Wagner JA. A dual PPAR alpha/gamma agonist increases adiponectin and improves plasma lipid profiles in healthy subjects.
Drugs R. D. 7: 99-110 (2006).
-
Deeg MA, Tan MH. Pioglitazone versus rosiglitazone: effects on lipids, lipoproteins, and apolipoproteins in head-to-head randomized clinical studies.
PPAR Res. 2008: 520465 (2008).
*
-
Defaux A, Zurich MG, Braissant O, Honegger P, Monnet-Tschudi F. Effects of the PPAR-beta agonist GW501516 in an in vitro model of brain inflammation and antibody-induced demyelination.
J. Neuroinflammation 6: 15 (2009).
*
-
DeFronzo RA. Dysfunctional fat cells, lipotoxicity and type 2 diabetes.
Int. J. Clin. Pract. Suppl. 143: 9-21 (2004).
-
Degenhardt T, Matilainen M, Herzig KH, Dunlop TW, Carlberg C. The insulin-like growth factor binding protein 1 gene is a primary target of peroxisome proliferator-activated receptors.
J. Biol. Chem. 281: 39607-39619 (2006).
*
-
Degenhardt T, Saramaki A, Malinen M, Rieck M, Vaisanen S, Huotari A, Herzig KH, Muller R, Carlberg C. Three members of the human pyruvate dehydrogenase kinase gene family are direct targets of the peroxisome proliferator-activated receptor beta/delta.
J. Mol. Biol. 372: 341-355 (2007).
*
-
Degenhardt T, Vaisanen S, Rakhshandehroo M, Kersten S, Carlberg C. Peroxisome proliferator-activated receptor alpha controls hepatic heme biosynthesis through ALAS1.
J. Mol. Biol. 388: 225-238 (2009).
*
-
Del V Cano M, Gehlbach PL. PPAR-alpha ligands as potential therapeutic agents for wet age-related macular degeneration.
PPAR Res. 2008: 821592 (2008).
*
-
Delage B, Rullier A, Capdepont M, Rullier E, Cassand P. The effect of body weight on altered expression of nuclear receptors and cyclooxygenase-2 in human colorectal cancers.
Nutr. J. 6: 20 (2007).
*
-
Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1.
J. Biol. Chem. 274: 32048-32054 (1999).
*
-
Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control.
J. Endocrinol. 169: 453-459 (2001).
*
-
Delerive P, Furman C, Teissier E, Fruchart J, Duriez P, Staels B. Oxidized phospholipids activate PPARalpha in a phospholipase A2-dependent manner.
FEBS Lett. 471: 34-38 (2000).
*
-
Delerive P, Gervois P, Fruchart JC, Staels B. Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators.
J. Biol. Chem. 275: 36703-36707 (2000).
*
-
DeLuca JG, Doebber TW, Kelly LJ, Kemp RK, Molon-Noblot S, Sahoo SP, Ventre J, Wu MS, Peters JM, Gonzalez FJ, Moller DE. Evidence for peroxisome proliferator-activated receptor (PPAR)alpha-independent peroxisome proliferation: effects of PPARgamma/delta-specific agonists in PPARalpha-null mice.
Mol. Pharmacol. 58: 470-476 (2000).
*
-
Demerjian M, Choi EH, Man MQ, Chang S, Elias PM, Feingold KR. Activators of PPARs and LXR decrease the adverse effects of exogenous glucocorticoids on the epidermis.
Exp. Dermatol. Feb 19 [Epub ahead of print].
-
Demerjian M, Man MQ, Choi EH, Brown BE, Crumrine D, Chang S, Mauro T, Elias PM, Feingold KR. Topical treatment with thiazolidinediones, activators of peroxisome proliferator-activated receptor-gamma, normalizes epidermal homeostasis in a murine hyperproliferative disease model.
Exp. Dermatol. 15: 154-160 (2006).
*
-
Demers A, Rodrigue-Way A, Tremblay A. Hexarelin signaling to PPARgamma in metabolic diseases.
PPAR Res. 2008: 364784 (2008).
*
-
Demizieux L. Control and regulation of mitochondrial oxidation of long-chained fatty acids.
J. Soc. Biol. 199: 143-155 (2005).
-
Deng QG, She H, Cheng JH, French SW, Koop DR, Xiong S, Tsukamoto H. Steatohepatitis induced by intragastric overfeeding in mice.
Hepatology 42: 905-914 (2005).
*
-
Deng T, Shan S, Li ZB, Wu ZW, Liao CZ, Ko B, Lu XP, Cheng J, Ning ZQ. A new retinoid-like compound that activates peroxisome proliferator-activated receptors and lowers blood glucose in diabetic mice.
Biol. Pharm. Bull. 28: 1192-1196 (2005).
*
-
Denning GM, Stoll LL. Peroxisome proliferator-activated receptors: potential therapeutic targets in lung disease?
Pediatr. Pulmonol. 41: 23-34 (2006).
-
Dentelli P, Trombetta A, Togliatto G, Zeoli A, Rosso A, Uberti B, Orso F, Taverna D, Pegoraro L, Brizzi MF. Formation of STAT5/PPARgamma transcriptional complex modulates angiogenic cell bioavailability in diabetes.
Arterioscler. Thromb. Vasc. Biol. 29: 114-120 (2009).
-
Derecka K, Sheldrick EL, Wathes DC, Abayasekara DR, Flint AP. A PPAR-independent pathway to PUFA-induced COX-2 expression.
Mol. Cell. Endocrinol. 287: 65-71 (2008).
-
Derlacz RA, Hyc K, Usarek M, Jagielski AK, Drozak J, Jarzyna R. PPAR-gamma-independent inhibitory effect of rosiglitazone on glucose synthesis in primary cultured rabbit kidney-cortex tubules.
Biochem. Cell. Biol. 86: 396-404 (2008).
-
Desouza CV, Gerety M, Hamel FG. Effects of a PPAR-gamma agonist, on growth factor and insulin stimulated endothelial cells.
Vascul. Pharmacol. Jun 8 [Epub ahead of print] (2009).
-
Desreumaux P, Dubuquoy L, Nutten S, Peuchmaur M, Englaro W, Schoonjans K, Derijard B, Desvergne B, Wahli W, Chambon P, Leibowitz MD, Colombel JF, Auwerx J. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies.
J. Exp. Med. 193: 827-838 (2001).
*
-
Desvergne B. RXR: from partnership to leadership in metabolic regulations.
Vitam. Horm. 75: 1-32 (2007).
-
Desvergne B, Feige JN, Casals-Casas C. PPAR-mediated activity of phthalates: a link to the obesity epidemic?
Mol. Cell. Endocrinol. 304: 43-48 (2009).
-
Desvergne B, IJpenberg A, Devchand PR, Wahli W. The peroxisome proliferator-activated receptors at the cross-road of diet and hormonal signalling.
J. Steroid Biochem. Mol. Biol. 65: 65-74 (1998).
-
Devchand PR, Ijpenberg A, Devesvergne B, Wahli W. PPARs: nuclear receptors for fatty acids, eicosanoids, and xenobiotics.
Adv. Exp. Med. Biol. 469: 231-236 (1999).
-
Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control.
Nature 384: 39-43 (1996).
*
-
Dewitt JC, Shnyra A, Badr MZ, Loveless SE, Hoban D, Frame SR, Cunard R, Anderson SE, Meade BJ, Peden-Adams MM, Luebke RW, Luster MI. Immunotoxicity of perfluorooctanoic acid and perfluorooctane sulfonate and the role of peroxisome proliferator-activated receptor alpha.
Crit. Rev. Toxicol. 39: 76-94 (2009).
-
Dharancy S, Lemoine M, Mathurin P, Serfaty L, Dubuquoy L. Peroxisome proliferator-activated receptors in HCV-related infection.
PPAR Res. 2009: 357204 (2009).
*
-
Dharancy S, Louvet A, Hollebecque A, Desreumaux P, Mathurin P, Dubuquoy L. Nuclear receptor PPAR and hepatology: pathophysiological and therapeutical aspects.
Gastroenterol. Clin. Biol. 32: 339-350 (2008).
-
Dharancy S, Malapel M, Perlemuter G, Roskams T, Cheng Y, Dubuquoy L, Podevin P, Conti F, Canva V, Philippe D, Gambiez L, Mathurin P, Paris JC, Schoonjans K, Calmus Y, Pol S, Auwerx J, Desreumaux P. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection.
Gastroenterology 128: 334-342 (2005).
*
-
Di Paola R, Cuzzocrea S. Peroxisome proliferator-activated receptors ligands and ischemia-reperfusion injury.
Naunyn. Schmiedebergs Arch. Pharmacol. 375: 157-175 (2007).
*
-
Di Paola R, Esposito E, Mazzon E, Genovese T, Muia C, Crisafulli C, Malleo G, Sessa E, Meli R, Cuzzocrea S. Absence of peroxisome proliferators-activated receptors (PPAR) alpha enhanced the multiple organ failure induced by zymosan.
Shock 26: 477-484 (2006).
*
-
Di Paola R, Mazzon E, Maiere D, Zito D, Britti D, De Majo M, Genovese T, Cuzzocrea S. Rosiglitazone reduces the evolution of experimental periodontitis in the rat.
J. Dent. Res. 85: 156-161 (2006).
-
Di ZL, Niu XL, Wei J, Li YQ, Chen GL, Wang NP. Expression of peroxisome proliferator-activated receptors Y changes with age in vascular smooth muscle cells of spontaneously hypertensive rat.
Sichuan Da Xue Xue Bao Yi Xue Ban 37: 204-207 (2006).
-
Di-Poi N, Desvergne B, Michalik L, Wahli W. Transcriptional repression of peroxisome proliferator-activated receptor beta/delta in murine keratinocytes by CCAAT/enhancer-binding proteins.
J. Biol. Chem. 280: 38700-38710 (2005).
*
-
Di-Poi N, Michalik L, Desvergne B, Wahli W. Functions of peroxisome proliferator-activated receptors (PPAR) in skin homeostasis.
Lipids 39: 1093-1099 (2004).
-
Diab A, Hussain RZ, Lovett-Racke AE, Chavis JA, Drew PD, Racke MK. Ligands for the peroxisome proliferator-activated receptor-gamma and the retinoid X receptor exert additive anti-inflammatory effects on experimental autoimmune encephalomyelitis.
J. Neuroimmunol. 148: 116-126 (2004).
-
Ding G, Cheng L, Qin Q, Frontin S, Yang Q. PPARdelta modulates lipopolysaccharide-induced TNFalpha inflammation signaling in cultured cardiomyocytes.
J. Mol. Cell. Cardiol. 40: 821-828 (2006).
*
-
Ding G, Fu M, Qin Q, Lewis W, Kim HW, Fukai T, Bacanamwo M, Chen EY, Schneider MD, Mangelsdorf DJ, Evans RM, Yang Q. Cardiac peroxisome proliferator-activated receptor gamma is essential in protecting cardiomyocytes from oxidative damage.
Cardiovasc. Res. 76: 269-279 (2007).
*
-
Ding J, Woo JT, Nagai K. The effects of retinoic acid on reversing the adipocyte differentiation into an osteoblastic tendency in ST2 cells, a murine bone marrow-derived stromal cell line.
Cytotechnology 36: 125-136 (2001).
*
-
Ding L, Liang X, Zhu D, Lou Y. Peroxisome proliferator-activated receptor alpha is involved in cardiomyocyte differentiation of murine embryonic stem cells in vitro.
Cell Biol. Int. 31: 1002-1009 (2007).
*
-
Ding Q, Jin T, Wang Z, Chen Y. Catalase potentiates retinoic acid-induced THP-1 monocyte differentiation into macrophage through inhibition of peroxisome proliferator-activated receptor gamma.
J. Leukoc. Biol. 81: 1568-1576 (2007).
*
-
Ding X, Lichti K, Kim I, Gonzalez FJ, Staudinger JL. Regulation of constitutive androstane receptor and its target genes by fasting, cAMP, hepatocyte nuclear factor alpha, and the coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha.
J. Biol. Chem. 281: 26540-26551 (2006).
*
-
Diradourian C, Girard J, Pegorier JP. Phosphorylation of PPARs: from molecular characterization to physiological relevance.
Biochimie 87: 33-38 (2005).
-
DiRenzo J, Soderstrom M, Kurokawa R, Ogliastro MH, Ricote M, Ingrey S, Horlein A, Rosenfeld MG, Glass CK. Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors.
Mol. Cell. Biol. 17: 2166-2176 (1997).
*
-
Dirkx R, Vanhorebeek I, Martens K, Schad A, Grabenbauer M, Fahimi D, Declercq P, Van Veldhoven PP, Baes M. Absence of peroxisomes in mouse hepatocytes causes mitochondrial and ER abnormalities.
Hepatology 41: 868-878 (2005).
*
-
Djouadi F, Aubey F, Schlemmer D, Bastin J. Peroxisome proliferator activated receptor delta (PPARdelta) agonist but not PPARalpha corrects carnitine palmitoyl transferase 2 (CPT2) deficiency in human muscle cells.
J. Clin. Endocrinol. Metab. 90: 1791-1797 (2005).
*
-
Djouadi F, Bastin J. PPARs as therapeutic targets for correction of inborn mitochondrial fatty acid oxidation disorders.
J. Inherit. Metab. Dis. Apr 4 [Epub ahead of print] (2008).
*
-
Djouadi F, Lecarpentier Y, Hebert JL, Charron P, Bastin J, Coirault C. A potential link between PPAR signaling and the pathogenesis of arrhythmogenic right ventricular cardiomyopathy (ARVC).
Cardiovasc. Res. Jun 4 [Epub ahead of print] (2009).
-
Djouadi F, Weinheimer CJ, Saffitz JE, Pitchford C, Bastin J, Gonzalez FJ, Kelly DP. A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor alpha-deficient mice.
J. Clin. Invest. 102: 1083-1091 (1998).
*
-
Dobrosi N, Toth BI, Nagy G, Dozsa A, Geczy T, Nagy L, Zouboulis CC, Paus R, Kovacs L, Bíro T. Endocannabinoids enhance lipid synthesis and apoptosis of human sebocytes via cannabinoid receptor-2-mediated signaling.
FASEB J. 22: 3685-3695 (2008).
*
-
Doggrell SA. Muraglitazar: beneficial or detrimental in the treatment of type 2 diabetes?
Expert Opin. Pharmacother. 7: 1229-1233 (2006).
-
Doi S, Masaki T, Arakawa T, Takahashi S, Kawai T, Nakashima A, Naito T, Kohno N, Yorioka N. Protective effects of peroxisome proliferator-activated receptor gamma ligand on apoptosis and hepatocyte growth factor induction in renal ischemia-reperfusion injury.
Transplantation 84: 207-213 (2007).
-
Doi T, Sakoda T, Akagami T, Naka T, Mori Y, Tsujino T, Masuyama T, Ohyanagi M. Aldosterone induces interleukin-18 through endothelin-1, angiotensin-II, Rho/Rho-kinase, and PPARs in cardiomyocytes.
Am. J. Physiol. Heart Circ. Physiol. 295: H1279-H1287 (2008).
*
-
Dolezalova R, Haluzik M, Bosanska L, Lacinova Z, Stulc T, Haluzik M. Effect of PPAR-gama agonist treatment on markers of endothelial dysfunction in patients with type 2 diabetes mellitus.
Physiol. Res. 56: 741-748 (2007).
*
-
Dong C, He L, Li J, Ye F, He M, Wang Y. Association of the Pro12Ala and C1431T polymorphism of the PPAR gamma2 gene and their haplotypes with obesity and type 2 diabetes.
Zhonghua Yi Xue Yi Chuan Xue Za Zhi 25: 447-451 (2008).
-
Dong YW, Wang XP, Wu K. Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor gamma involves angiogenesis inhibition.
World J. Gastroenterol. 15: 441-448 (2009).
*
-
Dongol B, Shah Y, Kim I, Gonzalez FJ, Hunt MC. The acyl-CoA thioesterase I is regulated by PPARalpha and HNF4alpha via a distal response element in the promoter.
J. Lipid Res. 48: 1781-1791 (2007).
*
-
Dongxia L, Qi H, Lisong L, Jincheng G. Association of peroxisome proliferator-activated receptor-gamma gene Pro12Ala and C161T polymorphisms with metabolic syndrome.
Circ. J. 72: 551-557 (2008).
*
-
Donkor J, Sparks LM, Xie H, Smith SR, Reue K. Adipose tissue lipin-1 expression is correlated with PPARalpha gene expression and insulin sensitivity in healthy young men.
J. Clin. Endocrinol. Metab. 93: 233-239 (2008).
*
-
Donnelly R, Wang B, Qu X. Type 2 diabetes in China: partnerships in education and research to evaluate new antidiabetic treatments.
Br. J. Clin. Pharmacol. 61: 702-705 (2006).
*
-
Donthamsetty S, Bhave VS, Mitra MS, Latendresse JR, Mehendale HM. Nonalcoholic steatohepatitic (NASH) mice are protected from higher hepatotoxicity of acetaminophen upon induction of PPARalpha with clofibrate.
Toxicol. Appl. Pharmacol. 230: 327-337 (2008).
-
Doonan F, Wallace DM, O'Driscoll C, Cotter TG. Rosiglitazone acts as a neuro-protectant in retinal cells via up-regulation of sestrin-1 and SOD-2.
J. Neurochem. 109: 631-643 (2009).
-
Dorfmeister B, Brandlhofer S, Schaap FG, Hermann M, Furnsinn C, Hagerty BP, Stangl H, Patsch W, Strobl W. Apolipoprotein AV does not contribute to hypertriglyceridaemia or triglyceride lowering by dietary fish oil and rosiglitazone in obese Zucker rats.
Diabetologia 49: 1324-1332 (2006).
*
-
Dos Santos Mendes S, Candi A, Vansteenbrugge M, Pignon MR, Bult H, Boudjeltia KZ, Munaut C, Raes M. Microarray analyses of the effects of NFkappaB or PI3K pathway inhibitors on the LPS-induced gene expression profile in RAW264.7 cells. Synergistic effects of rapamycin on LPS induced MMP9-overexpression.
Cell Signal. 21: 1109-1122 (2009).
*
-
Douglas JA, Erdos MR, Watanabe RM, Braun A, Johnston CL, Oeth P, Mohlke KL, Valle TT, Ehnholm C, Buchanan TA, Bergman RN, Collins FS, Boehnke M, Tuomilehto J. The peroxisome proliferator-activated receptor-gamma2 Pro12A1a variant: association with type 2 diabetes and trait differences.
Diabetes 50: 886-890 (2001).
*
-
Downie MM, Sanders DA, Maier LM, Stock DM, Kealey T. Peroxisome proliferator-activated receptor and farnesoid X receptor ligands differentially regulate sebaceous differentiation in human sebaceous gland organ cultures in vitro.
Br. J. Dermatol. 151: 766-775 (2004).
*
-
Drew PD, Storer PD, Xu J, Chavis JA. Hormone regulation of microglial cell activation: relevance to multiple sclerosis.
Brain Res. Brain Res. Rev. 48: 322-327 (2005).
-
Drew PD, Xu J, Racke MK. PPAR-gamma: therapeutic potential for multiple sclerosis.
PPAR Res. 2008: 627463 (2008).
*
-
Drew PD, Xu J, Storer PD, Chavis JA, Racke MK. Peroxisome proliferator-activated receptor agonist regulation of glial activation: relevance to CNS inflammatory disorders.
Neurochem. Int. 49: 183-189 (2006).
-
Dreyer C, Keller H, Mahfoudi A, Laudet V, Krey G, Wahli W. Positive regulation of the peroxisomal beta-oxidation pathway by fatty acids through activation of peroxisome proliferator-activated receptors (PPAR).
Biol. Cell 77: 67-76 (1993).
-
Drover VA, Abumrad NA. CD36-dependent fatty acid uptake regulates expression of peroxisome proliferator activated receptors.
Biochem. Soc. Trans. 33: 311-315 (2005).
*
-
Duan SZ, Ivashchenko CY, Usher MG, Mortensen RM. PPAR-gamma in the cardiovascular system.
PPAR Res. 2008: 745804 (2008).
*
-
Duan SZ, Usher MG, Mortensen RM. PPARs: the vasculature, inflammation and hypertension.
Curr. Opin. Nephrol. Hypertens. 18: 128-133 (2009).
-
Dubois M, Vantyghem MC, Schoonjans K, Pattou F. Thiazolidinediones in type 2 diabetes. Role of peroxisome proliferator-activated receptor gamma (PPARgamma).
Ann. Endocrinol. (Paris) 63: 511-523 (2002).
-
DuBois RN, Gupta R, Brockman J, Reddy BS, Krakow SL, Lazar MA. The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers.
Carcinogenesis 19: 49-53 (1998).
*
-
Dubois SG, Heilbronn LK, Smith SR, Albu JB, Kelley DE, Ravussin E. Decreased expression of adipogenic genes in obese subjects with type 2 diabetes.
Obesity (Silver Spring) 14: 1543-1552 (2006).
*
-
Dubrac S, Schmuth M. (P)PARsing epidermal development.
J. Invest. Dermatol. 126: 241-242 (2006).
*
-
Dubrac S, Stoitzner P, Pirkebner D, Elentner A, Schoonjans K, Auwerx J, Saeland S, Hengster P, Fritsch P, Romani N, Schmuth M. Peroxisome proliferator-activated receptor-alpha activation inhibits Langerhans cell function.
J. Immunol. 178: 4362-4372 (2007).
*
-
Dubuquoy L, Bourdon C, Peuchmaur M, Leibowitz MD, Nutten S, Colombel JF, Auwerx J, Desreumaux P. Peroxisome proliferator-activated receptor (PPAR) gamma: a new target for the treatment of inflammatory bowel disease.
Gastroenterol. Clin. Biol. 24: 719-724 (2000).
-
Dubuquoy L, Dharancy S, Nutten S, Pettersson S, Auwerx J, Desreumaux P. Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases.
Lancet 360: 1410-1418 (2002).
*
-
Dubuquoy L, Jansson EA, Deeb S, Rakotobe S, Karoui M, Colombel JF, Auwerx J, Pettersson S, Desreumaux P. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis.
Gastroenterology 124: 1265-1276 (2003).
*
-
Dubuquoy L, Louvet A, Hollebecque A, Mathurin P, Dharancy S. Peroxisome proliferator-activated receptors in HBV-related infection.
PPAR Res. 2009: 145124 (2009).
*
-
Duez H, Chao YS, Hernandez M, Torpier G, Poulain P, Mundt S, Mallat Z, Teissier E, Burton CA, Tedgui A, Fruchart JC, Fievet C, Wright SD, Staels B. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice.
J. Biol. Chem. 277: 48051-48057 (2002).
*
-
Duez H, Fruchart JC, Staels B. PPARS in inflammation, atherosclerosis and thrombosis.
J. Cardiovasc. Risk 8: 187-194 (2001).
-
Duez H, Lefebvre B, Poulain P, Pineda Torra I, Percevault F, Luc G, Peters JM, Gonzalez FJ, Gineste R, Helleboid S, Fruchart JC, Fievet C, Lefebvre P, Staels B. Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation.
Arterioscler. Thromb. Vasc. Biol. 25: 585-591 (2005).
*
-
Duffy D, Rader DJ. Drugs in development: targeting high-density lipoprotein metabolism and reverse cholesterol transport.
Curr. Opin. Cardiol. 20: 301-306 (2005).
-
Duffy DL. Genetic determinants of diabetes are similarly associated with other immune-mediated diseases.
Curr. Opin. Allergy Clin. Immunol. 7: 468-474 (2007).
-
Duhaney TA, Cui L, Rude MK, Lebrasseur NK, Ngoy S, De Silva DS, Siwik DA, Liao R, Sam F. Peroxisome proliferator-activated receptor alpha-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload.
Hypertension 49: 1084-1094 (2007).
-
Dullens SP, Mensink RP, Mariman EC, Plat J. Differentiated CaCo-2 cells as an in-vitro model to evaluate de-novo apolipoprotein A-I production in the small intestine.
Eur. J. Gastroenterol. Hepatol. 21: 642-649 (2009).
-
Dumasia R, Eagle KA, Kline-Rogers E, May N, Cho L, Mukherjee D. Role of PPAR- gamma agonist thiazolidinediones in treatment of pre-diabetic and diabetic individuals: a cardiovascular perspective.
Curr. Drug Targets Cardiovasc. Haemato. Disord. 5: 377-386 (2005).
-
Duncan JG, Fong JL, Medeiros DM, Finck BN, Kelly DP. Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptor-alpha/PGC-1alpha gene regulatory pathway.
Circulation 115: 909-917 (2007).
*
-
Duncan RE, Archer MC. Farnesol decreases serum triglycerides in rats: identification of mechanisms including up-regulation of PPARalpha and down-regulation of fatty acid synthase in hepatocytes.
Lipids 43: 619-627 (2008).
-
Dunlop TW, Vaisanen S, Frank C, Molnar F, Sinkkonen L, Carlberg C. The human peroxisome proliferator-activated receptor delta gene is a primary target of 1alpha,25-dihydroxyvitamin D(3) and its nuclear receptor.
J. Mol. Biol. 349: 248-260 (2005).
*
-
Dunn SE, Ousman SS, Sobel RA, Zuniga L, Baranzini SE, Youssef S, Crowell A, Loh J, Oksenberg J, Steinman L. Peroxisome proliferator-activated receptor (PPAR) alpha expression in T cells mediates gender differences in development of T cell-mediated autoimmunity.
J. Exp. Med. 204: 321-330 (2007).
*
-
Dupont J, Chabrolle C, Rame C, Tosca L, Coyral-Castel S. Role of the peroxisome proliferator-activated receptors, adenosine monophosphate-activated kinase, and adiponectin in the ovary.
PPAR Res. 2008: 176275 (2008).
*
-
Dushkin MI, Khoshchenko OM, Chasovsky MA, Pivovarova EN. The content of PPAR, LXR, and RXR and the PPAR DNA-binding activity in macrophages over the course of inflammation in mice.
Bull. Exp. Biol. Med. 147: 345-348 (2009).
-
Duval C, Fruchart JC, Staels B. PPAR alpha, fibrates, lipid metabolism and inflammation.
Arch. Mal. Coeur. Vaiss. 97: 665-672 (2004).
-
Duy SN, Baes M, Van Veldhoven PP. Degradation of very long chain dicarboxylic polyunsaturated fatty acids in mouse hepatocytes, a peroxisomal process.
Biochim. Biophys. Acta 1781: 400-405 (2008).
*
-
Dyroy E, Rost TH, Pettersen RJ, Halvorsen B, Gudbrandsen OA, Ueland T, Muna Z, Muller F, Nordrehaug JE, Aukrust P, Berge RK. Tetradecylselenoacetic acid, a PPAR ligand with antioxidant, antiinflammatory, and hypolipidemic properties.
Arterioscler. Thromb. Vasc. Biol. 27: 628-634 (2007).
*
-
Dyroy E, Yndestad A, Ueland T, Halvorsen B, Damas JK, Aukrust P, Berge RK. Antiinflammatory effects of tetradecylthioacetic acid involve both peroxisome proliferator-activated receptor alpha-dependent and -independent pathways.
Arterioscler. Thromb. Vasc. Biol. 25: 1364-1369 (2005).
*
-
Eastham LL, Mills CN, Niles RM. PPARalpha/gamma expression and activity in mouse and human melanocytes and melanoma cells.
Pharm. Res. 25: 1327-1333 (2008).
*
-
Edgar AD, Tomkiewicz C, Costet P, Legendre C, Aggerbeck M, Bouguet J, Staels B, Guyomard C, Pineau T, Barouki R. Fenofibrate modifies transaminase gene expression via a peroxisome proliferator activated receptor alpha-dependent pathway.
Toxicol. Lett. 98: 13-23 (1998).
-
Edgerton DS, Johnson KM, Cherrington AD. Current strategies for the inhibition of hepatic glucose production in type 2 diabetes.
Front. Biosci. 14: 1169-1181 (2009).
-
Edvardsson U, Alexandersson M, Brockenhuus von Lowenhielm H, Nystrom AC, Ljung B, Nilsson F, Dahllof B. A proteome analysis of livers from obese (ob/ob) mice treated with the peroxisome proliferator WY14,643.
Electrophoresis 20: 935-942 (1999).
*
-
Edwards IJ, O'Flaherty JT. Omega-3 fatty acids and PPARgamma in cancer.
PPAR Res. 2008: 358052 (2008).
*
-
Edwards IJ, Sun H, Hu Y, Berquin IM, O'Flaherty JT, Cline JM, Rudel LL, Chen YQ. In vivo and in vitro regulation of syndecan 1 in prostate cells by n-3 polyunsaturated fatty acids.
J. Biol. Chem. 283: 18441-18449 (2008).
*
-
Eeckhoute J, Briche I, Kurowska M, Formstecher P, Laine B. Hepatocyte nuclear factor 4 alpha ligand binding and F domains mediate interaction and transcriptional synergy with the pancreatic islet LIM HD transcription factor Isl1.
J. Mol. Biol. 364: 567-581 (2006).
*
-
Efrati S, Berman S, Chachashvili A, Cohen N, Siman-Tov Y, Averbukh Z, Weissgarten J. Rosiglitazone treatment attenuates renal tissue inflammation generated by urinary tract obstruction.
Nephrology (Carlton) 14: 189-197 (2009).
-
Ehrmann J Jr, Vavrusova N, Collan Y, Kolar Z. Peroxisome proliferator-activated receptors (PPARs) in health and disease.
Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 146: 11-14 (2002).
*
-
Eibl G. The role of PPAR-gamma and its interaction with COX-2 in pancreatic cancer.
PPAR Res. 2008: 326915 (2008).
*
-
Eibl G, Reber HA, Hines OJ, Go VL. COX and PPAR: possible interactions in pancreatic cancer.
Pancreas 29: 247-253 (2004).
-
Eichele K, Ramer R, Hinz B. R(+)-Methanandamide-induced apoptosis of human cervical carcinoma cells involves a cyclooxygenase-2-dependent pathway.
Pharm. Res. 26: 346-355 (2009).
*
-
Einstein M, Akiyama T, Castriota G, Wang C, McKeever B, Mosley R, Becker J, Moller D, Meinke P, Wood H, Berger J. The differential interactions of peroxisome proliferator-activated receptor gamma ligands with Tyr473 is a physical basis for their unique biological activities.
Mol. Pharmacol. 73: 62-74 (2008).
*
-
Ek J, Andersen G, Urhammer SA, Gaede PH, Drivsholm T, Borch-Johnsen K, Hansen T, Pedersen O. Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to type II diabetes mellitus.
Diabetologia 44: 2220-2226 (2001).
*
-
El Kebbaj Z, Andreoletti P, Mountassif D, Kabine M, Schohn H, Dauca M, Latruffe N, El Kebbaj MS, Cherkaoui-Malki M. Differential regulation of peroxisome proliferator-activated receptor (PPAR)-alpha1 and truncated PPARalpha2 as an adaptive response to fasting in the control of hepatic peroxisomal fatty acid beta-oxidation in the hibernating mammal.
Endocrinology 150: 1192-1201 (2009).
*
-
El Midaoui A, Wu L, Wang R, de Champlain J. Modulation of cardiac and aortic peroxisome proliferator-activated receptor-gamma expression by oxidative stress in chronically glucose-fed rats.
Am. J. Hypertens. 19: 407-412 (2006).
-
Elangbam CS, Tyler RD, Lightfoot RM. Peroxisome proliferator-activated receptors in atherosclerosis and inflammation - an update.
Toxicol. Pathol. 29: 224-231 (2001).
*
-
Eletto D, Leone A, Bifulco M, Tecce MF. Effect of unsaturated fat intake from Mediterranean diet on rat liver mRNA expression profile: selective modulation of genes involved in lipid metabolism.
Nutr. Metab. Cardiovasc. Dis. 15: 13-23 (2005).
-
Elholm M, Dam I, Jorgensen C, Krogsdam AM, Holst D, Kratchmarova I, Gottlicher M, Gustafsson JA, Berge R, Flatmark T, Knudsen J, Mandrup S, Kristiansen K. Acyl-CoA esters antagonize the effects of ligands on peroxisome proliferator-activated receptor alpha conformation, DNA binding, and interaction with co-factors.
J. Biol. Chem. 276: 21410-21416 (2001).
*
-
Elias AN, Lizotte P, Hofflich H. Evidence of acute pancreatitis in a patient with radioresistant-differentiated thyroid cancer.
J. Natl. Med. Assoc. 100: 285-287 (2008).
-
Elrod HA, Sun SY. PPARgamma and apoptosis in cancer.
PPAR Res. 2008: 704165 (2008).
*
-
Enders GA. Cyclooxygenase-2 overexpression abrogates the antiproliferative effects of TGF-beta.
Br. J. Cancer 97: 1388-1392 (2007).
*
-
Endresen MJ. The role of fatty acids in gene regulation. An example of an important nutritional factor which may influence our genes.
Tidsskr. Nor. Laegeforen. 115: 2084-2086 (1995).
-
Engdahl R, Monroy MA, Daly JM. 15-Deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2) mediates repression of TNF-alpha by decreasing levels of acetylated histone H3 and H4 at its promoter.
Biochem. Biophys. Res. Commun. 359: 88-93 (2007).
*
-
Enoki T, Ohnogi H, Nagamine K, Kudo Y, Sugiyama K, Tanabe M, Kobayashi E, Sagawa H, Kato I. Antidiabetic activities of chalcones isolated from a Japanese herb, Angelica keiskei.
J. Agric. Food Chem. 55: 6013-6017 (2007).
*
-
Eny KM, El-Sohemy A, Cornelis MC, Sung YK, Bae SC. Catalase and PPARgamma2 genotype and risk of systemic lupus erythematosus in Koreans.
Lupus 14: 351-355 (2005).
-
Epple R, Azimioara M, Russo R, Bursulaya B, Tian SS, Gerken A, Iskandar M. 1,3,5-Trisubstituted aryls as highly selective PPARdelta agonists.
Bioorg. Med. Chem. Lett. 16: 2969-2973 (2006).
-
Epple R, Russo R, Azimioara M, Cow C, Xie Y, Wang X, Wityak J, Karanewsky D, Gerken A, Iskandar M, Saez E, Martin Seidel H, Tian SS. 3,4,5-Trisubstituted isoxazoles as novel PPARdelta agonists: part 1.
Bioorg. Med. Chem. Lett. 16: 4376-4380 (2006).
-
Epstein S, Leroith D. Diabetes and fragility fractures - a burgeoning epidemic?
Bone 43: 3-6 (2008).
-
Erdogan M, Karadeniz M, Eroglu Z, Tezcanli B, Selvi N, Yilmaz C. The relationship of the peroxisome proliferator-activated receptor-gamma 2 exon 2 and exon 6 gene polymorphism in Turkish type 2 diabetic patients with and without nephropathy.
Diabetes Res. Clin. Pract. 78: 355-359 (2007).
-
Eriksson JG. The role of genes in growth and later health.
Nestle Nutr. Workshop Ser. Pediatr. Program 61: 69-77 (2008).
-
Erol A. PPARalpha activators may be good candidates as antiaging agents.
Med. Hypotheses 65: 35-38 (2005).
-
Erol A. The functions of PPARs in aging and longevity.
PPAR Res. 2007: 39654 (2007).
*
-
Escher P, Wahli W. Peroxisome proliferator-activated receptors: insight into multiple cellular functions.
Mutat. Res. 448: 121-138 (2000).
-
Escribano L, Simon AM, Perez-Mediavilla A, Salazar-Colocho P, Río JD, Frechilla D. Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model.
Biochem. Biophys. Res. Commun. 379: 406-410 (2009).
*
-
Esposito E, Cuzzocrea S, Meli R. Peroxisome proliferator-activated receptors and shock state.
ScientificWorldJournal 6: 1770-1782 (2006).
-
Esteves J, Laranjeira AF, Roggia MF, Dalpizol M, Scocco C, Kramer CK, Azevedo MJ, Canani LH. Diabetic retinopathy risk factors.
Arq. Bras. Endocrinol. Metabol. 52: 431-441 (2008).
-
Eun CS, Han DS, Lee SH, Jeon YC, Sohn JH, Kim YS, Lee J. Probiotics may reduce inflammation by enhancing peroxisome proliferator activated receptor gamma activation in HT-29 cells.
Korean J. Gastroenterol. 49: 139-146 (2007).
-
Eun CS, Han DS, Lee SH, Paik CH, Chung YW, Lee J, Hahm JS. Attenuation of colonic inflammation by PPARgamma in intestinal epithelial cells: effect on Toll-like receptor pathway.
Dig. Dis. Sci. 51: 693-697 (2006).
*
-
Evans D, Aberle J, Wendt D, Wolf A, Beisiegel U, Mann WA. A polymorphism, L162V, in the peroxisome proliferator-activated receptor alpha (PPARalpha) gene is associated with lower body mass index in patients with non-insulin-dependent diabetes mellitus.
J. Mol. Med. 79: 198-204 (2001).
*
-
Evans JL, Lin JJ, Goldfine ID. Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta.
Curr. Diabetes Rev. 1: 299-307 (2005).
-
Evans MJ, Mahaney PE, Borges-Marcucci L, Lai K, Wang S, Krueger JA, Gardell SJ, Huard C, Martinez RV, Vlasuk GP, Harnish DC. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia.
Am. J. Physiol. Gastrointest. Liver Physiol. 296: G543-G552 (2009).
*
-
Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity.
Nat. Med. 10: 355-361 (2004).
*
-
Evans-Molina C, Robbins RD, Kono T, Tersey SA, Vestermark GL, Nunemaker CS, Garmey JC, Deering TG, Keller SR, Maier B, Mirmira RG. PPAR-gamma activation restores islet function in diabetic mice through reduction of ER stress and maintenance of euchromatin structure.
Mol. Cell. Biol. 29: 2053-2067 (2009).
-
Ewaschuk J, Endersby R, Thiel D, Diaz H, Backer J, Ma M, Churchill T, Madsen K. Probiotic bacteria prevent hepatic damage and maintain colonic barrier function in a mouse model of sepsis.
Hepatology 46: 841-850 (2007).
*
-
Eynon N, Meckel Y, Sagiv M, Yamin C, Amir R, Sagiv M, Goldhammer E, Duarte JA, Oliveira J. Do PPARGC1A and PPARalpha polymorphisms influence sprint or endurance phenotypes?
Scand. J. Med. Sci. Sports Apr 20 [Epub ahead of print] (2009).
-
Fagerberg B, Schuster H, Birketvedt GS, Tonstad S, Ohman KP, Gause-Nilsson I; On Behalf Of The Sir Study Group. Improvement of postprandial lipid handling and glucose tolerance in a non-diabetic population by the dual PPARa/g agonist, tesaglitazar.
Diab. Vasc. Dis. Res. 4: 174-180 (2007).
-
Fainaru O, Shay T, Hantisteanu S, Goldenberg D, Domany E, Groner Y. TGFbeta-dependent gene expression profile during maturation of dendritic cells.
Genes Immun. 8: 239-244 (2007).
*
-
Faiola B, Falls JG, Peterson RA, Bordelon NR, Brodie TA, Cummings CA, Romach EH, Miller RT. PPAR alpha, more than PPAR delta, mediates the hepatic and skeletal muscle alterations induced by the PPAR agonist GW0742.
Toxicol. Sci. 105: 384-394 (2008).
*
-
Falcetti E, Flavell DM, Staels B, Tinker A, Haworth SG, Clapp LH. IP receptor-dependent activation of PPARgamma by stable prostacyclin analogues.
Biochem. Biophys. Res. Commun. 360: 821-827 (2007).
*
-
Fan B, Ikuyama S, Gu JQ, Wei P, Oyama JI, Inoguchi T, Nishimura J. Oleic acid-induced ADRP expression requires both AP-1 and PPAR-response elements,and is reduced by Pycnogenol through mRNA degradation in NMuLi liver cells.
Am. J. Physiol. Endocrinol. Metab. Apr 21 [Epub ahead of print] (2009).
*
-
Fan H, Zingarelli B, Harris V, Tempel GE, Halushka PV, Cook JA. Lysophosphatidic acid inhibits bacterial endotoxin-induced pro-inflammatory response: potential anti-inflammatory signaling pathways.
Mol. Med. 14: 422-428 (2008).
*
-
Fan P, Zhang B, Kuroki S, Saku K. Pitavastatin, a potent hydroxymethylglutaryl coenzyme A reductase inhibitor, increases cholesterol 7 alpha-hydroxylase gene expression in HepG2 cells.
Circ. J. 68: 1061-1066 (2004).
*
-
Fan W, Imamura T, Sonoda N, Sears DD, Patsouris D, Kim JJ, Olefsky JM. FOXO1 transrepresses PPARgamma transactivation, coordinating an insulin-induced feed-forward response in adipocytes.
J. Biol. Chem. 284: 12188-12197 (2009).
*
-
Fan W, Yanase T, Morinaga H, Mu YM, Nomura M, Okabe T, Goto K, Harada N, Nawata H. Activation of peroxisome proliferator activated receptor gamma and retinoid X receptor inhibits aromatase transcription via NF-kappaB.
Endocrinology 146: 85-92 (2005).
*
-
Fan Y, Wang Y, Tang Z, Zhang H, Qin X, Zhu Y, Guan Y, Wang X, Staels B, Chien S, Wang N. Suppression of proinflammatory adhesion molecules by PPAR-delta in human vascular endothelial cells.
Arterioscler. Thromb. Vasc. Biol. 28: 315-321 (2008).
-
Fan YY, Spencer TE, Wang N, Moyer MP, Chapkin RS. Chemopreventive n-3 fatty acids activate RXRalpha in colonocytes.
Carcinogenesis 24: 1541-1548 (2003).
*
-
Fang C, Yoon S, Tindberg N, Jarvelainen HA, Lindros KO, Ingelman-Sundberg M. Hepatic expression of multiple acute phase proteins and down-regulation of nuclear receptors after acute endotoxin exposure.
Biochem. Pharmacol. 67: 1389-1397 (2004).
*
-
Fang HL, Strom SC, Cai H, Falany CN, Kocarek TA, Runge-Morris M. Regulation of human hepatic hydroxysteroid sulfotransferase gene expression by the peroxisome proliferator-activated receptor alpha transcription factor.
Mol. Pharmacol. 67: 1257-1267 (2005).
*
-
Fang X, Dillon JS, Hu S, Harmon SD, Yao J, Anjaiah S, Falck JR, Spector AA. 20-Carboxy-arachidonic acid is a dual activator of peroxisome proliferator-activated receptors alpha and gamma.
Prostaglandins Other Lipid Mediat. 82: 175-184 (2007).
-
Fang X, Hu S, Xu B, Snyder G, Harmon S, Yao J, Liu Y, Sangras B, Falck J, Weintraub NL, Spector AA. 14,15-Dihydroxyeicosatrienoic acid activates peroxisome proliferator activated receptor alpha.
Am. J. Physiol. Heart Circ. Physiol. 290: H55-H63 (2006).
*
-
Fang X, Zhang L, Feng Y, Zhao Y, Dai J. Immunotoxic effects of perfluorononanoic acid on BALB/c mice.
Toxicol. Sci. 105: 312-321 (2008).
*
-
Fatehi-Hassanabad Z, Chan CB. Expression of PPARalpha modifies fatty acid effects on insulin secretion in uncoupling protein-2 knockout mice.
Nutr. Metab. (Lond.) 4: 6 (2007).
*
-
Fatehi-Hassanabad Z, Chan CB. Transcriptional regulation of lipid metabolism by fatty acids: a key determinant of pancreatic beta-cell function.
Nutr. Metab. (Lond.) 2: 1 (2005).
*
-
Fediuc S, Pimenta AS, Gaidhu MP, Ceddia RB. Activation of AMP-activated protein kinase, inhibition of pyruvate dehydrogenase activity, and redistribution of substrate partitioning mediate the acute insulin-sensitizing effects of troglitazone in skeletal muscle cells.
J. Cell Physiol. 215: 392-400 (2008).
*
-
Fehrenbacher JC, Loverme J, Clarke W, Hargreaves KM, Piomelli D, Taylor BK. Rapid pain modulation with nuclear receptor ligands.
Brain Res. Rev. 60: 114-124 (2009).
-
Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions.
Prog. Lipid Res. 45: 120-159 (2006).
*
-
Feige JN, Gelman L, Rossi D, Zoete V, Metivier R, Tudor C, Anghel SI, Grosdidier A, Lathion C, Engelborghs Y, Michielin O, Wahli W, Desvergne B. The endocrine disruptor mono-ethyl-hexyl-phthalate is a selective PPARgamma modulator which promotes adipogenesis.
J. Biol. Chem. 282: 19152-19166 (2007).
*
-
Feige JN, Gelman L, Tudor C, Engelborghs Y, Wahli W, Desvergne B. Fluorescence imaging reveals the nuclear behavior of PPAR/RXR heterodimers in the absence and presence of ligand.
J. Biol. Chem. 280: 17880-17890 (2005).
*
-
Feingold K, Kim MS, Shigenaga J, Moser A, Grunfeld C. Altered expression of nuclear hormone receptors and coactivators in mouse heart during the acute-phase response.
Am. J. Physiol. Endocrinol. Metab. 286: E201-E207 (2004).
*
-
Feingold KR, Moser A, Patsek SM, Shigenaga JK, Grunfeld C. Infection decreases fatty acid oxidation and nuclear hormone receptors in the diaphragm.
J. Lipid Res. May 14 [Epub ahead of print] (2009).
*
-
Feingold KR, Wang Y, Moser A, Shigenaga JK, Grunfeld C. LPS decreases fatty acid oxidation and nuclear hormone receptors in the kidney.
J. Lipid Res. 49: 2179-2187 (2008).
*
-
Feinstein DL, Spagnolo A, Akar C, Weinberg G, Murphy P, Gavrilyuk V, Russo CD. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?
Biochem. Pharmacol. 70: 177-188 (2005).
*
-
Feldman PL, Lambert MH, Henke BR. PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors?
Curr. Top. Med. Chem. 8: 728-749 (2008).
-
Feldon SE, O'loughlin CW, Ray DM, Landskroner-Eiger S, Seweryniak KE, Phipps RP. Activated human T lymphocytes express cyclooxygenase-2 and produce proadipogenic prostaglandins that drive human orbital fibroblast differentiation to adipocytes.
Am. J. Pathol. 169: 1183-1193 (2006).
*
-
Feng D, Zhang Y, Chen G. Cortical expression of peroxisome proliferator-activated receptor-alpha after human brain contusion.
J. Int. Med. Res. 36: 783-791 (2008).
-
Ferguson HE, Kulkarni A, Lehmann GM, Garcia-Bates TM, Thatcher TH, Huxlin KR, Phipps RP, Sime PJ. Electrophilic peroxisome proliferator activated receptor-gamma (PPARgamma) ligands have potent anti-fibrotic effects in human lung fibroblasts.
Am. J. Respir. Cell. Mol. Biol. Mar 13 [Epub ahead of print] (2009).
*
-
Ferguson LR. Dissecting the nutrigenomics, diabetes, and gastrointestinal disease interface: from risk assessment to health intervention.
OMICS 12: 237-244 (2008).
-
Fernandes-Santos C, Carneiro RE, Mendonca LD, Aguila MB, Mandarim-de-Lacerda CA. Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet.
Nutrition Mar 4 [Epub ahead of print] (2009).
-
Fernandes-Santos C, Evangelista Carneiro R, de Souza Mendonca L, Barbosa Aguila M, Alberto Mandarim-de-Lacerda C. Rosiglitazone aggravates nonalcoholic fatty pancreatic disease in C57BL/6 mice fed high-fat and high-sucrose diet.
Pancreas 38: e80-e86 (2009).
-
Fernandez AZ. PPARs as targets for the modulation of cardiovascular risk factors associated with the metabolic syndrome.
Curr. Opin. Investig. Drugs 5: 936-940 (2004).
-
Fernandez AZ. Peroxisome proliferator-activated receptors in the modulation of the immune/inflammatory response in atherosclerosis.
PPAR Res. 2008: 285842 (2008).
*
-
Fernandez PL. Stress and inflammatory bowell disease (I.B.D). Therapeutic strategies.
An. R. Acad. Nac. Med. (Madr.) 123: 219-229 (2006).
-
Ferno J, Vik-Mo AO, Jassim G, Havik B, Berge K, Skrede S, Gudbrandsen OA, Waage J, Lunder N, Mork S, Berge RK, Jorgensen HA, Steen VM. Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver.
Psychopharmacology (Berl.) 203: 73-84 (2009).
-
Ferre P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity.
Diabetes 53 Suppl. 1: S43-S50 (2004).
*
-
Fesinmeyer MD, Stanford JL, Brentnall TA, Mandelson MT, Farin FM, Srinouanprachanh S, Afsharinejad Z, Goodman GE, Barnett MJ, Austin MA. Association between the peroxisome proliferator-activated receptor gamma Pro12Ala variant and haplotype and pancreatic cancer in a high-risk cohort of smokers: a pilot study.
Pancreas May 11 [Epub ahead of print] (2009).
-
Festuccia WT, Blanchard PG, Turcotte V, Laplante M, Sariahmetoglu M, Brindley DN, Richard D, Deshaies Y. The PPARgamma agonist rosiglitazone enhances rat brown adipose tissue lipogenesis from glucose without altering glucose uptake.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 296: R1327-R1335 (2009).
-
Festuccia WT, Oztezcan S, Laplante M, Berthiaume M, Michel C, Dohgu S, Denis RG, Brito MN, Brito NA, Miller DS, Banks WA, Bartness TJ, Richard D, Deshaies Y. Peroxisome proliferator-activated receptor-gamma-mediated positive energy balance in the rat is associated with reduced sympathetic drive to adipose tissues and thyroid status.
Endocrinology 149: 2121-2130 (2008).
*
-
Fiatte C, Huin C, Bertin I, Lesuffleur T, Pluvinet A, Touche N, Plenat F, Dauca M, Domenjoud L, Schohn H. Genetic analysis of peroxisome proliferator-activated receptor gamma1 splice variants in human colorectal cell lines.
Int. J. Oncol. 29: 1601-1610 (2006).
*
-
Fidaleo M, Berardi E, Sartori C. Differential modulation of PPARalpha and gamma target gene expression in the liver and kidney of rats treated with aspirin.
Exp. Toxicol. Pathol. 59: 391-397 (2008).
*
-
Fievet C, Fruchart JC, Staels B. Genetically-engineered animals as research models for atherosclerosis : their use for the characterization of PPAR agonists in the treatment of cardiometabolic disorders.
Front. Biosci. 12: 4132-4156 (2007).
-
Fievet C, Fruchart JC, Staels B. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
Curr. Opin. Pharmacol. 6: 606-614 (2006).
-
Fievet C, Staels B. Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease.
Curr. Atheroscler. Rep. 11: 281-288 (2009).
-
Filzen GF, Bratton L, Cheng XM, Erasga N, Geyer A, Lee C, Lu G, Pulaski J, Sorenson RJ, Unangst PC, Trivedi BK, Xu X. Synthesis and SAR of selective benzothiophene, benzofuran, and indole-based peroxisome proliferator-activated receptor delta agonists.
Bioorg. Med. Chem. Lett. 17: 3630-3635 (2007).
-
Finck BN. Effects of PPARalpha on cardiac glucose metabolism: a transcriptional equivalent of the glucose-fatty acid cycle?
Expert Rev. Cardiovasc. Ther. 4: 161-171 (2006).
-
Finck BN. The PPAR regulatory system in cardiac physiology and disease.
Cardiovasc. Res. 73: 269-277 (2007).
*
-
Finck BN, Gropler MC, Chen Z, Leone TC, Croce MA, Harris TE, Lawrence JC Jr, Kelly DP. Lipin 1 is an inducible amplifier of the hepatic PGC-1alpha/PPARalpha regulatory pathway.
Cell Metab. 4: 199-210 (2006).
*
-
Fionda C, Nappi F, Piccoli M, Frati L, Santoni A, Cippitelli M. Inhibition of TRAIL gene expression by cyclopentenonic prostaglandin 15-deoxy-delta12,14-prostaglandin J2 in T lymphocytes.
Mol. Pharmacol. 72: 1246-1257 (2007).
*
-
Fiorito M, Torrente I, De Cosmo S, Guida V, Colosimo A, Prudente S, Flex E, Menghini R, Miccoli R, Penno G, Pellegrini F, Tassi V, Federici M, Trischitta V, Dallapiccola B. Interaction of DIO2 T92A and PPARgamma2 P12A polymorphisms in the modulation of metabolic syndrome.
Obesity (Silver Spring) 15: 2889-2895 (2007).
*
-
Fiorucci S, Rizzo G, Antonelli E, Renga B, Mencarelli A, Riccardi L, Antonio M, Pruzanski M, Pelllicciari R. Cross-talk between farnesoid X-receptor (FXR) and peroxisome proliferator-activated receptor (PPAR) gamma contributes to the anti-fibrotic activity of FXR ligands in rodent models of liver cirrhosis.
J. Pharmacol. Exp. Ther. 315: 58-68 (2005).
*
-
Fischer M, You M, Matsumoto M, Crabb DW. Peroxisome proliferator-activated receptor alpha (PPARalpha) agonist treatment reverses PPARalpha dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice.
J. Biol. Chem. 278: 27997-28004 (2003).
*
-
Fisher CD, Jackson JP, Lickteig AJ, Augustine LM, Cherrington NJ. Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis.
Arch. Toxicol. 82: 959-964 (2008).
*
-
Fitzgerald ML, Moore KJ, Freeman MW. Nuclear hormone receptors and cholesterol trafficking: the orphans find a new home.
J. Mol. Med. 80: 271-281 (2002).
*
-
Flachs P, Horakova O, Brauner P, Rossmeisl M, Pecina P, Franssen-van Hal N, Ruzickova J, Sponarova J, Drahota Z, Vlcek C, Keijer J, Houstek J, Kopecky J. Polyunsaturated fatty acids of marine origin upregulate mitochondrial biogenesis and induce beta-oxidation in white fat.
Diabetologia 48: 2365-2375 (2005).
*
-
Flachs P, Rossmeisl M, Bryhn M, Kopecky J. Cellular and molecular effects of n-3 polyunsaturated fatty acids on adipose tissue biology and metabolism.
Clin. Sci. (Lond.) 116: 1-16 (2009).
*
-
Flavell DM, Ireland H, Stephens JW, Hawe E, Acharya J, Mather H, Hurel SJ, Humphries SE. Peroxisome proliferator-activated receptor alpha gene variation influences age of onset and progression of type 2 diabetes.
Diabetes 54: 582-586 (2005).
*
-
Flavell DM, Jamshidi Y, Hawe E, Pineda Torra I, Taskinen MR, Frick MH, Nieminen MS, Kesaniemi YA, Pasternack A, Staels B, Miller G, Humphries SE, Talmud PJ, Syvanne M. Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease.
Circulation 105: 1440-1445 (2002).
*
-
Flavell DM, Pineda Torra I, Jamshidi Y, Evans D, Diamond JR, Elkeles RS, Bujac SR, Miller G, Talmud PJ, Staels B, Humphries SE. Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in type II diabetic subjects.
Diabetologia 43: 673-680 (2000).
*
-
Fletcher HA, Keyser A, Bowmaker M, Sayles PC, Kaplan G, Hussey G, Hill AV, Hanekom WA. Transcriptional profiling of mycobacterial antigen-induced responses in infants vaccinated with BCG at birth.
BMC Med. Genomics 2: 10 (2009).
*
-
Flores AM, Li L, Aneskievich BJ. Isolation and functional analysis of a keratinocyte-derived, ligand-regulated nuclear receptor comodulator.
J. Invest. Dermatol. 123: 1092-1101 (2004).
*
-
Florez JC, Jablonski KA, Sun MW, Bayley N, Kahn SE, Shamoon H, Hamman RF, Knowler WC, Nathan DM, Altshuler D. Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone.
J. Clin. Endocrinol. Metab. 92: 1502-1509 (2007).
*
-
Flowers MT, Keller MP, Choi Y, Lan H, Kendziorski CM, Ntambi JM, Attie AD. Liver gene expression analysis reveals endoplasmic reticulum stress and metabolic dysfunction in SCD1-deficient mice fed a very low-fat diet.
Physiol. Genomics 33: 361-372 (2008).
*
-
Floyd ZE, Wang ZQ, Kilroy G, Cefalu WT. Modulation of peroxisome proliferator-activated receptor gamma stability and transcriptional activity in adipocytes by resveratrol.
Metabolism 57S1: S32-S38 (2008).
-
Floyd ZE, Wang ZQ, Kilroy G, Cefalu WT. Modulation of peroxisome proliferator-activated receptor gamma stability and transcriptional activity in adipocytes by resveratrol.
Metabolism 57: S32-S38 (2008).
*
-
Folch-Puy E, Granell S, Iovanna JL, Barthet M, Closa D. Peroxisome proliferator-activated receptor gamma agonist reduces the severity of post-ERCP pancreatitis in rats.
World J. Gastroenterol. 12: 6458-6463 (2006).
*
-
Foreman JE, Chang SC, Ehresman DJ, Butenhoff JL, Anderson CR, Palkar PS, Kang BH, Gonzalez FJ, Peters JM. Differential hepatic effects of perfluorobutyrate (PFBA) mediated by mouse and human PPARalpha.
Toxicol. Sci. 110: 204-211 (2009).
*
-
Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta.
Proc. Natl. Acad. Sci. U.S.A. 94: 4312-4317 (1997).
*
-
Foucher C, Rattier S, Flavell DM, Talmud PJ, Humphries SE, Kastelein JJ, Ayyobi A, Pimstone S, Frohlich J, Ansquer JC, Steiner G; for the DAIS investigators. Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes.
Pharmacogenetics 14: 823-829 (2004).
-
Fourcade S, Savary S, Albet S, Gauthe D, Gondcaille C, Pineau T, Bellenger J, Bentejac M, Holzinger A, Berger J, Bugaut M. Fibrate induction of the adrenoleukodystrophy-related gene (ABCD2): promoter analysis and role of the peroxisome proliferator-activated receptor PPARalpha.
Eur. J. Biochem. 268: 3490-3500 (2001).
*
-
Fournier T, Handschuh K, Tsatsaris V, Evain-Brion D. Involvement of PPARgamma in human trophoblast invasion.
Placenta 28 Suppl. A: S76-S81 (2007).
-
Fournier T, Handschuh K, Tsatsaris V, Guibourdenche J, Evain-Brion D. Role of nuclear receptors and their ligands in human trophoblast invasion.
J. Reprod. Immunol. 77: 161-170 (2008).
-
Fournier T, Therond P, Handschuh K, Tsatsaris V, Evain-Brion D. PPARgamma and early human placental development.
Curr. Med. Chem. 15: 3011-3024 (2008).
-
Fournier T, Tsatsaris V, Handschuh K, Evain-Brion D. PPARs and the placenta.
Placenta 28: 65-76 (2007).
-
Frances F, Verdu F, Portoles O, Castello A, Sorlí JV, Guillen M, Corella D. PPAR-alpha L162V and PGC-1 G482S gene polymorphisms, but not PPAR-gamma P12A, are associated with alcohol consumption in a Spanish Mediterranean population.
Clin. Chim. Acta 398: 70-74 (2008).
*
-
Francis GA, Fayard E, Picard F, Auwerx J. Nuclear receptors and the control of metabolism.
Annu. Rev. Physiol. 65: 261-311 (2003).
*
-
Francis GA, Li G, Casey R, Wang J, Cao H, Leff T, Hegele RA. Peroxisomal proliferator activated receptor-gamma deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3).
BMC Med. Genet. 7: 3 (2006).
*
-
Francois M, Richette P, Corvol MT. Peroxisome proliferator-activated receptor gamma and its ligands in controlling interleukin-1beta target gene expression: a confusing story.
Drug News Perspect. 18: 257-261 (2005).
-
Francois M, Richette P, Tsagris L, Fitting C, Lemay C, Benallaoua M, Tahiri K, Corvol MT. Activation of the peroxisome proliferator-activated receptor alpha pathway potentiates interleukin-1 receptor antagonist production in cytokine-treated chondrocytes.
Arthritis Rheum. 54: 1233-1245 (2006).
*
-
Franks PW, Ekelund U, Brage S, Luan J, Schafer AJ, O'rahilly S, Barroso I, Wareham NJ. PPARGC1A coding variation may initiate impaired NEFA clearance during glucose challenge.
Diabetologia 50: 569-573 (2007).
*
-
Franks PW, Jablonski KA, Delahanty L, Hanson RL, Kahn SE, Altshuler D, Knowler WC, Florez JC; Diabetes Prevention Program Research Group. The Pro12Ala variant at the peroxisome proliferator-activated receptor gamma gene and change in obesity-related traits in the Diabetes Prevention Program.
Diabetologia 50: 2451-2460 (2007).
*
-
Fredenrich A, Grimaldi P. PPAR delta: an uncompletely known nuclear receptor.
Diabetes Metab. 31: 23-27 (2005).
*
-
Friedmann PS, Cooper HL, Healy E. Peroxisome proliferator-activated receptors and their relevance to dermatology.
Acta Derm. Venereol. 85: 194-202 (2005).
*
-
Fruchart JC. Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease.
Atherosclerosis Mar 20 [Epub ahead of print] (2009).
-
Fruchart JC. Novel peroxisome proliferator activated receptor-alpha agonists.
Am. J. Cardiol. 100: S41-S46 (2007).
*
-
Fruchart JC, Duriez P. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
Drugs Today (Barc.) 42: 39-64 (2006).
-
Fruchart JC, Duriez P, Staels B. Molecular mechanism of action of the fibrates.
J. Soc. Biol. 193: 67-75 (1999).
-
Fruchart JC, Duriez P, Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis.
Curr. Opin. Lipidol. 10: 245-257 (1999).
-
Fruchart JC, Staels B, Duriez P. PPARS, metabolic disease and atherosclerosis.
Pharmacol. Res. 44: 345-352 (2001).
*
-
Fu J, Oveisi F, Gaetani S, Lin E, Piomelli D. Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats.
Neuropharmacology 48: 1147-1153 (2005).
*
-
Fu Y, Zheng S, Lin J, Ryerse J, Chen A. Curcumin protects the rat liver from CCl4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation.
Mol. Pharmacol. 73: 399-409 (2008).
*
-
Fuenzalida K, Quintanilla R, Ramos P, Piderit D, Fuentealba RA, Martinez GR, Inestrosa NC, Bronfman M. Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis.
J. Biol. Chem. 282: 37006-37015 (2007).
*
-
Fuenzalida KM, Aguilera MC, Piderit DG, Ramos PC, Contador D, Quinones V, Rigotti A, Bronfman FC, Bronfman M. Peroxisome proliferator-activated receptor gamma is a novel target of the nerve growth factor signaling pathway in PC12 cells.
J. Biol. Chem. 280: 9604-9609 (2005).
*
-
Fujii H. PPARs-mediated intracellular signal transduction.
Nippon Rinsho 63: 565-571 (2005).
-
Fujii H. Anti-inflammatory action of PPARs.
Nippon Rinsho 63: 609-615 (2005).
-
Fujii H. Nuclear receptor PPARs and magnesium.
Clin. Calcium 15: 1814-1826 (2005).
-
Fujimura T, Kimura C, Oe T, Takata Y, Sakuma H, Aramori I, Mutoh S. A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties.
J. Pharmacol. Exp. Ther. 318: 863-871 (2006).
*
-
Fujishiro K, Fukui Y, Sato O, Kawabe K, Seto K, Motojima K. Analysis of tissue-specific and PPARalpha-dependent induction of FABP gene expression in the mouse liver by an in vivo DNA electroporation method.
Mol. Cell. Biochem. 239: 165-172 (2002).
*
-
Fukuda LE, Davel AP, Verissimo-Filho S, Lopes LR, Cachofeiro V, Lahera V, Rossoni LV. Fenofibrate and pioglitazone do not ameliorate the altered vascular reactivity in aorta of isoproterenol-treated rats.
J. Cardiovasc. Pharmacol. 52: 413-421 (2008).
-
Fukuen S, Iwaki M, Yasui A, Makishima M, Matsuda M, Shimomura I. Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity.
J. Biol. Chem. 280: 23653-23659 (2005).
*
-
Fukui N, Honda K, Ito E, Ishikawa K. Peroxisome proliferator-activated receptor-gamma negatively regulates allergic rhinitis in mice.
Allergol. Int. 58: 247-253 (2009).
-
Furnsinn C, Willson TM, Brunmair B. Peroxisome proliferator-activated receptor-delta, a regulator of oxidative capacity, fuel switching and cholesterol transport.
Diabetologia 50: 8-17 (2007).
*
-
Futter M, Diekmann H, Schoenmakers E, Sadiq O, Chatterjee K, Rubinsztein DC. Wild-type but not mutant huntingtin modulates the transcriptional activity of liver X receptors.
J. Med. Genet. May 17 [Epub ahead of print] (2009).
*
-
Fyffe SA, Alphey MS, Buetow L, Smith TK, Ferguson MA, Sorensen MD, Bjorkling F, Hunter WN. Recombinant human PPAR-beta/delta ligand-binding domain is locked in an activated conformation by endogenous fatty acids.
J. Mol. Biol. 356: 1005-1013 (2006).
*
-
Gacka M, Adamiec R. Mutations of peroxisome proliferator-activated receptor gamma (PPARgamma): clinical implications.
Postepy. Hig. Med. Dosw. (Online) 58: 483-489 (2004).
-
Gacka M, Bednarska-Chabowska D, Dobosz T, Szymaniec S, Jakobsche U, Lebioda A, Adamiec R. The Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma and immunological processes in patients with type 2 diabetes and insulin resistance.
Przegl. Lek. 64: 393-397 (2007).
-
Gaetani S, Kaye WH, Cuomo V, Piomelli D. Role of endocannabinoids and their analogues in obesity and eating disorders.
Eat. Weight Disord. 13: e42-e48 (2008).
-
Gaetano C, Colussi C, Capogrossi MC. PEDF, PPAR-gamma, p53: deadly circuits arise when worlds collide.
Cardiovasc. Res. 76: 195-196 (2007).
*
-
Galan-Rodriguez B, Suarez J, Gonzalez-Aparicio R, Bermudez-Silva FJ, Maldonado R, Robledo P, Rodriguez de Fonseca F, Fernandez-Espejo E. Oleoylethanolamide exerts partial and dose-dependent neuroprotection of substantia nigra dopamine neurons.
Neuropharmacology 56: 653-664 (2009).
-
Gale SE, Frolov A, Han X, Bickel PE, Cao L, Bowcock A, Schaffer JE, Ory DS. A regulatory role for 1-acylglycerol-3-phosphate-O-acyltransferase 2 in adipocyte differentiation.
J. Biol. Chem. 281: 11082-11089 (2006).
*
-
Gallardo-Soler A, Gomez-Nieto C, Luisa Campo M, Marathe C, Tontonoz P, Castrillo A, Corraliza I. Arginase I induction by modified lipoproteins in macrophages: a peroxisome proliferator-activated receptor-gamma/delta-mediated effect that links lipid metabolism and immunity.
Mol. Endocrinol. 22: 1394-1402 (2008).
*
-
Galli A, Ceni E, Crabb DW, Mello T, Salzano R, Grappone C, Milani S, Surrenti E, Surrenti C, Casini A. Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms.
Gut 53: 1688-1697 (2004).
*
-
Galli A, Mello T, Ceni E, Surrenti E, Surrenti C. The potential of antidiabetic thiazolidinediones for anticancer therapy.
Expert Opin. Investig. Drugs 15: 1039-1049 (2006).
-
Galli A, Pinaire J, Fischer M, Dorris R, Crabb DW. The transcriptional and DNA binding activity of peroxisome proliferator-activated receptor alpha is inhibited by ethanol metabolism. A novel mechanism for the development of ethanol-induced fatty liver.
J. Biol. Chem. 276: 68-75 (2001).
*
-
Gallicchio L, Kalesan B, Huang HY, Strickland P, Hoffman SC, Helzlsouer KJ. Genetic polymorphisms of peroxisome proliferator-activated receptors and the risk of cardiovascular morbidity and mortality in a community-based cohort in Washington county, Maryland.
PPAR Res. 2008: 276581 (2008).
*
-
Gambero A, Marostica M, Abdalla Saad MJ, Pedrazzoli J. Mesenteric adipose tissue alterations resulting from experimental reactivated colitis.
Inflamm. Bowel Dis. 13: 1357-1364 (2007).
*
-
Gampe RT Jr, Montana VG, Lambert MH, Miller AB, Bledsoe RK, Milburn MV, Kliewer SA, Willson TM, Xu HE. Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors.
Mol. Cell 5: 545-555 (2000).
*
-
Gan Q, Huang J, Zhou R, Niu J, Zhu X, Wang J, Zhang Z, Tong T. PPARgamma accelerates cellular senescence by inducing p16INK4alpha expression in human diploid fibroblasts.
J. Cell. Sci. 121: 2235-2245 (2008).
*
-
Gani OA. Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists?
Cardiovasc. Diabetol. 7: 6 (2008).
*
-
Gani OA, Sylte I. Molecular recognition of docosahexaenoic acid by peroxisome proliferator-activated receptors and retinoid-X receptor alpha.
J. Mol. Graph Model. 27: 217-224 (2008).
*
-
Garcia-Bueno B, Caso JR, Perez-Nievas BG, Lorenzo P, Leza JC. Effects of peroxisome proliferator-activated receptor gamma agonists on brain glucose and glutamate transporters after stress in rats.
Neuropsychopharmacology 32: 1251-1260 (2007).
-
Garcia-Bueno B, Madrigal JL, Perez-Nievas BG, Leza JC. Stress mediators regulate brain prostaglandin synthesis and peroxisome proliferator-activated receptor-gamma activation after stress in rats.
Endocrinology 149: 1969-1978 (2008).
*
-
Garcia-Verdugo I, Tattermusch S, Leduc D, Dif F, Touqui L. Regulation of MUC5AC expression by arachidonic acid metabolites.
Rev. Mal. Respir. 25: 1187 (2008).
-
Gardner OS, Dewar BJ, Graves LM. Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: an example of non-genomic signaling.
Mol. Pharmacol. 68: 933-941 (2005).
*
-
Garenc C, Aubert S, Laroche J, Girouard J, Vohl MC, Bergeron J, Rousseau F, Julien P. Population prevalence of APOE, APOC3 and PPAR-alpha mutations associated to hypertriglyceridemia in French Canadians.
J. Hum. Genet. 49: 691-700 (2004).
*
-
Gatfield D, Le Martelot G, Vejnar CE, Gerlach D, Schaad O, Fleury-Olela F, Ruskeepaa AL, Oresic M, Esau CC, Zdobnov EM, Schibler U. Integration of microRNA miR-122 in hepatic circadian gene expression.
Genes Dev. 23: 1313-1326 (2009).
*
-
Gatica A, Aguilera MC, Contador D, Loyola G, Pinto CO, Amigo L, Tichauer JE, Zanlungo S, Bronfman M. The cytochromes P450 CYP2C epoxygenase and CYP4A omega-hydroxylase mediate ciprofibrate-induced PPAR alpha-dependent peroxisomal proliferation in isolated rat liver cells.
J. Lipid Res. 48: 924-934 (2007).
*
-
Gaudel C, Schwartz C, Giordano C, Abumrad NA, Grimaldi P. Pharmacological activation of PPARbeta promotes rapid and calcineurin-dependent fiber remodeling and angiogenesis in mouse skeletal muscle.
Am. J. Physiol. Endocrinol. Metab. 295: E297-E304 (2008).
*
-
Gaudel CL, Grimaldi PA. Metabolic functions of peroxisome proliferator-activated receptor beta/delta in skeletal muscle.
PPAR Res. 2007: 86394 (2007).
*
-
Gauglitz GG, Herndon DN, Jeschke MG. Insulin resistance postburn: underlying mechanisms and current therapeutic strategies.
J. Burn Care Res. 29: 683-694 (2008).
-
Gaulton KJ, Willer CJ, Li Y, Scott LJ, Conneely KN, Jackson AU, Duren WL, Chines PS, Narisu N, Bonnycastle LL, Luo J, Tong M, Sprau AG, Pugh EW, Doheny KF, Valle TT, Abecasis GR, Tuomilehto J, Bergman RN, Collins FS, Boehnke M, Mohlke KL. Comprehensive association study of type 2 diabetes and related quantitative traits with 222 candidate genes.
Diabetes 57: 3136-3144 (2008).
-
Gbaguidi GF, Agellon LB. The atypical interaction of peroxisome proliferator-activated receptor alpha with liver X receptor alpha antagonizes the stimulatory effect of their respective ligands on the murine cholesterol 7alpha-hydroxylase gene promoter.
Biochim. Biophys. Acta 1583: 229-236 (2002).
*
-
Gbaguidi GF, Agellon LB. The inhibition of the human cholesterol 7alpha-hydroxylase gene (CYP7A1) promoter by fibrates in cultured cells is mediated via the liver X receptor alpha and peroxisome proliferator-activated receptor alpha heterodimer.
Nucleic Acids Res. 32: 1113-1121 (2004).
*
-
Ge K, Cho YW, Guo H, Hong TB, Guermah M, Ito M, Yu H, Kalkum M, Roeder RG. Alternative mechanisms by which mediator subunit MED1/TRAP220 regulates peroxisome proliferator-activated receptor gamma-stimulated adipogenesis and target gene expression.
Mol. Cell. Biol. 28: 1081-1091 (2008).
*
-
Gealekman O, Burkart A, Chouinard M, Nicoloro S, Straubhaar J, Corvera S. Enhanced angiogenesis in obesity and in response to PPARgamma activators through adipocyte VEGF and ANGPTL4 production.
Am. J. Physiol. Endocrinol. Metab. 295: E1056-E1064 (2008).
*
-
Geese WJ, Achanzar W, Rubin C, Hariharan N, Cheng P, Tomlinson L, Ordway N, Dracopoli NC, Delmonte T, Hui L, Krishnan B, Cosma G, Ranade K. Genetic and gene expression studies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-activated receptor gamma agonists.
Pharmacogenet. Genomics 18: 903-910 (2008).
-
Gelinas DS, McLaurin J. PPAR-alpha expression inversely correlates with inflammatory cytokines IL-1beta and TNF-alpha in aging rats.
Neurochem. Res. 30: 1369-1375 (2005).
*
-
Gelinas R, Labarthe F, Bouchard B, Janie MD, Guy C, Young ME, Des Rosiers C. Alterations in carbohydrate metabolism and its regulation in PPAR alpha null mouse hearts.
Am. J. Physiol. Heart Circ. Physiol. 294: H1571-H1580 (2008).
*
-
Gelman L, Feige JN, Desvergne B. Molecular basis of selective PPARgamma modulation for the treatment of type 2 diabetes.
Biochim. Biophys. Acta 1771: 1094-1107 (2007).
*
-
Gelman L, Fruchart JC, Auwerx J. An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer.
Cell. Mol. Life Sci. 55: 932-943 (1999).
*
-
Gelman L, Michalik L, Desvergne B, Wahli W. Kinase signaling cascades that modulate peroxisome proliferator-activated receptors.
Curr. Opin. Cell Biol. 17: 216-222 (2005).
*
-
Genini D, Carbone GM, Catapano CV. Multiple interactions between peroxisome proliferators-activated receptors and the ubiquitin-proteasome system and implications for cancer pathogenesis.
PPAR Res. 2008: 195065 (2008).
*
-
Genini D, Catapano CV. Block of nuclear receptor ubiquitination. A mechanism of ligand-dependent control of peroxisome proliferator-activated receptor delta activity.
J. Biol. Chem. 282: 11776-11785 (2007).
*
-
Genini D, Catapano CV. Control of peroxisome proliferator-activated receptor fate by the ubiquitin-proteasome system.
J. Recept. Signal Transduct. Res. 26: 679-692 (2006).
-
Genolet R, Wahli W, Michalik L. PPARs as drug targets to modulate inflammatory responses?
Curr. Drug Targets Inflamm. Allergy 3: 361-375 (2004).
-
Genovese T, Esposito E, Mazzon E, Crisafulli C, Paterniti I, Di Paola R, Galuppo M, Bramanti P, Cuzzocrea S. PPAR-alpha modulate the anti-inflammatory effect of glucocorticoids in the secondary damage in experimental spinal cord trauma.
Pharmacol. Res. 59: 338-350 (2009).
*
-
Genovese T, Esposito E, Mazzon E, Di Paola R, Meli R, Bramanti P, Piomeli D, Calignano A, Cuzzocrea S. Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury.
J. Pharmacol. Exp. Ther. 326: 12-23 (2008).
*
-
Genovese T, Mazzon E, Di Paola R, Muia C, Crisafulli C, Caputi AP, Cuzzocrea S. Role of endogenous and exogenous ligands for the peroxisome proliferator-activated receptor-alpha in the development of bleomycin-induced lung injury.
Shock 24: 547-555 (2005).
*
-
Genovese T, Mazzon E, Di Paola R, Muia C, Crisafulli C, Malleo G, Esposito E, Cuzzocrea S. Role of peroxisome proliferator-activated receptor-alpha in acute pancreatitis induced by cerulein.
Immunology 118: 559-570 (2006).
*
-
George J, Liddle C. Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets.
Mol. Pharm. 5: 49-59 (2008).
*
-
Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis.
World J. Gastroenterol. 15: 942-954 (2009).
*
-
Gerhold DL, Liu F, Jiang G, Li Z, Xu J, Lu M, Sachs JR, Bagchi A, Fridman A, Holder DJ, Doebber TW, Berger J, Elbrecht A, Moller DE, Zhang BB. Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-gamma agonists.
Endocrinology 143: 2106-2118 (2002).
*
-
Gerin I, Bommer GT, Lidell ME, Cederberg A, Enerback S, Macdougald OA. On the role of FOX transcription factors in adipocyte differentiation and insulin-stimulated glucose uptake.
J. Biol. Chem. 284: 10755-10763 (2009).
*
-
Gervois P, Chopin-Delannoy S, Fadel A, Dubois G, Kosykh V, Fruchart JC, Najïb J, Laudet V, Staels B. Fibrates increase human REV-ERBalpha expression in liver via a novel peroxisome proliferator-activated receptor response element.
Mol. Endocrinol. 13: 400-409 (1999).
*
-
Gervois P, Fruchart JC, Staels B. Drug insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors.
Nat. Clin. Pract. Endocrinol. Metab. 3: 145-156 (2007).
*
-
Gervois P, Fruchart JC, Staels B. Inflammation, dyslipidaemia, diabetes and PPARs: pharmacological interest of dual PPARalpha and PPARgamma agonists.
Int. J. Clin. Pract. Suppl. 143: 22-29 (2004).
-
Gervois P, Kleemann R, Pilon A, Percevault F, Koenig W, Staels B, Kooistra T. Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate.
J. Biol. Chem. 279: 16154-1660 (2004).
*
-
Gervois P, Torra IP, Fruchart JC, Staels B. Regulation of lipid and lipoprotein metabolism by PPAR activators.
Clin. Chem. Lab. Med. 38: 3-11 (2000).
-
Ghanaat-Pour H, Sjoholm A. Gene expression regulated by pioglitazone and exenatide in normal and diabetic rat islets exposed to lipotoxicity.
Diabetes Metab. Res. Rev. 25: 163-184 (2009).
-
Ghosh AK, Bhattacharyya S, Wei J, Kim S, Barak Y, Mori Y, Varga J. Peroxisome proliferator-activated receptor-gamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator.
FASEB J. Apr 24 [Epub ahead of print] (2009).
*
-
Ghosh AK, Wei J, Wu M, Varga J. Constitutive Smad signaling and Smad-dependent collagen gene expression in mouse embryonic fibroblasts lacking peroxisome proliferator-activated receptor-gamma.
Biochem. Biophys. Res. Commun. 374: 231-236 (2008).
*
-
Ghosh M, Ai Y, Narko K, Wang Z, Peters JM, Hla T. PPARdelta is pro-tumorigenic in a mouse model of COX-2-induced mammary cancer.
Prostaglandins Other Lipid Mediat. 88: 97-100 (2009).
-
Ghosh M, Wang H, Ai Y, Romeo E, Luyendyk JP, Peters JM, Mackman N, Dey SK, Hla T. COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARdelta activation.
J. Exp. Med. 204: 2053-2061 (2007).
*
-
Ghoussaini M, Meyre D, Lobbens S, Charpentier G, Clement K, Charles MA, Tauber M, Weill J, Froguel P. Implication of the Pro12Ala polymorphism of the PPAR-gamma 2 gene in type 2 diabetes and obesity in the French population.
BMC Med. Genet. 6: 11 (2005).
*
-
Giaginis C, Katsamangou E, Tsourouflis G, Zizi-Serbetzoglou D, Kouraklis G, Theocharis S. Peroxisome proliferator-activated receptor-gamma and retinoid X receptor-alpha expression in pancreatic ductal adenocarcinoma: association with clinicopathological parameters, tumor proliferative capacity, and patients' survival.
Med. Sci. Monit. 15: BR148-BR156 (2009).
-
Giaginis C, Margeli A, Theocharis S. Peroxisome proliferator-activated receptor-gamma ligands as investigational modulators of angiogenesis.
Expert Opin. Investig. Drugs 16: 1561-1572 (2007).
-
Giaginis C, Spanopoulou E, Theocharis S. PPAR-gamma signaling pathway in placental development and function: a potential therapeutic target in the treatment of gestational diseases.
Expert Opin. Ther. Targets 12: 1049-1063 (2008).
-
Giaginis C, Theocharis S, Tsantili-Kakoulidou A. Investigation of the lipophilic behaviour of some thiazolidinediones. Relationships with PPAR-gamma activity.
J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 857: 181-187 (2007).
-
Giaginis C, Theocharis S, Tsantili-Kakoulidou A. Quantitative structure-activity relationships for PPAR-gamma binding and gene transactivation of tyrosine-based agonists using multivariate statistics.
Chem. Biol. Drug Des. 72: 257-264 (2008).
-
Giaginis C, Tsantili-Kakoulidou A, Theocharis S. Peroxisome proliferator-activated receptor-gamma ligands as bone turnover modulators.
Expert Opin. Investig. Drugs 16: 195-207 (2007).
-
Giaginis C, Tsantili-Kakoulidou A, Theocharis S. Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism.
Fundam. Clin. Pharmacol. 21: 231-244 (2007).
*
-
Giaginis C, Tsantili-Kakoulidou A, Theocharis S. Peroxisome proliferator-activated receptor-gamma ligands: potential pharmacological agents for targeting the angiogenesis signaling cascade in cancer.
PPAR Res. 2008: 431763 (2008).
*
-
Giaginis C, Tsourouflis G, Theocharis S. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands: novel pharmacological agents in the treatment of ischemia reperfusion injury.
Curr. Mol. Med. 8: 562-579 (2008).
-
Giercksky KE. COX-2 inhibition and prevention of cancer.
Best Pract. Res. Clin. Gastroenterol. 15: 821-833 (2001).
*
-
Gilde AJ, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors at the crossroads of obesity, diabetes, and cardiovascular disease.
J. Am. Coll. Cardiol. 48: A24-A32 (2006).
-
Gilde AJ, Van Bilsen M. Peroxisome proliferator-activated receptors (PPARS): regulators of gene expression in heart and skeletal muscle.
Acta Physiol. Scand. 178: 425-434 (2003).
*
-
Gilles S, Mariani V, Bryce M, Mueller MJ, Ring J, Jakob T, Pastore S, Behrendt H, Traidl-Hoffmann C. Pollen-derived E1-phytoprostanes signal via PPAR-gamma and NF-kappaB-dependent mechanisms.
J. Immunol. 182: 6653-6658 (2009).
-
Gillio-Meina C, Phang S, Mather J, Knight B, Kennedy T. Expression patterns and role of prostaglandin-endoperoxide synthases, prostaglandin E synthases, prostacyclin synthase, prostacyclin receptor, peroxisome proliferator-activated receptor delta (PPARD) and retinoid X receptor alpha (RXRA) in rat
Reproduction 137: 537-552 (2009).
-
Gimble JM, Robinson CE, Wu X, Kelly KA, Rodriguez BR, Kliewer SA, Lehmann JM, Morris DC. Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells.
Mol. Pharmacol. 50: 1087-1094 (1996).
*
-
Giordano TJ, Au AY, Kuick R, Thomas DG, Rhodes DR, Wilhelm KG Jr, Vinco M, Misek DE, Sanders D, Zhu Z, Ciampi R, Hanash S, Chinnaiyan A, Clifton-Bligh RJ, Robinson BG, Nikiforov YE, Koenig RJ. Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation.
Clin. Cancer Res. 12: 1983-1993 (2006).
*
-
Giral H, Villa-Bellosta R, Catalan J, Sorribas V. Cytotoxicity of peroxisome proliferator-activated receptor alpha and gamma agonists in renal proximal tubular cell lines.
Toxicol. In Vitro 21: 1066-1076 (2007).
-
Girnun GD, Naseri E, Vafai SB, Qu L, Szwaya JD, Bronson R, Alberta JA, Spiegelman BM. Synergy between PPARgamma ligands and platinum-based drugs in cancer.
Cancer Cell 11: 395-406 (2007).
*
-
Gizard F, Amant C, Barbier O, Bellosta S, Robillard R, Percevault F, Sevestre H, Krimpenfort P, Corsini A, Rochette J, Glineur C, Fruchart JC, Torpier G, Staels B. PPARalpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16.
J. Clin. Invest. 115: 3228-3238 (2005).
*
-
Gizard F, Bruemmer D. Transcriptional control of vascular smooth muscle cell proliferation by peroxisome proliferator-activated receptor-gamma: therapeutic implications for cardiovascular diseases.
PPAR Res. 2008: 429123 (2008).
*
-
Gizard F, Nomiyama T, Zhao Y, Findeisen HM, Heywood EB, Jones KL, Staels B, Bruemmer D. The PPARalpha/p16INK4a pathway inhibits vascular smooth muscle cell proliferation by repressing cell cycle-dependent telomerase activation.
Circ. Res. 103: 1155-1163 (2008).
-
Glass CK, Ogawa S. Combinatorial roles of nuclear receptors in inflammation and immunity.
Nat. Rev. Immunol. 6: 44-55 (2006).
*
-
Gloerich J, Ijlst L, Wanders RJ, Ferdinandusse S. Bezafibrate induces FALDH in human fibroblasts; implications for Sjogren-Larsson syndrome.
Mol. Genet. Metab. 89: 111-115 (2006).
*
-
Gloerich J, van den Brink DM, Ruiter JP, van Vlies N, Vaz FM, Wanders RJ, Ferdinandusse S. Metabolism of phytol to phytanic acid in the mouse and the role of PPARalpha in its regulation.
J. Lipid Res. 48: 77-85 (2007).
*
-
Gocke AR, Hussain RZ, Yang Y, Peng H, Weiner J, Ben LH, Drew PD, Stuve O, Lovett-Racke AE, Racke MK. Transcriptional modulation of the immune response by peroxisome proliferator-activated receptor-alpha agonists in autoimmune disease.
J. Immunol. 182: 4479-4487 (2009).
-
Goetzman ES. The regulation of acyl-CoA dehydrogenases in adipose tissue by rosiglitazone.
Obesity (Silver Spring) 17: 196-198 (2009).
*
-
Goetzman ES, Tian L, Wood PA. Differential induction of genes in liver and brown adipose tissue regulated by peroxisome proliferator-activated receptor-alpha during fasting and cold exposure in acyl-CoA dehydrogenase-deficient mice.
Mol. Genet. Metab. 84: 39-47 (2005).
*
-
Gogolak P, Rethi B, Szatmari I, Lanyi A, Dezso B, Nagy L, Rajnavolgyi E. Differentiation of CD1a- and CD1a+ monocyte-derived dendritic cells is biased by lipid environment and PPARgamma.
Blood 109: 643-652 (2007).
*
-
Gohlke JM, Thomas R, Zhang Y, Rosenstein MC, Davis AP, Murphy C, Becker KG, Mattingly CJ, Portier CJ. Genetic and environmental pathways to complex diseases.
BMC Syst. Biol. 3: 46 (2009).
*
-
Goke B, Gause-Nilsson I, Persson A; On Behalf Of The Gallant 8 Study Group. The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes.
Diab. Vasc. Dis. Res. 4: 204-213 (2007).
-
Goldstein BJ, Rosenstock J, Anzalone D, Tou C, Ohman KP. Effect of tesaglitazar, a dual PPARalpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial.
Curr. Med. Res. Opin. 22: 2575-2590 (2006).
-
Golembesky AK, Gammon MD, North KE, Bensen JT, Schroeder JC, Teitelbaum SL, Neugut AI, Santella RM. Peroxisome proliferator-activated receptor-alpha (PPARA) genetic polymorphisms and breast cancer risk: a Long Island ancillary study.
Carcinogenesis 29: 1944-1949 (2008).
*
-
Gollamudi R, Gupta D, Goel S, Mani S. Novel orphan nuclear receptors-coregulator interactions controlling anti-cancer drug metabolism.
Curr. Drug Metab. 9: 611-613 (2008).
-
Gomes Mde B. Glitazones and the metabolic syndrome: mechanism of action, pathophysiology and therapeutic indications.
Arq. Bras. Endocrinol. Metabol. 50: 271-280 (2006).
-
Gong H, Xie W. Orphan nuclear receptors, PXR and LXR: new ligands and therapeutic potential.
Expert Opin. Ther. Targets 8: 49-54 (2004).
-
Gong X, Tsai SW, Yan B, Rubin LP. Cooperation between MEF2 and PPARgamma in human intestinal beta,beta-carotene 15,15'-monooxygenase gene expression.
BMC Mol. Biol. 7: 7 (2006).
*
-
Gong Z, Huang C, Sheng X, Zhang Y, Li Q, Wang MW, Peng L, Zang YQ. The role of tanshinone IIA in the treatment of obesity through peroxisome proliferator-activated receptor gamma antagonism.
Endocrinology 150: 104-113 (2009).
*
-
Gong Z, Xie D, Deng Z, Bostick RM, Muga SJ, Hurley TG, Hebert JR. The PPARgamma Pro12Ala polymorphism and risk for incident sporadic colorectal adenomas.
Carcinogenesis 26: 579-585 (2005).
*
-
Gonthier MP, Hoareau L, Festy F, Matias I, Valenti M, Bes-Houtmann S, Rouch C, Robert-Da Silva C, Chesne S, Lefebvre d'Hellencourt C, Cesari M, Di Marzo V, Roche R. Identification of endocannabinoids and related compounds in human fat cells.
Obesity (Silver Spring) 15: 837-845 (2007).
*
-
Gonzalez FJ. Recent update on the PPAR alpha-null mouse.
Biochimie 79: 139-144 (1997).
-
Gonzalez FJ, Cheung C. Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment.
J. Pharmacol. Exp. Ther. 327: 288-299 (2008).
-
Gonzalez FJ, Fernandez-Salguero P, Lee SS, Pineau T, Ward JM. Xenobiotic receptor knockout mice.
Toxicol. Lett. 82-83: 117-121 (1995).
-
Gonzalez FJ, Shah YM. PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators.
Toxicology 246: 2-8 (2008).
*
-
Gonzalez R, Collado JA, Nell S, Briceno J, Tamayo MJ, Fraga E, Bernardos A, Lopez-Cillero P, Pascussi JM, Rufian S, Vilarem MJ, Mata Mde L, Brigelius-Flohe R, Maurel P, Muntane J. Cytoprotective properties of alpha-tocopherol are related to gene regulation in cultured D-galactosamine-treated human hepatocytes.
Free Radic. Biol. Med. 43: 1439-1452 (2007).
-
Gonzalez-Periz A, Planaguma A, Gronert K, Miquel R, Lopez-Parra M, Titos E, Horrillo R, Ferre N, Deulofeu R, Arroyo V, Rodes J, Claria J. Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA.
FASEB J. 20: 2537-2539 (2006).
*
-
Gopinathan L, Hannon DB, Peters JM, Vanden Heuvel JP. Regulation of peroxisome proliferator-activated receptor-alpha by MDM2.
Toxicol. Sci. 108: 48-58 (2009).
*
-
Gopinathan L, Hannon DB, Smith Iii RW, Peters JM, Vanden Heuvel JP. Regulation of peroxisome proliferator-activated receptors by E6-associated protein.
PPAR Res. 2008: 746935 (2008).
*
-
Gordon JN, Sabatino AD, Macdonald TT. The pathophysiologic rationale for biological therapies in inflammatory bowel disease.
Curr. Opin. Gastroenterol. 21: 431-437 (2005).
-
Gorla-Bajszczak A, Juge-Aubry C, Pernin A, Burger AG, Meier CA. Conserved amino acids in the ligand-binding and tau(i) domains of the peroxisome proliferator-activated receptor alpha are necessary for heterodimerization with RXR.
Mol. Cell. Endocrinol. 147: 37-47 (1999).
-
Goto T, Takahashi N, Kato S, Egawa K, Ebisu S, Moriyama T, Fushiki T, Kawada T. Phytol directly activates peroxisome proliferator-activated receptor alpha (PPARalpha) and regulates gene expression involved in lipid metabolism in PPARalpha-expressing HepG2 hepatocytes.
Biochem. Biophys. Res. Commun. 337: 440-445 (2005).
*
-
Gotoh S, Ohgari Y, Nakamura T, Osumi T, Taketani S. Heme-binding to the nuclear receptor retinoid X receptor alpha (RXRalpha) leads to the inhibition of the transcriptional activity.
Gene 423: 207-214 (2008).
*
-
Gould Rothberg BE, Sundseth SS, DiPippo VA, Brown PJ, Winegar DA, Gottshalk WK, Shenoy SG, Rothberg JM. The characterization of PPAR alpha ligand drug action in an in vivo model by comprehensive differential gene expression profiling.
Funct. Integr. Genomics 1: 294-304 (2001).
*
-
Gouni-Berthold I, Giannakidou E, Faust M, Berthold HK, Krone W. The peroxisome proliferator-activated receptor delta +294T/C polymorphism in relation to lipoprotein metabolism in patients with diabetes mellitus type 2 and in non-diabetic controls.
Atherosclerosis 183: 336-341 (2005).
-
Gouni-Berthold I, Krone W. Peroxisome proliferator-activated receptor alpha (PPARalpha) and athero-sclerosis.
Curr. Drug Targets Cardiovasc. Haematol. Disord. 5: 513-523 (2005).
-
Goyenechea E, Dolores Parra M, Alfredo Martinez J. Weight regain after slimming induced by an energy-restricted diet depends on interleukin-6 and peroxisome-proliferator-activated-receptor-gamma2 gene polymorphisms.
Br. J. Nutr. 96: 965-972 (2006).
*
-
Grabacka M, Plonka PM, Urbanska K, Reiss K. Peroxisome proliferator-activated receptor alpha activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt.
Clin. Cancer Res. 12: 3028-3036 (2006).
*
-
Grabacka M, Reiss K. Anticancer properties of PPARalpha - effects on cellular metabolism and inflammation.
PPAR Res. 2008: 930705 (2008).
*
-
Grau R, Diaz-Munoz MD, Cacheiro-Llaguno C, Fresno M, Iniguez MA. Role of peroxisome proliferator-activated receptor alpha in the control of cyclooxygenase 2 and vascular endothelial growth factor: involvement in tumor growth.
PPAR Res. 2008: 352437 (2008).
*
-
Gray SL, Dalla Nora E, Vidal-Puig AJ. Mouse models of PPAR-gamma deficiency: dissecting PPAR-gamma's role in metabolic homoeostasis.
Biochem. Soc. Trans. 33: 1053-1058 (2005).
*
-
Green S. PPAR: a mediator of peroxisome proliferator action.
Mutat. Res. 333: 101-109 (1995).
-
Green S, Wahli W. Peroxisome proliferator-activated receptors: finding the orphan a home.
Mol. Cell. Endocrinol. 100: 149-153 (1994).
*
-
Greger DL, Gropp F, Morel C, Sauter S, Blum JW. Nuclear receptor and target gene mRNA abundance in duodenum and colon of dogs with chronic enteropathies.
Domest. Anim. Endocrinol. 31: 327-329 (2006).
*
-
Gregoire FM, Zhang F, Clarke HJ, Gustafson TA, Sears DD, Favelyukis S, Lenhard J, Rentzeperis D, Clemens LE, Mu Y, Lavan BE. MBX-102/JNJ39659100, a novel peroxisome proliferator activated receptor-gamma ligand with weak transactivation activity retains full anti-diabetic properties in the absence of side effects.
Mol. Endocrinol. Apr 23 [Epub ahead of print] (2009).
*
-
Gremlich S, Nolan C, Roduit R, Burcelin R, Peyot ML, Delghingaro-Augusto V, Desvergne B, Michalik L, Prentki M, Wahli W. Pancreatic islet adaptation to fasting is dependent on PPARalpha transcriptional up-regulation of fatty acid oxidation.
Endocrinology 146: 375-382 (2005).
*
-
Grenier E, Schwalm Maupas F, Beaulieu JF, Seidman EG, Delvin E, Sane AT, Tremblay E, Garofalo C, Levy E. Effect of retinoic acid on cell proliferation and differentiation as well as on lipid synthesis, lipoprotein secretion and apolipoprotein biogenesis.
Am. J. Physiol. Gastrointest. Liver Physiol. 293: G1178-G1189 (2007).
*
-
Gressner OA, Gao C, Rehbein K, Lahme B, Siluschek M, Berg T, Muller T, Gressner AM. Elevated concentrations of 15-deoxy-delta12,14-prostaglandin J2 in chronic liver disease propose therapeutic trials with peroxisome proliferator activated receptor gamma-inducing drugs.
Liver Int. 29: 730-735 (2009).
*
-
Grey A. Thiazolidinedione-induced skeletal fragility - mechanisms and implications.
Diabetes Obes. Metab. 11: 275-284 (2009).
*
-
Griesbacher T, Pommer V, Schuligoi R, Tiran B, Peskar BA. Anti-inflammatory actions of perfluorooctanoic acid and peroxisome proliferator-activated receptors (PPAR) alpha and gamma in experimental acute pancreatitis.
Int. Immunopharmacol. 8: 325-329 (2008).
-
Grimaldi PA. Regulatory functions of PPARbeta in metabolism: implications for the treatment of metabolic syndrome.
Biochim. Biophys. Acta 1771: 983-990 (2007).
*
-
Grimaldi PA. Peroxisome proliferator-activated receptors as sensors of fatty acids and derivatives.
Cell. Mol. Life Sci. 64: 2459-2464 (2007).
*
-
Grobe JL, Venegas-Pont MR, Sigmund CD, Ryan MJ. The PPARgamma agonist rosiglitazone enhances rat brown adipose tissue lipogenesis from glucose without altering glucose uptake.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 296: R1325-R1326 (2009).
*
-
Gross B, Staels B. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.
Best Pract. Res. Clin. Endocrinol. Metab. 21: 687-710 (2007).
-
Grozovsky R, Ribich S, Rosene ML, Mulcahey MA, Huang SA, Patti ME, Bianco AC, Kim BW. Type 2 deiodinase expression is induced by PPAR-gamma agonists in skeletal myocytes.
Endocrinology 150: 1976-1983 (2009).
*
-
Grun F, Watanabe H, Zamanian Z, Maeda L, Arima K, Chubacha R, Gardiner DM, Kanno J, Iguchi T, Blumberg B. Endocrine disrupting organotin compounds are potent inducers of adipogenesis in vertebrates.
Mol. Endocrinol. 20: 2141-2155 (2006).
*
-
Guan Y. Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome.
J. Am. Soc. Nephrol. 15: 2801-2815 (2004).
*
-
Guan Y. Targeting peroxisome proliferator-activated receptors (PPARs) in kidney and urologic disease.
Minerva Urol. Nefrol. 54: 65-79 (2002).
-
Guan Y, Breyer MD. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease.
Kidney Int. 60: 14-30 (2001).
*
-
Guan Y, Zhang Y, Breyer MD. The role of PPARs in the transcriptional control of cellular processes.
Drug News Perspect. 15: 147-154 (2002).
-
Gudbrandsen OA, Rodríguez E, Wergedahl H, Mørk S, Reseland JE, Skorve J, Palou A, Berge RK. Trans-10, cis-12-conjugated linoleic acid reduces the hepatic triacylglycerol content and the leptin mRNA level in adipose tissue in obese Zucker fa/fa rats.
Br. J. Nutr. Mar 19 [Epub ahead of print] (2009).
*
-
Guerre-Millo M, Rouault C, Poulain P, Andre J, Poitout V, Peters JM, Gonzalez FJ, Fruchart JC, Reach G, Staels B. PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance.
Diabetes 50: 2809-2814 (2001).
*
-
Guettier JM, Park JY, Cochran EK, Poitou C, Basdevant A, Meier M, Clement K, Magre J, Gorden P. Leptin therapy for partial lipodystrophy linked to a PPAR-gamma mutation.
Clin. Endocrinol. (Oxf.) 68: 547-554 (2008).
*
-
Gui Y, Cai Z, Silha JV, Murphy LJ. Variations in parametrial white adipose tissue mass during the mouse estrous cycle: relationship with the expression of peroxisome proliferator-activated receptor-gamma and retinoic acid receptor-alpha.
Can. J. Physiol. Pharmacol. 84: 887-892 (2006).
-
Guilherme A, Tesz GJ, Guntur KV, Czech MP. Tumor necrosis factor-alpha induces caspase-mediated cleavage of peroxisome proliferator-activated receptor gamma in adipocytes.
J. Biol. Chem. 284: 17082-17091 (2009).
*
-
Guillot N, Debard C, Calzada C, Vidal H, Lagarde M, Vericel E. Effects of docosahexaenoic acid on some megakaryocytic cell gene expression of some enzymes controlling prostanoid synthesis.
Biochem. Biophys. Res. Commun. 372: 924-928 (2008).
*
-
Guillou H, Martin P, Jan S, D'Andrea S, Roulet A, Catheline D, Rioux V, Pineau T, Legrand P. Comparative effect of fenofibrate on hepatic desaturases in wild-type and peroxisome proliferator-activated receptor alpha-deficient mice.
Lipids 37: 981-989 (2002).
-
Gundling F, Schumm-Draeger PM, Schepp W. Hepatogenous diabetes - diagnostics and treatment.
Z. Gastroenterol. 47: 436-445 (2009).
-
Gunther T, Schule R. Fat or bone? A non-canonical decision.
Nat. Cell Biol. 9: 1229-1231 (2007).
*
-
Guo CB, Li S. Advances in the study of anti-atherosclerosis drugs.
Yao Xue Xue Bao 42: 231-235 (2007).
-
Guo D, Sarkar J, Ahmed MR, Viswakarma N, Jia Y, Yu S, Sambasiva Rao M, Reddy JK. Peroxisome proliferator-activated receptor (PPAR)-binding protein (PBP) but not PPAR-interacting protein (PRIP) is required for nuclear translocation of constitutive androstane receptor in mouse liver.
Biochem. Biophys. Res. Commun. 347: 485-495 (2006).
*
-
Guo D, Sarkar J, Suino-Powell K, Xu Y, Matsumoto K, Jia Y, Yu S, Khare S, Haldar K, Rao MS, Foreman JE, Monga SP, Peters JM, Xu HE, Reddy JK. Induction of nuclear translocation of constitutive androstane receptor by peroxisome proliferator-activated receptor alpha synthetic ligands in mouse liver.
J. Biol. Chem. 282: 36766-36776 (2007).
*
-
Guo GL, Choudhuri S, Klaassen CD. Induction profile of rat organic anion transporting polypeptide 2 (oatp2) by prototypical drug-metabolizing enzyme inducers that activate gene expression through ligand-activated transcription factor pathways.
J. Pharmacol. Exp. Ther. 300: 206-212 (2002).
*
-
Guo L, Fang H, Collins J, Fan XH, Dial S, Wong A, Mehta K, Blann E, Shi L, Tong W, Dragan YP. Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor alpha agonists.
BMC Bioinformatics 7: S18 (2006).
*
-
Guo L, Hu WR, Lian JH, Ji W, Deng T, Qian M, Gong BQ. Anti-hyperlipidemic properties of CM108 (a flavone derivative) in vitro and in vivo.
Eur. J. Pharmacol. 551: 80-86 (2006).
*
-
Guo L, Zhang L, Sun Y, Muskhelishvili L, Blann E, Dial S, Shi L, Schroth G, Dragan YP. Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells.
Mol. Divers. 10: 349-360 (2006).
-
Gupta D, Jetton TL, Mortensen RM, Zhong Duan S, Peshavaria M, Leahy JL. In vivo and in vitro studies of a functional peroxisome proliferator-activated receptor gamma response element in the mouse PDX-1 promoter.
J. Biol. Chem. 283: 32462-32470 (2008).
*
-
Gupta RA, Tan J, Krause WF, Geraci MW, Willson TM, Dey SK, DuBois RN. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer.
Proc. Natl. Acad. Sci. U.S.A. 97: 13275-13280 (2000).
*
-
Gurley C, Nichols J, Liu S, Phulwani NK, Esen N, Kielian T. Microglia and astrocyte activation by Toll-like receptor ligands: modulation by PPAR-gamma agonists.
PPAR Res. 2008: 453120 (2008).
*
-
Gurnell M. 'Striking the right balance' in targeting PPARgamma in the metabolic syndrome: novel insights from human genetic studies.
PPAR Res. 2007: 83593 (2007).
*
-
Gurnell M, Chatterjee VK. Nuclear receptors in disease: thyroid receptor beta, peroxisome-proliferator-activated receptor gamma and orphan receptors.
Essays Biochem. 40: 169-189 (2004).
-
Gurnell M, Wentworth JM, Agostini M, Adams M, Collingwood TN, Provenzano C, Browne PO, Rajanayagam O, Burris TP, Schwabe JW, Lazar MA, Chatterjee VK. A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis.
J. Biol. Chem. 275: 5754-5759 (2000).
*
-
Gutgesell A, Ringseis R, Brandsch C, Stangl GI, Hirche F, Eder K. Peroxisome proliferator-activated receptor alpha and enzymes of carnitine biosynthesis in the liver are down-regulated during lactation in rats.
Metabolism 58: 226-232 (2009).
*
-
Gutierrez PT, Folch-Puy E, Bulbena O, Closa D. Oxidized lipids present in ascitic fluid interferes the regulation of the macrophages during acute pancreatitis, promoting an exacerbation of the inflammatory response.
Gut 57: 642-648 (2008).
-
Guzman M, Lo Verme J, Fu J, Oveisi F, Blazquez C, Piomelli D. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha).
J. Biol. Chem. 279: 27849-27854 (2004).
*
-
Gyamfi MA, Wan YJ. Mechanisms of resistance of hepatocyte retinoid X receptor alpha-null mice to WY-14,643-induced hepatocyte proliferation and cholestasis.
J. Biol. Chem. 284: 9321-9330 (2009).
*
-
Gyongyosi A, Nagy L. Potential therapeutic use of PPARgamma-programed human monocyte-derived dendritic cells in cancer vaccination therapy.
PPAR Res. 2008: 473804 (2008).
*
-
Hafstad AD, Khalid AM, Hagve M, Lund T, Larsen TS, Severson DL, Clarke K, Berge RK, Aasum E. Cardiac PPARalpha activation causes increased fatty acid oxidation, reducing efficiency and post-ischemic functional loss.
Cardiovasc. Res. Apr 27 [Epub ahead of print] (2009).
-
Hall JM, McDonnell DP. The molecular mechanisms underlying the pro-inflammatory actions of thiazolidinediones (TZDs) in human macrophages.
Mol. Endocrinol. 21: 1756-1768 (2007).
*
-
Hall MG, Quignodon L, Desvergne B. Peroxisome proliferator-activated receptor beta/delta in the brain: facts and hypothesis.
PPAR Res. 2008: 780452 (2008).
*
-
Haluzik M. Peroxisome proliferator activated receptors (PPAR) and insulin sensitivity: experimental studies.
Cesk. Fysiol. 55: 163-168 (2006).
-
Haluzik M, Anderlova K, Dolelalova R, Adamikova A, Haluzikova D, Housova J, Svacina S, Haluzik M. Serum adipocyte fatty acid binding protein levels in patients with type 2 diabetes mellitus and obesity: the influence of fenofibrate treatment.
Physiol. Res. 58: 93-99 (2009).
*
-
Haluzik MM, Haluzik M. PPAR-alpha and insulin sensitivity.
Physiol. Res. 55: 115-122 (2006).
*
-
Haluzik MM, Lacinova Z, Dolinkova M, Haluzikova D, Housa D, Horinek A, Vernerova Z, Kumstyrova T, Haluzik M. Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels.
Endocrinology 147: 4517-4524 (2006).
*
-
Hamada T, Kotani K, Tsuzaki K, Sano Y, Murata T, Tabata M, Sato S, Sakane N. Association of Pro12Ala polymorphism in the peroxisome proliferator-activated receptor gamma2 gene with small dense low-density lipoprotein in the general population.
Metabolism 56: 1345-1349 (2007).
*
-
Hamblin M, Chang L, Fan Y, Zhang J, Chen YE. PPARs and the cardiovascular system.
Antioxid. Redox Signal. Dec 8 [Epub ahead of print] (2008).
-
Hamilton G, Proitsi P, Jehu L, Morgan A, Williams J, O'Donovan MC, Owen MJ, Powell JF, Lovestone S. Candidate gene association study of insulin signaling genes and Alzheimer's disease: evidence for SOS2, PCK1, and PPARgamma as susceptibility loci.
Am. J. Med. Genet. B. Neuropsychiatr. Genet. 144: 508-16 (2007).
-
Hammarstedt A, Andersson CX, Rotter Sopasakis V, Smith U. The effect of PPARgamma ligands on the adipose tissue in insulin resistance.
Prostaglandins Leukot. Essent. Fatty Acids 73: 65-75 (2005).
*
-
Hamza MS, Pott S, Vega VB, Thomsen JS, Kandhadayar GS, Ng PW, Chiu KP, Pettersson S, Wei CL, Ruan Y, Liu ET. De-novo identification of PPARgamma/RXR binding sites and direct targets during adipogenesis.
PLoS ONE 4: e4907 (2009).
*
-
Han H, Shin SW, Seo CY, Kwon HC, Han JY, Kim IH, Kwak JY, Park JI. 15-Deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ (2)) sensitizes human leukemic HL-60 cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through Akt downregulation.
Apoptosis 12: 2101-2114 (2007).
*
-
Han JK, Lee HS, Yang HM, Hur J, Jun SI, Kim JY, Cho CH, Koh GY, Peters JM, Park KW, Cho HJ, Lee HY, Kang HJ, Oh BH, Park YB, Kim HS. Peroxisome proliferator-activated receptor-delta agonist enhances vasculogenesis by regulating endothelial progenitor cells through genomic and nongenomic activations of the phosphatidylinositol 3-kinase/Akt pathway.
Circulation 118: 1021-1033 (2008).
-
Han JL, Ding RY, Zhao L, Ren Z, Jiang XJ. Rosiglitazone attenuates allergic inflammation and inhibits expression of galectin-3 in a mouse model of allergic rhinitis.
J. Int. Med. Res. 36: 830-836 (2008).
-
Han K, Song H, Moon I, Augustin R, Moley K, Rogers M, Lim H. Utilization of DR1 as true RARE in regulating the Ssm, a novel retinoic acid-target gene in the mouse testis.
J. Endocrinol. 192: 539-551 (2007).
*
-
Han KL, Choi JS, Lee JY, Song J, Joe MK, Jung MH, Hwang JK. Therapeutic potential of peroxisome proliferators-activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes.
Diabetes 57: 737-745 (2008).
*
-
Han S, Ritzenthaler JD, Zheng Y, Roman J. PPARbeta/delta agonist stimulates human lung carcinoma cell growth through inhibition of PTEN expression: the involvement of PI3-K and NF-kappaB signals.
Am. J. Physiol. Lung Cell. Mol. Physiol. 294: L1238-L1249 (2008).
*
-
Han S, Roman J. Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways.
Mol. Cancer Ther. 5: 430-437 (2006).
-
Han S, Sun X, Ritzenthaler JD, Roman J. Fish oil inhibits human lung carcinoma cell growth by suppressing integrin-linked kinase.
Mol. Cancer Res. 7: 108-117 (2009).
*
-
Han SH, Quon MJ, Koh KK. Beneficial vascular and mtabolic effects of peroxisome proliferator-activated receptor-alpha activators.
Hypertension 46: 1086-1092 (2005).
-
Han SW, Roman J. Activated PPARgamma targets surface and intracellular signals that inhibit the proliferation of lung carcinoma cells.
PPAR Res. 2008: 254108 (2008).
*
-
Han X, Benight N, Osuntokun B, Loesch K, Frank S, Denson L. Tumour necrosis factor alpha blockade induces an anti- inflammatory growth hormone signalling pathway in experimental colitis.
Gut 56: 73-81 (2007).
*
-
Han X, Osuntokun B, Benight N, Loesch K, Frank SJ, Denson LA. Signal transducer and activator of transcription 5b promotes mucosal tolerance in pediatric Crohn's disease and murine colitis.
Am. J. Pathol. 169: 1999-2013 (2006).
*
-
Hancock CR, Han DH, Chen M, Terada S, Yasuda T, Wright DC, Holloszy JO. High-fat diets cause insulin resistance despite an increase in muscle mitochondria.
Proc. Natl. Acad. Sci. U.S.A. 105: 7815-7820 (2008).
*
-
Handeli S, Simon JA. A small-molecule inhibitor of Tcf/beta-catenin signaling down-regulates PPARgamma and PPARdelta activities.
Mol. Cancer Ther. 7: 521-529 (2008).
-
Hanley K, Jiang Y, Crumrine D, Bass NM, Appel R, Elias PM, Williams ML, Feingold KR. Activators of the nuclear hormone receptors PPARalpha and FXR accelerate the development of the fetal epidermal permeability barrier.
J. Clin. Invest. 100: 705-712 (1997).
*
-
Hansen L, Ekstrom CT, Palacios RT, Anant M, Wassermann K, Reinhardt RR. The Pro12Ala variant of the PPARG gene is a risk factor for PPARgamma/alpha agonist induced edema in type 2 diabetic patients.
J. Clin. Endocrinol. Metab. 91: 3446-3450 (2006).
*
-
Hansen MK, Connolly TM. Nuclear receptors as drug targets in obesity, dyslipidemia and atherosclerosis.
Curr. Opin. Investig. Drugs 9: 247-255 (2008).
-
Hao CY, Moore DH, Wong P, Bennington JL, Lee NM, Chen LC. Alteration of gene expression in macroscopically normal colonic mucosa from individuals with a family history of sporadic colon cancer.
Clin. Cancer Res. 11: 1400-1407 (2005).
*
-
Hao K, Liu S, Niu T. A sparse marker extension tree algorithm for selecting the best set of haplotype tagging single nucleotide polymorphisms.
Genet. Epidemiol. 29: 336-352 (2005).
-
Harada K, Isse K, Kamihira T, Shimoda S, Nakanuma Y. Th1 cytokine-induced downregulation of PPARgamma in human biliary cells relates to cholangitis in primary biliary cirrhosis.
Hepatology 41: 1329-1338 (2005).
*
-
Harada K, Nakanuma Y. Biliary innate immunity and cholangiopathy.
Hepatol. Res. 37 Suppl. 3: S430-S437 (2007).
*
-
Haraguchi G, Kosuge H, Maejima Y, Suzuki JI, Imai T, Yoshida M, Isobe M. Pioglitazone reduces systematic inflammation and improves mortality in apolipoprotein E knockout mice with sepsis.
Intensive Care Med. 34: 1304-1312 (2008).
*
-
Harano Y, Yasui K, Toyama T, Nakajima T, Mitsuyoshi H, Mimani M, Hirasawa T, Itoh Y, Okanoue T. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver.
Liver Int. 26: 613-620 (2006).
*
-
Hardisty JF, Elwell MR, Ernst H, Greaves P, Kolenda-Roberts H, Malarkey DE, Mann PC, Tellier PA. Histopathology of hemangiosarcomas in mice and hamsters and liposarcomas/fibrosarcomas in rats associated with PPAR agonists.
Toxicol. Pathol. 35: 928-941 (2007).
*
-
Harikumar KB, Aggarwal BB. Resveratrol: a multitargeted agent for age-associated chronic diseases.
Cell Cycle 7: 1020-1035 (2008).
*
-
Harnack K, Andersen G, Somoza V. Quantitation of alpha-linolenic acid elongation to eicosapentaenoic and docosahexaenoic acid as affected by the ratio of n6/n3 fatty acids.
Nutr. Metab. (Lond.) 6: 8 (2009).
*
-
Harries MJ, Paus R. Scarring alopecia and the PPAR-gamma connection.
J. Invest. Dermatol. 129: 1066-1070 (2009).
*
-
Harrington WW, S Britt C, G Wilson J, O Milliken N, G Binz J, C Lobe D, R Oliver W, C Lewis M, M Ignar D. The effect of PPARalpha, PPARdelta, PPARgamma, and PPARpan agonists on body weight, body mass, and serum lipid profiles in diet-induced obese AKR/J mice.
PPAR Res. 2007: 97125 (2007).
*
-
Harris G, Ghazallah RA, Nascene D, Wuertz B, Ondrey FG. PPAR activation and decreased proliferation in oral carcinoma cells with 4-HPR.
Otolaryngol. Head Neck Surg. 133: 695-701 (2005).
-
Hart CM. The role of PPARgamma in pulmonary vascular disease.
J. Investig. Med. 56: 518-521 (2008).
-
Hart CM, Roman J, Reddy R, Sime PJ. PPARgamma: a novel molecular target in lung disease.
J. Investig. Med. 56: 515-517 (2008).
-
Hashimoto T, Cook WS, Qi C, Yeldandi AV, Reddy JK, Rao MS. Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting.
J. Biol. Chem. 275: 28918-28928 (2000).
*
-
Hashimoto T, Fujita T, Usuda N, Cook W, Qi C, Peters JM, Gonzalez FJ, Yeldandi AV, Rao MS, Reddy JK. Peroxisomal and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype.
J. Biol. Chem. 274: 19228-19236 (1999).
*
-
Hayashida K, Kume N, Minami M, Inui-Hayashida A, Mukai E, Toyohara M, Kita T. Peroxisome proliferator-activated receptor alpha ligands activate transcription of lectin-like oxidized low density lipoprotein receptor-1 gene through GC box motif.
Biochem. Biophys. Res. Commun. 323: 1116-1123 (2004).
*
-
Hays T, Rusyn I, Burns AM, Kennett MJ, Ward JM, Gonzalez FJ, Peters JM. Role of peroxisome proliferator-activated receptor-alpha (PPARalpha) in bezafibrate-induced hepatocarcinogenesis and cholestasis.
Carcinogenesis 26: 219-227 (2005).
*
-
Hazra S, M Dubinett S. Ciglitazone mediates COX-2 dependent suppression of PGE2 in human non-small cell lung cancer cells.
Prostaglandins Leukot. Essent. Fatty Acids 77: 51-58 (2007).
*
-
Hazra S, Peebles KA, Sharma S, Mao JT, Dubinett SM. The role of PPARgamma in the cyclooxygenase pathway in lung cancer.
PPAR Res. 2008: 790568 (2008).
*
-
He CQ, Ding NZ, Fan W. YY1 repressing peroxisome proliferator-activated receptor delta promoter.
Mol. Cell. Biochem. 308: 247-252 (2008).
*
-
He T, Lu T, d'Uscio LV, Lam CF, Lee HC, Katusic ZS. Angiogenic function of prostacyclin biosynthesis in human endothelial progenitor cells.
Circ. Res. 103: 80-88 (2008).
*
-
He W. PPARgamma2 polymorphism and human health.
PPAR Res. 2009: 849538 (2009).
*
-
He Z, Hu Y, Feng L, Bao D, Wang L, Li Y, Wang J, Liu G, Xi Y, Wen L, Lucia A. Is there an association between PPARGC1A genotypes and endurance capacity in Chinese men?
Scand. J. Med. Sci. Sports 18: 195-204 (2008).
-
Hebbachi AM, Knight BL, Wiggins D, Patel DD, Gibbons GF. Peroxisome proliferator-activated receptor alpha-deficiency abolishes the response of lipogenic gene expression to re-feeding: restoration of the normal response by activation of liver X receptor alpha.
J. Biol. Chem. 283: 4866-4876 (2008).
*
-
Hee Kim Y, Jae Han H. High glucose-induced prostaglandin E2 and peroxisome proliferator-activated receptor delta promotes mouse embryonic stem cells proliferation.
Stem Cells 26: 745-755 (2008).
*
-
Hegele RA, Pollex RL. Genetic and physiological insights into the metabolic syndrome.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 289: R663-R669 (2005).
*
-
Heikkinen S, Auwerx J, Argmann CA. PPARgamma in human and mouse physiology.
Biochim. Biophys. Acta 1771: 999-1013 (2007).
*
-
Heilbronn LK, Campbell LV. Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity.
Curr. Pharm. Des. 14: 1225-1230 (2008).
-
Heimburger M, Palmblad J. The peroxisome proliferator-activated receptor alpha (PPARalpha) ligand WY 14,643 does not interfere with leukotriene B4 induced adhesion of neutrophils to endothelial cells.
Biochem. Biophys. Res. Commun. 249: 371-374 (1998).
*
-
Heinaniemi M, Carlberg C. Screening for PPAR responsive regulatory modules in cancer.
PPAR Res. 2008: 749073 (2008).
*
-
Heinaniemi M, Uski JO, Degenhardt T, Carlberg C. Meta-analysis of primary target genes of peroxisome proliferator-activated receptors.
Genome Biol. 8: R147 (2007).
*
-
Helenius K, Yang Y, Alasaari J, Makela TP. Mat1 inhibits peroxisome proliferator-activated receptor gamma-mediated adipocyte differentiation.
Mol. Cell. Biol. 29: 315-323 (2009).
*
-
Hellemans K, Kerckhofs K, Hannaert JC, Martens G, Van Veldhoven P, Pipeleers D. Peroxisome proliferator-activated receptor alpha-retinoid X receptor agonists induce beta-cell protection against palmitate toxicity.
FEBS J. 274: 6094-6105 (2007).
*
-
Heneka MT, Landreth GE. PPARs in the brain.
Biochim. Biophys. Acta 1771: 1031-1045 (2007).
*
-
Heneka MT, Landreth GE, Hull M. Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders.
Nat. Clin. Pract. Neurol. 3: 496-504 (2007).
-
Henke BR, Blanchard SG, Brackeen MF, Brown KK, Cobb JE, Collins JL, Harrington WW Jr, Hashim MA, Hull-Ryde EA, Kaldor I, Kliewer SA, Lake DH, Leesnitzer LM, Lehmann JM, Lenhard JM, Orband-Miller LA, Miller JF, Mook RA Jr, Noble SA, Oliver W Jr, et al. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
J. Med. Chem. 41: 5020-5036 (1998).
*
-
Hennig B, Reiterer G, Majkova Z, Oesterling E, Meerarani P, Toborek M. Modification of environmental toxicity by nutrients: implications in atherosclerosis.
Cardiovasc. Toxicol. 5: 153-160 (2005).
-
Hennuyer N, Tailleux A, Torpier G, Mezdour H, Fruchart JC, Staels B, Fievet C. PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
Arterioscler. Thromb. Vasc. Biol. 25: 1897-1902 (2005).
*
-
Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.
Lancet Jun 8 [Epub ahead of print] (2009).
-
Hernandez-Trujillo Y, Rodriguez-Esparragon F, Macias-Reyes A, Caballero-Hidalgo A, Rodriguez-Perez JC. Rosiglitazone but not losartan prevents Nrf-2 dependent CD36 gene expression up-regulation in an in vivo atherosclerosis model.
Cardiovasc. Diabetol. 7: 3 (2008).
-
Hertz R, Bar-Tana J. Peroxisome proliferator-activated receptor (PPAR) alpha activation and its consequences in humans.
Toxicol. Lett. 102-103: 85-90 (1998).
-
Hertz R, Berman I, Keppler D, Bar-Tana J. Activation of gene transcription by prostacyclin analogues is mediated by the peroxisome-proliferators-activated receptor (PPAR).
Eur. J. Biochem. 235: 242-247 (1996).
*
-
Herzlich AA, Tuo J, Chan CC. Peroxisome proliferator-activated receptor and age-related macular degeneration.
PPAR Res. 2008: 389507 (2008).
*
-
Higa R, Gonzalez E, Pustovrh MC, White V, Capobianco E, Martinez N, Jawerbaum A. PPARdelta and its activator PGI2 are reduced in diabetic embryopathy: involvement of PPARdelta activation in lipid metabolic and signalling pathways in rat embryo early organogenesis.
Mol. Hum. Reprod. 13: 103-110 (2007).
*
-
Higashiyama H, Billin AN, Okamoto Y, Kinoshita M, Asano S. Expression profiling of peroxisome proliferator-activated receptor-delta (PPAR-delta) in mouse tissues using tissue microarray.
Histochem. Cell Biol. 127: 485-494 (2007).
*
-
Higuchi S, Wu R, Zhou M, Ravikumar TS, Wang P. Downregulation of hepatic cytochrome P-450 isoforms and PPAR-gamma: their role in hepatic injury and proinflammatory responses in a double-hit model of hemorrhage and sepsis.
J. Surg. Res. 137: 46-52 (2007).
*
-
Hihi AK, Michalik L, Wahli W. PPARs: transcriptional effectors of fatty acids and their derivatives.
Cell. Mol. Life Sci. 59: 790-798 (2002).
*
-
Hill MR, Clarke S, Rodgers K, Thornhill B, Peters JM, Gonzalez FJ, Gimble JM. Effect of peroxisome proliferator-activated receptor alpha activators on tumor necrosis factor expression in mice during endotoxemia.
Infect. Immun. 67: 3488-3493 (1999).
*
-
Hirai T, Fukui Y, Motojima K. PPARalpha agonists positively and negatively regulate the expression of several nutrient/drug transporters in mouse small intestine.
Biol. Pharm. Bull. 30: 2185-2190 (2007).
*
-
Hiromori Y, Nishikawa J, Yoshida I, Nagase H, Nakanishi T. Structure-dependent activation of peroxisome proliferator-activated receptor (PPAR) gamma by organotin compounds.
Chem. Biol. Interact. 180: 238-244 (2009).
-
Hirotani M, Tsukamoto T, Bourdeaux J, Sadano H, Osumi T. Stabilization of peroxisome proliferator-activated receptor alpha by the ligand.
Biochem. Biophys. Res. Commun. 288: 106-110 (2001).
*
-
Hoareau L, Buyse M, Festy F, Ravanan P, Gonthier MP, Matias I, Petrosino S, Tallet F, d'Hellencourt CL, Cesari M, Di Marzo V, Roche R. Anti-inflammatory effect of palmitoylethanolamide on human adipocytes.
Obesity (Silver Spring) 17: 431-438 (2009).
*
-
Hodgkinson CP, Ye S. Microarray analysis of peroxisome proliferator-activated receptor-gamma induced changes in gene expression in macrophages.
Biochem. Biophys. Res. Commun. 308: 505-510 (2003).
*
-
Hoeks J, Hesselink MK, Russell AP, Mensink M, Saris WH, Mensink RP, Schrauwen P. Peroxisome proliferator-activated receptor-gamma coactivator-1 and insulin resistance: acute effect of fatty acids.
Diabetologia 49: 2419-2426 (2006).
*
-
Hoekstra M, Out R, Kar Kruijt J, Van Eck M, Van Berkel TJ. Diet induced regulation of genes involved in cholesterol metabolism in rat liver parenchymal and Kupffer cells.
J. Hepatol. 42: 400-407 (2005).
*
-
Hojo M, Takada I, Kimura W, Fukuda K, Yasugi S. Expression patterns of the chicken peroxisome proliferator-activated receptors (PPARs) during the development of the digestive organs.
Gene Expr. Patterns 6: 171-179 (2006).
*
-
Holden PR, Tugwood JD. Peroxisome proliferator-activated receptor alpha: role in rodent liver cancer and species differences.
J. Mol. Endocrinol. 22: 1-8 (1999).
*
-
Holdsworth-Carson S, Permezel M, Rice G, Lappas M. Preterm and infection-driven preterm labour: the role of peroxisome proliferator-activated receptors and retinoid X receptor.
Reproduction 137: 1007-1015 (2009).
-
Holdsworth-Carson SJ, Permezel M, Riley C, Rice GE, Lappas M. Peroxisome proliferator-activated receptors and retinoid X receptor-alpha in term human gestational tissues: tissue specific and labour-associated changes.
Placenta 30: 176-186 (2009).
-
Holla VR, Mann JR, Shi Q, Dubois RN. Prostaglandin E2 regulates the nuclear receptor NR4A2 in colorectal cancer.
J. Biol. Chem. 281: 2676-2682 (2006).
*
-
Hollingshead HE, Borland MG, Billin AN, Willson TM, Gonzalez FJ, Peters JM. Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) and inhibition of cyclooygenase-2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms.
Carcinogenesis 29: 169-176 (2008).
*
-
Hollingshead HE, Morimura K, Adachi M, Kennett MJ, Billin AN, Willson TM, Gonzalez FJ, Peters JM. PPARbeta/delta protects against experimental colitis through a ligand-independent mechanism.
Dig. Dis. Sci. 52: 2912-2919 (2007).
*
-
Holmes A, Mesa J, Neill B, Chung J, Carey A, Steinberg G, Kemp B, Southgate R, Lancaster G, Bruce C, Watt M, Febbraio M. Prolonged interleukin-6 administration enhances glucose tolerance and increases skeletal muscle PPARalpha and UCP2 expression in rats.
J. Endocrinol. 198: 367-374 (2008).
*
-
Holness MJ, Greenwood GK, Smith ND, Sugden MC. Peroxisome proliferator-activated receptor-alpha and glucocorticoids interactively regulate insulin secretion during pregnancy.
Diabetes 55: 3501-3508 (2006).
*
-
Holness MJ, Greenwood GK, Smith ND, Sugden MC. PPARalpha activation and increased dietary lipid oppose thyroid hormone signalling and rescue impaired glucose-stimulated insulin secretion in hyperthyroidism.
Am. J. Physiol. Endocrinol. Metab. 295: E1380-E1389 (2008).
*
-
Holst D, Luquet S, Nogueira V, Kristiansen K, Leverve X, Grimaldi PA. Nutritional regulation and role of peroxisome proliferator-activated receptor delta in fatty acid catabolism in skeletal muscle.
Biochim. Biophys. Acta 1633: 43-50 (2003).
*
-
Holvoet P. Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease.
Verh. K. Acad. Geneeskd. Belg. 70: 193-219 (2008).
-
Holzapfel J, Heun R, Lutjohann D, Jessen F, Maier W, Kolsch H. PPARD haplotype influences cholesterol metabolism but is no risk factor of Alzheimer's disease.
Neurosci. Lett. 408: 57-61 (2006).
*
-
Hondares E, Mora O, Yubero P, de la Concepcion MR, Iglesias R, Giralt M, Villarroya F. Thiazolidinediones and rexinoids induce PGC-1alpha gene transcription. An auto-regulatory loop controls PGC-1alpha expression in adipocytes via PPARgamma co-activation.
Endocrinology 147: 2829-2838 (2006).
*
-
Hong C, Tontonoz P. Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors.
Curr. Opin. Genet. Dev. 18: 461-467 (2008).
-
Hong KM, Belperio JB, Keane MP, Burdick MD, Strieter RM. Differentiation of human circulating fibrocytes as mediated by transforming growth factor-beta and peroxisome proliferator activated receptor-gamma.
J. Biol. Chem. 282: 22910-22920 (2007).
*
-
Honka MJ, Vanttinen M, Iozzo P, Virtanen KA, Lautamaki R, Hallsten K, Borra RJ, Takala T, Viljanen AP, Kemppainen J, Pihlajamaki J, Knuuti J, Nuutila P, Laakso M. The Pro12Ala polymorphism of the PPARgamma2 gene is associated with hepatic glucose uptake during hyperinsulinemia in subjects with type 2 diabetes mellitus.
Metabolism 58: 541-546 (2009).
-
Hontecillas R, Bassaganya-Riera J. Peroxisome proliferator-activated receptor gamma is required for regulatory CD4+ T cell-mediated protection against colitis.
J. Immunol. 178: 2940-2949 (2007).
*
-
Hontecillas R, Diguardo M, Duran E, Orpi M, Bassaganya-Riera J. Catalpic acid decreases abdominal fat deposition, improves glucose homeostasis and upregulates PPAR alpha expression in adipose tissue.
Clin. Nutr. 27: 764-772 (2008).
-
Hontecillas R, Wannemeulher MJ, Zimmerman DR, Hutto DL, Wilson JH, Ahn DU, Bassaganya-Riera J. Nutritional regulation of porcine bacterial-induced colitis by conjugated linoleic acid.
J. Nutr. 132: 2019-2027 (2002).
*
-
Hoo RL, Chow WS, Yau MH, Xu A, Tso AW, Tse HF, Fong CH, Tam S, Chan L, Lam KS. Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production.
Arterioscler. Thromb. Vasc. Biol. 27: 2777-2782 (2007).
-
Hoon Lee J, Joe EH, Jou I. PPAR-alpha activators suppress STAT1 inflammatory signaling in lipopolysaccharide-activated rat glia.
Neuroreport 16: 829-833 (2005).
-
Hopkins TA, Sugden MC, Holness MJ, Kozak R, Dyck JR, Lopaschuk GD. Control of cardiac pyruvate dehydrogenase activity in peroxisome proliferator-activated receptor-alpha transgenic mice.
Am. J. Physiol. Heart Circ. Physiol. 285: H270-H276 (2003).
*
-
Horia E, Watkins BA. Complementary actions of docosahexaenoic acid and genistein on COX-2, PGE2 and invasiveness in MDA-MB-231 breast cancer cells.
Carcinogenesis 28: 809-815 (2007).
*
-
Hosooka T, Noguchi T, Kotani K, Nakamura T, Sakaue H, Inoue H, Ogawa W, Tobimatsu K, Takazawa K, Sakai M, Matsuki Y, Hiramatsu R, Yasuda T, Lazar MA, Yamanashi Y, Kasuga M. Dok1 mediates high-fat diet-induced adipocyte hypertrophy and obesity through modulation of PPAR-gamma phosphorylation.
Nat. Med. 14: 188-193 (2008).
*
-
Hossain MA, Tsujita M, Gonzalez FJ, Yokoyama S. Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes.
J. Cardiovasc. Pharmacol. 51: 258-266 (2008).
-
Hostetler HA, Kier AB, Schroeder F. Very-long-chain and branched-chain fatty acyl-CoAs are high affinity ligands for the peroxisome proliferator-activated receptor alpha (PPARalpha).
Biochemistry 45: 7669-7681 (2006).
*
-
Hostetler HA, McIntosh AL, Atshaves BP, Storey SM, Payne HR, Kier AB, Schroeder F. Liver type fatty acid binding protein (L-FABP) directly interacts with peroxisome proliferator-activated receptor-alpha in cultured primary hepatocytes.
J. Lipid Res. Mar 16 [Epub ahead of print] (2009).
*
-
Hostetler HA, Petrescu AD, Kier AB, Schroeder F. Peroxisome proliferator-activated receptor alpha interacts with high affinity and is conformationally responsive to endogenous ligands.
J. Biol. Chem. 280: 18667-18682 (2005).
*
-
Hostetler HA, Syler LR, Hall LN, Zhu G, Schroeder F, Kier AB. A novel high-throughput screening assay for putative antidiabetic agents through PPARalpha interactions.
J. Biomol. Screen 13: 855-861 (2008).
-
Hounoki H, Sugiyama E, Mohamed SG, Shinoda K, Taki H, Abdel-Aziz HO, Maruyama M, Kobayashi M, Miyahara T. Activation of peroxisome proliferator-activated receptor gamma inhibits TNF-alpha-mediated osteoclast differentiation in human peripheral monocytes in part via suppression of monocyte chemoattractant protein-1 expression.
Bone 42: 765-774 (2008).
-
Houseknecht KL, Cole BM, Steele PJ. Peroxisome proliferator-activated receptor gamma (PPARgamma) and its ligands: a review.
Domest. Anim. Endocrinol. 22: 1-23 (2002).
*
-
Housley WJ, O'Conor CA, Nichols F, Puddington L, Lingenheld EG, Zhu L, Clark RB. PPARgamma regulates retinoic acid-mediated DC induction of Tregs.
J. Leukoc. Biol. Apr 28 [Epub ahead of print] (2009).
*
-
Houston MC. The role of mercury and cadmium heavy metals in vascular disease, hypertension, coronary heart disease, and myocardial infarction.
Altern. Ther. Health Med. 13: S128-S133 (2007).
-
Howarth AG, Jiang Y, Pannirselvam M, Wiehler WB, Berger JP, Severson DL, Anderson TJ, Triggle CR. A non-thiazolidinedione PPARgamma agonist reverses endothelial dysfunction in diabetic (db/db -/-) mice.
J. Pharmacol. Exp. Ther. 316: 364-370 (2006).
*
-
Howroyd P, Swanson C, Dunn C, Cattley RC, Corton JC. Decreased longevity and enhancement of age-dependent lesions in mice lacking the nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha).
Toxicol. Pathol. 32: 591-599 (2004).
*
-
Hsieh CC, Huang CJ, Lin BF. Low and high levels of alpha-tocopherol exert opposite effects on IL-2 possibly through the modulation of PPAR-gamma, IkappaBalpha, and apoptotic pathway in activated splenocytes.
Nutrition 22: 433-440 (2006).
*
-
Hsieh PS, Jin JS, Chiang CF, Chan PC, Chen CH, Shih KC. COX-2-mediated inflammation in fat is crucial for obesity-linked insulin resistance and fatty liver.
Obesity (Silver Spring) Feb 26 [Epub ahead of print] (2009).
-
Hsu MH, Savas U, Griffin KJ, Johnson EF. Identification of peroxisome proliferator-responsive human genes by elevated expression of the peroxisome proliferator-activated receptor alpha in HepG2 cells.
J. Biol. Chem. 276: 27950-27958 (2001).
*
-
Hsu SC, Huang CJ. Reduced fat mass in rats fed a high oleic acid-rich safflower oil diet is associated with changes in expression of hepatic PPARalpha and adipose SREBP-1c-regulated genes.
J. Nutr. 136: 1779-1785 (2006).
*
-
Hsun-Wei Huang T, Peng G, Qian Li G, Yamahara J, Roufogalis BD, Li Y. Salacia oblonga root improves postprandial hyperlipidemia and hepatic steatosis in Zucker diabetic fatty rats: activation of PPAR-alpha.
Toxicol. Appl. Pharmacol. 210: 225-235 (2006).
*
-
Hu C, Jia W, Fang Q, Zhang R, Wang C, Lu J, Xiang K. Peroxisome proliferator-activated receptor (PPAR) delta genetic polymorphism and its association with insulin resistance index and fasting plasma glucose concentrations in Chinese subjects.
Diabet. Med. 23: 1307-1312 (2006).
*
-
Hu T, Foxworthy P, Siesky A, Ficorilli JV, Gao H, Li S, Christe M, Ryan T, Cao G, Eacho P, Michael MD, Michael LF. Hepatic peroxisomal fatty acid beta oxidation is regulated by liver X receptor alpha (LXRalpha).
Endocrinology 146: 5380-5387 (2005).
*
-
Hu X, Feng Y, Liu X, Zhao XF, Yu JH, Yang YS, Sydow-Backman M, Horling J, Zierath JR, Leng Y. Effect of a novel non-thiazolidinedione peroxisome proliferator-activated receptor alpha/gamma agonist on glucose uptake.
Diabetologia 50: 1048-1057 (2007).
*
-
Hu X, Feng Y, Shen Y, Zhao XF, Yu JH, Yang YS, Leng Y. Antidiabetic effect of a novel non-thiazolidinedione PPAR gamma/alpha agonist on ob/ob mice.
Acta Pharmacol. Sin. 27: 1346-1352 (2006).
-
Hua Y, Xue J, Sun F, Zhu L, Xie M. Aspirin inhibits MMP-2 and MMP-9 expressions and activities through upregulation of PPARalpha/gamma and TIMP gene expressions in ox-LDL-stimulated macrophages derived from human monocytes.
Pharmacology 83: 18-25 (2008).
-
Huang D, Yang C, Wang Y, Liao Y, Huang K. PARP-1 suppresses adiponectin expression through poly(ADP-ribosyl)ation of PPARgamma in cardiac fibroblasts.
Cardiovasc. Res. 81: 98-107 (2009).
-
Huang H, Wu D, Fu J, Chen G. Multiple myeloma cells undergo differentiation upon exposure to rosiglitazone and all-trans retinoic acid.
Leuk. Lymphoma 50: 966-973 (2009).
-
Huang JC. The role of peroxisome proliferator-activated receptors in the development and physiology of gametes and preimplantation embryos.
PPAR Res. 2008: 732303 (2008).
*
-
Huang TH, Li Y, Razmovski-Naumovski V, Tran VH, Li GQ, Duke CC, Roufogalis BD. Gypenoside XLIX isolated from Gynostemma pentaphyllum inhibits nuclear factor-kappaB activation via a PPAR-alpha-dependent pathway.
J. Biomed. Sci. 13: 535-548 (2006).
*
-
Huang TH, Peng G, Kota BP, Li GQ, Yamahara J, Roufogalis BD, Li Y. Pomegranate flower improves cardiac lipid metabolism in a diabetic rat model: role of lowering circulating lipids.
Br. J. Pharmacol. 145: 767-774 (2005).
*
-
Huang TH, Tran VH, Roufogalis BD, Li Y. Gypenoside XLIX, a naturally occurring gynosaponin, PPAR-alpha dependently inhibits LPS-induced tissue factor expression and activity in human THP-1 monocytic cells.
Toxicol. Appl. Pharmacol. 218: 30-36 (2007).
*
-
Huang TH, Tran VH, Roufogalis BD, Li Y. Gypenoside XLIX, a naturally occurring PPAR-alpha activator, inhibits cytokine-induced vascular cell adhesion molecule-1 expression and activity in human endothelial cells.
Eur. J. Pharmacol. 565: 158-165 (2007).
*
-
Huang W, Eum SY, Andras IE, Hennig B, Toborek M. PPARalpha and PPARgamma attenuate HIV-induced dysregulation of tight junction proteins by modulations of matrix metalloproteinase and proteasome activities.
FASEB J. 23: 1596-1606 (2009).
*
-
Huang W, Rha GB, Han MJ, Eum SY, Andras IE, Zhong Y, Hennig B, Toborek M. PPARalpha and PPARgamma effectively protect against HIV-induced inflammatory responses in brain endothelial cells.
J. Neurochem. 107: 497-509 (2008).
-
Huang WP, Yin WH, Chen JW, Jen HL, Young MS, Lin SJ. Fenofibrate attenuates endothelial monocyte adhesion in chronic heart failure: an in vitro study.
Eur. J. Clin. Invest. Jun 15 [Epub ahead of print] (2009).
-
Hui Y, Yu-Yuan L, Yu-Qiang N, Wei-Hong S, Yan-Lei D, Xiao-Bo L, Yong-Jian Z. Effect of peroxisome proliferator-activated receptors-gamma and co-activator-1alpha genetic polymorphisms on plasma adiponectin levels and susceptibility of non-alcoholic fatty liver disease in Chinese people.
Liver Int. 28: 385-392 (2008).
*
-
Humar B, D'Orazio D, Albrecht C, Bauerfeind P, Muller H, Dobbie Z, Bendik I. Expression of putative anticancer targets in familial adenomatous polyposis and its association with the APC mutation status.
Int. J. Oncol. 19: 1179-1186 (2001).
-
Hummasti S, Tontonoz P. The peroxisome proliferator-activated receptor N-terminal domain controls isotype-selective gene expression and adipogenesis.
Mol. Endocrinol. 20: 1261-1275 (2006).
*
-
Hummasti S, Tontonoz P. HRASLS3 is a PPARgamma-selective target gene that promotes adipocyte differentiation.
J. Lipid Res. 49: 2535-2544 (2008).
*
-
Hummasti S, Tontonoz P. Adopting new orphans into the family of metabolic regulators.
Mol. Endocrinol. 22: 1743-1753 (2008).
*
-
Hung SH, Yeh CH, Huang HT, Wu P, Ho ML, Chen CH, Wang C, Chao D, Wang GJ. Pioglitazone and dexamethasone induce adipogenesis in D1 bone marrow stromal cell line, but not through the peroxisome proliferator-activated receptor-gamma pathway.
Life Sci. 82: 561-569 (2008).
*
-
Hunt M, O'Byrne J, Solaas K, Frode Kase B, Alexson SEH. New insights into bile acid amidation.
Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 24. June 18-19 (2004). *
-
Hunt MC, Yang YZ, Eggertsen G, Carneheim CM, Gafvels M, Einarsson C, Alexson SE. The peroxisome proliferator-activated receptor alpha (PPARalpha) regulates bile acid biosynthesis.
J. Biol. Chem. 275: 28947-28953 (2000).
*
-
Hunter J, Kassam A, Winrow CJ, Rachubinski RA, Capone JP. Crosstalk between the thyroid hormone and peroxisome proliferator-activated receptors in regulating peroxisome proliferator-responsive genes.
Mol. Cell. Endocrinol. 116: 213-221 (1996).
-
Hunter RL, Choi DY, Ross SA, Bing G. Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague-Dawley rats.
Neurosci. Lett. 432: 198-201 (2008).
-
Huss JM, Kelly DP. Nuclear receptor signaling and cardiac energetics.
Circ. Res. 95: 568-578 (2004).
*
-
Huss JM, Torra IP, Staels B, Giguere V, Kelly DP. Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle.
Mol. Cell Biol. 24: 9079-9091 (2004).
*
-
Hutchins H. Omega-3 fatty acids: recommendations for therapeutics and prevention.
MedGenMed. 7: 18 (2005).
*
-
Hwang D. Fatty acids and immune responses - a new perspective in searching for clues to mechanism.
Annu. Rev. Nutr. 20: 431-456 (2000).
*
-
Hwang J, Kleinhenz DJ, Rupnow HL, Campbell AG, Thule PM, Sutliff RL, Hart CM. The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice.
Vascul. Pharmacol. 46: 456-462 (2007).
*
-
Hwang JT, Lee MS, Kim HJ, Sung MJ, Kim HY, Kim MS, Kwon DY. Antiobesity effect of ginsenoside Rg3 involves the AMPK and PPAR-gamma signal pathways.
Phytother. Res. 23: 262-266 (2009).
-
Hwang SJ, Kang HJ, Song JJ, Kang JS, Woo JS, Chae SW, Lee HM. Up-regulation of peroxidase proliferator-activated receptor gamma in cholesteatoma.
Laryngoscope 116: 58-61 (2006).
-
Hyong A, Jadhav V, Lee S, Tong W, Rowe J, Zhang JH, Tang J. Rosiglitazone, a PPAR gamma agonist, attenuates inflammation after surgical brain injury in rodents.
Brain Res. 1215: 218-224 (2008).
-
Hyyti OM, Portman MA. Molecular mechanisms of cross-talk between thyroid hormone and peroxisome proliferator activated receptors: focus on the heart.
Cardiovasc. Drugs Ther. 20: 463-469 (2006).
-
Iankova I, Petersen RK, Annicotte JS, Chavey C, Hansen JB, Kratchmarova I, Sarruf D, Benkirane M, Kristiansen K, Fajas L. PPARgamma recruits the P-TEFb complex to activate transcription and promote adipogenesis.
Mol. Endocrinol. 20: 1494-1505 (2006).
*
-
Ibabe A, Herrero A, Cajaraville MP. Modulation of peroxisome proliferator-activated receptors (PPARs) by PPARalpha- and PPARgamma-specific ligands and by 17beta-estradiol in isolated zebrafish hepatocytes.
Toxicol. In Vitro 19: 725-735 (2005).
-
Icre G, Wahli W, Michalik L. Functions of the peroxisome proliferator-activated receptor (PPAR) alpha and beta in skin homeostasis, epithelial repair, and morphogenesis.
J. Investig. Dermatol. Symp. Proc. 11: 30-35 (2006).
-
Ide T, Shimano H, Yoshikawa T, Yahagi N, Amemiya-Kudo M, Matsuzaka T, Nakakuki M, Yatoh S, Iizuka Y, Tomita S, Ohashi K, Takahashi A, Sone H, Gotoda T, Osuga J, Ishibashi S, Yamada N. Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling.
Mol. Endocrinol. 17: 1255-1267 (2003).
*
-
Ide T, Tsunoda M, Mochizuki T, Murakami K. Enhancement of insulin signaling through inhibition of tissue lipid accumulation by activation of peroxisome proliferator-activated receptor (PPAR) a in obese mice.
Med. Sci. Monit. 10: BR388-BR395 (2004).
*
-
Iglesias P, Diez JJ. Peroxisome proliferator-activated receptor gamma agonists in renal disease.
Eur. J. Endocrinol. 154: 613-621 (2006).
*
-
Iglseder B, Oberkofler H, Felder TK, Klein K, Paulweber B, Krempler F, Tregouet DA, Patsch W. Associations of PPARGC1A haplotypes with plaque score but not with intima-media thickness of carotid arteries in middle-aged subjects.
Stroke 37: 2260-2265 (2006).
-
Ii M, Hoshiga M, Negoro N, Fukui R, Nakakoji T, Kohbayashi E, Shibata N, Furutama D, Ishihara T, Hanafusa T, Losordo DW, Ohsawa N. Adrenal androgen dehydroepiandrosterone sulfate inhibits vascular remodeling following arterial injury.
Atherosclerosis Feb 27 [Epub ahead of print] (2009).
-
Ijichi N, Ikeda K, Horie-Inoue K, Yagi K, Okazaki Y, Inoue S. Estrogen-related receptor alpha modulates the expression of adipogenesis-related genes during adipocyte differentiation.
Biochem. Biophys. Res. Commun. 358: 813-818 (2007).
*
-
IJpenberg A, Tan NS, Gelman L, Kersten S, Seydoux J, Xu J, Metzger D, Canaple L, Chambon P, Wahli W, Desvergne B. In vivo activation of PPAR target genes by RXR homodimers.
EMBO J. 23: 2083-2091 (2004).
*
-
Ikeda I, Konno R, Shimizu T, Ide T, Takahashi N, Kawada T, Nagao K, Inoue N, Yanagita T, Hamada T, Morinaga Y, Tomoyori H, Imaizumi K, Suzuki K. Campest-5-en-3-one, an oxidized derivative of campesterol, activates PPARalpha, promotes energy consumption and reduces visceral fat deposition in rats.
Biochim. Biophys. Acta 1760: 800-807 (2006).
*
-
Ikeda I, Tomimoto A, Wada K, Fujisawa T, Fujita K, Yonemitsu K, Nozaki Y, Endo H, Takahashi H, Yoneda M, Inamori M, Kubota K, Saito S, Nagashima Y, Nakagama H, Nakajima A. 5-Aminosalicylic acid given in the remission stage of colitis suppresses colitis-associated cancer in a mouse colitis model.
Clin. Cancer Res. 13: 6527-6531 (2007).
*
-
Im SS, Kim JW, Kim TH, Song XL, Kim SY, Kim HI, Ahn YH. Identification and characterization of peroxisome proliferator response element in the mouse GLUT2 promoter.
Exp. Mol. Med. 37: 101-110 (2005).
*
-
Imai T. Functional genetic dissection of nuclear receptor signalling in obesity, diabetes and liver regeneration using spatiotemporally controlled somatic mutagenesis in the mouse.
Keio. J. Med. 52: 198-203 (2003).
*
-
Imamura K, Lu J, Kaminishi M. Roles of PPARs in carcinogenesis.
Nippon Rinsho 63: 584-588 (2005).
-
Imanishi T, Kobayashi K, Kuroi A, Ikejima H, Akasaka T. Pioglitazone inhibits angiotensin II-induced senescence of endothelial progenitor cell.
Hypertens. Res. 31: 757-765 (2008).
*
-
Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, Li Y, Goetz R, Mohammadi M, Esser V, Elmquist JK, Gerard RD, Burgess SC, Hammer RE, Mangelsdorf DJ, Kliewer SA. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21.
Cell. Metab. 5: 415-425 (2007).
*
-
Inamoto T, Azuma H, Ubai T, Katsuoka Y. Association of PPAR-gamma with BCG immunotherapy.
Med. Hypotheses 72: 231 (2009).
-
Inamoto T, Shah JB, Kamat AM. Friend or foe? Role of peroxisome proliferator-activated receptor-gamma in human bladder cancer.
Urol. Oncol. Jan 20 [Epub ahead of print] (2009).
-
Inestrosa NC, Godoy JA, Quintanilla RA, Koenig CS, Bronfman M. Peroxisome proliferator-activated receptor gamma is expressed in hippocampal neurons and its activation prevents beta-amyloid neurodegeneration: role of Wnt signaling.
Exp. Cell Res. 304: 91-104 (2005).
*
-
Inestrosa NC, Toledo EM. The role of Wnt signaling in neuronal dysfunction in Alzheimer's disease.
Mol. Neurodegener. 3: 9 (2008).
-
Inoue H. Endogenous ligands for PPARs.
Nippon Rinsho 63: 578-583 (2005).
-
Inoue I. Hyperlipidemia and peroxisome proliferator-activated receptor (PPAR) - regulation of the PPARalpha gene by CLOCK: BMAL1.
Nippon Rinsho 63: 643-656 (2005).
-
Inoue I, Goto S, Matsunaga T, Nakajima T, Awata T, Hokari S, Komoda T, Katayama S. The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+,Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells.
Metabolism 50: 3-11 (2001).
*
-
Inoue I, Itoh F, Aoyagi S, Tazawa S, Kusama H, Akahane M, Mastunaga T, Hayashi K, Awata T, Komoda T, Katayama S. Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB.
Biochem. Biophys. Res. Commun. 290: 131-139 (2002).
*
-
Inoue I, Shino K, Noji S, Awata T, Katayama S. Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells.
Biochem. Biophys. Res. Commun. 246: 370-374 (1998).
*
-
Inoue J, Satoh S, Kita M, Nakahara M, Hachimura S, Miyata M, Nishimaki-Mogami T, Sato R. PPARalpha gene expression is up-regulated by LXR and PXR activators in the small intestine.
Biochem. Biophys. Res. Commun. 371: 675-678 (2008).
*
-
Inoue S, Imamura M, Umezawa A, Tabata Y. Attachment, proliferation and adipogenic differentiation of adipo-stromal cells on self-assembled monolayers of different chemical compositions.
J. Biomater. Sci. Polym. Ed. 19: 893-914 (2008).
-
Inui S, Lee YF, Chang E, Shyr CR, Chang C. Differential and bi-directional regulation between TR2/TR4 orphan nuclear receptors and a specific ligand mediated-peroxisome proliferator-activated receptor alpha in human HaCaT keratinocytes.
J. Dermatol. Sci. 31: 65-71 (2003).
-
Ip E, Farrell G, Hall P, Robertson G, Leclercq I. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice.
Hepatology 39: 1286-1296 (2004).
*
-
Ip E, Farrell GC, Robertson G, Hall P, Kirsch R, Leclercq I. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice.
Hepatology 38: 123-132 (2003).
*
-
Iqbal M, Duffy P, Evans P, Cloughley G, Allan B, Lledó A, Verdaguer X, Riera A. The conjugate addition-Peterson olefination reaction for the preparation of cross-conjugated cyclopentenone, PPAR-gamma ligands.
Org. Biomol. Chem. 6: 4649-4661 (2008).
-
Iruretagoyena MI, Sepulveda SE, Lezana JP, Hermoso M, Bronfman M, Gutierrez MA, Jacobelli SH, Kalergis AM. Inhibition of NF-kappaB enhances the capacity of immature dendritic cells to induce antigen-specific tolerance in experimental autoimmune encephalomyelitis.
J. Pharmacol. Exp. Ther. 318: 59-67 (2006).
*
-
Ishiguro H, Okubo Y, Ohtsuki T, Yamakawa-Kobayashi K, Arinami T. Mutation analysis of the retinoid X receptor beta, nuclear-related receptor 1, and peroxisome proliferator-activated receptor alpha genes in schizophrenia and alcohol dependence.
Am. J. Med. Genet. 114: 15-23 (2002).
*
-
Ishii H, Horie Y, Ohshima S, Anezaki Y, Kinoshita N, Dohmen T, Kataoka E, Sato W, Goto T, Sasaki J, Sasaki T, Watanabe S, Suzuki A, Ohnishi H. Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocyte-specific Pten-deficient mice.
J. Hepatol. 50: 562-571 (2009).
-
Ishizuka M, Sawada T, Okada T, Nagata H, Takagi K, Horie T, Kubota K. Influence of tumor peroxisome proliferator-activated receptor gamma and delta expression on postoperative mortality of patients undergoing colorectal cancer surgery.
J. Invest. Surg. 22: 105-111 (2009).
-
Islam KK, Knight BL, Frayn KN, Patel DD, Gibbons GF. Deficiency of PPARalpha disturbs the response of lipogenic flux and of lipogenic and cholesterogenic gene expression to dietary cholesterol in mouse white adipose tissue.
Biochim. Biophys. Acta 1734: 259-268 (2005).
*
-
Islinger M, Luers GH, Li KW, Loos M, Volkl A. Rat liver peroxisomes after fibrate treatment. A survey using quantitative mass spectrometry.
J. Biol. Chem. 282: 23055-23069 (2007).
*
-
Israelian-Konaraki Z, Reaven PD. Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications.
Cardiology 103: 1-9 (2004).
-
Issemann I, Prince RA, Tugwood JD, Green S. The peroxisome proliferator-activated receptor:retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs.
J. Mol. Endocrinol. 11: 37-47 (1993).
-
Ito O, Nakamura Y, Tan L, Ishizuka T, Sasaki Y, Minami N, Kanazawa M, Ito S, Sasano H, Kohzuki M. Expression of cytochrome P-450 4 enzymes in the kidney and liver: regulation by PPAR and species-difference between rat and human.
Mol. Cell. Biochem. 284: 141-148 (2006).
*
-
Ito Y, Yamanoshita O, Asaeda N, Tagawa Y, Lee CH, Aoyama T, Ichihara G, Furuhashi K, Kamijima M, Gonzalez FJ, Nakajima T. Di(2-ethylhexyl)phthalate induces hepatic tumorigenesis through a peroxisome proliferator-activated receptor alpha-independent pathway.
J. Occup. Health 49: 172-182 (2007).
-
Ito Y, Yamanoshita O, Kurata Y, Kamijima M, Aoyama T, Nakajima T. Induction of peroxisome proliferator-activated receptor alpha (PPARalpha)-related enzymes by di(2-ethylhexyl) phthalate (DEHP) treatment in mice and rats, but not marmosets.
Arch. Toxicol. 81: 219-226 (2007).
*
-
Itoh H. PPARs and hypertension
Nippon Rinsho 63: 631-642 (2005).
-
Itoh T, Murota I, Yoshikai K, Yamada S, Yamamoto K. Synthesis of docosahexaenoic acid derivatives designed as novel PPARgamma agonists and antidiabetic agents.
Bioorg. Med. Chem. 14: 98-108 (2005).
*
-
Itoh T, Yamamoto K. Peroxisome proliferator activated receptor gamma and oxidized docosahexaenoic acids as new class of ligand.
Naunyn. Schmiedebergs. Arch. Pharmacol. 377: 541-547 (2008).
*
-
Itoi Y, Takatori M, Hyakusoku H, Mizuno H. Comparison of readily available scaffolds for adipose tissue engineering using adipose-derived stem cells.
J. Plast. Reconstr. Aesthet. Surg. Apr 13 [Epub ahead of print] (2009).
-
Iwashita A, Muramatsu Y, Yamazaki T, Muramoto M, Kita Y, Yamazaki S, Mihara K, Moriguchi A, Matsuoka N. Neuroprotective efficacy of the peroxisome proliferator-activated receptor delta-selective agonists in vitro and in vivo.
J. Pharmacol. Exp. Ther. 320: 1087-1096 (2007).
*
-
Izzo AA, Piscitelli F, Capasso R, Marini P, Cristino L, Petrosino S, Di Marzo V. Basal and fasting/refeeding-regulated tissue levels of endogenous PPAR-alpha ligands in Zucker rats.
Obesity (Silver Spring) Jun 11 [Epub ahead of print] (2009).
-
Jagannath K, Chaluvadi MR, Mullangi R, Mamidi NV, Srinivas NR. Intravenous pharmacokinetics, oral bioavailability and dose proportionality of ragaglitazar, a novel PPAR-dual activator in rats.
Biopharm. Drug Dispos. 25: 323 (2004).
*
-
Jahnke VE, Sabido O, Freyssenet DG. Control of mitochondrial biogenesis, ROS level and cytosolic Ca2+ concentration during the cell cycle and the onset of differentiation in L6E9 myoblasts.
Am. J. Physiol. Cell Physiol. 296: C1185-C1194 (2009).
*
-
Jahoor A, Patel R, Bryan A, Do C, Krier J, Watters C, Wahli W, Li G, Williams SC, Rumbaugh KP. Peroxisome proliferator activated receptors mediate host cell pro-inflammatory responses to P. aeruginosa autoinducer.
J. Bacteriol. 190: 4408-4415 (2008).
*
-
Jain S, Pulikuri S, Zhu Y, Qi C, Kanwar YS, Yeldandi AV, Rao MS, Reddy JK. Differential expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) and its coactivators steroid receptor coactivator-1 and PPAR-binding protein PBP in the brown fat, urinary bladder, colon, and breast of the mouse.
Am. J. Pathol. 153: 349-354 (1998).
*
-
Jakel H, Nowak M, Helleboid-Chapman A, Fruchart-Najib J, Fruchart JC. Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins?
Ann. Med. 38: 2-10 (2006).
-
Jakobsen MA, Petersen RK, Kristiansen K, Lange M, Lillevang ST. Peroxisome proliferator-activated receptor alpha, delta, gamma1 and gamma2 expressions are present in human monocyte-derived dendritic cells and modulate dendritic cell maturation by addition of subtype-specific ligands.
Scand. J. Immunol. 63: 330-337 (2006).
*
-
Jalouli M, Carlsson L, Ameen C, Linden D, Ljungberg A, Michalik L, Eden S, Wahli W, Oscarsson J. Sex difference in hepatic peroxisome proliferator-activated receptor alpha expression: influence of pituitary and gonadal hormones.
Endocrinology 144: 101-109 (2003).
*
-
James SY, Lin F, Kolluri SK, Dawson MI, Zhang XK. Regulation of retinoic acid receptor beta expression by peroxisome proliferator-activated receptor gamma ligands in cancer cells.
Cancer Res. 63: 3531-3538 (2003).
*
-
Jamshidi Y, Flavell DM, Hawe E, MacCallum PK, Meade TW, Humphries SE. Genetic determinants of the response to bezafibrate treatment in the lower extremity arterial disease event reduction (LEADER) trial.
Atherosclerosis 163: 183-192 (2002).
-
Jan HJ, Lee CC, Lin YM, Lai JH, Wei HW, Lee HM. Rosiglitazone reduces cell invasiveness by inducing MKP-1 in human U87MG glioma cells.
Cancer Lett. 277: 141-148 (2009).
-
Jana M, Jana A, Liu X, Ghosh S, Pahan K. Involvement of phosphatidylinositol 3-kinase-mediated up-regulation of IkappaBalpha in anti-inflammatory effect of gemfibrozil in microglia.
J. Immunol. 179: 4142-4152 (2007).
*
-
Jandeleit-Dahm KA, Calkin A, Tikellis C, Thomas M. Direct antiatherosclerotic effects of PPAR agonists.
Curr. Opin. Lipidol. 20: 24-29 (2009).
-
Jansen S, Cashman K, Thompson J, Pantaleon M, Kaye P. Glucose deprivation, oxidative stress and peroxisome proliferator activated receptor alpha (PPAR-alpha) cause peroxisome proliferation in preimplantation mouse embryos.
Reproduction Jun 16 [Epub ahead of print] (2009).
-
Jansson EA. Pivotal role of the nuclear receptor PPARgamma in colon epithelial cells.
Ph.D. Thesis, Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, Sweden (2004). *
-
Jarrar MH, Baranova A. PPARgamma activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: the importance of interplay with TGFbeta signalling.
J. Cell. Mol. Med. 11: 71-87 (2007).
*
-
Jaudszus A, Krokowski M, Mockel P, Darcan Y, Avagyan A, Matricardi P, Jahreis G, Hamelmann E. cis-9,trans-11-Conjugated linoleic acid inhibits allergic sensitization and airway inflammation via a PPARgamma-related mechanism in mice.
J. Nutr. 138: 1336-1342 (2008).
-
Jay MA, Ren J. Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus.
Curr. Diabetes Rev. 3: 33-39 (2007).
-
Jaziri R, Lobbens S, Aubert R, Pean F, Lahmidi S, Vaxillaire M, Porchay I, Bellili N, Tichet J, Balkau B, Froguel P, Marre M, Fumeron F. The PPARG Pro12Ala polymorphism is associated with a decreased risk of developing hyperglycemia over 6 years and combines with the effect of the APM1 G-11391A single nucleotide polymorphism: the data from an epidemiological study
Diabetes 55: 1157-1162 (2006).
*
-
Jazurek M, Dobrzyn P, Dobrzyn A. Regulation of gene expression by long-chain fatty acids.
Postepy. Biochem. 54: 242-250 (2008).
-
Jeffery B, Choudhury AI, Horley N, Bruce M, Tomlinson SR, Roberts RA, Gray TJ, Barrett DA, Shaw PN, Kendall D, Bell DR. Peroxisome proliferator activated receptor alpha regulates a male-specific cytochrome P450 in mouse liver.
Arch. Biochem. Biophys. 429: 231-236 (2004).
*
-
Jeninga EH, van Beekum O, van Dijk AD, Hamers N, Hendriks-Stegeman BI, Bonvin AM, Berger R, Kalkhoven E. Impaired PPARgamma function through mutation of a conserved salt bridge (R425C) in familial partial lipodystrophy.
Mol. Endocrinol. 21: 1049-1065 (2007).
*
-
Jennewein C, Kuhn AM, Schmidt MV, Meilladec-Jullig V, von Knethen A, Gonzalez FJ, Brune B. Sumoylation of peroxisome proliferator-activated receptor gamma by apoptotic cells prevents lipopolysaccharide-induced NCoR removal from kappaB binding sites mediating transrepression of proinflammatory cytokines.
J. Immunol. 181: 5646-5652 (2008).
-
Jeon EJ, Lee SK, Park YS, Kim DH, Yum JH, Park CS. The effects of peroxisome proliferator-activated receptor-gamma agonist on a murine model of experimental allergic rhinitis.
Otolaryngol. Head Neck Surg. 139: 124-130 (2008).
-
Ji CG, Zhang JZ. Protein polarization is critical to stabilizing AF-2 and helix-2' domains in ligand binding to PPAR-gamma.
J. Am. Chem. Soc. 130: 17129-17133 (2008).
*
-
Ji JD, Kim HJ, Rho YH, Choi SJ, Lee YH, Cheon HJ, Sohn J, Song GG. Inhibition of IL-10-induced STAT3 activation by 15-deoxy-Delta12,14-prostaglandin J2.
Rheumatology (Oxford) 44: 983-988 (2005).
*
-
Ji SL, Huang QY. PPARgamma variants and complex diseases.
Yi Chuan 28: 993-1002 (2006).
-
Ji Y, Liu J, Wang Z, Liu N, Gou W. PPARgamma agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway.
Lab. Invest. May 18 [Epub ahead of print] (2009).
*
-
Jia Y, Qi C, Kashireddi P, Surapureddi S, Zhu YJ, Rao MS, Le Roith D, Chambon P, Gonzalez FJ, Reddy JK. Transcription coactivator PBP, the peroxisome proliferator-activated receptor (PPAR)-binding protein, is required for PPARalpha-regulated gene expression in liver.
J. Biol. Chem. 279: 24427-24434 (2004).
*
-
Jia Y, Qi C, Zhang Z, Zhu YT, Rao SM, Zhu YJ. Peroxisome proliferator-activated receptor-binding protein null mutation results in defective mammary gland development.
J. Biol. Chem. 280: 10766-10773 (2005).
*
-
Jiang B, Liang P, Zhang B, Huang X, Xiao X. Enhancement of PPAR-beta activity by repetitive low-grade H2O2 stress protects human umbilical vein endothelial cells from subsequent oxidative stress-induced apoptosis.
Free Radic. Biol. Med. 46: 555-563 (2009).
-
Jiang B, Liang P, Zhang B, Song J, Huang X, Xiao X. Role of PPAR-beta in hydrogen peroxide-induced apoptosis in human umbilical vein endothelial cells.
Atherosclerosis 204: 353-358 (2009).
-
Jiang J, Gajalakshmi V, Wang J, Kuriki K, Suzuki S, Nakamura S, Akasaka S, Ishikawa H, Tokudome S. Influence of the C161T but not Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma on colorectal cancer in an Indian population.
Cancer Sci. 96: 507-512 (2005).
*
-
Jiang WG, Davies G, Kynaston H, Mason MD, Fodstad O. Does the PGC-1/PPARgamma pathway play a role in Com-1/p8 mediated cell growth inhibition in prostate cancer?
Int. J. Mol. Med. 18: 1169-1175 (2006).
*
-
Jiang Y, Mishima H, Sakai S, Liu YK, Ohyabu Y, Uemura T. Gene expression analysis of major lineage-defining factors in human bone marrow cells: effect of aging, gender, and age-related disorders.
J. Orthop. Res. 26: 910-917 (2008).
-
Jiang YD, Xiong JT, Cao J, Li GZ, Wang SR. Effects of peroxisome proliferators activated receptors on caveolin-1 expression in foam cells.
Zhonghua Xin Xue Guan Bing Za Zhi 35: 661-665 (2007).
-
Jiang YJ, Kim P, Elias PM, Feingold KR. LXR and PPAR activators stimulate cholesterol sulfotransferase (SULT2B1b) in human keratinocytes.
J. Lipid Res. 46: 2657-2666 (2005).
*
-
Jiang YJ, Lu B, Kim P, Elias PM, Feingold KR. Regulation of ABCA1 expression in human keratinocytes and murine epidermis.
J. Lipid Res. 47: 2248-2258 (2006).
*
-
Jiang YJ, Lu B, Kim P, Paragh G, Schmitz G, Elias PM, Feingold KR. PPAR and LXR activators regulate ABCA12 expression in human keratinocytes.
J. Invest. Dermatol. 128: 104-109 (2008).
*
-
Jiang YJ, Uchida Y, Lu B, Kim P, Mao C, Akiyama M, Elias PM, Holleran WM, Grunfeld C, Feingold KR. Ceramide stimulates ABCA12 expression via PPARa in human keratinocytes.
J. Biol. Chem. May 8 [Epub ahead of print] (2009).
*
-
Jin S, Mathis AS, Rosenblatt J, Minko T, Friedman GS, Gioia K, Serur DS, Knipp GT. Insights into cyclosporine A-induced atherosclerotic risk in transplant recipients: macrophage scavenger receptor regulation.
Transplantation 77: 497-504 (2004).
-
Jing L, Li WM, Zhou LJ, Li S, Kou JJ, Song J. Expression of renin-angiotensin system and peroxisome proliferator-activated receptors in alcoholic cardiomyopathy.
Alcohol Clin. Exp. Res. 32: 1999-2007 (2008).
-
Jo SH, Yang C, Miao Q, Marzec M, Wasik MA, Lu P, Wang YL. Peroxisome proliferator-activated receptor gamma promotes lymphocyte survival through its actions on cellular metabolic activities.
J. Immunol. 177: 3737-3745 (2006).
*
-
Jobgen W, Fu WJ, Gao H, Li P, Meininger CJ, Smith SB, Spencer TE, Wu G. High fat feeding and dietary L-arginine supplementation differentially regulate gene expression in rat white adipose tissue.
Amino Acids 37: 187-198 (2009).
*
-
Johansen A, Jensen DP, Bergholdt R, Mortensen HB, Pociot F, Nerup J, Hansen T, Pedersen O; The Danish Society of Childhood Diabetes. IRS1, KCNJ11, PPARgamma2 and HNF-1alpha: do amino acid polymorphisms in these candidate genes support a shared aetiology between type 1 and type 2 diabetes?
Diabetes Obes. Metab. 8: 75-82 (2006).
-
Johmura Y. Characterization of novel genes regulating adipocyte differentiation.
Yakugaku Zasshi 127: 135-142 (2007).
-
Johnson DR, Stebulis JA, Rossetti RG, Burstein SH, Zurier RB. Suppression of fibroblast metalloproteinases by ajulemic acid, a nonpsychoactive cannabinoid acid.
J. Cell. Biochem. 100: 184-190 (2007).
*
-
Johnson EF, Hsu MH, Savas U, Griffin KJ. Regulation of P450 4A expression by peroxisome proliferator activated receptors.
Toxicology 181-182: 203-206 (2002).
*
-
Johnson EF, Palmer CN, Griffin KJ, Hsu MH. Role of the peroxisome proliferator-activated receptor in cytochrome P450 4A gene regulation.
FASEB J. 10: 1241-1248 (1996).
*
-
Johnson TE, Zhang X, Shi S, Umbenhauer DR. Statins and PPARalpha agonists induce myotoxicity in differentiated rat skeletal muscle cultures but do not exhibit synergy with co-treatment.
Toxicol. Appl. Pharmacol. 208: 210-221 (2005).
*
-
Johnson W, Harris SE, Starr JM, Whalley LJ, Deary IJ. PPARG Pro12Ala genotype and risk of cognitive decline in elders? Maybe with diabetes.
Neurosci. Lett. 434: 50-55 (2008).
-
Johnston TP, Waxman DJ. Circulating free fatty acids are increased independently of PPAR-gamma activity after administration of poloxamer 407 to mice.
Can. J. Physiol. Pharmacol. 86: 643-649 (2008).
-
Jones DC, Ding X, Daynes RA. Nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha) is expressed in resting murine lymphocytes. The PPARalpha in T and B lymphocytes is both transactivation and transrepression competent.
J. Biol. Chem. 277: 6838-6845 (2002).
*
-
Jones DC, Manning BM, Daynes RA. A role for the peroxisome proliferator-activated receptor alpha in T-cell physiology and ageing immunobiology.
Proc. Nutr. Soc. 61: 363-369 (2002).
*
-
Jones JR, Barrick C, Kim KA, Lindner J, Blondeau B, Fujimoto Y, Shiota M, Kesterson RA, Kahn BB, Magnuson MA. Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance.
Proc. Natl. Acad. Sci. U.S.A. 102: 6207-6212 (2005).
*
-
Jones KS, Alimov AP, Rilo HL, Jandacek RP, Woollett LA, Penberthy WT. A high throughput live transparent animal bioassay to identify non-toxic small molecules or genes that regulate vertebrate fat metabolism for obesity drug development.
Nutr. Metab. (Lond.) 5: 23 (2008).
*
-
Jorsal A, Tarnow L, Lajer M, Ek J, Hansen T, Pedersen O, Parving HH. The PPARgamma2 Pro12Ala variant predicts ESRD and mortality in patients with type 1 diabetes and diabetic nephropathy.
Mol. Genet. Metab. 94: 347-351 (2008).
*
-
Jouzeau JY, Moulin D, Koufany M, Sebillaud S, Bianchi A, Netter P. Pathophysiological relevance of peroxisome proliferators activated receptors (PPAR) to joint diseases - the pro and con of agonists.
J. Soc. Biol. 202: 289-312 (2008).
-
Jozkowicz A, Was H, Taha H, Kotlinowski J, Mleczko K, Cisowski J, Weigel G, Dulak J. 15d-PGJ2 upregulates synthesis of IL-8 in endothelial cells through induction of oxidative stress.
Antioxid. Redox Signal. 10: 2035-2046 (2008).
-
Jucker B, Yang D, Casey W, Olzinski A, Williams C, Lenhard S, Legos J, Hawk T, Sarkar S, Newsholme S. Selective PPARdelta agonist treatment increases skeletal muscle lipid metabolism without altering mitochondrial energy coupling: an in vivo magnetic resonance spectroscopy study.
Am. J. Physiol. Endocrinol. Metab. 293: E1256-E1264 (2007).
*
-
Juge-Aubry CE, Gorla-Bajszczak A, Pernin A, Lemberger T, Wahli W, Burger AG, Meier CA. Peroxisome proliferator-activated receptor mediates cross-talk with thyroid hormone receptor by competition for retinoid X receptor. Possible role of a leucine zipper-like heptad repeat.
J. Biol. Chem. 270: 18117-18122 (1995).
*
-
Jump DB. Fatty acid regulation of gene transcription.
Crit. Rev. Clin. Lab. Sci. 41: 41-78 (2004).
-
Jump DB. Dietary polyunsaturated fatty acids and regulation of gene transcription.
Curr. Opin. Lipidol. 13: 155-164 (2002).
-
Jump DB, Botolin D, Wang Y, Xu J, Christian B, Demeure O. Fatty acid regulation of hepatic gene transcription.
J. Nutr. 135: 2503-2506 (2005).
*
-
Jump DB, Botolin D, Wang Y, Xu J, Demeure O, Christian B. Docosahexaenoic acid (DHA) and hepatic gene transcription.
Chem. Phys. Lipids 153: 3-13 (2008).
*
-
Jump DB, Clarke SD, Thelen A, Liimatta M, Ren B, Badin MV. Dietary fat, genes, and human health.
Adv. Exp. Med. Biol. 422: 167-176 (1997).
-
Jump DB, Thelen A, Mater M. Dietary polyunsaturated fatty acids and hepatic gene expression.
Lipids 34: S209-S112 (1999).
-
Jump DB, Thelen A, Ren B, Mater M. Multiple mechanisms for polyunsaturated fatty acid regulation of hepatic gene transcription.
Prostaglandins Leukot. Essent. Fatty Acids 60: 345-349 (1999).
-
Jung D, Fried M, Kullak-Ublick GA. Human apical sodium-dependent bile salt transporter gene (SLC10A2) is regulated by the peroxisome proliferator-activated receptor alpha.
J. Biol. Chem. 277: 30559-30566 (2002).
*
-
Jung SH, Park SY, Kim-Pak Y, Lee HK, Park KS, Shin KH, Ohuchi K, Shin HK, Keum SR, Lim SS. Synthesis and PPAR-gamma ligand-binding activity of the new series of 2'-hydroxychalcone and thiazolidinedione derivatives.
Chem. Pharm. Bull. (Tokyo) 54: 368-371 (2006).
*
-
Jung TW, Lee MW, Lee YJ, Kim SM, Lee KT, Whang WK, Cheon HJ, Jeong YT, Chung KW, Cho JM, Kim DH, Jung TW. Regulation of adiponectin receptor 2 expression via PPAR-alpha in NIT-1 cells.
Endocr. J. Apr 1 [Epub ahead of print] (2009).
*
-
Kacerovsky-Bielesz G, Chmelik M, Ling C, Pokan R, Szendroedi J, Farukuoye M, Kacerovsky M, Schmid AI, Gruber S, Wolzt M, Moser E, Pacini G, Smekal G, Groop L, Roden M. Short-term exercise training does not stimulate skeletal muscle ATP synthesis in relatives of humans with type 2 diabetes.
Diabetes 58: 1333-1341 (2009).
-
Kadowaki K, Fukino K, Negishi E, Ueno K. Sex differences in PPARgamma expressions in rat adipose tissues.
Biol. Pharm. Bull. 30: 818-820 (2007).
*
-
Kadowaki T. Recent advances in PPARs research - basic and clinical aspects.
Nippon Rinsho 63: 539-548 (2005).
-
Kadowaki T, Hara K, Yamauchi T, Terauchi Y, Tobe K, Nagai R. Molecular mechanism of insulin resistance and obesity.
Exp. Biol. Med. (Maywood) 228: 1111-1117 (2003).
*
-
Kagechika H, Miyachi H. PPARs as molecular targets for drug discovery.
Nippon Rinsho 63: 549-555 (2005).
-
Kaidashev IP, Rasin AM, Shlykova OA, Gorbas' IM, Smirnova IP, Petrushov AV, Rasin MS. Frequency of the Pro 12Ala gene polymorphism PPARgamma2 in Ukrainian population and its possible role in metabolic syndrome development.
Tsitol. Genet. 41: 43-47 (2007).
-
Kaimal R, Song X, Yan B, King R, Deng R. Differential modulation of farnesoid X receptor signaling pathway by thiazolidinediones.
J. Pharmacol. Exp. Ther. Apr 15 [Epub ahead of print] (2009).
*
-
Kainuma M, Kasuga JI, Hosoda S, Wakabayashi KI, Tanatani A, Nagasawa K, Miyachi H, Makishima M, Hashimoto Y. Diphenylmethane skeleton as a multi-template for nuclear receptor ligands: preparation of FXR and PPAR ligands.
Bioorg. Med. Chem. Lett. 16: 3213-3218 (2006).
*
-
Kaipainen A, Kieran MW, Huang S, Butterfield C, Bielenberg D, Mostoslavsky G, Mulligan R, Folkman J, Panigrahy D. PPARalpha deficiency in inflammatory cells suppresses tumor growth.
PLoS ONE 2: e260 (2007).
*
-
Kakiuchi-Kiyota S, Vetro JA, Suzuki S, Varney ML, Han HY, Nascimento M, Pennington KL, Arnold LL, Singh RK, Cohen SM. Effects of the PPARgamma agonist troglitazone on endothelial cells in vivo and in vitro: differences between human and mouse.
Toxicol. Appl. Pharmacol. 237: 83-90 (2009).
*
-
Kallwitz ER, McLachlan A, Cotler SJ. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease.
World J. Gastroenterol. 14: 22-28 (2008).
*
-
Kambia N, Renault N, Dilly S, Farce A, Dine T, Gressier B, Luyckx M, Brunet C, Chavatte P. Molecular modelling of phthalates: PPARs interactions.
J. Enzyme Inhib. Med. Chem. 23: 611-616 (2008).
-
Kamijo Y, Hora K, Kono K, Takahashi K, Higuchi M, Ehara T, Kiyosawa K, Shigematsu H, Gonzalez FJ, Aoyama T. PPARalpha protects proximal tubular cells from acute fatty acid toxicity.
J. Am. Soc. Nephrol. 18: 3089-3100 (2007).
*
-
Kamijo Y, Hora K, Nakajima T, Kono K, Takahashi K, Ito Y, Higuchi M, Kiyosawa K, Shigematsu H, Gonzalez FJ, Aoyama T. Peroxisome proliferator-activated receptor alpha protects against glomerulonephritis induced by long-term exposure to the plasticizer di-(2-ethylhexyl)phthalate.
J. Am. Soc. Nephrol. 18: 176-188 (2007).
*
-
Kaminishi M. Diversity of gastric carcinogenesis.
Oncology 69 Suppl. 1: 1-8 (2005).
-
Kanayama T, Kobayashi N, Mamiya S, Nakanishi T, Nishikawa JI. Organotin compounds promote adipocyte differentiation as agonists of the peroxisome proliferator-activated receptor (PPAR) gamma / retinoid X receptor (RXR) pathway.
Mol. Pharmacol. 67: 766-774 (2005).
*
-
Kane CD, Francone OL, Stevens KA. Differential regulation of the cynomolgus, human, and rat acyl-CoA oxidase promoters by PPARalpha.
Gene 380: 84-94 (2006).
*
-
Kang HJ, Cinn YG, Hwang SJ, Won Chae S, Woo JS, Lee SH, Lee HM. Up-regulation of peroxisome proliferator-activated receptor gamma in perennial allergic rhinitis.
Arch. Otolaryngol. Head Neck Surg. 132: 1196-1200 (2006).
-
Kang HW, Bhimidi GR, Odom DP, Brun PJ, Fernandez ML, McGrane MM. Altered lipid catabolism in the vitamin A deficient liver.
Mol. Cell. Endocrinol. 271: 18-27 (2007).
-
Kang HY, Chung E, Lee M, Cho Y, Kang WH. Expression and function of peroxisome proliferator-activated receptors in human melanocytes.
Br. J. Dermatol. 150: 462-468 (2004).
*
-
Kang HY, Lee JY, Lee JS, Choi YM. Peroxisome proliferator-activated receptors-gamma activator, ciglitazone, inhibits human melanocyte growth through induction of apoptosis.
Arch. Dermatol. Res. 297: 472-476 (2006).
*
-
Kang K, Hatano B, Lee CH. PPARdelta agonists and metabolic diseases.
Curr. Atheroscler. Rep. 9: 72-77 (2007).
-
Kang KW, Lee SJ, Kim SG. Molecular mechanism of Nrf2 activation by oxidative stress.
Antioxid. Redox Signal. 7: 1664-1673 (2005).
-
Kang MS, Hirai S, Goto T, Kuroyanagi K, Lee JY, Uemura T, Ezaki Y, Takahashi N, Kawada T. Dehydroabietic acid, a phytochemical, acts as ligand for PPARs in macrophages and adipocytes to regulate inflammation.
Biochem. Biophys. Res. Commun. 369: 333-338 (2008).
*
-
Kang SA, Hong K, Jang KH, Kim YY, Choue R, Lim Y. Altered mRNA expression of hepatic lipogenic enzyme and PPARalpha in rats fed dietary levan from Zymomonas mobilis.
J. Nutr. Biochem. 17: 419-426 (2006).
*
-
Kanjanabuch T, Ma LJ, Chen J, Pozzi A, Guan Y, Mundel P, Fogo AB. PPAR-gamma agonist protects podocytes from injury.
Kidney Int. 71: 1232-1239 (2007).
*
-
Kannisto K, Chibalin A, Glinghammar B, Zierath JR, Hamsten A, Ehrenborg E. Differential expression of peroxisomal proliferator activated receptors alpha and delta in skeletal muscle in response to changes in diet and exercise.
Int. J. Mol. Med. 17: 45-52 (2006).
*
-
Kao YH, Hsieh HP, Chitlimalla SK, Pan WY, Kuo CC, Tsai YC, Lin WH, Chuang SE, Chang JY. A novel peroxisome proliferator-activated receptor alpha/gamma agonist, BPR1H0101, inhibits topoisomerase II catalytic activity in human cancer cells.
Anticancer Drugs 19: 151-158 (2008).
-
Kapadia R, Yi JH, Vemuganti R. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists.
Front. Biosci. 13: 1813-1826 (2008).
-
Karger S, Berger K, Eszlinger M, Tannapfel A, Dralle H, Paschke R, Fuhrer D. Evaluation of peroxisome proliferator-activated receptor-gamma expression in benign and malignant thyroid pathologies.
Thyroid 15: 997-1003 (2005).
-
Karlsen TH. Genome-wide association studies reach hepatology.
J. Hepatol. 50: 1278-1280 (2009).
-
Karlsson HK, Ahlsen M, Zierath JR, Wallberg-Henriksson H, Koistinen HA. Insulin signaling and glucose transport in skeletal muscle from first-degree relatives of type 2 diabetic patients.
Diabetes 55: 1283-1288 (2006).
*
-
Karnati S, Baumgart-Vogt E. Peroxisomes in mouse and human lung: their involvement in pulmonary lipid metabolism.
Histochem. Cell Biol. 130: 719-740 (2008).
-
Karnik P, Tekeste Z, McCormick TS, Gilliam AC, Price VH, Cooper KD, Mirmirani P. Hair follicle stem cell-specific PPARgamma deletion causes scarring alopecia.
J. Invest. Dermatol. 129: 1243-1257 (2009).
*
-
Kasai S, Inoue T, Yoshitomi H, Hihara T, Matsuura F, Harada H, Shinoda M, Tanaka I. Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs.
J. Pharmacol. Sci. 108: 40-48 (2008).
*
-
Kasai T, Miyauchi K, Yokoyama T, Aihara K, Daida H. Efficacy of peroxisome proliferative activated receptor (PPAR)-alpha ligands, fenofibrate, on intimal hyperplasia and constrictive remodeling after coronary angioplasty in porcine models.
Atherosclerosis 188: 274-280 (2006).
-
Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F, Ebenbichler CF, Patsch JR, Tilg H. Adiponectin and its receptors in non-alcoholic steatohepatitis.
Gut 54: 117-121 (2005).
*
-
Kashireddy PV, Rao MS. Lack of peroxisome proliferator-activated receptor a in mice enhances methionine and choline deficient diet-induced steatohepatitis.
Hepatol. Res. 30: 104-110 (2004).
-
Kassam A, Hunter J, Rachubinski RA, Capone JP. Subtype- and response element-dependent differences in transactivation by peroxisome proliferator-activated receptors alpha and gamma.
Mol. Cell. Endocrinol. 141: 153-162 (1998).
-
Kassam A, Winrow CJ, Fernandez-Rachubinski F, Capone JP, Rachubinski RA. The peroxisome proliferator response element of the gene encoding the peroxisomal beta-oxidation enzyme enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase is a target for constitutive androstane receptor beta/9-cis-retinoic acid receptor-mediated
J. Biol. Chem. 275: 4345-4350 (2000).
*
-
Kasuga JI, Makishima M, Hashimoto Y, Miyachi H. Design and synthesis of substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor alpha/delta dual agonists.
Bioorg. Med. Chem. Lett. 16: 554-558 (2006).
*
-
Kasuga JI, Nakagome I, Aoyama A, Sako K, Ishizawa M, Ogura M, Makishima M, Hirono S, Hashimoto Y, Miyachi H. Design, synthesis, and evaluation of potent, structurally novel peroxisome proliferator-activated receptor (PPAR) delta-selective agonists.
Bioorg. Med. Chem. 15: 5177-5190 (2007).
*
-
Kasuga JI, Oyama T, Nakagome I, Aoyama A, Sako K, Makishima M, Hirono S, Morikawa K, Hashimoto Y, Miyachi H. Design and synthesis of peroxisome proliferator-activated receptor (PPAR) delta agonists and its implication to the driving force to elicit PPAR delta selectivity.
Yakugaku Zasshi 129: 709-718 (2009).
-
Kasuga JI, Yamasaki D, Araya Y, Nakagawa A, Makishima M, Doi T, Hashimoto Y, Miyachi H. Design, synthesis, and evaluation of a novel series of alpha-substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) alpha/delta dual agonists for the treatment of metabolic syndrome.
Bioorg. Med. Chem. 14: 8405-8414 (2006).
-
Katayama K, Wada K, Nakajima A, Mizuguchi H, Hayakawa T, Nakagawa S, Kadowaki T, Nagai R, Kamisaki Y, Blumberg RS, Mayumi T. A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model.
Gastroenterology 124: 1315-1324 (2003).
*
-
Kaul D, Anand PK, Khanna A. Functional genomics of PPAR-gamma in human immunomodulatory cells.
Mol. Cell. Biochem. 290: 211-215 (2006).
*
-
Kaul D, Gautam A, Sikand K. Importance of LXR-alpha transcriptome in the modulation of innate immunity.
Mol. Cell. Biochem. 292: 53-57 (2006).
*
-
Kawachi H, Moriya NH, Korai T, Tanaka SY, Watanabe M, Matsui T, Kawada T, Yano H. Nitric oxide suppresses preadipocyte differentiation in 3T3-L1 culture.
Mol. Cell. Biochem. 300: 61-67 (2007).
*
-
Kawada T. Lipid metabolism related nuclear receptor - the structure, function, expression and classification of peroxisome proliferation-activated receptor (PPAR).
Nippon Rinsho 56: 1722-1728 (1998).
-
Kawada T, Goto T, Hirai S, Kang MS, Uemura T, Yu R, Takahashi N. Dietary regulation of nuclear receptors in obesity-related metabolic syndrome.
Asia Pac. J. Clin. Nutr. 17 Suppl. 1: 126-130 (2008).
-
Kawada T, Kamei Y, Fujita A, Hida Y, Takahashi N, Sugimoto E, Fushiki T. Carotenoids and retinoids as suppressors on adipocyte differentiation via nuclear receptors.
Biofactors 13: 103-109 (2000).
-
Kawai M, Namba N, Mushiake S, Etani Y, Nishimura R, Makishima M, Ozono K. Growth hormone stimulates adipogenesis of 3T3-L1 cells through activation of the Stat5A/5B-PPARgamma pathway.
J. Mol. Endocrinol. 38: 19-34 (2007).
*
-
Kawai T, Masaki T, Doi S, Arakawa T, Yokoyama Y, Doi T, Kohno N, Yorioka N. PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta.
Lab. Invest. 89: 47-58 (2009).
*
-
Kawashima A, Harada T, Imada K, Yano T, Mizuguchi K. Eicosapentaenoic acid inhibits interleukin-6 production in interleukin-1beta-stimulated C6 glioma cells through peroxisome proliferator-activated receptor-gamma.
Prostaglandins Leukot. Essent. Fatty Acids 79: 59-65 (2008).
*
-
Keech A. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, a randomized, placebo-controlled trial: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481].
Cardiovasc. Diabetol. 4: 13 (2005).
*
-
Keller H, Devchand PR, Perroud M, Wahli W. PPAR alpha structure-function relationships derived from species-specific differences in responsiveness to hypolipidemic agents.
Biol. Chem. 378: 651-655 (1997).
-
Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, Wahli W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers.
Proc. Natl. Acad. Sci. U.S.A. 90: 2160-2164 (1993).
*
-
Keller H, Mahfoudi A, Dreyer C, Hihi AK, Medin J, Ozato K, Wahli W. Peroxisome proliferator-activated receptors and lipid metabolism.
Ann. N. Y. Acad. Sci. 684: 157-173 (1993).
*
-
Keller JM, Collet P, Bianchi A, Huin C, Bouillaud-Kremarik P, Becuwe P, Schohn H, Domenjoud L, Dauca M. Implications of peroxisome proliferator-activated receptors (PPARS) in development, cell life status and disease.
Int. J. Dev. Biol. 44: 429-442 (2000).
*
-
Kelly D, Campbell JI, King TP, Grant G, Jansson EA, Coutts AG, Pettersson S, Conway S. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA.
Nat. Immunol. 5: 104-112 (2004).
*
-
Kelly KJ, Wu P, Patterson CE, Temm CJ, Dominguez JH. LOX-1 and inflammation: a new mechanism for renal injury in obesity and diabetes.
Am. J. Physiol. Renal Physiol. 294: F1136-F1145 (2008).
*
-
Kempna P, Hofer G, Mullis PE, Fluck CE. Pioglitazone inhibits androgen production in NCI-H295R cells by regulating gene expression of CYP17 and HSD3B2.
Mol. Pharmacol. 71: 787-798 (2007).
*
-
Kennedy A, Martinez K, Chuang CC, Lapoint K, McIntosh M. Saturated fatty acid-mediated inflammation and insulin resistance in adipose tissue: mechanisms of action and implications.
J. Nutr. 139: 1-4 (2009).
*
-
Kennedy A, Overman A, Lapoint K, Hopkins R, West T, Chuang CC, Martinez K, Bell D, McIntosh MK. Conjugated linoleic acid-mediated inflammation and insulin resistance in human adipocytes are attenuated by resveratrol.
J. Lipid Res. 50: 225-232 (2009).
*
-
Kepez A, Oto A, Dagdelen S. Peroxisome proliferator-activated receptor-gamma: novel therapeutic target linking adiposity, insulin resistance, and atherosclerosis.
BioDrugs 20: 121-135 (2006).
-
Kershaw EE, Schupp M, Guan HP, Gardner NP, Lazar MA, Flier JS. PPARgamma regulates adipose triglyceride lipase in adipocytes in vitro and in vivo.
Am. J. Physiol. Endocrinol. Metab. 293: E1736-E1745 (2007).
*
-
Kersten S. Peroxisome proliferator activated receptors and obesity.
Eur. J. Pharmacol. 440: 223-234 (2002).
*
-
Kersten S. Peroxisome proliferator activated receptors and lipoprotein metabolism.
PPAR Res. 2008: 132960 (2008).
*
-
Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease.
Nature 405: 421-424 (2000).
*
-
Kersten S, Mandard S, Escher P, Gonzalez FJ, Tafuri S, Desvergne B, Wahli W. The peroxisome proliferator-activated receptor alpha regulates amino acid metabolism.
FASEB J. 15: 1971-1978 (2001).
*
-
Kersten S, Mandard S, Tan NS, Escher P, Metzger D, Chambon P, Gonzalez FJ, Desvergne B, Wahli W. Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene.
J. Biol. Chem. 275: 28488-28493 (2000).
*
-
Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting.
J. Clin. Invest. 103: 1489-1498 (1999).
*
-
Kersten S, Wahli W. Peroxisome proliferator activated receptor agonists.
EXS 89: 141-151 (2000).
-
Keshava N, Caldwell JC. Key issues in the role of peroxisome proliferator-activated receptor agonism and cell signaling in trichloroethylene toxicity.
Environ. Health Perspect. 114: 1464-1470 (2006).
*
-
Khan QH, Pontefract DE, Iyengar S, Ye S. Evidence of differing genotypic effects of PPARalpha in women and men.
J. Med. Genet. 41: e79 (2004).
*
-
Kharroubi I, Lee CH, Hekerman P, Darville MI, Evans RM, Eizirik DL, Cnop M. BCL-6: a possible missing link for anti-inflammatory PPAR-delta signalling in pancreatic beta cells.
Diabetologia 49: 2350-2358 (2006).
*
-
Khodadadi I, Griffin B, Thumser A. Differential effects of long-chain fatty acids and clofibrate on gene expression profiles in cardiomyocytes.
Arch. Iran. Med. 11: 42-49 (2008).
-
Kholaifi AA, Amer A, Jeffery B, Gray TJ, Roberts RA, Bell DR. Species-specific kinetics and zonation of hepatic DNA synthesis induced by ligands of PPARalpha.
Toxicol. Sci. 104: 74-85 (2008).
*
-
Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host.
J. Lipid Res. 45: 1169-1196 (2004).
*
-
Kiaei M. Peroxisome proliferator-activated receptor-gamma in amyotrophic lateral sclerosis and Huntington's disease.
PPAR Res. 2008: 418765 (2008).
*
-
Kiaei M, Kipiani K, Chen J, Calingasan NY, Beal MF. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis.
Exp. Neurol. 191: 331-336 (2005).
-
Kiec-Wilk B, Dembinska-Kiec A, Olszanecka A, Bodzioch M, Kawecka-Jaszcz K. The selected pathophysiological aspects of PPARs activation.
J. Physiol. Pharmacol. 56: 149-162 (2005).
*
-
Kielian T, Syed MM, Liu S, Phulwani NK, Phillips N, Wagoner G, Drew PD, Esen N. The synthetic peroxisome proliferator-activated receptor-gamma agonist ciglitazone attenuates neuroinflammation and accelerates encapsulation in bacterial brain abscesses.
J. Immunol. 180: 5004-5016 (2008).
*
-
Kilgore KS, Billin AN. PPARbeta/delta ligands as modulators of the inflammatory response.
Curr. Opin. Investig. Drugs 9: 463-469 (2008).
-
Kilpealinen TO, Lakka TA, Laaksonen DE, Lindstorm J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Lindi V, Tuomilehto J, Uusitupa M, Laakso M. SNPs in PPARg associate with type 2 diabetes and interact with physical activity.
Med. Sci. Sports Exerc. 40: 25-33 (2008).
-
Kilroy GE, Zhang X, Floyd ZE. PPAR-gamma AF-2 domain functions as a component of a ubiquitin-dependent degradation signal.
Obesity (Silver Spring) 17: 665-673 (2009).
*
-
Kim DJ, Oh B, Kim YY. Splicing factor ASF/SF2 and transcription factor PPAR-gamma cooperate to directly regulate transcription of uncoupling protein-3.
Biochem. Biophys. Res. Commun. 378: 877-882 (2009).
*
-
Kim DY, Yuan HD, Chung IK, Chung SH. Compound K, intestinal metabolite of ginsenoside, attenuates hepatic lipid accumulation via AMPK activation in human hepatoma cells.
J. Agric. Food Chem. 57: 1532-1537 (2009).
*
-
Kim E, Chen F, Wang CC, Harrison LE. CDK5 is a novel regulatory protein in PPARgamma ligand-induced antiproliferation.
Int. J. Oncol. 28: 191-194 (2006).
*
-
Kim E, Li K, Lieu C, Tong S, Kawai S, Fukutomi T, Zhou Y, Wands J, Li J. Expression of apolipoprotein C-IV is regulated by Ku antigen/peroxisome proliferator-activated receptor gamma complex and correlates with liver steatosis.
J. Hepatol. 49: 787-798 (2008).
*
-
Kim EK, Kwon KB, Koo BS, Han MJ, Song MY, Song EK, Han MK, Park JW, Ryu DG, Park BH. Activation of peroxisome proliferator-activated receptor-gamma protects pancreatic beta-cells from cytokine-induced cytotoxicity via NFkappaB pathway.
Int. J. Biochem. Cell Biol. 39: 1260-1275 (2007).
*
-
Kim GS, Lee GY, Nedumaran B, Park YY, Kim KT, Park SC, Lee YC, Kim JB, Choi HS. The orphan nuclear receptor DAX-1 acts as a novel transcriptional corepressor of PPARgamma.
Biochem. Biophys. Res. Commun. 370: 264-268 (2008).
*
-
Kim H, Haluzik M, Asghar Z, Yau D, Joseph JW, Fernandez AM, Reitman ML, Yakar S, Stannard B, Heron-Milhavet L, Wheeler MB, LeRoith D. Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis.
Diabetes 52: 1770-1778 (2003).
*
-
Kim H, Haluzik M, Gavrilova O, Yakar S, Portas J, Sun H, Pajvani UB, Scherer PE, Leroith D. Thiazolidinediones improve insulin sensitivity in adipose tissue and reduce the hyperlipidaemia without affecting the hyperglycaemia in a transgenic model of type 2 diabetes.
Diabetologia 47: 2215-2225 (2004).
*
-
Kim HG, Han EH, Jeong HG. Effect of troglitazone on CYP1A1 induction.
Toxicology 246: 166-171 (2008).
*
-
Kim HI, Koh YK, Kim TH, Kwon SK, Im SS, Choi HS, Kim KS, Ahn YH. Transcriptional activation of SHP by PPAR-gamma in liver.
Biochem. Biophys. Res. Commun. 360: 301-306 (2007).
*
-
Kim HJ, Ham SA, Kim SU, Hwang JY, Kim JH, Chang KC, Yabe-Nishimura C, Kim JH, Seo HG. Transforming growth factor-beta1 is a molecular target for the peroxisome proliferator-activated receptor delta.
Circ. Res. 102: 193-200 (2008).
-
Kim HJ, Jung TW, Kang ES, Kim DJ, Ahn CW, Lee KW, Lee HC, Cha BS. Depot-specific regulation of perilipin by rosiglitazone in a diabetic animal model.
Metabolism 56: 676-685 (2007).
*
-
Kim HJ, Kim MY, Jin H, Kim HJ, Kang SS, Kim HJ, Lee JH, Chang KC, Hwang JY, Yabe-Nishimura C, Kim JH, Seo HG. Peroxisome proliferator-activated receptor delta regulates extracellular matrix and apoptosis of vascular smooth muscle cells through the activation of transforming growth factor-beta1/Smad3.
Circ. Res. May 21 [Epub ahead of print] (2009).
-
Kim HY, Kim JR, Kim HS. Upregulation of lipopolysaccharide-induced interleukin-10 by prostaglandin A1 in mouse peritoneal macrophages.
J. Microbiol. Biotechnol. 18: 1170-1178 (2008).
-
Kim J, Ahn JH, Kim JH, Yu YS, Kim HS, Ha J, Shinn SH, Oh YS. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway.
Exp. Eye Res. 84: 886-893 (2007).
-
Kim J, Han DC, Kim JM, Lee SY, Kim SJ, Woo JR, Lee JW, Jung SK, Yoon KS, Cheon HG, Kim SS, Hong SH, Kwon BM. PPAR gamma partial agonist, KR-62776, inhibits adipocyte differentiation via activation of ERK.
Cell. Mol. Life Sci. Apr 7 [Epub ahead of print] (2009).
*
-
Kim JE, Chen J. Regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis.
Diabetes 53: 2748-2756 (2004).
*
-
Kim JJ, Li P, Huntley J, Chang JP, Arden KC, Olefsky JM. FoxO1 haploinsufficiency protects against high fat diet-induced insulin resistance with enhanced PPARgamma activation in adipose tissue.
Diabetes 58: 1275-1282 (2009).
-
Kim JY, Tillison K, Lee JH, Rearick DA, Smas C. The adipose tissue triglyceride lipase ATGL/PNPLA2 is downregulated by insulin and TNFalpha in 3T3-L1 adipocytes and is a target for transactivation by PPARgamma.
Am. J. Physiol. Endocrinol. Metab. 291: E115-E127 (2006).
*
-
Kim K, Lee S, Valentine RJ. Association of Pro12Ala polymorphism in the peroxisome proliferative-activated receptor gamma2 gene with obesity and hypertension in Korean women.
J. Nutr. Sci. Vitaminol. (Tokyo) 53: 239-246 (2007).
*
-
Kim KH, Shin HJ, Kim K, Choi HM, Rhee SH, Moon HB, Kim HH, Yang US, Yu DY, Cheong J. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma.
Gastroenterology 132: 1955-1967 (2007).
*
-
Kim KY, Ahn JH, Cheon HG. Apoptotic action of PPARgamma activation in human non-small cell lung cancer is mediated via proline oxidase-induced ROS formation.
Mol. Pharmacol. 72: 674-685 (2007).
*
-
Kim KY, Cho HS, Jung WH, Kim SS, Cheon HG. Phosphatase and tensin homolog deleted on chromosome 10 suppression is an important process in peroxisome proliferator-activated receptor-gamma signaling in adipocytes and myotubes.
Mol. Pharmacol. 71: 1554-1562 (2007).
*
-
Kim KY, Kim JK, Jeon JH, Yoon SR, Choi I, Yang Y. c-Jun N-terminal kinase is involved in the suppression of adiponectin expression by TNF-alpha in 3T3-L1 adipocytes.
Biochem. Biophys. Res. Commun. 327: 460-467 (2005).
*
-
Kim MJ, Deplewski D, Ciletti N, Michel S, Reichert U, Rosenfield RL. Limited cooperation between peroxisome proliferator-activated receptors and retinoid X receptor agonists in sebocyte growth and development.
Mol. Genet. Metab. 74: 362-369 (2001).
*
-
Kim MK, Chae YN, Kim HS, Choi SH, Son MH, Kim SH, Kim JK, Moon HS, Park SK, Shin YA, Kim JG, Lee CH, Lim JI, Shin CY. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
Arch. Pharm. Res. 32: 721-727 (2009).
*
-
Kim MK, Chae YN, Son MH, Kim SH, Kim JK, Moon HS, Park CS, Bae MH, Kim E, Han T, Choi HH, Shin YA, Ahn BN, Lee CH, Lim JI, Shin CY. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
Eur. J. Pharmacol. 595: 119-125 (2008).
*
-
Kim MS, Sweeney 1 TR, Shigenaga JK, Chui LG, Moser A, Grunfeld C, Feingold KR. Tumor necrosis factor and interleukin 1 decrease RXRalpha, PPARalpha, PPARgamma, LXRalpha, and the coactivators SRC-1, PGC-1alpha, and PGC-1beta in liver cells.
Metabolism 56: 267-279 (2007).
*
-
Kim S, Hong I, Hwang JS, Choi JK, Rho HS, Kim DH, Chang I, Lee SH, Lee MO, Hwang JS. Phytosphingosine stimulates the differentiation of human keratinocytes and inhibits TPA-induced inflammatory epidermal hyperplasia in hairless mouse skin.
Mol. Med. 12: 17-24 (2006).
*
-
Kim S, Sohn I, Lee YS, Lee YS. Hepatic gene expression profiles are altered by genistein supplementation in mice with diet-induced obesity.
J. Nutr. 135: 33-41 (2005).
*
-
Kim SH, Nam GW, Lee HK, Moon SJ, Chang IS. The effects of Musk T on peroxisome proliferator-activated receptor [PPAR]-alpha activation, epidermal skin homeostasis and dermal hyaluronic acid synthesis.
Arch. Dermatol. Res. 298: 273-282 (2006).
*
-
Kim SL, Kim EM, Cheong SJ, Lee CM, Kim DW, Jeong HJ, Lim ST, Sohn MH, Yim CY. The effect of PPAR-gamma agonist on 18F-FDG uptake in tumor and macrophages and tumor cells.
Nucl. Med. Biol. 36: 427-433 (2009).
-
Kim SR, Lee KS, Park HS, Park SJ, Min KH, Jin SM, Lee YC. Involvement of IL-10 in PPARgamma-mediated anti-inflammatory response in asthma.
Mol. Pharmacol. 68: 1568-1575 (2005).
*
-
Kim TH, Kim H, Park JM, Im SS, Bae JS, Kim MY, Yoon HG, Cha JY, Kim KS, Ahn YH. Interrelationship between LXRalpha, SREBP-1c, PPARgamma and SHP in the transcriptional regulation of glucokinase gene expression in liver.
J. Biol. Chem. 284: 15071-15083 (2009).
*
-
Kim WK, Lee CY, Kang MS, Kim MH, Ryu YH, Bae KH, Shin SJ, Lee SC, Ko Y. Effects of leptin on lipid metabolism and gene expression of differentiation-associated growth factors and transcription factors during differentiation and maturation of 3T3-L1 preadipocytes.
Endocr. J. 55: 827-837 (2008).
*
-
Kimura H, Li X, Torii K, Okada T, Takahashi N, Fujii H, Ishihara S, Yoshida H. A natural PPAR-gamma agonist, 15-deoxy-delta 12,14-prostaglandin J2, may act as an enhancer of PAI-1 in human proximal renal tubular cells under hypoxic and inflammatory conditions.
Nephrol. Dial. Transplant. 23: 2496-2503 (2008).
-
Kino T, Chrousos GP. Combating atherosclerosis with LXRalpha and PPARalpha agonists: is rational multitargeted polypharmacy the future of therapeutics in complex diseases?
Mol. Interv. 4: 254-257 (2004).
*
-
Kino T, Rice KC, Chrousos GP. The PPARdelta agonist GW501516 suppresses interleukin-6-mediated hepatocyte acute phase reaction via STAT3 inhibition.
Eur. J. Clin. Invest. 37: 425-433 (2007).
*
-
Kinoshita H, Azma T, Iranami H, Nakahata K, Kimoto Y, Dojo M, Yuge O, Hatano Y. Synthetic peroxisome proliferator-activated receptor-gamma agonists restore impaired vasorelaxation via ATP-sensitive K+ channels by high glucose.
J. Pharmacol. Exp. Ther. 318: 312-318 (2006).
*
-
Kintscher U, Goetze S, Wakino S, Kim S, Nagpal S, Chandraratna RA, Graf K, Fleck E, Hsueh WA, Law RE. Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes.
Eur. J. Pharmacol. 401: 259-270 (2000).
*
-
Kirchmair J, Ristic S, Eder K, Markt P, Wolber G, Laggner C, Langer T. Fast and efficient in silico 3D screening: toward maximum computational efficiency of pharmacophore-based and shape-based approaches.
J. Chem. Inf. Model. 47: 2182-2196 (2007).
*
-
Kita R, Kita-Sasai Y, Hanaoka I, Kimura T, Kokuryu H, Takamatsu S, Osaki Y, Tomono N, Hachiya T, Shimizu T. Beneficial effect of bezafibrate on primary sclerosing cholangitis (three case reports).
Am. J. Gastroenterol. 97: 1849-1851 (2002).
*
-
Kitajima K, Miura SI, Mastuo Y, Uehara Y, Saku K. Newly developed PPAR-alpha agonist (R)-K-13675 inhibits the secretion of inflammatory markers without affecting cell proliferation or tube formation.
Atherosclerosis 203: 75-81 (2009).
-
Kitz Kramer D, Al-Khalili L, Guigas B, Leng Y, Garcia-Roves PM, Krook A. Role of AMP kinase and PPARdelta in the regulation of lipid and glucose metabolism in human skeletal muscle.
J. Biol. Chem. 282: 19313-19320 (2007).
*
-
Kiyomizu M, Kitawaki J, Obayashi H, Ohta M, Koshiba H, Ishihara H, Honjo H. Association of two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene with adenomyosis, endometriosis, and leiomyomata in Japanese women.
J. Soc. Gynecol. Investig. 13: 372-377 (2006).
-
Klaassen CD, Slitt AL. Regulation of hepatic transporters by xenobiotic receptors.
Curr. Drug Metab. 6: 309-328 (2005).
-
Klaunig JE, Babich MA, Baetcke KP, Cook JC, Corton JC, David RM, DeLuca JG, Lai DY, McKee RH, Peters JM, Roberts RA, Fenner-Crisp PA. PPARalpha agonist-induced rodent tumors: modes of action and human relevance.
Crit. Rev. Toxicol. 33: 655-780 (2003).
-
Klebl FH, Bregenzer N, Rogler G, Straub RH, Scholmerich J, Andus T. Treatment of pouchitis with dehydroepiandrosterone (DHEA) - a case report.
Z. Gastroenterol. 41: 1087-1090 (2003).
-
Kleemann R, Gervois PP, Verschuren L, Staels B, Princen HM, Kooistra T. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation.
Blood 101: 545-551 (2003).
*
-
Kleemann R, Verschuren L, van Erk MJ, Nikolsky Y, Cnubben NH, Verheij ER, Smilde AK, Hendriks HF, Zadelaar S, Smith GJ, Kaznacheev V, Nikolskaya T, Melnikov A, Hurt-Camejo E, van der Greef J, van Ommen B, Kooistra T. Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis.
Genome Biol. 8: R200 (2007).
*
-
Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors.
Proc. Natl. Acad. Sci. U.S.A. 91: 7355-7359 (1994).
*
-
Kliewer SA, Lehmann JM, Milburn MV, Willson TM. The PPARs and PXRs: nuclear xenobiotic receptors that define novel hormone signaling pathways.
Recent Prog. Horm. Res. 54: 345-367 (1999).
-
Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation.
Cell 83: 813-819 (1995).
*
-
Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard JM, Lehmann JM. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma.
Proc. Natl. Acad. Sci. U.S.A. 94: 4318-4323 (1997).
*
-
Kliewer SA, Willson TM. The nuclear receptor PPARgamma - bigger than fat.
Curr. Opin. Genet. Dev. 8: 576-581 (1998).
-
Kliewer SA, Xu HE, Lambert MH, Willson TM. Peroxisome proliferator-activated receptors: from genes to physiology.
Recent Prog. Horm. Res. 56: 239-263 (2001).
*
-
Klopper JP, Sharma V, Berenz A, Hays WR, Loi M, Pugazhenthi U, Said S, Haugen BR. Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression.
Mol. Cancer 8: 16 (2009).
-
Klotz L, Dani I, Edenhofer F, Nolden L, Evert B, Paul B, Kolanus W, Klockgether T, Knolle P, Diehl L. Peroxisome proliferator-activated receptor gamma control of dendritic cell function contributes to development of CD4+ T cell anergy.
J. Immunol. 178: 2122-2131 (2007).
*
-
Klotz L, Hucke S, Thimm D, Classen S, Gaarz A, Schultze J, Edenhofer F, Kurts C, Klockgether T, Limmer A, Knolle P, Burgdorf S. Increased antigen cross-presentation but impaired cross-priming after activation of peroxisome proliferator-activated receptor gamma is mediated by up-regulation of B7H1.
J. Immunol. Jun 17 [Epub ahead of print] (2009).
-
Klotz L, Schmidt S, Heun R, Klockgether T, Kolsch H. Association of the PPARgamma gene polymorphism Pro12Ala with delayed onset of multiple sclerosis.
Neurosci. Lett. 449: 81-83 (2009).
-
Knapp P, Jarzabek K, Blachnio A, Zbroch T. The role of peroxisome proliferator-activated receptors (PPAR) in carcinogenesis.
Ginekol. Pol. 77: 643-651 (2006).
-
Knauf C, Rieusset J, Foretz M, Cani PD, Uldry M, Hosokawa M, Martinez E, Bringart M, Waget A, Kersten S, Desvergne B, Gremlich S, Wahli W, Seydoux J, Delzenne NM, Thorens B, Burcelin R. Peroxisome proliferator-activated receptor-alpha-null mice have increased white adipose tissue glucose utilization, GLUT4, and fat mass. Role in liver and brain.
Endocrinology 147: 4067-4078 (2006).
*
-
Knebel B, Janssen OE, Hahn S, Jacob S, Gleich J, Kotzka J, Muller-Wieland D. Increased low grade inflammatory serum markers in patients with polycystic ovary syndrome (PCOS) and their relationship to PPARgamma gene variants.
Exp. Clin. Endocrinol. Diabetes 116: 481-486 (2008).
-
Knight BL, Hebbachi A, Hauton D, Brown AM, Wiggins D, Patel DD, Gibbons GF. A role for PPAR-alpha in the control of SREBP activity and lipid synthesis in the liver.
Biochem. J. 389: 413-421 (2005).
*
-
Knight BL, Patel DD, Humphreys SM, Wiggins D, Gibbons GF. Inhibition of cholesterol absorption associated with a PPAR alpha-dependent increase in ABC binding cassette transporter A1 in mice.
J. Lipid Res. 44: 2049-2058 (2003).
*
-
Knight TR, Choudhuri S, Klaassen CD. Induction of hepatic glutathione S-transferases in male mice by prototypes of various classes of microsomal enzyme inducers.
Toxicol. Sci. 106: 329-338 (2008).
*
-
Knouff C, Auwerx J. PPARgamma calls for activation in moderation: lessons from genetics and pharmacology.
Endocr. Rev. 25: 899-918 (2004).
*
-
Ko GJ, Kang YS, Han SY, Lee MH, Song HK, Han KH, Kim HK, Han JY, Cha DR. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.
Nephrol. Dial. Transplant. 23: 2750-2760 (2008).
-
Kobuke T, Tazuma S, Hyogo H, Chayama K. A ligand for peroxisome proliferator-activated receptor gamma inhibits human cholangiocarcinoma cell growth: potential molecular targeting strategy for cholangioma.
Dig. Dis. Sci. 51: 1650-1657 (2006).
*
-
Kocdor H, Kocdor M, Canda T, Gurel D, Cehreli R, Yilmaz O, Alakavuklar M, Guner G. Chemopreventive efficacies of rosiglitazone, fenretinide and their combination against rat mammary carcinogenesis.
Clin.Transl. Oncol. 11: 243-249 (2009).
-
Koch A, Konig B, Stangl GI, Eder K. PPARalpha mediates transcriptional upregulation of novel organic cation transporters-2 and -3 and enzymes involved in hepatic carnitine synthesis.
Exp. Biol. Med. (Maywood) 233: 356-365 (2008).
*
-
Kockx M, Gervois PP, Poulain P, Derudas B, Peters JM, Gonzalez FJ, Princen HM, Kooistra T, Staels B. Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha.
Blood 93: 2991-2998 (1999).
*
-
Koeck T, Willard B, Crabb JW, Kinter M, Stuehr DJ, Aulak KS. Glucose-mediated tyrosine nitration in adipocytes: targets and consequences.
Free Radic. Biol. Med. 46: 884-892 (2009).
-
Koh KK, Quon MJ, Rosenson RS, Chung WJ, Han SH. Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates.
Int. J. Cardiol. 124: 149-159 (2008).
-
Koh WP, Yuan JM, Van Den Berg D, Ingles SA, Yu MC. Peroxisome proliferator-activated receptor (PPAR) gamma gene polymorphisms and colorectal cancer risk among Chinese in Singapore.
Carcinogenesis 27: 1797-1802 (2006).
*
-
Kohalmy K, Tamasi V, Kobori L, Sarvary E, Pascussi JM, Porrogi P, Rozman D, Prough RA, Meyer UA, Monostory K. Dehydroepiandrosterone induces human CYP2B6 through the constitutive androstane receptor.
Drug Metab. Dispos. 35: 1495-1501 (2007).
*
-
Kohjima M, Enjoji M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, Fujino T, Yada M, Yada R, Harada N, Takayanagi R, Nakamuta M. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease.
Int. J. Mol. Med. 20: 351-358 (2007).
*
-
Kohno H, Suzuki R, Sugie S, Tanaka T. Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands.
BMC Cancer 5: 46 (2005).
*
-
Koika V, Marioli D, Saltamavros A, Vervita V, Koufogiannis K, Adonakis G, Decavalas G, Georgopoulos N. Association of the Pro12Ala polymorphism in peroxisome proliferator-activated receptor 2 (PPARgamma2) with decreased basic metabolic rate (BMR) in women with polycystic ovary syndrome (PCOS).
Eur. J. Endocrinol. May 22 [Epub ahead of print] (2009).
-
Koirala K, Wan YL, Liu YC, Wang X, Cui W, Wang CL, Chen HN, Wang HY, Zhu J. Effects of peroxisome proliferator-activated receptor-gamma ligand troglitazone on colon cancer cell growth.
Beijing Da Xue Xue Bao 38: 385-388 (2006).
-
Koivisto AM, Helisalmi S, Pihlajamaki J, Hiltunen M, Koivisto K, Moilanen L, Kuusisto J, Helkala EL, Hanninen T, Kervinen K, Kesaniemi YA, Laakso M, Soininen H. Association analysis of peroxisome proliferator-activated receptor gamma polymorphisms and late onset Alzheimer's disease in the Finnish population.
Dement. Geriatr. Cogn. Disord. 22: 449-453 (2006).
-
Kok T, Bloks VW, Wolters H, Havinga R, Jansen PL, Staels B, Kuipers F. Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice.
Biochem. J. 369: 539-547 (2003).
*
-
Kok T, Wolters H, Bloks VW, Havinga R, Jansen PL, Staels B, Kuipers F. Induction of hepatic ABC transporter expression is part of the PPARalpha-mediated fasting response in the mouse.
Gastroenterology 124: 160-171 (2003).
*
-
Komeda T. Obesity and NASH in Japan.
Hepatol. Res. 33: 83-86 (2005).
-
Kondoh K, Tsuji N, Asanuma K, Kobayashi D, Watanabe N. Inhibition of estrogen receptor beta-mediated human telomerase reverse transcriptase gene transcription via the suppression of mitogen-activated protein kinase signaling plays an important role in 15-deoxy-Delta(12,14)-prostaglandin J(2)-induced
Exp. Cell Res. 313: 3486-3496 (2007).
*
-
Kong J, Li YC. Molecular mechanism of 1,25-dihydroxyvitamin D3 inhibition of adipogenesis in 3T3-L1 cells.
Am. J. Physiol. Endocrinol. Metab. 290: E916-E924 (2006).
*
-
Konig B, Koch A, Giggel K, Dordschbal B, Eder K, Stangl GI. Monocarboxylate transporter (MCT)-1 is up-regulated by PPARalpha.
Biochim. Biophys. Acta 1780: 899-904 (2008).
*
-
Konig B, Spielmann J, Haase K, Brandsch C, Kluge H, Stangl GI, Eder K. Effects of fish oil and conjugated linoleic acids on expression of target genes of PPARalpha and sterol regulatory element-binding proteins in the liver of laying hens.
Br. J. Nutr. 100: 355-363 (2008).
*
-
Kono K, Kamijo Y, Hora K, Takahashi K, Higuchi M, Kiyosawa K, Shigematsu H, Gonzalez FJ, Aoyama T. PPARalpha attenuates the proinflammatory response in activated mesangial cells.
Am. J. Physiol. Renal Physiol. 296: F328-F336 (2009).
*
-
Konopleva M, Elstner E, McQueen TJ, Tsao T, Sudarikov A, Hu W, Schober WD, Wang RY, Chism D, Kornblau SM, Younes A, Collins SJ, Koeffler HP, Andreeff M. Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias.
Mol. Cancer Ther. 3: 1249-1262 (2004).
-
Konturek PC, Kania J, Raithel M, Ocker M, Rembiasz K, Hahn EG, Konturek SJ. Implication of peroxisome proliferator-activated receptor gamma and proinflammatory cytokines in gastric carcinogenesis: link to Helicobacter pylori-infection.
J. Pharmacol. Sci. 96: 134-143 (2005).
*
-
Kopij M, Rapak A. The role of nuclear receptors in cell death.
Postepy. Hig. Med. Dosw. (Online) 62: 571-581 (2008).
-
Kornbluth A. What happened to drug trials in ulcerative colitis? Problems, PPARs, placebos, and (possible) progress.
Am. J. Gastroenterol. 96: 3232-3234 (2001).
*
-
Korner A, Kiess W, Stumvoll M, Kovacs P. Polygenic contribution to obesity: genome-wide strategies reveal new targets.
Front. Horm. Res. 36: 12-36 (2008).
-
Kostadinova R, Wahli W, Michalik L. PPARs in diseases: control mechanisms of inflammation.
Curr. Med. Chem. 12: 2995-3009 (2005).
-
Kota BP, Huang TH, Roufogalis BD. An overview on biological mechanisms of PPARs.
Pharmacol. Res. 51: 85-94 (2005).
*
-
Kotronen A, Yki-Jarvinen H, Aminoff A, Bergholm R, Pietilainen K, Westerbacka J, Talmud P, Humphries S, Hamsten A, Isomaa B, Groop L, Orho-Melander M, Ehrenborg E, Fisher R. Genetic variation in the ADIPOR2 gene is associated with liver fat content and its surrogate markers in three independent cohorts.
Eur. J. Endocrinol. 160: 593-602 (2009).
-
Koufany M, Moulin D, Bianchi A, Muresan M, Sebillaud S, Netter P, Weryha G, Jouzeau JY. Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis.
Arthritis Res. Ther. 10: R6 (2008).
*
-
Kourtidis A, Srinivasaiah R, Carkner RD, Brosnan MJ, Conklin DS. PPARgamma protects ERBB2-positive breast cancer cells from palmitate toxicity.
Breast Cancer Res. 11: R16 (2009).
*
-
Koutsogiannaki S, Evangelinos N, Koliakos G, Kaloyianni M. Cytotoxic mechanisms of Zn(2+) and Cd(2+) involve Na(+)/H(+) exchanger (NHE) activation by ROS.
Aquat. Toxicol. 78: 315-324 (2006).
-
Krag MB, Rasmussen LM, Hansen TK, Frystyk J, Flyvbjerg A, Moller N, Jorgensen JO. Peroxisome proliferator-activated receptor gamma agonism reduces the insulin-stimulated increase in circulating interleukin-6 in growth hormone (GH) replaced GH-deficient adults.
Clin. Endocrinol. (Oxf.) Dec 3 [Epub ahead of print] (2008).
*
-
Kramer DK, Ahlsen M, Norrbom J, Jansson E, Hjeltnes N, Gustafsson T, Krook A. Human skeletal muscle fibre type variations correlate with PPARalpha, PPARdelta and PGC-1alpha mRNA.
Acta Physiol. (Oxf.) 188: 207-216 (2006).
*
-
Kratzner R, Frohlich F, Lepler K, Schroder M, Roher K, Dickel C, Tzvetkov MV, Quentin T, Oetjen E, Knepel W. A peroxisome proliferator-activated receptor gamma-retinoid X receptor heterodimer physically interacts with the transcriptional activator PAX6 to inhibit glucagon gene transcription.
Mol. Pharmacol. 73: 509-517 (2008).
*
-
Krause WF, DuBois RN. The molecular basis for prevention of colorectal cancer.
Clin. Colorectal Cancer 1: 47-54 (2001).
*
-
Kreisler A, Gele P, Wiart JF, Lhermitte M, Destee A, Bordet R. Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not.
Brain Res. 1135: 77-84 (2007).
-
Krey G, Braissant O, L'Horset F, Kalkhoven E, Perroud M, Parker MG, Wahli W. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay.
Mol. Endocrinol. 11: 779-791 (1997).
*
-
Kristiansen G, Jacob J, Buckendahl AC, Grutzmann R, Alldinger I, Sipos B, Kloppel G, Bahra M, Langrehr JM, Neuhaus P, Dietel M, Pilarsky C. Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times.
Clin. Cancer Res. 12: 6444-6451 (2006).
*
-
Kronke G, Kadl A, Ikonomu E, Bluml S, Furnkranz A, Sarembock IJ, Bochkov VN, Exner M, Binder BR, Leitinger N. Expression of heme oxygenase-1 in human vascular cells is regulated by peroxisome proliferator-activated receptors.
Arterioscler. Thromb. Vasc. Biol. 27: 1276-1282 (2007).
*
-
Krskova-Tybitanclova K, Macejova D, Brtko J, Baculikova M, Krizanova O, Zorad S. Short term 13-cis-retinoic acid treatment at therapeutic doses elevates expression of leptin, GLUT4, PPARgamma and aP2 in rat adipose tissue.
J. Physiol. Pharmacol. 59: 731-743 (2008).
-
Krzystyniak KL. Current strategies for anticancer chemoprevention and chemoprotection.
Acta Pol. Pharm. 59: 473-478 (2002).
-
Kuenzli S, Saurat JH. Peroxisome proliferator-activated receptors in cutaneous biology.
Br. J. Dermatol. 149: 229-236 (2003).
*
-
Kuenzli S, Saurat JH. Peroxisome proliferator-activated receptors as new molecular targets in psoriasis.
Curr. Drug Targets Inflamm. Allergy 3: 205-211 (2004).
-
Kuliczkowska J, Filus A, Trzmiel A, Tworowska U, Demissie M, Jedrzejuk D, Milewicz A. PPAR-gamma2 Pro12Ala polymorphism in the population of obese and non-obese men of the city of Wroclaw.
Endokrynol. Pol. 59: 312-315 (2008).
-
Kumar AP, Piedrafita FJ, Reynolds WF. Peroxisome proliferator-activated receptor gamma ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the -463GA promoter polymorphism.
J. Biol. Chem. 279: 8300-8315 (2004).
*
-
Kumar PM, Hemalatha R, Mahajan SC, Karthikeyan C, Moorthy NS, Trivedi P. Quantitative structure activity analysis of 2-alkoxydihydrocinnamates as PPARalpha/gamma dual agonist.
Med. Chem. 4: 273-277 (2008).
-
Kumei S, Motomura W, Yoshizaki T, Takakusaki K, Okumura T. Troglitazone increases expression of E-cadherin and claudin 4 in human pancreatic cancer cells.
Biochem. Biophys. Res. Commun. 380: 614-619 (2009).
-
Kummer MP, Heneka MT. PPARs in Alzheimer's disease.
PPAR Res. 2008: 403896 (2008).
*
-
Kuniyasu H. The roles of dietary PPARgamma ligands for metastasis in colorectal cancer.
PPAR Res. 2008: 529720 (2008).
*
-
Kuriki K, Hirose K, Matsuo K, Wakai K, Ito H, Kanemitsu Y, Hirai T, Kato T, Hamajima N, Takezaki T, Suzuki T, Saito T, Tanaka R, Tajima K. Meat, milk, saturated fatty acids, the Pro12Ala and C161T polymorphisms of the PPARgamma gene and colorectal cancer risk in Japanese.
Cancer Sci. 97: 1226-1235 (2006).
*
-
Kuroda T, Hirota H, Fujio Y, Sugiyama S, Masaki M, Hiramoto Y, Shioyama W, Okamoto K, Hori M, Yamauchi-Takihara K. Carbacyclin induces carnitine palmitoyltransferase-1 in cardiomyocytes via peroxisome proliferator-activated receptor (PPAR) delta independent of the IP receptor signaling pathway.
J. Mol. Cell. Cardiol. 43: 54-62 (2007).
*
-
Kusu R, Oishi A, Kakizawa K, Kimura T, Toda C, Hashizume K, Ueda K, Kojima N. Effects of phthalate ester derivatives including oxidized metabolites on coactivator recruiting by PPARalpha and PPARgamma.
Toxicol. In Vitro 22: 1534-1538 (2008).
-
Kuusisto J, Andrulionyte L, Laakso M. Atherosclerosis and cardiovascular risk reduction with PPAR agonists.
Curr. Atheroscler. Rep. 9: 274-280 (2007).
-
Kyoko U, Seiji U, Shinichi I, Masakazu T, Shinji K, Tohru F, Masunori M. Comparative effects of pitavastatin and probucol on oxidative stress, Cu/Zn superoxide dismutase, PPAR-gamma, and aortic stiffness in hypercholesterolemia.
Am. J. Physiol. Heart Circ. Physiol. 291: H2522-H2532 (2006).
*
-
Labinskyy V, Bellomo M, Chandler MP, Young ME, Lionetti V, Qanud K, Bigazzi F, Sampietro T, Stanley WC, Recchia FA. Chronic activation of peroxisome proliferator-activated receptor-alpha with fenofibrate prevents alterations in cardiac metabolic phenotype without changing the onset of decompensation in pacing-induced heart failure.
J. Pharmacol. Exp. Ther. 321: 165-171 (2007).
*
-
Lacour S, Gautier JC, Pallardy M, Roberts R. Cytokines as potential biomarkers of liver toxicity.
Cancer Biomark. 1: 29-39 (2005).
-
Lacroix L, Mian C, Barrier T, Talbot M, Caillou B, Schlumberger M, Bidart JM. PAX8 and peroxisome proliferator-activated receptor gamma 1 gene expression status in benign and malignant thyroid tissues.
Eur. J. Endocrinol. 151: 367-374 (2004).
*
-
Laffitte BA, Joseph SB, Walczak R, Pei L, Wilpitz DC, Collins JL, Tontonoz P. Autoregulation of the human liver X receptor alpha promoter.
Mol. Cell Biol. 21: 7558-7568 (2001).
*
-
Lagou V, Scott RA, Manios Y, Chen TL, Wang G, Grammatikaki E, Kortsalioudaki C, Liarigkovinos T, Moschonis G, Roma-Giannikou E, Pitsiladis YP. Impact of peroxisome proliferator-activated receptors gamma and delta on adiposity in toddlers and preschoolers in the GENESIS study.
Obesity (Silver Spring) 16: 913-918 (2008).
*
-
Lahiri S, Sen T, Palit G. Involvement of glucocorticoid receptor and peroxisome proliferator activated receptor-gamma in pioglitazone mediated chronic gastric ulcer healing in rats.
Eur. J. Pharmacol. 609: 118-125 (2009).
*
-
Lai DY. Rodent carcinogenicity of peroxisome proliferators and issues on human relevance.
J. Environ. Sci. Health C. Environ. Carcinog. Ecotoxicol. Rev. 22: 37-55 (2004).
-
Lai PH, Wang WL, Ko CY, Lee YC, Yang WM, Shen TW, Chang WC, Wang JM. HDAC1/HDAC3 modulates PPARG2 transcription through the sumoylated CEBPD in hepatic lipogenesis.
Biochim. Biophys. Acta 1783: 1803-1814 (2008).
*
-
Laidler P, Dulinska J, Mrozicki S. Does the inhibition of c-myc expression mediate the anti-tumor activity of PPAR's ligands in prostate cancer cell lines?
Arch. Biochem. Biophys. 462: 1-12 (2007).
*
-
Lakatos HF, Thatcher TH, Kottmann RM, Garcia TM, Phipps RP, Sime PJ. The role of PPARs in lung fibrosis.
PPAR Res. 2007: 71323 (2007).
*
-
Lalloyer F, Vandewalle B, Percevault F, Torpier G, Kerr-Conte J, Oosterveer M, Paumelle R, Fruchart JC, Kuipers F, Pattou F, Fievet C, Staels B. Peroxisome proliferator-activated receptor alpha improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets.
Diabetes 55: 1605-1613 (2006).
*
-
Lampen A, Leifheit M, Voss J, Nau H. Molecular and cellular effects of cis-9, trans-11-conjugated linoleic acid in enterocytes: effects on proliferation, differentiation, and gene expression.
Biochim. Biophys. Acta 1735: 30-40 (2005).
*
-
Lampen A, Meyer S, Nau H. Phytanic acid and docosahexaenoic acid increase the metabolism of all-trans-retinoic acid and CYP26 gene expression in intestinal cells.
Biochim. Biophys. Acta 1521: 97-106 (2001).
*
-
Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J, Capella G, Canzian F; Bellvitge Colorectal Cancer Study Group. Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer.
Cancer Res. 63: 3560-3566 (2003).
*
-
Landreth G. Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease.
Curr. Alzheimer Res. 4: 159-164 (2007).
-
Landrier JF, Thomas C, Grober J, Duez H, Percevault F, Souidi M, Linard C, Staels B, Besnard P. Statin induction of liver fatty acid-binding protein (L-FABP) gene expression is PPARalpha-dependent.
J. Biol. Chem. 279: 45512-45518 (2004).
*
-
Landrier JF, Thomas C, Grober J, Zaghini I, Petit V, Poirier H, Niot I, Besnard P. The gene encoding the human ileal bile acid-binding protein (I-BABP) is regulated by peroxisome proliferator-activated receptors.
Biochim. Biophys. Acta 1735: 41-49 (2005).
*
-
Lapinskas PJ, Brown S, Leesnitzer LM, Blanchard S, Swanson C, Cattley RC, Corton JC. Role of PPARalpha in mediating the effects of phthalates and metabolites in the liver.
Toxicology 207: 149-163 (2005).
*
-
Laplante M, Festuccia WT, Soucy G, Blanchard PG, Renaud A, Berger JP, Olivecrona G, Deshaies Y. Tissue-specific postprandial clearance is the major determinant of PPARgamma-induced triglyceride lowering in the rat.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 296: R57-R66 (2009).
*
-
Lappas M, Permezel M, Rice GE. 15-Deoxy-delta(12,14)-prostaglandin J(2) and troglitazone regulation of the release of phospholipid metabolites, inflammatory cytokines and proteases from human gestational tissues.
Placenta 27: 1060-1072 (2006).
-
Larsen LN, Granlund L, Holmeide AK, Skattebol L, Nebb HI, Bremer J. Sulfur-substituted and alpha-methylated fatty acids as peroxisome proliferator-activated receptor activators.
Lipids 40: 49-57 (2005).
-
Larsen PJ, Lykkegaard K, Larsen LK, Fleckner J, Sauerberg P, Wassermann K, Wulff EM. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.
Eur. J. Pharmacol. 596: 173-179 (2008).
-
Larsen ST, Nielsen GD. The adjuvant effect of di-(2-ethylhexyl) phthalate is mediated through a PPARalpha-independent mechanism.
Toxicol. Lett. 170: 223-228 (2007).
*
-
Larter CZ, Yeh MM, Cheng J, Williams J, Brown S, Dela Pena A, Bell-Anderson KS, Farrell GC. Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation.
J. Gastroenterol. Hepatol. 23: 267-275 (2008).
*
-
Latini G, Del Vecchio A, Massaro M, Verrotti A, DE Felice C. In utero exposure to phthalates and fetal development.
Curr. Med. Chem. 13: 2527-2534 (2006).
-
Latini G, Scoditti E, Verrotti A, De Felice C, Massaro M. Peroxisome proliferator-activated receptors as mediators of phthalate-induced effects in the male and female reproductive tract: epidemiological and experimental evidence.
PPAR Res. 2008: 359267 (2008).
*
-
Latruffe N, Cherkaoui Malki M, Nicolas-Frances V, Clemencet MC, Jannin B, Berlot JP. Regulation of the peroxisomal beta-oxidation-dependent pathway by peroxisome proliferator-activated receptor alpha and kinases.
Biochem. Pharmacol. 60: 1027-1032 (2000).
*
-
Latruffe N, Cherkaoui Malki M, Nicolas-Frances V, Jannin B, Clemencet MC, Hansmannel F, Passilly-Degrace P, Berlot JP. Peroxisome-proliferator-activated receptors as physiological sensors of fatty acid metabolism: molecular regulation in peroxisomes.
Biochem. Soc. Trans. 29: 305-309 (2001).
*
-
Latruffe N, Vamecq J. Peroxisome proliferators and peroxisome proliferator activated receptors (PPARs) as regulators of lipid metabolism.
Biochimie 79: 81-94 (1997).
-
Latruffe N, Vamecq J, Cherkaoui Malki M. Genetic-dependency of peroxisomal cell functions - emerging aspects.
J. Cell. Mol. Med. 7: 238-248 (2003).
*
-
Laurent D, Gounarides JS, Gao J, Boettcher BR. Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats.
Diabetes Obes. Metab. Jan 19 [Epub ahead of print] (2009).
-
Lawrence JW, Li Y, Chen S, DeLuca JG, Berger JP, Umbenhauer DR, Moller DE, Zhou G. Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) alpha.
J. Biol. Chem. 276: 31521-31527 (2001).
*
-
Lazennec G, Canaple L, Saugy D, Wahli W. Activation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators.
Mol. Endocrinol. 14: 1962-1975 (2000).
*
-
Le Jossic-Corcos C, Duclos S, Ramirez LC, Zaghini I, Chevillard G, Martin P, Pineau T, Bournot P. Effects of peroxisome proliferator-activated receptor alpha activation on pathways contributing to cholesterol homeostasis in rat hepatocytes.
Biochim. Biophys. Acta 1683: 49-58 (2004).
*
-
le Maire A, Grimaldi M, Roecklin D, Dagnino S, Vivat-Hannah V, Balaguer P, Bourguet W. Activation of RXR-PPAR heterodimers by organotin environmental endocrine disruptors.
EMBO Rep. 10: 367-373 (2009).
*
-
Le May C, Cauzac M, Diradourian C, Perdereau D, Girard J, Burnol AF, Pegorier JP. Fatty acids induce L-CPT I gene expression through a PPARalpha-independent mechanism in rat hepatoma cells.
J. Nutr. 135: 2313-2319 (2005).
*
-
Le May C, Pineau T, Bigot K, Kohl C, Girard J, Pegorier JP. Reduced hepatic fatty acid oxidation in fasting PPARalpha null mice is due to impaired mitochondrial hydroxymethylglutaryl-CoA synthase gene expression.
FEBS Lett. 475: 163-166 (2000).
*
-
Le Mee S, Hennebert O, Ferrec C, Wulfert E, Morfin R. 7beta-Hydroxy-epiandrosterone-mediated regulation of the prostaglandin synthesis pathway in human peripheral blood monocytes.
Steroids 73: 1148-1159 (2008).
-
Leahy JL. Thiazolidinediones in prediabetes and early type 2 diabetes: what can be learned about that disease's pathogenesis.
Curr. Diab. Rep. 9: 215-220 (2009).
-
Leaver MJ, Ezaz MT, Fontagne S, Tocher DR, Boukouvala E, Krey G. Multiple peroxisome proliferator-activated receptor beta subtypes from Atlantic salmon (Salmo salar).
J. Mol. Endocrinol. 38: 391-400 (2007).
*
-
Lebovic DI, Mwenda JM, Chai DC, Mueller MD, Santi A, Fisseha S, D'Hooghe T. PPAR-gamma receptor ligand induces regression of endometrial explants in baboons: a prospective, randomized, placebo- and drug-controlled study.
Fertil. Steril. 88: 1108-1119 (2007).
*
-
Lebovitz H. Diabetes: assessing the pipeline.
Atheroscler. Suppl. 7: 43-49 (2006).
-
Lebovitz HE. Insulin resistance - a common link between type 2 diabetes and cardiovascular disease.
Diabetes Obes. Metab. 8: 237-249 (2006).
-
Lecka-Czernik B, Ackert-Bicknell C, Adamo ML, Marmolejos V, Churchill GA, Shockley KR, Reid IR, Grey A, Rosen CJ. Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the IGF regulatory system in vitro and in vivo.
Endocrinology 148: 903-911 (2007).
*
-
Lecka-Czernik B, Suva LJ. Resolving the two "bony" faces of PPAR-gamma.
PPAR Res. 2006: 27489 (2006).
*
-
Leclercq IA. Pathogenesis of steatohepatitis: insights from the study of animal models.
Acta Gastroenterol. Belg. 70: 25-31 (2007).
-
Leclercq IA, Lebrun VA, Starkel P, Horsmans YJ. Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPARgamma agonist pioglitazone.
Lab. Invest. 87: 56-65 (2007).
*
-
Lecomte J, Flament S, Salamone S, Boisbrun M, Mazerbourg S, Chapleur Y, Grillier-Vuissoz I. Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines.
Breast Cancer Res. Treat. 112: 437-451 (2008).
-
Lee BC, Doo HK, Ahn SY, Byun SH, Kim SI, Park HK, Hong M, Ha E, Yim SV, Yin C, Leem KH, Ahn YM. Peroxisome proliferator-activated receptor-gamma Pro12Ala polymorphism is associated with the susceptibility to ischemic stroke in Taeeumin classified by Sasang medicine.
Neurol. Res. 29 Suppl. 1: 32-37 (2007).
-
Lee BC, Lee HJ, Chung JH. Peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism is associated with reduced risk for ischemic stroke with type 2 diabetes.
Neurosci. Lett. 410: 141-145 (2006).
*
-
Lee BC, Lee KC, Lee H, Mach RH, Katzenellenbogen JA. Synthesis and binding affinity of a fluorine-substituted peroxisome proliferator-activated gamma (PPARgamma) ligand as a potential positron emission tomography (PET) imaging agent.
Bioconjug. Chem. 18: 507-513 (2007).
*
-
Lee CH, Chawla A, Urbiztondo N, Liao D, Boisvert WA, Evans RM, Curtiss LK. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta.
Science 302: 453-457 (2003).
*
-
Lee CH, Kang K, Mehl IR, Nofsinger R, Alaynick WA, Chong LW, Rosenfeld JM, Evans RM. Peroxisome proliferator-activated receptor delta promotes very low-density lipoprotein-derived fatty acid catabolism in the macrophage.
Proc. Natl. Acad. Sci. U.S.A. 103: 2434-2439 (2006).
*
-
Lee CH, Kim HD, Shin SM, Kim SG. A novel mechanism of PPARgamma regulation of TGFbeta1: implication in cancer biology.
PPAR Res. 2008: 762398 (2008).
*
-
Lee CH, Olson P, Hevener A, Mehl I, Chong LW, Olefsky JM, Gonzalez FJ, Ham J, Kang H, Peters JM, Evans RM. PPARdelta regulates glucose metabolism and insulin sensitivity.
Proc. Natl. Acad. Sci. U.S.A. 103: 3444-3449 (2006).
*
-
Lee E, Ahn MY, Kim HJ, Kim IY, Han SY, Kang TS, Hong JH, Park KL, Lee BM, Kim HS. Effect of di(n-butyl) phthalate on testicular oxidative damage and antioxidant enzymes in hyperthyroid rats.
Environ. Toxicol. 22: 245-255 (2007).
-
Lee GY, Kim NH, Zhao ZS, Cha BS, Kim YS. Peroxisomal-proliferator-activated receptor alpha activates transcription of the rat hepatic malonyl-CoA decarboxylase gene: a key regulation of malonyl-CoA level.
Biochem. J. 378: 983-990 (2004).
*
-
Lee HJ, Ju J, Paul S, So JY, Decastro A, Smolarek A, Lee MJ, Yang CS, Newmark HL, Suh N. Mixed tocopherols prevent mammary tumorigenesis by inhibiting estrogen action and activating PPAR-gamma.
Clin. Cancer Res. Jun 9 [Epub ahead of print] (2009).
-
Lee HK, Lee BH, Park SA, Kim CW. The proteomic analysis of an adipocyte differentiated from human mesenchymal stem cells using two-dimensional gel electrophoresis.
Proteomics 6: 1223-1229 (2006).
*
-
Lee IK, Lee JH, Yun BS. Polychlorinated compounds with PPAR-gamma agonistic effect from the medicinal fungus Phellinus ribis.
Bioorg. Med. Chem. Lett. 18: 4566-4568 (2008).
*
-
Lee J, Hong EM, Byun HW, Choi MH, Jang HJ, Eun CS, Kae SH, Choi HS. The effect of PPARalpha and PPARgamma ligands on inflammation and ABCA1 expression in cultured gallbladder epithelial cells.
Dig. Dis. Sci. 53: 1707-1715 (2008).
*
-
Lee J, Hong EM, Koh DH, Choi MH, Jang HJ, Kae SH, Choi HS. HMG-CoA reductase inhibitors (statins) activate expression of PPARalpha/PPARgamma and ABCA1 in cultured gallbladder epithelial cells.
Dig. Dis. Sci. Feb 19 [Epub ahead of print] (2009).
*
-
Lee J, Jung E, Lee J, Kim S, Huh S, Kim Y, Kim Y, Byun SY, Kim YS, Park D. Isorhamnetin represses adipogenesis in 3T3-L1 cells.
Obesity (Silver Spring) 17: 226-232 (2009).
*
-
Lee JH, Banerjee A, Ueno Y, Ramaiah SK. Potential relationship between hepatobiliary osteopontin and peroxisome proliferator-activated receptor alpha expression following ethanol-associated hepatic injury in vivo and in vitro.
Toxicol. Sci. 106: 290-299 (2008).
*
-
Lee JH, Yu SM, Yoon EK, Lee WK, Jung JC, Kim SJ. 15-Deoxy-delta(12,14)-prostaglandinJ2 regulates dedifferentiation through peroxisome proliferator-activated receptor-gamma-dependent pathway but not COX-2 expression in articular chondrocytes.
J. Korean Med. Sci. 22: 891-897 (2007).
*
-
Lee JH, Zhou J, Xie W. PXR and LXR in hepatic steatosis: a new dog and an old dog with new tricks.
Mol. Pharm. 5: 60-66 (2008).
*
-
Lee JI, Paik YH, Lee KS, Lee JW, Kim YS, Jeong S, Kwon KS, Lee DH, Kim HG, Shin YW, Kim MA. A peroxisome-proliferator activated receptor-gamma ligand could regulate the expression of leptin receptor on human hepatic stellate cells.
Histochem. Cell Biol. 127: 495-502 (2007).
*
-
Lee JS, Choi YM, Kang HY. PPAR-gamma agonist, ciglitazone, increases pigmentation and migration of human melanocytes.
Exp. Dermatol. 16: 118-123 (2007).
*
-
Lee JW, Bajwa PJ, Carson MJ, Jeske DR, Cong Y, Elson CO, Lytle C, Straus DS. Fenofibrate represses interleukin-17 and interferon-gamma expression and improves colitis in interleukin-10-deficient mice.
Gastroenterology 133: 108-123 (2007).
*
-
Lee KJ, Ha ES, Kim MK, Lee SH, Suh JS, Lee SH, Park KH, Park JH, Kim DJ, Kang D, Kim BC, Jeoung D, Kim YK, Kim HD, Hahn JH. CD36 signaling inhibits the translation of heat shock protein 70 induced by oxidized low density lipoprotein through activation of peroxisome proliferators-activated receptor gamma.
Exp. Mol. Med. 40: 658-668 (2008).
*
-
Lee KS, Kim SR, Park SJ, Park HS, Min KH, Jin SM, Lee MK, Kim UH, Lee YC. Peroxisome proliferator activated receptor-gamma modulates reactive oxygen species generation and activation of nuclear factor-kappaB and hypoxia-inducible factor 1alpha in allergic airway disease of mice.
J. Allergy Clin. Immunol. 118: 120-127 (2006).
*
-
Lee KS, Park JH, Lee S, Lim HJ, Park HY. PPARdelta activation inhibits angiotensin II induced cardiomyocyte hypertrophy by suppressing intracellular Ca(2+) signaling pathway.
J. Cell. Biochem. 106: 823-834 (2009).
-
Lee KS, Park SJ, Hwang PH, Yi HK, Song CH, Chai OH, Kim JS, Lee MK, Lee YC. PPAR-gamma modulates allergic inflammation through up-regulation of PTEN.
FASEB J. 19: 1033-1035 (2005).
*
-
Lee SJ, Yang EK, Kim SG. Peroxisome proliferator-activated receptor-gamma and retinoic acid X receptor alpha represses the TGFbeta1 gene via PTEN-mediated S6K1 inhibition: role for Zf9 dephosphorylation.
Mol. Pharmacol. 70: 415-425 (2006).
*
-
Lee SK, Kim HJ, Chi SG, Jang JY, Nam KD, Kim NH, Joo KR, Dong SH, Kim BH, Chang YW, Lee JI, Chang R. Saccharomyces boulardii activates expression of peroxisome proliferator-activated receptor-gamma in HT-29 cells.
Korean J. Gastroenterol. 45: 328-334 (2005).
-
Lee SK, Kim YW, Chi SG, Joo YS, Kim HJ. The effect of Saccharomyces boulardii on human colon cells and inflammation in rats with trinitrobenzene sulfonic acid-induced colitis.
Dig. Dis. Sci. 54: 255-263 (2009).
*
-
Lee SS, Chan WY, Lo CK, Wan DC, Tsang DS, Cheung WT. Requirement of PPARalpha in maintaining phospholipid and triglyceride homeostasis during energy deprivation.
J. Lipid Res. 45: 2025-2037 (2004).
*
-
Lee SY, Kang EJ, Hur GY, Jung KH, Jung HC, Lee SY, Kim JH, Shin C, In KH, Kang KH, Yoo SH, Shim JJ. Peroxisome proliferator activated receptor gamma (PPARgamma) inhibits cigarette smoke solution-induced mucin production in human airway epithelial (NCI-H292) cells.
Am. J. Physiol. Lung Cell. Mol. Physiol. 291: L84-L90 (2006).
*
-
Lee TI, Kao YH, Chen YC, Chen YJ. Proinflammatory cytokine and ligands modulate cardiac peroxisome proliferator-activated receptors.
Eur. J. Clin. Invest. 39: 23-30 (2009).
*
-
Lee TS, Lin CY, Tsai JY, Wu YL, Su KH, Lu KY, Hsiao SH, Pan CC, Kou YR, Hsu YP, Ho LT. Resistin increases lipid accumulation by affecting class A scavenger receptor, CD36 and ATP-binding cassette transporter-A1 in macrophages.
Life Sci. 84: 97-104 (2009).
*
-
Lee WJ, Jung HD, Lee HJ, Kim BS, Lee SJ, Kim DW. Influence of substance-P on cultured sebocytes.
Arch. Dermatol. Res. 300: 311-316 (2008).
*
-
Lee Y, Thompson JT, de Lera AR, Vanden Heuvel JP. Isomer-specific effects of conjugated linoleic acid on gene expression in RAW 264.7.
J. Nutr. Biochem. Nov 5 [Epub ahead of print] (2008).
*
-
Lee YJ, Suh HN, Han HJ. Effect of BSA-induced ER stress on SGLTs protein expression levels and alpha-MG uptake in renal proximal tubule cells.
Am. J. Physiol. Renal Physiol. 296: F1405-F1416 (2009).
*
-
Lee YK, Lee WS, Hwang JT, Kwon DY, Surh YJ, Park OJ. Curcumin exerts antidifferentiation effect through AMPKalpha-PPAR-gamma in 3T3-L1 adipocytes and antiproliferatory effect through AMPKalpha-COX-2 in cancer cells.
J. Agric. Food Chem. 57: 305-310 (2009).
*
-
Lee YR, Yu HN, Noh EM, Kim JS, Song EK, Han MK, Kim BS, Lee SH, Park J. Peroxisome proliferator-activated receptor gamma and retinoic acid receptor synergistically up-regulate the tumor suppressor PTEN in human promyeloid leukemia cells.
Int. J. Hematol. 85: 231-237 (2007).
-
Lefterova MI, Zhang Y, Steger DJ, Schupp M, Schug J, Cristancho A, Feng D, Zhuo D, Stoeckert CJ Jr, Liu XS, Lazar MA. PPARgamma and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale.
Genes Dev. 22: 2941-2952 (2008).
*
-
Legendre C, Causse E, Chaput E, Salvayre R, Pineau T, Edgar AD. Fenofibrate induces a selective increase of protein-bound homocysteine in rodents: a PPARalpha-mediated effect.
Biochem. Biophys. Res. Commun. 295: 1052-1056 (2002).
*
-
Lehmann GM, Garcia-Bates TM, Smith TJ, Feldon SE, Phipps RP. Regulation of lymphocyte function by PPARgamma: relevance to thyroid eye disease-related inflammation.
PPAR Res. 2008: 895901 (2008).
*
-
Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs.
J. Biol. Chem. 272: 3406-3410 (1997).
*
-
Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma).
J. Biol. Chem. 270: 12953-12956 (1995).
*
-
Lehrke M, Pascual G, Glass CK, Lazar MA. Gaining weight: the Keystone Symposium on PPAR and LXR.
Genes Dev. 19: 1737-1742 (2005).
*
-
Leibovitz E, Schiffrin EL. PPAR activation: a new target for the treatment of hypertension.
J. Cardiovasc. Pharmacol. 50: 120-125 (2007).
-
Leisewitz AV, Urrutia CR, Martinez GR, Loyola G, Bronfman M. A PPARs cross-talk concertedly commits C6 glioma cells to oligodendrocytes and induces enzymes involved in myelin synthesis.
J. Cell. Physiol. 217: 367-376 (2008).
*
-
Lelliott CJ, Ljungberg A, Ahnmark A, William-Olsson L, Ekroos K, Elmgren A, Arnerup G, Shoulders CC, Oscarsson J, Linden D. Hepatic PGC-1beta overexpression induces combined hyperlipidemia and modulates the response to PPARalpha activation.
Arterioscler. Thromb. Vasc. Biol. 27: 2707-2713 (2007).
-
Lemann M. Treatment of chronic inflammatory bowel diseases.
Bull. Acad. Natl. Med. 191: 1125-1141 (2007).
-
Lemay DG, Hwang DH. Genome-wide identification of peroxisome proliferator response elements using integrated computational genomics.
J. Lipid Res. 47: 1583-1587 (2006).
*
-
Lemberger T, Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology.
Annu. Rev. Cell. Dev. Biol. 12: 335-363 (1996).
-
Lemberger T, Saladin R, Vazquez M, Assimacopoulos F, Staels B, Desvergne B, Wahli W, Auwerx J. Expression of the peroxisome proliferator-activated receptor alpha gene is stimulated by stress and follows a diurnal rhythm.
J. Biol. Chem. 271: 1764-1769 (1996).
*
-
Lemoine CM, McClelland GB, Lyons CN, Mathieu-Costello O, Moyes CD. Control of mitochondrial gene expression in the aging rat myocardium.
Biochem. Cell. Biol. 84: 191-198 (2006).
-
Lemoine M, Barbu V, Girard PM, Kim M, Bastard JP, Wendum D, Paye F, Housset C, Capeau J, Serfaty L. Altered hepatic expression of SREBP-1 and PPARgamma is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients.
AIDS 20: 387-395 (2006).
*
-
Lemoine M, Capeau J, Serfaty L. PPAR and liver injury in HIV-infected patients.
PPAR Res. 2009: 906167 (2009).
*
-
Lenhard JM. PPAR gamma/RXR as a molecular target for diabetes.
Receptors Channels 7: 249-258 (2001).
-
Lennon R, Welsh GI, Singh A, Satchell SC, Coward RJ, Tavare JM, Mathieson PW, Saleem MA. Rosiglitazone enhances glucose uptake in glomerular podocytes using the glucose transporter GLUT1.
Diabetologia Jun 17 [Epub ahead of print] (2009).
-
Leone TC, Weinheimer CJ, Kelly DP. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders.
Proc. Natl. Acad. Sci. U.S.A. 96: 7473-7478 (1999).
*
-
Leslie DS, Dascher CC, Cembrola K, Townes MA, Hava DL, Hugendubler LC, Mueller E, Fox L, Roura-Mir C, Moody DB, Vincent MS, Gumperz JE, Illarionov PA, Besra GS, Reynolds CG, Brenner MB. Serum lipids regulate dendritic cell CD1 expression and function.
Immunology 125: 289-301 (2008).
*
-
Leung WK, Bai AH, Chan VY, Yu J, Chan MW, To KF, Wu JR, Chan KK, Fu YG, Chan FK, Sung JJ. Effect of peroxisome proliferator activated receptor gamma ligands on growth and gene expression profiles of gastric cancer cells.
Gut 53: 331-338 (2004).
*
-
Levy E, Spahis S, Sinnett D, Peretti N, Maupas-Schwalm F, Delvin E, Lambert M, Lavoie MA. Intestinal cholesterol transport proteins: an update and beyond.
Curr. Opin. Lipidol. 18: 310-318 (2007).
-
Lewis JD, Lichtenstein GR, Stein RB, Deren JJ, Judge TA, Fogt F, Furth EE, Demissie EJ, Hurd LB, Su CG, Keilbaugh SA, Lazar MA, Wu GD. An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis.
Am. J. Gastroenterol. 96: 3323-3328 (2001).
*
-
Li AC, Binder CJ, Gutierrez A, Brown KK, Plotkin CR, Pattison JW, Valledor AF, Davis RA, Willson TM, Witztum JL, Palinski W, Glass CK. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma.
J. Clin. Invest. 114: 1564-1576 (2004).
*
-
Li AC, Glass CK. PPAR and LXR-dependent pathways controlling lipid metabolism and development of atherosclerosis.
J. Lipid Res. 45: 2161-2173 (2004).
*
-
Li AC, Palinski W. Peroxisome proliferator-activated receptors: how their effects on macrophages can lead to the development of a new drug therapy against atherosclerosis.
Annu. Rev. Pharmacol. Toxicol. 46: 1-39 (2006).
*
-
Li B, Reynolds JM, Stout RD, Bernlohr DA, Suttles J. Regulation of Th17 differentiation by epidermal fatty acid-binding protein.
J. Immunol. 182: 7625-7633 (2009).
-
Li CB, Li XX, Chen YG, Zhang C, Zhang MX, Zhao XQ, Hao MX, Hou XY, Gong ML, Zhao YX, Bu PL, Zhang Y. Effects and mechanisms of PPARalpha activator fenofibrate on myocardial remodeling in hypertension.
J. Cell. Mol. Med. Aug 27 [Epub ahead of print] (2008).
*
-
Li H, Ruan XZ, Powis SH, Fernando R, Mon WY, Wheeler DC, Moorhead JF, Varghese Z. EPA and DHA reduce LPS-induced inflammation responses in HK-2 cells: evidence for a PPAR-gamma-dependent mechanism.
Kidney Int. 67: 867-874 (2005).
*
-
Li J, Wang N. Peroxisome proliferator-activated receptor-gamma in vascular biology.
Cardiovasc. Hematol. Disord. Drug Targets 7: 109-117 (2007).
-
Li L, Cheng LX, Nsenga R, He MA, Wu TC. Association between Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma 2 and myocardial infarction in the Chinese Han population.
Clin. Cardiol. 29: 300-304 (2006).
-
Li L, Gao PJ, Xi R, Wu CF, Zhu DL, Yan J, Lu GP. Pioglitazone inhibits homocysteine-induced migration of vascular smooth musclecells through a peroxisome proliferator-activated receptor gamma-independentmechanism.
Clin. Exp. Pharmacol. Physiol. 35: 1471-1476 (2008).
*
-
Li L, Nelson ED, Seburg RA, Reed RA. Nucleophilic group transfer reactivity for fibric acid derived drug molecules.
J. Pharm. Sci. 95: 1954-1966 (2006).
*
-
Li L, Prabhakaran K, Zhang X, Borowitz JL, Isom GE. PPARalpha-mediated up-regulation of uncoupling protein-2 switches cyanide-induced apoptosis to necrosis in primary cortical cells.
Toxicol. Sci. 93: 136-145 (2006).
*
-
Li LL, Ma XL, Ran JX, Sun XF, Xu LM, Ren J, Mao XM. Genetic polymorphism of peroxisome proliferator-activated receptor-gamma 2 Pro12Ala on ethnic susceptibility to diabetes in Uygur, Kazak and Han subjects.
Clin. Exp. Pharmacol Physiol. 35: 187-191 (2008).
-
Li M, Indra AK, Warot X, Brocard J, Messaddeq N, Kato S, Metzger D, Chambon P. Skin abnormalities generated by temporally controlled RXRalpha mutations in mouse epidermis.
Nature 407: 633-636 (2000).
*
-
Li M, Lee TW, Yim AP, Mok TS, Chen GG. Apoptosis induced by troglitazone is both peroxisome proliferator-activated receptor-gamma- and ERK-dependent in human non-small lung cancer cells.
J. Cell. Physiol. 209: 428-438 (2006).
*
-
Li MY, Hsin MK, Yip J, Mok TS, Underwood MJ, Chen GG. PPARgamma activation extinguishes smoking carcinogen by inhibiting NNK-mediated proliferation.
Am. J. Respir. Cell. Mol. Biol. Apr 3 [Epub ahead of print] (2009).
*
-
Li R, Zheng W, Pi R, Gao J, Zhang H, Wang P, Le K, Liu P. Activation of peroxisome proliferator-activated receptor-alpha prevents glycogen synthase 3beta phosphorylation and inhibits cardiac hypertrophy.
FEBS Lett. 581: 3311-3316 (2007).
*
-
Li RJ, Qiu SD, Chen HX, Tian H, Wang HX. The immunotherapeutic effects of Astragalus polysaccharide in type 1 diabetic mice.
Biol. Pharm. Bull. 30: 470-476 (2007).
*
-
Li RW, Douglas TD, Maiyoh GK, Adeli K, Theriault AG. Green tea leaf extract improves lipid and glucose homeostasis in a fructose-fed insulin-resistant hamster model.
J. Ethnopharmacol. 104: 24-31 (2006).
-
Li S, Gokden N, Okusa MD, Bhatt R, Portilla D. Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF.
Am. J. Physiol. Renal Physiol. 289: F469-F480 (2005).
*
-
Li T, Jahan A, Chiang JY. Bile acids and cytokines inhibit the human cholesterol 7 alpha-hydroxylase gene via the JNK/c-Jun pathway in human liver cells.
Hepatology 43: 1202-1210 (2006).
*
-
Li WM, Jing L, Song J, Zhou LJ. Role of renin-angiotensin system, PPARalpha, PPARgamma in the development of alcoholic cardiomyopathy.
Zhonghua Xin Xue Guan Bing Za Zhi 36: 630-635 (2008).
-
Li X, Han de W, Zhao LF, Yin L. Effect of endotoxin on the expression of peroxisome proliferator-activated receptor alpha in the development of nonalcoholic steatohepatitis in rats.
Zhonghua Gan Zang Bing Za Zhi 13: 89-91 (2005).
-
Li X, Hansen PA, Xi L, Chandraratna RA, Burant CF. Distinct mechanisms of glucose lowering by specific agonists for peroxisomal proliferator activated receptor-gamma (PPARgamma) and retinoic acid X receptors (RXR).
J. Biol. Chem. 280: 38317-38327 (2005).
*
-
Li X, Kimura H, Hirota K, Sugimoto H, Kimura N, Takahashi N, Fujii H, Yoshida H. Hypoxia reduces the expression and anti-inflammatory effects of peroxisome proliferator-activated receptor-gamma in human proximal renal tubular cells.
Nephrol. Dial. Transplant. 22: 1041-1051 (2007).
-
Li X, Yang X, Xu Y, Jiang X, Li X, Nan F, Tang H. Troglitazone inhibits cell proliferation by attenuation of epidermal growth factor receptor signaling independent of peroxisome proliferator-activated receptor gamma.
Cell Res. May 5 [Epub ahead of print] (2009).
-
Li XH, Zou HJ, Wu AH, Ye YL, Shen JH. Structure-based drug design of a novel family of chalcones as PPARalpha agonists: virtual screening, synthesis, and biological activities in vitro.
Acta Pharmacol. Sin. 28: 2040-2052 (2007).
*
-
Li Y, Kovach A, Suino-Powell K, Martynowski D, Xu HE. Structural and biochemical basis for the binding selectivity of PPARgamma to PGC-1alpha.
J. Biol. Chem. 283: 19132-19139 (2008).
*
-
Li Y, Nara TY, Nakamura MT. Peroxisome proliferator activated receptor is required for feedback regulation of highly unsaturated fatty acid synthesis.
J. Lipid Res. 46: 2423-2431 (2005).
*
-
Li Y, Qi Y, Huang TH, Yamahara J, Roufogalis BD. Pomegranate flower: a unique traditional antidiabetic medicine with dual PPAR-alpha/-gamma activator properties.
Diabetes Obes. Metab. 10: 10-17 (2008).
-
Li Y, Wen X, Spataro BC, Hu K, Dai C, Liu Y. Hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists.
J. Am. Soc. Nephrol. 17: 54-65 (2006).
*
-
Li Z, Liao C, Ko BC, Shan S, Tong EH, Yin Z, Pan D, Wong VK, Shi L, Ning ZQ, Hu W, Zhou J, Chung SS, Lu XP. Design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compounds as PPARalpha selective activators.
Bioorg. Med. Chem. Lett. 14: 3507-3511 (2004).
*
-
Li Z, Zhu XY, Li M, Bai YL, Hu J. Protective effect of ghrelin on left ventricular remodeling in spontaneously hypertensive rats is associated with the peroxisome proliferator-activated receptor gamma-dependent pathway.
Chin. Med. J. (Engl.) 121: 2299-2304 (2008).
-
Liang HL, Ouyang Q. A clinical trial of rosiglitazone and 5-aminosalicylate combination for ulcerative colitis.
Zhonghua Nei Ke Za Zhi 45: 548-551 (2006).
-
Liang YJ, Liu YC, Chen CY, Lai LP, Shyu KG, Juang SJ, Wang BW, Leu JG. Comparison of PPARdelta and PPARgamma in inhibiting the pro-inflammatory effects of C-reactive protein in endothelial cells.
Int. J. Cardiol. Apr 21 [Epub ahead of print] (2009).
-
Liangpunsakul S, Wou SE, Wineinger KD, Zeng Y, Cyganek I, Jayaram HN, Crabb D. Effects of WY-14,643 on the phosphorylation and activation of AMP-dependent protein kinase.
Arch. Biochem. Biophys. 485: 10-15 (2009).
-
Liao C, Liu B, Shi L, Zhou J, Lu XP. Construction of a virtual combinatorial library using SMILES strings to discover potential structure-diverse PPAR modulators.
Eur. J. Med. Chem. 40: 632-640 (2005).
*
-
Libby P, Plutzky J. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.
Am. J. Cardiol. 99: 27-40 (2007).
-
Lichtor T, Spagnolo A, Glick RP, Feinstein DL. PPAR-gamma thiazolidinedione agonists and immunotherapy in the treatment of brain tumors.
PPAR Res. 2008: 547470 (2008).
*
-
Lickteig AJ, Cheng X, Augustine LM, Klaassen CD, Cherrington NJ. Tissue distribution, ontogeny and induction of the transporters multidrug and toxin extrusion (MATE) 1 and MATE2 mRNA expression levels in mice.
Life Sci. 83: 59-64 (2008).
-
Lieber CS, Leo MA, Wang X, Decarli LM. Effect of chronic alcohol consumption on hepatic SIRT1 and PGC-1alpha in rats.
Biochem. Biophys. Res. Commun. 370: 44-48 (2008).
*
-
Lillycrop KA, Phillips ES, Jackson AA, Hanson MA, Burdge GC. Dietary protein restriction of pregnant rats induces and folic acid supplementation prevents epigenetic modification of hepatic gene expression in the offspring.
J. Nutr. 135: 1382-1386 (2005).
*
-
Lim HJ, Lee S, Park JH, Lee KS, Choi HE, Chung KS, Lee HH, Park HY. PPARdelta agonist L-165041 inhibits rat vascular smooth muscle cell proliferation and migration via inhibition of cell cycle.
Atherosclerosis 202: 446-454 (2009).
-
Lim SW, Hong SP, Jeong SW, Kim B, Bak H, Ryoo HC, Lee SH, Ahn SK. Simultaneous effect of ursolic acid and oleanolic acid on epidermal permeability barrier function and epidermal keratinocyte differentiation via peroxisome proliferator-activated receptor-alpha.
J. Dermatol. 34: 625-634 (2007).
-
Lin BC, Sullivan R, Lee Y, Moran S, Glover E, Bradfield CA. Deletion of the aryl hydrocarbon receptor associated protein 9 leads to cardiac malformation and embryonic lethality.
J. Biol. Chem. 282: 35924-35932 (2007).
*
-
Lin CL, Wang MH, Qin YF, Fang M, Xie BB, Zhong XY. Differentiation of SWO-38 glioma cells induced by CDA-2 is mediated by peroxisome proliferator-activated receptor gamma.
J. Neurooncol. May 12 [Epub ahead of print] (2009).
-
Lin CY, Gurlo T, Haataja L, Hsueh WA, Butler PC. Activation of peroxisome proliferator-activated receptors-gamma (PPAR-gamma) by rosiglitazone prevents human islet cells against human-islet amyloid polypeptide toxicity by a PI3 kinase-dependent pathway.
J. Clin. Endocrinol. Metab. 90: 6678-6686 (2005).
*
-
Lin HY, Yu IC, Wang RS, Chen YT, Liu NC, Altuwaijri S, Hsu CL, Ma WL, Jokinen J, Sparks JD, Yeh S, Chang C. Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor.
Hepatology 47: 1924-1935 (2008).
*
-
Lin MS, Chen WC, Bai X, Wang YD. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
J. Dig. Dis. 8: 82-88 (2007).
-
Lin Q, Ruuska SE, Shaw NS, Dong D, Noy N. Ligand selectivity of the peroxisome proliferator-activated receptor alpha.
Biochemistry 38: 185-190 (1999).
*
-
Linard C, Gremy O, Benderitter M. Reduction of peroxisome proliferation-activated receptor gamma expression by gamma-irradiation as a mechanism contributing to inflammatory response in rat colon: modulation by the 5-ASA agonist.
J. Pharmacol. Exp. Ther. 324: 911-920 (2008).
*
-
Ling C, Del Guerra S, Lupi R, Ronn T, Granhall C, Luthman H, Masiello P, Marchetti P, Groop L, Del Prato S. Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion.
Diabetologia 51: 615-622 (2008).
*
-
Ling C, Wegner L, Andersen G, Almgren P, Hansen T, Pedersen O, Groop L, Vaag A, Poulsen P. Impact of the peroxisome proliferator activated receptor-gamma coactivator-1beta (PGC-1beta) Ala203Pro polymorphism on in vivo metabolism, PGC-1beta expression and fibre type composition in human skeletal muscle.
Diabetologia 50: 1615-1620 (2007).
*
-
Linsalata M, Giannini R, Notarnicola M, Cavallini A. Peroxisome proliferator-activated receptor gamma and spermidine/spermine N1-acetyltransferase gene expressions are significantly correlated in human colorectal cancer.
BMC Cancer 6: 191 (2006).
*
-
Linz W, Wohlfart P, Baader M, Breitschopf K, Falk E, Schafer HL, Gerl M, Kramer W, Rutten H. The peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats.
Acta Pharmacol. Sin. Jun 8 [Epub ahead of print] (2009).
-
Liou JY, Ghelani D, Yeh S, Wu KK. Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3{varepsilon}.
Cancer Res. 67: 3185-3191 (2007).
*
-
Liou JY, Lee S, Ghelani D, Matijevic-Aleksic N, Wu KK. Protection of endothelial survival by peroxisome proliferator-activated receptor-delta mediated 14-3-3 upregulation.
Arterioscler. Thromb. Vasc. Biol. 26: 1481-1487 (2006).
-
Liou JY, Wu CC, Chen BR, Yen LB, Wu KK. Nonsteroidal anti-inflammatory drugs induced endothelial apoptosis by perturbing PPAR-delta transcriptional pathway.
Mol. Pharmacol. 74: 1399-1406 (2008).
*
-
Lipozencic J. The 1st world congress on gender-specific medicine men, women and medicine a new view of the biology of sex/gender differences and aging.
Acta Dermatovenerol. Croat. 14: 132-134 (2006).
-
Lira FS, Rosa JC, Yamashita AS, Koyama CH, Batista ML Jr, Seelaender M. Endurance training induces depot-specific changes in IL-10/TNF-alpha ratio in rat adipose tissue.
Cytokine 45: 80-85 (2009).
-
Liu D, Zeng BX, Shang Y. Decreased expression of peroxisome proliferator-activated receptor-gamma in endotoxin-induced acute lung injury.
Physiol. Res. 55: 291-299 (2006).
*
-
Liu DS, Liu WJ, Chen L, Ou XM, Wang T, Feng YL, Zhang SF, Xu D, Chen YJ, Wen FQ. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates acrolein-induced airway mucus hypersecretion in rats.
Toxicology 260: 112-119 (2009).
*
-
Liu G, Moon TW, Metcalfe CD, Lee LE, Trudeau VL. A teleost in vitro reporter gene assay to screen for agonists of the peroxisome proliferator-activated receptors.
Environ. Toxicol. Chem. 24: 2260-2266 (2005).
-
Liu GH, Qu J, Shen X. Thioredoxin-mediated negative autoregulation of peroxisome proliferator-activated receptor alpha transcriptional activity.
Mol. Biol. Cell. 17: 1822-1833 (2006).
*
-
Liu HR, Tao L, Gao E, Qu Y, Lau WB, Lopez BL, Christopher TA, Koch W, Yue TL, Ma XL. Rosiglitazone inhibits hypercholesterolemia-induced myeloperoxidase upregulation - a novel mechanism for the cardioprotective effects of PPAR agonists.
Cardiovasc. Res. 81: 344-352 (2009).
*
-
Liu J, Xia Q, Zhang Q, Li H, Zhang J, Li A, Xiu R. Peroxisome proliferator-activated receptor-gamma ligands 15-deoxy-delta-prostaglandin J2 and pioglitazone inhibit H2O2-induced tumor necrosis factor-alpha and lipopolysaccharide-induced CXC chemokine expression in neonatal rat cardiac myocytes.
Shock Jan 19 [Epub ahead of print] (2009).
-
Liu JJ, Hu T, Wu XY, Wang CZ, Xu Y, Zhang Y, Xiao RZ, Lin DJ, Huang RW, Liu Q. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone-induced apoptosis in leukemia K562 cells and its mechanisms of action.
Int. J. Toxicol. 28: 123-131 (2009).
-
Liu JJ, Liu PQ, Lin DJ, Xiao RZ, Huang M, Li XD, He Y, Huang RW. Downregulation of cyclooxygenase-2 expression and activation of caspase-3 are involved in peroxisome proliferator-activated receptor-gamma agonists induced apoptosis in human monocyte leukemia cells in vitro.
Ann. Hematol. 86: 173-183 (2007).
*
-
Liu K, Xu L, Berger JP, Macnaul KL, Zhou G, Doebber TW, Forrest MJ, Moller DE, Jones AB. Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia.
J. Med. Chem. 48: 2262-2265 (2005).
*
-
Liu M, Guo HW, Wan WT, Luo X, Zhang SX, Xue K, Ma YY. Association of peroxisome proliferator-activated-receptors-gamma C161-->T gene polymorphism with metabolic syndrome and dietary predisposition.
Zhonghua Yu Fang Yi Xue Za Zhi 42: 494-498 (2008).
-
Liu MH, Li J, Shen P, Husna B, Tai ES, Yong EL. A natural polymorphism in peroxisome proliferator-activated receptor-alpha hinge region attenuates transcription due to defective release of nuclear receptor corepressor from chromatin.
Mol. Endocrinol. 22: 1078-1092 (2008).
*
-
Liu XF, Li H. Regulation of fat metabolism by PPARs.
Yi Chuan. 28: 243-248 (2006).
-
Liu Y, Lou SY, He YM. Effects of berberine on cell proliferation, peroxisome proliferation activated receptor gamma, CAAT/enhancer binding protein mRNA and protein expression in 3T3-L1 pre-adipocytes.
Zhongguo Zhong Xi Yi Jie He Za Zhi 28: 1005-1009 (2008).
-
Liu Y, Yuan Z, Liu Y, Zhang J, Yin P, Wang D, Wang Y, Kishimoto C, Ma A. PPARgamma gene C161T substitution is associated with reduced risk of coronary artery disease and decreased proinflammatory cytokine expression.
Am. Heart J. 154: 718-724 (2007).
*
-
Liu Y, Zhang Y, Schmelzer K, Lee TS, Fang X, Zhu Y, Spector AA, Gill S, Morisseau C, Hammock BD, Shyy JY. The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase.
Proc. Natl. Acad. Sci. U.S.A. 102: 16747-16752 (2005).
*
-
Ljungberg A, Linden D, Ameen C, Bergstrom G, Oscarsson J. Importance of PPARalpha for the effects of growth hormone on hepatic lipid and lipoprotein metabolism.
Growth Horm. IGF Res. 17: 154-164 (2007).
-
Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, Piomelli D. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the antiinflammatory actions of palmitoylethanolamide.
Mol. Pharmacol. 67: 15-19 (2005).
*
-
Loane DJ, Deighan BF, Clarke RM, Griffin RJ, Lynch AM, Lynch MA. Interleukin-4 mediates the neuroprotective effects of rosiglitazone in the aged brain.
Neurobiol. Aging 30: 920-931 (2009).
-
Lobaccaro JM, Repa JJ, Lu TT, Caira F, Henry-Berger J, Volle DH, Mangelsdorf DJ. Regulation of lipid metabolism by the orphan nuclear receptors.
Ann. Endocrinol. (Paris) 62: 239-247 (2001).
-
Loffler M, Bilban M, Reimers M, Waldhausl W, Stulnig T. Blood glucose lowering nuclear receptor agonists only partially normalize hepatic gene expression in db/db mice.
J. Pharmacol. Exp. Ther. 316: 797-804 (2006).
*
-
Loichot C, Jesel L, Tesse A, Tabernero A, Schoonjans K, Roul G, Carpusca I, Auwerx J, Andriantsitohaina R. Deletion of peroxisome proliferator-activated receptor-alpha induces an alteration of cardiac functions.
Am. J. Physiol. Heart Circ. Physiol. 291: H161-H166 (2006).
*
-
Long GG, Reynolds VL, Lopez-Martinez A, Ryan TE, White SL, Eldridge SR. Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lack of evidence for urolithiasis as an inciting event.
Toxicol. Pathol. 36: 218-231 (2008).
*
-
Long YC, Glund S, Garcia-Roves PM, Zierath JR. Calcineurin regulates skeletal muscle metabolism via coordinated changes in gene expression.
J. Biol. Chem. 282: 1607-1614 (2007).
*
-
Looze C, Yui D, Leung L, Ingham M, Kaler M, Yao X, Wu WW, Shen RF, Daniels MP, Levine SJ. Proteomic profiling of human plasma exosomes identifies PPARgamma as an exosome-associated protein.
Biochem. Biophys. Res. Commun. 378: 433-438 (2009).
*
-
Lopez D, McLean MP. Activation of the rat scavenger receptor class B type I gene by PPARalpha.
Mol. Cell. Endocrinol. 251: 67-77 (2006).
-
Lopez-Parra M, Claria J, Titos E, Planaguma A, Parrizas M, Masferrer JL, Jimenez W, Arroyo V, Rivera F, Rodes J. The selective cyclooxygenase-2 inhibitor celecoxib modulates the formation of vasoconstrictor eicosanoids and activates PPARgamma. Influence of albumin.
J. Hepatol. 42: 75-81 (2005).
*
-
Lopez-Soriano J, Chiellini C, Maffei M, Grimaldi PA, Argiles JM. Roles of skeletal muscle and PPARs in the development and treatment of obesity.
Endocr. Rev. 27: 318-329 (2006).
*
-
Lorente-Cebrian S, Perez-Matute P, Martinez JA, Marti A, Moreno-Aliaga MJ. Effects of eicosapentaenoic acid (EPA) on adiponectin gene expression and secretion in primary cultured rat adipocytes.
J. Physiol. Biochem. 62: 61-69 (2006).
-
Louet JF, Coste A, Amazit L, Tannour-Louet M, Wu RC, Tsai SY, Tsai MJ, Auwerx J, O'Malley BW. Oncogenic steroid receptor coactivator-3 is a key regulator of the white adipogenic program.
Proc. Natl. Acad. Sci. U.S.A. 103: 17868-17873 (2006).
*
-
Loverme J, La Rana G, Russo R, Calignano A, Piomelli D. The search for the palmitoylethanolamide receptor.
Life Sci. 77: 1685-1698 (2005).
*
-
Loverme J, Russo R, La Rana G, Fu J, Farthing J, Raso G, Meli R, Hohmann A, Calignano A, Piomelli D. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha.
J. Pharmacol. Exp. Ther. 319: 1051-1061 (2006).
*
-
Lovett-Racke AE, Hussain RZ, Northrop S, Choy J, Rocchini A, Matthes L, Chavis JA, Diab A, Drew PD, Racke MK. Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease.
J. Immunol. 172: 5790-5798 (2004).
*
-
Lowe DB, Bifulco N, Bullock WH, Claus T, Coish P, Dai M, Dela Cruz FE, Dickson D, Fan D, Hoover-Litty H, Li T, Ma X, Mannelly G, Monahan MK, Muegge I, O'Connor S, Rodriguez M, Shelekhin T, Stolle A, Sweet L, Wang M, Wang Y, Zhang C, Zhang HJ, et al. Substituted indanylacetic acids as PPAR-alpha-gamma activators.
Bioorg. Med. Chem. Lett. 16: 297-301 (2006).
*
-
Lu B, Moser AH, Shigenaga JK, Feingold KR, Grunfeld C. Type II nuclear hormone receptors, coactivator, and target gene repression in adipose tissue in the acute-phase response.
J. Lipid Res. 47: 2179-2190 (2006).
*
-
Lu H, Lei X, Klaassen C. Gender differences in renal nuclear receptors and aryl hydrocarbon receptor in 5/6 nephrectomized rats.
Kidney Int. 70: 1920-1928 (2006).
*
-
Lu IL, Huang CF, Peng YH, Lin YT, Hsieh HP, Chen CT, Lien TW, Lee HJ, Mahindroo N, Prakash E, Yueh A, Chen HY, Goparaju CM, Chen X, Liao CC, Chao YS, Hsu JT, Wu SY. Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities.
J. Med. Chem. 49: 2703-2712 (2006).
*
-
Lu J, Chen M, Stanley SE, Li E. Effect of heterodimer partner RXRalpha on PPARgamma activation function-2 helix in solution.
Biochem. Biophys. Res. Commun. 365: 42-46 (2008).
*
-
Lu Z, Dong B, Mo X, Chen T, Wu H, Zhang Y, Xiao H. Pro12Ala polymorphism in PPAR gamma 2 associated with essential hypertension in Chinese nonagenarians/centenarians.
Exp. Gerontol. 43: 1108-1113 (2008).
-
Lubet RA, Fischer SM, Steele VE, Juliana MM, Desmond R, Grubbs CJ. Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers.
Int. J. Cancer 123: 2254-2259 (2008).
*
-
Luc G, Jacob N, Bouly M, Fruchart JC, Staels B, Giral P. Fenofibrate increases homocystinemia through a PPARalpha-mediated mechanism.
J. Cardiovasc. Pharmacol. 43: 452-453 (2004).
-
Luci S, Geissler S, Konig B, Koch A, Stangl GI, Hirche F, Eder K. PPARalpha agonists up-regulate organic cation transporters in rat liver cells.
Biochem. Biophys. Res. Commun. 350: 704-708 (2006).
*
-
Luci S, Hirche F, Eder K. Fasting and caloric restriction increases mRNA concentrations of novel organic cation transporter-2 and carnitine concentrations in rat tissues.
Ann. Nutr. Metab. 52: 58-67 (2008).
-
Ludovico O, Pellegrini F, Di Paola R, Minenna A, Mastroianno S, Cardellini M, Marini MA, Andreozzi F, Vaccaro O, Sesti G, Trischitta V. Heterogeneous effect of peroxisome proliferator-activated receptor gamma2 Ala12 variant on type 2 diabetes risk.
Obesity (Silver Spring) 15: 1076-1081 (2007).
*
-
Ludtke A, Buettner J, Schmidt HH, Worman HJ. New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand.
J. Med. Genet. 44: e88 (2007).
-
Ludtke A, Buettner J, Wu W, Muchir A, Schroeter A, Zinn-Justin S, Spuler S, Schmidt HH, Worman HJ. Peroxisome proliferator-activated receptor gamma C190S mutation causes partial lipodystrophy.
J. Clin. Endocrinol. Metab. 92: 2248-2255 (2007).
*
-
Lui WO, Zeng L, Rehrmann V, Deshpande S, Tretiakova M, Kaplan EL, Leibiger I, Leibiger B, Enberg U, Hoog A, Larsson C, Kroll TG. CREB3L2-PPARgamma fusion mutation identifies a thyroid signaling pathway regulated by intramembrane proteolysis.
Cancer Res. 68: 7156-7164 (2008).
*
-
Lundasen T, Hunt MC, Nilsson LM, Sanyal S, Angelin B, Alexson SE, Rudling M. PPARalpha is a key regulator of hepatic FGF21.
Biochem. Biophys. Res. Commun. 360: 437-440 (2007).
*
-
Lunde IG, Ekmark M, Rana ZA, Buonanno A, Gundersen K. PPARdelta expression is influenced by muscle activity and induces slow muscle properties in adult rat muscles after somatic gene transfer.
J. Physiol. 582: 1277-1287 (2007).
*
-
Luo Y, Yin W, Signore AP, Zhang F, Hong Z, Wang S, Graham SH, Chen J. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
J. Neurochem. 97: 435-448 (2006).
-
Luquet S, Gaudel C, Holst D, Lopez-Soriano J, Jehl-Pietri C, Fredenrich A, Grimaldi PA. Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes.
Biochim. Biophys. Acta 1740: 313-317 (2005).
*
-
Luquet S, Lopez-Soriano J, Holst D, Gaudel C, Jehl-Pietri C, Fredenrich A, Grimaldi PA. Roles of peroxisome proliferator-activated receptor delta (PPARdelta) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome.
Biochimie 86: 833-837 (2004).
-
Lymboussaki A, Gemelli C, Testa A, Facchini G, Ferrari F, Mavilio F, Grande A. PPARdelta is a ligand dependent negative regulator of vitamin D3 induced monocyte differentiation.
Carcinogenesis 30: 230-237 (2009).
*
-
Lyssenko V, Almgren P, Anevski D, Orho-Melander M, Sjogren M, Saloranta C, Tuomi T, Groop L; Botnia Study Group. Genetic prediction of future type 2 diabetes.
PLoS Med. 2: e345 (2005).
*
-
Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomi T, Berglund G, Altshuler D, Nilsson P, Groop L. Clinical risk factors, DNA variants, and the development of type 2 diabetes.
N. Engl. J. Med. 359: 2220-2232 (2008).
*
-
Lytle C, Tod TJ, Vo KT, Lee JW, Atkinson RD, Straus DS. The peroxisome proliferator-activated receptor gamma ligand rosiglitazone delays the onset of inflammatory bowel disease in mice with interleukin 10 deficiency.
Inflamm. Bowel Dis. 11: 231-243 (2005).
*
-
Løvås K, Røst TH, Skorve J, Ulvik RJ, Gudbrandsen OA, Bohov P, Wensaas AJ, Rustan AC, Berge RK, Husebye ES. Tetradecylthioacetic acid attenuates dyslipidaemia in male patients with type 2 diabetes mellitus, possibly by dual PPAR-alpha/delta activation and increased mitochondrial fatty acid oxidation.
Diabetes Obes. Metab. 11: 304-314 (2009).
-
Ma X, Shah YM, Guo GL, Wang T, Krausz KW, Idle JR, Gonzalez FJ. Rifaximin is a gut-specific human pregnane X receptor activator.
J. Pharmacol. Exp. Ther. 322: 391-398 (2007).
*
-
Macdonald N, Holden PR, Roberts RA. Addition of peroxisome proliferator-activated receptor alpha to guinea pig hepatocytes confers increased responsiveness to peroxisome proliferators.
Cancer Res. 59: 4776-4780 (1999).
*
-
Macejova D, Krizanova O, Brtko J. Different mRNA expression profiling of nuclear retinoid, thyroid, estrogen and PPARgamma receptors, their coregulators and selected genes in rat liver and spleen in response to short-term in vivo administration of 13-cis retinoic acid.
Toxicol. Lett. 184: 114-120 (2009).
*
-
Macias-Gonzalez M, Cardona F, Queipo-Ortuno M, Bernal R, Martin M, Tinahones FJ. PPARgamma mRNA expression is reduced in peripheral blood mononuclear cells after fat overload in patients with metabolic syndrome.
J. Nutr. 138: 903-907 (2008).
*
-
MacLaren LA, Guzeloglu A, Michel F, Thatcher WW. Peroxisome proliferator-activated receptor (PPAR) expression in cultured bovine endometrial cells and response to omega-3 fatty acid, growth hormone and agonist stimulation in relation to series 2 prostaglandin production.
Domest. Anim. Endocrinol. 30: 155-169 (2006).
*
-
Maclennan NK, Rahib L, Shin C, Fang Z, Horvath S, Dean J, Liao JC, McCabe ER, Dipple KM. Targeted disruption of glycerol kinase gene in mice: expression analysis in liver shows alterations in network partners related to glycerol kinase activity.
Hum. Mol. Genet. 15: 405-415 (2006).
*
-
Madhavan GR, Chakrabarti R, Anantha Reddy K, Rajesh BM, Balraju V, Bheema Rao P, Rajagopalan R, Iqbal J. Dual PPAR-alpha and -gamma activators derived from novel benzoxazinone containing thiazolidinediones having antidiabetic and hypolipidemic potential.
Bioorg. Med. Chem. 14: 584-591 (2006).
*
-
Madrazo JA, Kelly DP. The PPAR trio: regulators of myocardial energy metabolism in health and disease.
J. Mol. Cell. Cardiol. 44: 968-975 (2008).
*
-
Madsen L, Petersen RK, Sorensen MB, Jorgensen C, Hallenborg P, Pridal L, Fleckner J, Amri EZ, Krieg P, Furstenberger G, Berge RK, Kristiansen K. Adipocyte differentiation of 3T3-L1 preadipocytes is dependent on lipoxygenase activity during the initial stages of the differentiation process.
Biochem. J. 375: 539-549 (2003).
*
-
Maeda T, Kiguchi N, Fukazawa Y, Yamamoto A, Ozaki M, Kishioka S. Peroxisome proliferator-activated receptor gamma activation relieves expression of behavioral sensitization to methamphetamine in mice.
Neuropsychopharmacology 32: 1133-1140 (2007).
-
Maeda T, Wakasawa T, Funabashi M, Fukushi A, Fujita M, Motojima K, Tamai I. Regulation of Octn2 transporter (SLC22A5) by peroxisome proliferator activated receptor alpha.
Biol. Pharm. Bull. 31: 1230-1236 (2008).
*
-
Maeyama K, Emi M, Chihara K. Role of PPARgamma in inflammatory response related to mast cells.
Nippon Yakurigaku Zasshi 122: 325-330 (2003).
-
Maeyama K, Emi M, Tachibana M. Nuclear receptors as targets for drug development: peroxisome proliferator-activated receptor gamma in mast cells: its roles in proliferation and differentiation.
J. Pharmacol. Sci. 97: 190-194 (2005).
*
-
Magee TR, Han G, Cherian B, Khorram O, Ross MG, Desai M. Down-regulation of transcription factor peroxisome proliferator-activated receptor in programmed hepatic lipid dysregulation and inflammation in intrauterine growth-restricted offspring.
Am. J. Obstet. Gynecol. 199: 271.e1-e5 (2008).
-
Maggi LB Jr, Sadeghi H, Weigand C, Scarim AL, Heitmeier MR, Corbett JA. Anti-inflammatory actions of 15-deoxy-delta 12,14-prostaglandin J2 and troglitazone: evidence for heat shock-dependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression.
Diabetes 49: 346-355 (2000).
*
-
Maher J, Aleksunes L, Dieter M, Tanaka Y, Peters J, Manautou J, Klaassen C. Nrf2 and PPARalpha-mediated regulation of hepatic Mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid.
Toxicol. Sci. 106: 319-328 (2008).
*
-
Maher JM, Cheng X, Slitt AL, Dieter MZ, Klaassen CD. Induction of the Mrp family of transporters by chemical activators of receptor-mediated pathways in mouse liver.
Drug Metab. Dispos. 33: 956-962 (2005).
*
-
Mahindroo N, Huang CF, Peng YH, Wang CC, Liao CC, Lien TW, Chittimalla SK, Huang WJ, Chai CH, Prakash E, Chen CP, Hsu TA, Peng CH, Lu IL, Lee LH, Chang YW, Chen WC, Chou YC, Chen CT, Goparaju CM, Chen YS, Lan SJ, Yu MC, Chen X, Chao YS, Wu SY, Hsieh HP. Novel indole-based peroxisome proliferator-activated receptor agonists: design, SAR, structural biology, and biological activities.
J. Med. Chem. 48: 8194-8208 (2005).
*
-
Mahindroo N, Wang CC, Liao CC, Huang CF, Lu IL, Lien TW, Peng YH, Huang WJ, Lin YT, Hsu MC, Lin CH, Tsai CH, Hsu JT, Chen X, Lyu PC, Chao YS, Wu SY, Hsieh HP. Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies.
J. Med. Chem. 49: 1212-1216 (2006).
*
-
Maia-Fernandes T, Roncon-Albuquerque R Jr, Leite-Moreira AF. Cardiovascular actions of adiponectin: pathophysiologic implications.
Rev. Port. Cardiol. 27: 1431-1449 (2008).
-
Maiuri L, Luciani A, Giardino I, Raia V, Villella VR, D'Apolito M, Pettoello-Mantovani M, Guido S, Ciacci C, Cimmino M, Cexus ON, Londei M, Quaratino S. Tissue transglutaminase activation modulates inflammation in cystic fibrosis via PPARgamma down-regulation.
J. Immunol. 180: 7697-7705 (2008).
*
-
Majai G, Sarang Z, Csomos K, Zahuczky G, Fesus L. PPARgamma-dependent regulation of human macrophages in phagocytosis of apoptotic cells.
Eur. J. Immunol. 37: 1343-1354 (2007).
*
-
Makowski L, Noland RC, Koves TR, Xing W, Ilkayeva OR, Muehlbauer MJ, Stevens RD, Muoio DM. Metabolic profiling of PPARalpha-/- mice reveals defects in carnitine and amino acid homeostasis that are partially reversed by oral carnitine supplementation.
FASEB J. 23: 586-604 (2009).
*
-
Malchiodi-Albedi F, Matteucci A, Bernardo A, Minghetti L. PPAR-gamma, microglial cells, and ocular inflammation: new venues for potential therapeutic approaches.
PPAR Res. 2008: 295784 (2008).
*
-
Malecki MT, Cyganek K, Mirkiewicz-Sieradzka B, Wolkow PP, Wanic K, Skupien J, Solnica B, Sieradzki J. Alanine variant of the Pro12Ala polymorphism of the PPARgamma gene might be associated with decreased risk of diabetic retinopathy in type 2 diabetes.
Diabetes Res. Clin. Pract. 80: 139-145 (2008).
-
Malur A, McCoy AJ, Arce S, Barna BP, Kavuru MS, Malur AG, Thomassen MJ. Deletion of PPARgamma in alveolar macrophages is associated with a Th-1 pulmonary inflammatory response.
J. Immunol. 182: 5816-5822 (2009).
-
Mamnoor PK, Hegde P, Datla SR, Damarla RK, Rajagopalan R, Chakrabarti R. Antihypertensive effect of ragaglitazar: a novel PPARalpha and gamma dual activator.
Pharmacol. Res. 54: 129-135 (2006).
*
-
Man MQ, Barish GD, Schmuth M, Crumrine D, Barak Y, Chang S, Jiang Y, Evans RM, Elias PM, Feingold KR. Deficiency of PPARbeta/delta in the epidermis results in defective cutaneous permeability barrier homeostasis and increased inflammation.
J. Invest. Dermatol. 128: 370-377 (2008).
*
-
Man MQ, Choi EH, Schmuth M, Crumrine D, Uchida Y, Elias PM, Holleran WM, Feingold KR. Basis for improved permeability barrier homeostasis induced by PPAR and LXR activators: liposensors stimulate lipid synthesis, lamellar body secretion, and post-secretory lipid processing.
J. Invest. Dermatol. 126: 386-392 (2006).
*
-
Mandard S, Muller M, Kersten S. Peroxisome proliferator-activated receptor alpha target genes.
Cell. Mol. Life Sci. 61: 393-416 (2004).
*
-
Mandard S, Stienstra R, Escher P, Tan NS, Kim I, Gonzalez FJ, Wahli W, Desvergne B, Muller M, Kersten S. Glycogen synthase 2 is a novel target gene of peroxisome proliferator-activated receptors.
Cell. Mol. Life Sci. 64: 1145-1157 (2007).
*
-
Mandard S, Zandbergen F, Tan NS, Escher P, Patsouris D, Koenig W, Kleemann R, Bakker A, Veenman F, Wahli W, Muller M, Kersten S. The direct PPAR target FIAF/PGAR/ANGPTL4 is present in blood plasma as a truncated protein that is increased by fenofibrate treatment.
J. Biol. Chem. 279: 34411-34420 (2004).
*
-
Mangan S, Clancy P, Golledge J. Modulation of endothelial cell thrombomodulin by PPAR ligands - variation according to environment.
Thromb. Res. 121: 827-834 (2008).
-
Mansouri R, Bauge E, Staels B, Gervois P. Systemic and distal repercussions of liver-specific peroxisome proliferator-activated receptor-alpha control of the acute phase response.
Endocrinology 149: 3215-3223 (2008).
*
-
Mansure JJ, Nassim R, Kassouf W. Peroxisome proliferator-activated receptor gamma in bladder cancer: a promising therapeutic target.
Cancer Biol. Ther. 8: 6-15 (2009).
-
Maraldi NM, Capanni C, Mattioli E, Columbaro M, Squarzoni S, Parnaik WK, Wehnert M, Lattanzi G. A pathogenic mechanism leading to partial lipodistrophy and prospects for pharmacological treatment of insulin resistance syndrome.
Acta Biomed. 78 Suppl. 1: 207-215 (2007).
-
Marathe C, Bradley MN, Hong C, Chao L, Wilpitz D, Salazar J, Tontonoz P. Preserved glucose tolerance in high fat diet-fed C57BL/6 mice transplanted with PPARgamma -/-, PPARdelta -/-, PPARgamma delta -/- or LXRalpha beta -/- bone marrow.
J. Lipid Res. 50: 214-224 (2009).
-
Marchesini G, Suppini A, Forlani G. NAFLD treatment: cognitive-behavioral therapy has entered the arena.
J. Hepatol. 43: 926-928 (2005).
*
-
Marcus SL, Miyata KS, Rachubinski RA, Capone JP. Transactivation by PPAR/RXR heterodimers in yeast is potentiated by exogenous fatty acid via a pathway requiring intact peroxisomes.
Gene Expr. 4: 227-239 (1995).
-
Marian E, Baraldo S, Visentin A, Papi A, Saetta M, Fabbri LM, Maestrelli P. Up-regulated membrane and nuclear leukotriene B4 receptors in COPD.
Chest 129: 1523-1530 (2006).
*
-
Marie PJ. Transcription factors controlling osteoblastogenesis.
Arch. Biochem. Biophys. 473: 98-105 (2008).
*
-
Marin HE, Peraza MA, Billin AN, Willson TM, Ward JM, Kennett MJ, Gonzalez FJ, Peters JM. Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesis.
Cancer Res. 66: 4394-4401 (2006).
*
-
Marion-Letellier R, Butler M, Dechelotte P, Playford RJ, Ghosh S. Comparison of cytokine modulation by natural peroxisome proliferator-activated receptor gamma ligands with synthetic ligands in intestinal-like Caco-2 cells and human dendritic cells.
Am. J. Clin. Nutr. 87: 939-948 (2008).
*
-
Marion-Letellier R, Dechelotte P, Iacucci M, Ghosh S. Dietary modulation of peroxisome proliferator-activated receptor gamma.
Gut 58: 586-593 (2009).
-
Mark M, Kastner P, Ghyselinck NB, Krezel W, Dupe V, Chambon P. Genetic control of the development by retinoic acid.
C. R. Seances Soc. Biol. Fil. 191: 77-90 (1997).
-
Markt P, Petersen RK, Flindt EN, Kristiansen K, Kirchmair J, Spitzer G, Distinto S, Schuster D, Wolber G, Laggner C, Langer T. Discovery of novel PPAR ligands by a virtual screening approach based on pharmacophore modeling, 3D shape, and electrostatic similarity screening.
J. Med. Chem. 51: 6303-6317 (2008).
*
-
Markt P, Schuster D, Kirchmair J, Laggner C, Langer T. Pharmacophore modeling and parallel screening for PPAR ligands.
J. Comput. Aided Mol. Des. 21: 575-590 (2007).
-
Marmolino D, Acquaviva F. Friedreich's ataxia: from the (GAA)(n) repeat mediated silencing to new promising molecules for therapy.
Cerebellum Jan 23 [Epub ahead of print] (2009).
-
Marmolino D, Acquaviva F, Pinelli M, Monticelli A, Castaldo I, Filla A, Cocozza S. PPAR-gamma agonist azelaoyl PAF increases frataxin protein and mRNA expression. New implications for the Friedreich's ataxia therapy.
Cerebellum Dec 23 [Epub ahead of print] (2008).
-
Marra F, Efsen E, Romanelli RG, Caligiuri A, Pastacaldi S, Batignani G, Bonacchi A, Caporale R, Laffi G, Pinzani M, Gentilini P. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells.
Gastroenterology 119: 466-478 (2000).
*
-
Marrapodi M, Chiang JY. Peroxisome proliferator-activated receptor alpha (PPARalpha) and agonist inhibit cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription.
J. Lipid Res. 41: 514-520 (2000).
*
-
Marshall TG, Lee RE, Marshall FE. Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b.
Theor. Biol. Med. Model. 3: 1 (2006).
*
-
Marsillach J, Camps J, Ferre N, Beltran R, Rull A, Mackness B, Mackness M, Joven J. Paraoxonase-1 is related to inflammation, fibrosis and PPAR delta in experimental liver
| |
